Final Programme Esmo2023

-
Chair(s): Kosei Hasegawa, JP; Mansoor Raza Mirza, DK
07:08 - 07:13 One LBA TBC
07:13 - 07:28 Invited Discussant one LBA TBC, 745MO and 746MO
K. Hasegawa, Saitama Medical University International Medical Center, Saitama, JP
07:28 - 07:33 One LBA TBC
07:33 - 07:48 Invited Discussant one LBA TBC and 747MO

M.R. Mirza, Rigshospitalet, Copenhagen, DK
20.10.2023
10:15 - 11:45 Type: Industry Satellite Symposium Salamanca
Title: AstraZeneca - Evolving Paradigms in Hormone Receptor- Auditorium -
Positive Breast Cancer: The Rise of Antibody-Drug Conjugates Hall 3
Chair(s): Javier Cortés, ES
10:15 - 10:20 Welcome and Introduction

J. Cortés, Hospital Ruber Internacional, Madrid, ES
10:20 - 10:45 Antibody-Drug Conjugates for HR-Positive Breast Cancer: Where Are We Today?
P. Fasching, University Hospital Erlangen, Erlangen, DE
10:45 - 11:10 Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion

S. Hurvitz, UCLA Hematology/Oncology Santa Monica, Santa Monica, US
11:10 - 11:30 New Antibody-Drug Conjugates on the Horizon

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine
and Dentistry, London, GB
11:30 - 11:40 Audience Q&A
J. Cortés1, P. Fasching2, S. Hurvitz3, P. Schmid4, 1Hospital Ruber Internacional, Madrid,

ES, 2University Hospital Erlangen, Erlangen, DE, 3UCLA Hematology/Oncology Santa
Monica, Santa Monica, US, 4Cancer Research UK Barts Centre - Barts and The London
School of Medicine and Dentistry, London, GB
11:40 - 11:45 Concluding Remarks

Last update: 28-09-2023 07:08:08am Programme

10:15 - 11:45 Type: Industry Satellite Symposium Málaga Auditorium
Title: Seagen - HER2-Targeted Therapies in mCRC: Are We - Hall 10
Ready for a Paradigm Shift?
Chair(s): Salvatore Siena, IT

S. Siena, UNIMI - Università degli Studi di Milano Statale, Milan, IT
10:20 - 10:35 HER2 as an Actionable Target in HER2+ mCRC

K. Ng, Dana Farber Cancer Institute, Boston, US
10:35 - 10:55 The Role of HER2 Testing in mCRC

R. Adams, Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff,
GB
10:55 - 11:15 Exploring New Opportunities to Improve Outcomes in Patients with HER2+
mCRC
11:15 - 11:40 Panel Discussion and Interactive Q&A
S. Siena1, K. Ng2, R. Adams3, 1UNIMI - Università degli Studi di Milano Statale, Milan,
IT, 2Dana Farber Cancer Institute, Boston, US, 3Velindre Cancer Centre - Velindre NHS
University Trust - NHS Wales, Cardiff, GB
11:40 - 11:45 Closing Remarks


10:15 - 11:40 Type: Industry Satellite Symposium Santander
Title: Deciphera - Expert perspectives: management of Auditorium - Hall 9
advanced GIST –now and in the future
Chair(s): Cesar Serrano, ES
10:15 - 10:20 Welcome and introduction

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
10:20 - 10:40 Overview of advanced GIST: understanding the pathogenesis for this rare cancer
A. Napolitano, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London,
GB
10:40 - 11:00 Reviewing advanced GIST management and addressing current challenges to
care
S. Watson, Institut Curie, Paris, FR
11:00 - 11:20 Individualising treatment, ctDNA and future advanced GIST management
11:20 - 11:40 Discussion and conclusions


10:15 - 11:45 Type: Industry Satellite Symposium Toledo Auditorium
Title: Astellas Pharma Europe Ltd - The evolving treatment - Hall 3
landscape in LA/mUC
Chair(s): Ignacio Duran Martinez, ES
10:15 - 10:20 Housekeeping and introductions

I. Duran Martinez, HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES
10:20 - 10:30 First-line therapy for patients with LA/mUC: The transformation of the treatment
landscape and current unmet needs
10:30 - 10:50 Overview of current trials investigating first-line treatment of LA/mUC

T. Friedlander, UCSF - University of California San Francisco, San Francisco, US
10:50 - 11:30 Clinical experiences with first-line treatment of LA/mUC
F. Schlürmann1, T. Friedlander2, 1CHRU Brest - Hopital Augustin Morvan, Brest, FR,

2UCSF - University of California San Francisco, San Francisco, US
11:30 - 11:40 Panel discussion
I. Duran Martinez1, F. Schlürmann2, T. Friedlander3, 1HUMV - Hospital Universitario

Marques de Valdecilla, Santander, ES, 2CHRU Brest - Hopital Augustin Morvan, Brest,
FR, 3UCSF - University of California San Francisco, San Francisco, US
11:40 - 11:45 Summary and close


10:15 - 11:45 Type: Industry Satellite Symposium Oviedo
Title: Bristol Myers Squibb - Immuno-Oncology Landscape for GI Auditorium -
Cancers: Perspectives on Current Practices and Recent Advances Hall 7
Chair(s): John Bridgewater, GB
10:15 - 10:20 Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices

and Recent Advances
J. Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, GB
10:20 - 10:40 Immunotherapeutic Advances in the Treatment of Esophageal Cancer

P. Thuss-Patience, Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE
10:40 - 11:00 Update on Immuno-Oncology for the Treatment of Gastric Cancer

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES
11:00 - 11:20 Advances in Immuno-Oncology for the Treatment of Colorectal Cancer

M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES
11:20 - 11:40 Roundtable Case Discussion, Q&A
J. Bridgewater1, M.E. Elez Fernandez2, P. Thuss-Patience3, T. Fleitas4, 1UCL Cancer

Institute - Paul O'Gorman Building, London, GB, 2Vall d'Hebron University Hospital,
Barcelona, ES, 3Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE,
4Hospital Clinico Universitario de Valencia, Valencia, ES
11:40 - 11:45 Summary and Close

J. Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:15 - 11:45 Type: Industry Satellite Symposium León
Title: Servier - Are brain cancer patients finally able to benefit Auditorium -
from precision medicine approaches? Hall 7
Chair(s): Carmen Balana, ES
10:15 - 10:25 Introduction: The Sword of Damocles hanging over each patient
C. Balana, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans
Trias i Pujol), Badalona, ES
10:25 - 10:45 IDH Mutated Glioma: A Decade’s journey from bench to bedside
T. Cloughesy, Ronald Reagan UCLA Medical Center University of California, Los Angeles,
US
10:45 - 11:00 Connecting the dots: Understanding recent clinical evidence in the framework of
previous studies and current practice
M. Van Den Bent, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL
11:00 - 11:15 The evolving paradigm for clinical management of glioma

S. Erridge, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB
11:15 - 11:30 Navigating the paradigm shift: Thriving in the new era glioma care
G. Tabatabai, Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE
11:30 - 11:45 Q&A Session
C. Balana1, G. Tabatabai2, T. Cloughesy3, M. Van Den Bent4, S. Erridge5, 1ICO - Institut

Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona,
ES, 2Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE, 3Ronald Reagan
UCLA Medical Center University of California, Los Angeles, US, 4Erasmus MC - Daniel
den Hoed Cancer Center, Rotterdam, NL, 5Institute of Genetics and Cancer, University of
Edinburgh, Edinburgh, GB

12:00 - 13:45 Type: Opening session Madrid Auditorium - Hall 6
Title: Opening session
12:00 - 12:17 Welcome and Presidential address

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES
12:17 - 12:22 Scientific Chair address

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
Svizzera Italiana (IOSI), Bellinzona, CH
12:22 - 12:27 Presentation of the ESMO awards 2023
12:27 - 12:46 ESMO Award 2023

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
12:46 - 13:05 ESMO Award for Translational Research 2023

N. Turner, The Royal Marsden Hospital - Chelsea, London, GB
13:05 - 13:24 ESMO Women for Oncology Award 2023

G. Long, University of Sydney, Sydney, AU
13:24 - 13:43 ESMO Lifetime Achievement Award 2023

A.T.C. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
13:43 - 13:45 Closure of the Opening Ceremony

14:00 - 15:40 Type: Proffered Paper session Barcelona Auditorium

Title: Proffered Paper session 1 - Gastrointestinal - Hall 9
tumours, upper digestive
Chair(s): Magnus Nilsson, SE; Elizabeth Smyth, GB
14:00 - 14:10 LBA74 - Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and

adjuvant therapy in locally-advanced gastric and gastroesophageal junction
cancer: The Phase 3 KEYNOTE-585 study
K. Shitara1, S.Y. Rha2, L. Wyrwicz3, T. Oshima4, N. Karaseva5, M. Osipov6, H. Yasui7, H.

Yabusaki8, S. Afanasyev9, Y.-K. Park10, S.-E. Al-Batran11, T. Yoshikawa12, P. Yanez
Weber13, M. Di Bartolomeo14, S. Lonardi15, X. Fang16, C.-S. Shih16, P. Bhagia16, Y.-J.
Bang17, 1National Cancer Center Hospital East, Kashiwa, JP, 2Yonsei Cancer Center,
Yonsei University Health System & Songdang Institute for Clinical Research, Seoul, KR,
3Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, PL, 4Kanagawa
Cancer Center, Yokohama, JP, 5SPb SBHI Clinical Oncology Dispensary, Saint-Petersburg,
RU, 6Leningrad Regional Clinical Hospital, Saint-Petersburg, RU, 7Kobe City Medical
Center General Hospital, Kobe, JP, 8Niigata Cancer Center Hospital, Niigata, JP, 9Cancer
Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk,

RU, 10Chonnam National University Hwasun Hospital, Hwasun, KR, 11Krankenhaus
Nordwest, UCT-University Cancer Center, Frankfurt, DE, 12National Cancer Center
Hospital, Tokyo, JP, 13Universidad de La Frontera, James Lind Cancer Research Center,
Temuco, CL, 14Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 15IOV -
Istituto Oncologico Veneto IRCCS, Padova, IT, 16Merck & Co., Inc., Rahway, US, 17Seoul
National University College of Medicine, Seoul, KR
14:10 - 14:20 LBA73 - Pathological complete response (pCR) to durvalumab plus 5-

fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric
and gastroesophageal junction cancer (GC/GEJC): interim results of the global,
Phase 3 MATTERHORN study
Y. Janjigian1, S.-E. Al-Batran2, Z. Wainberg3, E. Van Cutsem4, D. Molena1, K. Muro5, W.J.

Hyung6, L. Wyrwicz7, D.-Y. Oh 8, T. Omori9, M. Moehler10, M. Garrido11, S. Cunha Sousa
Oliveira12, M. Liberman13, V. Castro Oliden14, M. Bilici15, J. Kurland16, I. Xynos17, H.
Mann17, J. Tabernero18, 1Memorial Sloan Kettering Cancer Center, New York, US,
2Krankenhaus Nordwest, University Cancer Center, Frankfurt, DE, 3David Geffen School
of Medicine at UCLA, Los Angeles, US, 4University Hospitals Leuven and KU Leuven,
Leuven, BE, 5Aichi Cancer Center Hospital, Nagoya, JP, 6Yonsei University College of
Medicine, Seoul, KR, 7Maria Sklodowska-Curie National Research Institute of Oncology,
Warsaw, PL, 8Seoul National University Hospital; Cancer Research Institute, Seoul
National University College of Medicine, Seoul, KR, 9Osaka International Cancer
Institute, Osaka, JP, 10Johannes Gutenberg-University Clinic, Mainz, DE, 11SAGA Clinical
Trial Centre and Universidad Mayor, Santiago, CL, 12Northern Riograndense League
Against Cancer, Natal, Rio Grande do Norte, BR, 13Centre Hospitalier de l'Université de
Montréal, Centre de Recherche du CHUM, Montreal, CA, 14National Institute of
Neoplastic Diseases (INEN), Lima, PE, 15Atatürk University Faculty of Medicine,
Erzurum, TR, 16AstraZeneca, Gaithersburg, US, 17AstraZeneca, Cambridge, GB, 18Vall
d’Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,
Barcelona, ES
14:20 - 14:30 Invited Discussant LBA74 and LBA73

E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital,
Oxford, GB
14:30 - 14:40 Q&A
14:40 - 14:50 LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active

surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge
cluster randomised trial
B. Van Der Wilk1, B.M. Eyck1, B. Wijnhoven2, S. Lagarde3, C. Rosman4, B.J. Noordman5,
M. Valkema1, P.-P. Coene6, J.-W. Dekker 7, H. Hartgrink8, J. Heisterkamp9, E.
Kouwenhoven10, G. Nieuwenhuijzen11, J.-P. Pierie12, J. Van Sandick13, M. Sosef14, M.
Spaander2, E. Van Der Zaag15, E. Steyerberg8, J. Van Lanschot1, 1Erasmus MC - Erasmus
University Rotterdam, Rotterdam, NL, 2Erasmus MC, Rotterdam, NL, 3Erasmus Medical
Center, Rotterdam, NL, 4Radboud University Medical Center, Nijmegen, NL, 5Erasmus
University Medical Center, Rotterdam, NL, 6Maasstad Ziekenhuis, Rotterdam, NL,
7Reinier de Graaf Hospital (Gasthuis), Delft, NL, 8LUMC-Leiden University Medical
Center, Leiden, NL, 9ETZ - Elisabeth-TweeSteden Hospital, Tilburg, NL,

10Ziekenhuisgroep Twente (ZGT), Almelo, NL, 11Catharina Hospital Eindhoven,
Eindhoven, NL, 12MCL - Medisch Centrum Leeuwarden, Leeuwarden, NL, 13NKI-AVL -
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL,
14Zuyderland Medical Center, Heerlen, NL, 15Gelre Ziekenhuizen, Apeldoorn, NL
14:50 - 15:00 Invited Discussant LBA75

M. Nilsson, Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE
15:00 - 15:10 Q&A
15:10 - 15:20 1511O - Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+
Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma:
Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled
KEYNOTE-811 Study
Y. Janjigian1, A. Kawazoe2, Y. Bai3, J. Xu4, S. Lonardi5, J.-P. Metges6, P. Yanez Weber7, L.

Wyrwicz8, L. Shen9, Y. Ostapenko10, M. Bilici11, H.C. Chung12, K. Shitara13, S. Qin14, E.
Van Cutsem15, J. Tabernero16, K. Li17, C.-S. Shih18, P. Bhagia18, S.Y. Rha12, 1Memorial
Sloan Kettering Cancer Center and Weill Cornel Medical College, New York, US,
2National Cancer Center Hospital East, Kashiwa, JP, 3Harbin Medical University
Hospital, Harbin, CN, 4Fifth Medical Center, Chinese PLA General Hospital, Beijing, CN,
5Istituto Oncologico Veneto IOV-IRCCS, Padova, IT, 6University Hospital of Brest, Brest,
FR, 7Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL,
8Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw,
PL, 9Peking University Cancer Hospital & Institute, Beijing, CN, 10Clinic of National
Cancer Institute, Kyiv, UA, 11Atatürk University, Erzurum, TR, 12Yonsei Cancer Center,
Yonsei University College of Medicine, Seoul, KR, 13National Cancer Hospital East,
Kashiwa, JP, 14Cancer Center of People’s Liberation Army, Nanjing, CN, 15University
Hospitals Gasthuisberg and KU Leuven, Leuven, BE, 16Vall d’Hebron Hospital Campus
and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES, 17Merck & Co.
Inc., Rahway, US, 18Merck & Co., Inc., Rahway, US
15:20 - 15:30 Invited Discussant 1511O

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig,
DE
15:30 - 15:40 Q&A
14:00 - 15:45 Type: Proffered Paper session Sevilla Auditorium

Title: Proffered Paper session - Non-metastatic NSCLC and - Hall 9
other thoracic malignancies
Chair(s): Rafal Dziadziuszko, PL; Fiona Blackhall, GB
14:00 - 14:10 1261O - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the
phase 3 CheckMate 816 trial

M. Awad1, P. Forde2, N. Girard3, J. Spicer4, C. Wang5, S. Lu6, T. Mitsudomi7, E. Felip8, S.
Broderick2, S.J. Swanson1, J. Brahmer2, K. Kerr9, G. Saylors10, K.-N. Chen11, J.L. Cai12, J.
Mahmood12, J. Neely12, D. Balli12, N. Hu12, M. Provencio Pulla13, 1Dana-Farber Cancer
Institute, Boston, US, 2The Bloomberg–Kimmel Institute for Cancer Immunotherapy,
Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore,
US, 3Institut Curie, Paris, FR, 4McGill University Health Centre, Montreal, CA, 5Tianjin
Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN,
6Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University,
Shanghai, CN, 7Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP,

8Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, ES,
9Aberdeen Royal Infirmary, Aberdeen, GB, 10Charleston Oncology, Charleston, US,
11Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, 12Bristol
Myers Squibb, Princeton, US, 13Hospital Universitario Puerta de Hierro, Madrid, ES
14:10 - 14:20 LBA56 - Overall survival in the KEYNOTE-671 study of perioperative

pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
J. Spicer1, S. Gao2, M. Liberman3, T. Kato4, M. Tsuboi5, S.-H. Lee6, K.-N. Chen7, C.

Dooms8, M. Majem9, E. Eigendorff10, G. Martinengo11, O. Bylicki12, M. Garassino13, D.
Rodriguez Abreu14, J. Chaft15, S. Novello16, J. Yang17, S. Keller18, A. Samkari18, H.
Wakelee19, 1McGill University, Montréal, CA, 2National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijng, CN, 3Centre Hospitalier de Universite to Montréal
(CHUM), Montreal, CA, 4Kanagawa Cancer Center, Yokohama, JP, 5National Cancer
Center Hospital East, Kashiwa, JP, 6Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, and Department of Health Sciences and
Technology, Samsung Advanced Institute for Health Sciences and Technology,
Sungkyunkwan University, Seoul, KR, 7Peking University Cancer Hospital and Institute,
Beijing, CN, 8UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven,
BE, 9Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 10Zentralklinik Bad Berka
GmbH, Bad Berka, DE, 11Sanatorio Parque, Rosario, AR, 12Hôpital d'Instruction des
Armées Sainte Anne Toulon, Toulon, Cedex, FR, 13Knapp Center for Biomedical
Discovery, The University of Chicago, Chicago, US, 14Hospital Universitario Insular de
Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES,
15Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US,
16University of Turin, A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, IT, 17Merck &
Co., Inc. - Rahway, Rahway, US, 18Merck & Co., Inc., Rahway, US, 19Stanford University
School of Medicine, Stanford Cancer Institute, Stanford, US
14:20 - 14:30 Invited Discussant 1261O and LBA56

J. Naidoo, Beaumont Hospital, Dublin, IE
14:30 - 14:35 Q&A
14:35 - 14:45 LBA60 - Stereotactic body radiation therapy with sequential

immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung
cancer
Z.-R. Zhao1, S. Liu2, T. Zhou1, G. Chen1, Z.-H. Ye3, Z.-C. Li1, J.-D. Wu1, Y. Yang1, M. Xi1, Y.-
B. Lin1, H. Yang1, 1Sun Yat-sen University Cancer Center, Guangzhou, CN, 2Sun Yat-sen

University Cancer Center, Guangzhou, CN, 3The University of Hong Kong - Shenzhen
Hospital, Shenzhen, CN
14:45 - 14:55 1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of

radiochemotherapy (RCT) in patients with inoperable stage III non-small cell
lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label,
randomised, controlled trial.
P. Vera1, F. Le Tinier2, P. Chaumet-Riffaud3, E. Martin4, N. Pourel5, P. Boisselier6, N.

Salem7, C. Le Pechoux8, E. Giroux-Leprieur9, S. Guillerm10, C. Audigier Valette11, D.
Lerouge12, C. Massabeau13, P. Moisson14, A. Larrouy15, S. Hapdey1, A. Langlais16, E.
Amour16, G. Zalcman17, P. Giraud18, S. Thureau1, 1Centre Henri Becquerel, ROUEN, FR,
2Centre Oscar Lambret, Lille, FR, 3Hôpital National des 15-20, Paris, FR, 4Centre
Georges-François Leclerc (Dijon), Dijon, FR, 5Institut Sainte-Catherine, Avignon, Cedex,

FR, 6ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 7Institut Paoli-
Calmettes, Marseille, Cedex, FR, 8Institut Gustave Roussy, Villejuif, Cedex, FR,
9University Paris-Saclay, UVSQ, APHP – Ambroise Paré Hospital, Boulogne-Billancourt,
FR, 10Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Paris, FR, 11CHITS
Toulon Sainte-Musse, Toulon, FR, 12Centre Francois Baclesse, Caen, Cedex, FR,
13Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR, 14Hopital René
Huguenin - Institut Curie, Saint-Cloud, FR, 15ICPN - Centre de Cancerologie Paris Nord,
Sarcelles, FR, 16French Cooperative Thoracic Intergroup, Paris, FR, 17Hopital Bichat -
Claude-Bernard AP-HP, Paris, FR, 18HEGP - Hopital Europeen Georges-Pompidou - AP-HP,
Paris, FR
14:55 - 15:05 Invited Discussant LBA60 and 1291O

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL
15:05 - 15:10 Q&A
15:10 - 15:20 LBA98 - Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in
untreated metastatic thymic carcinoma: RELEVENT phase II trial
C. Proto1, S. Manglaviti1, G. Galli1, M. Imbimbo2, M.F. Alvisi3, F. Zollo3, M. Perrino4, M.

Giuliano5, E. Pietroluongo5, Z. Ballatore6, A. Chella7, A. Fabbri1, R. Vigorito1, F.G.M. De
Braud8, G. Pasello9, I. Petrini7, R. Berardi10, P. Zucali4, M. Ganzinelli1, M. Garassino11, G.
Lo Russo1, 1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, 2Fondazione
IRCCS Istituto Nazionale dei Tumori, CHUV - Centre Hospitalier Universitaire Vaudois,
Lausanne, CH, 3Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT,
4IRCCS Humanitas Research Hospital, Rozzano, IT, 5AOU "Federico II", Napoli, IT, 6AOU
delle Marche, Torrette di Ancona, IT, 7AOU Pisana - Stabilimento di Santa Chiara, Pisa,
IT, 8Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Milano, Milan, IT,
9University of Padova Medical School, Padova, Italy; Medical Oncology 2, Veneto
Institute of Oncology IOV-IRCCS, Padova, IT, 10Università Politecnica delle Marche, AOU
delle Marche, Ancona, IT, 11Fondazione IRCCS Istituto Nazionale dei Tumori, The
University of Chicago, Chicago, US
15:20 - 15:30 LBA92 - Tarlatamab for patients (pts) with previously treated small cell lung
cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study

L. Paz-Ares1, M.-J. Ahn2, E. Felip3, S. Handzhiev4, I. Korantzis5, H. Izumi6, K. Ohashi7, M.
Majem8, J. Wolf9, M. Reck10, H.-D. Hummel11, F. Blackhall12, A.-M. Dingemans13, T.
Owonikoko14, S. Ramalingam15, J. Sands16, T. Jiang17, S. Mukherjee17, E. Anderson17,
B.C. Cho18, 1Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO-
H12o Lung Cancer Unit and Ciberonc, Madrid, ES, 2Samsung Medical Center (SMC) -
Sungkyunkwan University School of Medicine, Seoul, KR, 3Vall d'Hebron University
Hospital, Barcelona, ES, 4Universitätsklinikum Krems, Krems an der Donau, AT, 5St
Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, 6National Cancer Center Hospital
East, Kashiwa, JP, 7Okayama University Hospital, Okayama, JP, 8Hospital de la Santa
Creu i Sant Pau, Barcelona, ES, 9Universitätsklinikum Köln (AöR), Cologne, DE, 10Airway
Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf,
Grosshansdorf, DE, 11Universitätsklinikum Würzburg, Comprehensive Cancer Center
Mainfranken, Wuerzburg, DE, 12The Christie NHS Foundation Trust, Manchester, GB,
13Erasmus MC Cancer Institute, University Medical Center, Rotterdam, NL, 14UPMC
Hillman Cancer Center, Pittsburgh, US, 15Winship Cancer Institute of Emory University,
Atlanta, US, 16Dana-Farber Cancer Institute, Harvard Medical School, Boston, US,
17Amgen Inc., Thousand Oaks, US, 18Yonsei Cancer Centre, Yonsei University College of
Medicine, Seoul, KR

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES
15:40 - 15:45 Q&A
14:00 - 15:40 Type: Proffered Paper session Bilbao Auditorium -

Title: Proffered Paper session - Breast cancer, early NCC
stage
Chair(s): Stephen Johnston, GB; Sara Tolaney, US
14:00 - 14:10 LBA17 - Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk
early breast cancer: results from a preplanned monarchE overall survival interim
analysis, including 5-year efficacy outcomes
N. Harbeck1, P. Rastogi2, J. O'Shaughnessy3, F. Boyle4, J. Cortés5, H. Rugo6, M. Goetz7,

E. Hamilton8, C. Huang9, E. Senkus-Konefka10, A. Tryakin11, P. Neven12, J. Huober13, R.J.
Wei14, V. Andre14, M. Muñoz14, B. San Antonio14, A. Shahir14, M. Martin Jimenez15, S.
Johnston16, 1Ludwig Maximilians University Hospital, Munich, DE, 2University of
Pittsburgh Medical Center, Pittsburgh, US, 3Baylor University Medical Center, Dallas,
US, 4University of Sydney, Sydney, AU, 5Hospital Ruber Internacional, Madrid, ES,
6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, 7Mayo
Clinic, Rochester, US, 8Sarah Cannon Research Institute-Cancer Centre, Nashville, US,
9NTUH - National Taiwan University Hospital, Taipei City, TW, 10Medical University of
Gdansk, Gdansk, PL, 11Altai Branch of N. N. Blokhin Russian Cancer Research Centre,
Barnaul, RU, 12University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE,
13Kantonsspital St. Gallen, St. Gallen, CH, 14Eli Lilly and Company, Indianapolis, US,
15Gregorio Marañón General University Hospital, Madrid, ES, 16Royal Marsden NHS
Foundation Trust, London, GB
14:10 - 14:20 LBA18 - Pembrolizumab or placebo plus chemotherapy followed by

pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the
phase 3 KEYNOTE-522 study
P. Schmid1, J. Cortés2, R. Dent3, L. Pusztai4, H. Mcarthur5, S. Kummel6, C. Denkert7, Y.H.

Park8, R. Hui9, N. Harbeck10, M. Takahashi11, T. Foukakis12, M.A. Mouret Reynier13, M.
Ferreira14, S.-A. Im15, F. Cardoso16, Y. Ding17, W. Pan17, K. Tryfonidis17, J.
O'Shaughnessy18, 1Barts Cancer Institute, Queen Mary University of London, London,
GB, 2Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Faculty
of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, 3Duke –
National University of Singapore Medical School, Singapore, SG, 4Yale Cancer Center,
New Haven, US, 5University of Texas Southwestern Medical Center, Dallas, US, 6Kliniken
Essen-Mitte, Essen, Germany and Charité – Universitätsmedizin Berlin, Department of
Gynecology with Breast Center, Berlin, DE, 7Philipps-University Marburg and University
Hospital Marburg, Marburg, DE, 8Sungkyunkwan University School of Medicine, Seoul,
KR, 9Westmead Hospital and the University of Sydney, Sydney, NSW, Australia and
Centre of Cancer Medicine, School of Clinical Medicine, University of Hong Kong, Hong
Kong, HK, 10LMU University Hospital, Munich, DE, 11Hokkaido University Hospital,
Sapporo, JP, 12Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska
University Hospital, Solna, SE, 13Centre Jean Perrin, Clermont-Ferrand, FR, 14Instituto
Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, PT, 15Seoul
National University Hospital, Seoul, KR, 16Champalimaud Clinical Center/Champalimaud
Foundation, Lisbon, PT, 17Merck & Co., Inc., Rahway, US, 18Texas Oncology, US Oncology
Network, Dallas, US
14:20 - 14:30 LBA19 - Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin

with or without atezolizumab followed by an adjuvant anthracycline regimen in
high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo
randomized study
L. Gianni1, C. Huang2, D. Egle3, B. Bermejo4, C. Zamagni5, M. Thill6, A. Anton Torres7, G.

Bianchini8, E. Sevillano Fernandez9, S. Russo10, E. Ciruelos11, R. Greil12, V.
Semiglazov13, M. Colleoni14, C. Kelly15, G. Mariani16, L. Del Mastro17, R. Spezia1, H.
Ali18, G. Viale14, 1Fondazione Michelangelo, Milan, IT, 2National Taiwan University
Hospital and Taiwan Breast Cancer Consortium, Taipei, TW, 3BrustGesundheitZentrum
Tirol, Medical University, Innsbruck, AT, 4Hospital Clínico Universitario de Valencia,
INCLIVA; Department of Medicine, Universidad de Valencia; CIBERONC-ISCIII, Madrid,
ES, 5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, 6Agaplesion
Markus Krankenhaus,, Frankfurt am Main, DE, 7Hospital Universitario Miguel Servet
Instituto Investigación Sanitaria de Aragon Universidad de Zaragoza, Zaragoza, ES,
8IRCCS San Raffaele Hospital, Milan, IT, 9Hospital Universitario HM Sanchinarro, Centro
Integral Oncológico Clara Campal, Unidad Central de Ensayos Clínicos, Madrid, ES,
10Azienda Sanitaria Friuli Centrale, Udine, IT, 11Hospital Universitario 12 de octubre,
Madrid, ES, 12Paracelsus Medical University; Salzburg Cancer Research Institute-CCCIT

and Cancer cluster, Salzburg, AT, 13NN Petrov Research Inst of Oncology, Saint-
Petersburg, RU, 14IEO Istituto Europeo di Oncologia IRCCS, Milan, IT, 15Cancer Trials
Ireland & Mater Misericordiae University Hospital, Dublin, IE, 16IRCCS Istituto
Nazionale Tumori, Milan, IT, 17IRCCS Ospedale Policlinico San Martino, Università degli
Studi di Genova, Genova, IT, 18Cancer Research UK Cambridge Institute, University of
Cambridge, Cambridge, GB
14:30 - 14:45 Invited Discussant LBA17, LBA18 and LBA19

K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US

14:45 - 14:55 Q&A
14:55 - 15:05 LBA20 - A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO)
with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy
(ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer
(BC)
S. Loi1, G. Curigliano2, R. Salgado3, R.I. Romero Diaz4, S. Delaloge5, C. Rojas6, M. Kok7,

C. Saura Manich8, N. Harbeck9, E. Mittendorf10, D. Yardley11, L. Pusztai12, A. Suarez
Zaizar13, A. Ungureanu14, F. Ades15, R. Chandra16, R. Nathani17, M. Pacius16, J. Wu16,
H. Mcarthur18, 1Peter MacCallum Cancer Centre, Melbourne, AU, 2European Institute of
Oncology, IRCCS; University of Milano, Milan, IT, 3GZA Ziekenhuizen Campus Sint-
Augustinus, Wilrijk, BE, 4Consultorio de Oncólogo Médico, Tlalnepantla de Baz, MX,
5Institut Gustave Roussy, Villejuif, FR, 6Bradford Hill, Independencia, CL, 7Netherlands
Cancer Institute, Amsterdam, NL, 8Vall d'Hebron University Hospital, Barcelona, ES,
9Ludwig Maximilians University Hospital, Munich, DE, 10Dana Farber/Brigham and
Women's Cancer Center, Boston, US, 11Sarah Cannon Research Center and Tennessee
Oncology, Chattanooga, US, 12Smilow Cancer Hospital at Yale University School of
Medicine, New Heaven, US, 13CENEIT Oncologicos, Ciudad de Mexico, MX, 14Amethyst
Radiotherapy Center Cluj, Floresti, RO, 15Bristol-Myers Squibb, Lawrenceville, US,
16BMS - Bristol-Myers Squibb, Cambridge, US, 17Bristol Myers Squibb, Cambridge, US,
18University of Texas Southwestern Medical Center, Dallas, US
15:05 - 15:15 LBA21 - KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro)

or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo
+ endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
F. Cardoso1, H. Mcarthur2, P. Schmid3, J. Cortés4, N. Harbeck5, M. Telli6, D. Cescon7, J.

O'Shaughnessy8, P. Fasching9, Z. Shao10, D. Loirat11, Y.H. Park12, M. González
Fernández13, Z. Liu14, H. Yasojima15, Y. Ding16, L. Jia16, V. Karantza16, K. Tryfonidis16, A.
Bardia17, 1Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, PT,
2University of Texas Southwestern Medical Center, Dallas, US, 3Barts Cancer Institute,
Queen Mary University of London, London, GB, 4Quironsalud Group, Barcelona, Spain
and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences,
Department of Medicine, Madrid, ES, 5LMU University Hospital, Munich, DE, 6Stanford
University School of Medicine, Stanford, US, 7Princess Margaret Cancer Centre, Toronto,
CA, 8Texas Oncology, US Oncology Network, Dallas, US, 9Comprehensive Cancer Center
Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Erlangen, DE, 10Fudan
University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College,
Fudan University, Shanghai, CN, 11Institut Curie, Paris, FR, 12Sungkyunkwan University
School of Medicine, Seoul, KR, 13IMAT-Oncomedica, Montería, CO, 14Henan Breast
Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer
Hospital, Zhengzhou, Henan, CN, 15NHO Osaka National Hospital, Osaka, JP, 16Merck &
Co., Inc., Rahway, US, 17Harvard Medical School, Boston, US

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
15:25 - 15:40 Q&A

14:00 - 15:30 Type: Educational session Granada Auditorium -
Title: Optimising overall survival in advanced renal Hall 3
cancer
Chair(s): Cristina Suarez Rodriguez, ES; Thomas Powles, GB
14:00 - 14:25 Evolving frontline treatment paradigms

T. Choueiri, Dana Farber Cancer Institute, Boston, US
14:25 - 14:50 What is the role of localised therapies in metastatic RCC?

A. Bex, Royal Free London NHS Foundation Trust, London, GB
14:50 - 15:15 Data from sequencing trials and new therapeutic targets
C. Suarez Rodriguez, Vall d'Hebron University Hospital, Barcelona, ES
15:15 - 15:30 Discussion
14:00 - 15:30 Type: Educational session Burgos Auditorium -

Title: Therapeutic view on tumour immune Hall 3
microenvironment: It's TIME
Chair(s): Tanja de Gruijl, NL; Gary Middleton, GB
14:00 - 14:20 Immune suppressive cell populations in TME

V. Bronte, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
14:20 - 14:40 Site specific TME

W. Zou, Michigan Medicine University of Michigan, Ann Arbor, US
14:40 - 15:00 How tumour-draining lymph nodes inform the content of the TME and vice versa
T. De Gruijl, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL
15:00 - 15:20 Modulating TME to overcome primary and acquired resistance

S. Zelenay, Cancer Research UK Manchester Institute, Manchester, GB
15:20 - 15:30 Q&A and Discussion

14:00 - 15:30 Type: Educational session Salamanca Auditorium
Title: First-line therapy in advanced melanoma: What is - Hall 3
my preferred choice?
Chair(s): Teresa Petrella, CA; Reinhard Dummer, CH
14:00 - 14:25 My preferred choice is PD-1 monotherapy, and these are the reasons why
T. Petrella, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA
14:25 - 14:50 My preferred choice is combined immunotherapy with PD1+CTLA-4, and these
are the reasons why
A.M. Arance Fernandez, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
14:50 - 15:15 I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons
why
R. Dummer, USZ - University Hospital Zürich, Zurich, CH
14:00 - 15:30 Type: Educational session Santander

Title: Neuro-Oncology 101: All you need to know to take Auditorium - Hall 9
care of brain tumour patients
Chair(s): Matthias Holdhoff, US; Emeline Tabouret, FR
14:00 - 14:20 WHO classification simplified for the busy clinician

M. Holdhoff, Johns Hopkins University, Baltimore, US
14:20 - 14:40 Glioma beyond TMZ/RT

E. Galanis, Mayo Clinic - Rochester, Rochester, US
14:40 - 15:00 Brain metastases: When radiation is (not!) indicated

S. Lukacova, Aarhus University Hospital, Aarhus, DK
15:00 - 15:20 Supportive care: Antiepileptics, steroids and anticoagulation

A. Pace, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT
14:00 - 15:30 Type: Special session Oviedo Auditorium - Hall 7

Title: Women for Oncology

14:00 - 15:30 Type: Special session León Auditorium
Title: In collaboration with SIOG: Fundamentals in geriatric - Hall 7
oncology in clinical practice
Chair(s): Ravindran Kanesvaran, SG; Etienne Brain, FR
14:00 - 14:20 Geriatric assessment: It is primetime now?

L. Biganzoli, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato,
IT
14:20 - 14:40 Optimizing oncologic care in older patients with advanced lung cancer
E. Quoix, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR
14:40 - 15:00 Optimizing oncologic care in older patients with advanced breast cancer
E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR
15:00 - 15:20 Optimizing oncologic care in older patients with advanced colorectal cancer
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

14:00 - 15:30 Type: Patient Advocacy session Cádiz
Title: The importance to address the caregivers’ needs: The Auditorium -
perspective of the caregivers NCC
Chair(s): Bettina Ryll, SE; Katie Rizvi, RO
14:00 - 14:15 Caregiver? Carer? Who are they?

S. Yghemonos, Eurocarers, Brussels, BE
14:15 - 14:30 Caregivers’ needs along the patient journey: What do oncologists need to know?
B. Ryll, Melanoma Patient Network Europe MPNE, Uppsala, SE
14:30 - 14:45 Caregivers’ needs along the patient journey: What do nurses need to know?
K. Rizvi, YCE - Youth Cancer Europe, Cluj-Napoca, RO
14:45 - 15:00 Caregivers after patient end of life: The caregivers’ role continues…as do their
needs!
S. Chaturvedi, King's College Hospital - NHS Foundation Trust, London, GB
15:00 - 15:15 Cancer patient groups and their help to support caregivers: Guide for healthcare
professionals
M. Leal, Portuguese League Against Cancer, Lisbon, PT
15:25 - 15:45 Conclusion

14:00 - 15:30 Type: Special session Ávila Auditorium - NCC
Title: ESMO-MCBS: 2023 revolution
Chair(s): Nathan Cherny, IL; Dario Trapani, IT
14:00 - 14:05 Introduction

D. Trapani, Università degli Studi di Milano, Milan, IT
14:05 - 14:30 A guide through the new ESMO-MCBS v2.0

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL
14:30 - 14:55 ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-

MCBS:H)
B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna,
AT
14:55 - 15:20 Setting International Standards in Analysing Patient-Reported Outcomes and

Quality of Life Endpoints (SISAQOL-IMI): Two years update
M. Pe, EORTC, Brussels, BE
15:20 - 15:30 Conclusions and perspectives, discussion and Q&A

14:15 - 15:00 Type: Challenge your Expert Valencia Auditorium

Title: First-line treatment of EGFR mutated NSCLC: - Hall 10
Choosing between many options
Chair(s): Enriqueta Felip, ES
14:15 - 14:30 Presentation by Expert EGFR

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US
14:30 - 14:45 Presentation by Expert ALK

G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
14:45 - 15:00 Discussion led by Chair

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

14:15 - 15:30 Type: Multidisciplinary session Málaga
Title: Integrating locoregional strategies into the management Auditorium -
of metastatic breast cancer (mBC) patients Hall 10
Chair(s): Lisa Carey, US; Adam Sonabend, US
14:15 - 14:20 Presentation of case with extra cranial met / condition

M. Banys- Paluchowski, UKSH - Universitätsklinikum Schleswig-Holstein - Campus
Lübeck, Lübeck, DE
14:20 - 14:35 Integrating locoregional and systemic therapies for non-CNS metastatic disease
A. Kirby, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
14:35 - 14:40 Presentation of case with CNS met / condition

A. Fitzpatrick, King's College London, London, GB
14:40 - 14:55 Integrating locoregional and systemic therapies for CNS metastatic disease
T. Bachelot, Centre Léon Bérard, Lyon, FR
14:55 - 15:10 Beyond medical oncology in the management of metastatic disease: When to
involve a surgeon or a radiation doctor or interventional radiologist
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine,
Chapel Hill, US
14:15 - 15:00 Type: Challenge your Expert Toledo

Title: East meets West in the management of head and neck Auditorium - Hall
cancer: Learning from each other 3
Chair(s): Jean-Pascal Machiels, BE
14:15 - 14:35 Presentation by Expert

B. Keam, Seoul National University Hospital, Seoul, KR

J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-
Lambert, BE
16:00 - 17:30 Type: Proffered Paper session Barcelona Auditorium - Hall 9

Title: Proffered Paper session - NSCLC,
metastatic
Chair(s): Marina Garassino, US
16:00 - 16:10 LBA63 - SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus
Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-
Small Cell Lung Cancer (NSCLC)

H. Borghaei1, M. Johnson2, E. Garon3, K. He4, D. Planchard5, M. Reck6, S. Popat7, R.S.
Herbst8, T. Leal9, D. Dumoulin10, F. De Marinis11, C. Reynolds12, W. Theelen13, I.
Percent14, V. Gutierrez Calderon15, A.-C. Madroszyk Flandin16, R. Shazer17, X. Yan17, R.
Harrigan17, S. Peters18, 1Fox Chase Cancer Center, Philadelphia, US, 2Sarah Cannon
Research Institute, Tennessee Oncology, Nashville, US, 3University of California, Los
Angeles, US, 4The Ohio State University, Columbus, US, 5Institut Gustave Roussy,
Villejuif, FR, 6LungenClinic Grosshansdorf, Grosshansdorf, DE, 7The Royal Marsden
Hospital NHS Foundation Trust, London, GB, 8Yale University, New Haven, US, 9Emory
University, Atlanta, US, 10Erasmus Medisch Centrum, Rotterdam, NL, 11European
Institute of Oncology, IRCC, Milan, IT, 12Florida Cancer Specialists and Research
Institute - North Region (SCRI), Ocala, US, 13Netherlands Cancer Institute, Amsterdam,
NL, 14Florida Cancer Specialists and Research Institute - South Region (SCRI), Fort
Myers, US, 15Hospital Regional Universitario de Malaga, Malaga, ES, 16Institut Paoli-
Calmettes, Marseille, FR, 17Mirati Therapeutics, Inc., San Diego, US, 18Centre
Hospitalier Universitaire Vaudois, Lausanne, CH
16:10 - 16:20 LBA64 - Overall Survival from a Phase II Randomised Double-Blind Trial
(PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab
(pembro) + CT in Metastatic Non-Squamous NSCLC
S. Peters1, A.L. Ortega Granados2, F. De Marinis3, G. Lo Russo4, M. Schenker5, E.

Arriola6, J. Puig7, D.H. Lee8, M. Reck9, Z. Szijgyarto10, E. Buss11, N. Stjepanovic11, S.M.
Lim12, 1Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, CH,
2Hospital Universitario de Jaén, Jaén, ES, 3Istituto Europeo di Oncologia (IRCCS), Milan,
IT, 4Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 5Policlinica Sf. Nectarie,
Centrul de Oncologie, Craiova, RO, 6Hospital del Mar, Parc de Salut Mar, Barcelona, ES,
7Centro Polivalente de Asistencia e Investigación Clínica, CER San Juan, San Juan, AR,
8University of Ulsan, College of Medicine, Asan Medical Center, Seoul, KR, 9Lungen
Clinic, Airway Research Center North, Center for Lung Research, Grosshansdorf, DE,
10GSK, Stevenage, GB, 11GSK, Baar, CH, 12Yonsei Cancer Center, Severance Hospital,
Yonsei University College of Medicine, Seoul, KR

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
16:30 - 16:40 Q&A
16:40 - 16:50 LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in
patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC)
harboring a KRASG12C mutation
M. Garassino1, W. Theelen2, R. Jotte3, J. Laskin4, F. De Marinis5, C. Aguado6, F. Badin7, I.

Chmielewska8, M. Hochmair9, S. Lu10, E. Nadal11, G. Ostoros12, E. Felip13, A. Spira14, C.
Lane15, J. He15, R. Chao15, P. Jänne16, 1The University of Chicago, Chicago, US, 2The
Netherlands Cancer Institute, Amsterdam, NL, 3Rocky Mountain Cancer Centers,
Greenwood Village, US, 4BC Cancer Vancouver Centre, University of British Columbia,
Vancouver, CA, 5Istituto Europeo di Oncologia, Milan, IT, 6Hospital Universitario Clínico
San Carlos, Madrid, ES, 7Baptist Health Medical Group, Lexington, US, 8Medical
University of Lublin, Lublin, PL, 9Karl Landsteiner Institute for Lung Research and
Pulmonary Oncology, Vienna, AT, 10Shanghai Lung Cancer Center, Shanghai Jiao Tong

University, Shanghai, CN, 11Institut Català d'Oncologia (ICO), Barcelona, ES, 12National
Korányi Institute of Pulmonology, Budapest, HU, 13Vall d'Hebron University Hospital,
Barcelona, ES, 14Virginia Cancer Specialists, Fairfax, VA; US Oncology Research, The
Woodlands, US, 15Mirati Therapeutics, Inc., San Diego, US, 16Dana Farber Cancer
Institute, Boston, US
16:50 - 17:00 LBA66 - Afatinib versus chemotherapy for treatment-naïve non-small cell lung
cancer with a sensitizing uncommon epidermal growth factor receptor mutation:
a phase III study (ACHILLES/TORG1834)
S. Miura1, H. Tanaka1, T. Misumi2, H. Yoshioka3, T. Kurata3, T. Tokito4, T. Fukuhara5, Y.

Sato6, Y. Shiraishi7, S. Kusuhara8, S. Teraoka9, T. Kato10, H. Horinouchi11, Y. Takiguchi12,
Y. Goto13, K. Tanaka14, M. Kanazu15, S. Ikeda16, E. Ichihara17, H. Okamoto18, 1Niigata
Cancer Center Hospital, Niigata, JP, 2Yokohama City University Hospital, Yokohama, JP,
3Kansai Medical University, Hirakata, JP, 4Kurume University, Kurume, JP, 5Miyagi
Cancer Center, Natori, JP, 6Kobe City Medical Center General Hospital, Kobe, JP, 7Kyushu
University Hospital, Fukuoka, JP, 8Kitasato University Hospital, Sagamihara, JP,
9Wakayama Medical University, Wakayama, JP, 10Kanagawa Cancer Center, Yokohama, JP,
11National Cancer Center - Tsukiji Campus, Chuo-ku, JP, 12Chiba University, School of
Medicine, Chiba, JP, 13Fujita Health University, Toyoake, JP, 14Kyushu university hospital,
Fukuoka, JP, 15National Hospital Organization Toneyama Hospital, Toyonaka, JP,
16Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, 17Okayama
University Hospital, Okayama, JP, 18Yokohama Municipal Citizen's Hospital, Yokohama, JP
17:00 - 17:10 LBA67 - A Phase 3, Randomized study of atezolizumab plus bevacizumab and
chemotherapy in patients with EGFR or ALK mutated in non-small cell lung
cancer (ATTLAS, KCSG-LU19-04)
M.-J. Ahn1, S. Park2, T.M. Kim3, J.-Y. Han 4, G.-W. Lee 5, B. Shim6, Y.-G. Lee7, S.-W. Kim 8, I.-
H. Kim9, S. Lee10, Y.J. Kim11, J.H. Park12, S.G. Park13, K. Lee14, E.J. Kang15, J.W. Kim16,
S.-H. Shin17, 1Samsung Medical Center (SMC) - Sungkyunkwan University School of
Medicine, Seoul, KR, 2Samsung Medical Center, Seoul, KR, 3Seoul National University -
College of Medicine - Yeongeon Medical Campus, Seoul, KR, 4National Cancer Center -
Graduate School of Cancer Science and Policy, Goyang, KR, 5Gyeongsang National
University Hospital and Gyeongsang National University School of Medicine, Jinju, KR,
6The Catholic University of Korea - St. Vincent's Hospital, Suwon, KR, 7Samsung Medical
Center (SMC)-Kangbuk Samsung Hospital, Seoul, KR, 8Asan Medical Center - University
of Ulsan, Seoul, KR, 9Inje University Haeundae Paik Hospital, Busan, KR, 10Dong-A
University Medical Center, Busan, KR, 11SNUBH - Seoul National University Bundang
Hospital, Seongnam, KR, 12Konkuk University Medical Center, Seoul, KR, 13Chosun
University Hospital, Gwangju, KR, 14Chungbuk National University Hospital, Cheongju,
KR, 15Korea University Guro Hospital, Seoul, KR, 16Korea University Anam Hospital,
Seoul, KR, 17Kosin Univeristy Gospel Hospital, Busan, KR
17:10 - 17:20 Invited Discussant LBA65, LBA66 and LBA67

F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB
17:20 - 17:30 Q&A

16:00 - 17:30 Type: Proffered Paper session Sevilla Auditorium - Hall
Title: Proffered Paper session 1 - Gynaecological 9
cancers
Chair(s): David SP Tan, SG; Ana Oaknin, ES
16:00 - 16:10 LBA36 - Efficacy and Safety of Senaparib as Maintenance Treatment in Patients
with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A
Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
X. Wu1, J. Liu2, X. Wang3, J. Wang4, L. Wang5, J. Zhu6, B. Kong7, J. Fei8, Y. Tang9, B. Xia10,
Z. Liang11, K. Wang12, Z. Lin13, Y. Huang14, H. Zheng15, A. Lin16, K. Jiang17, W. Wang18,
X. Wang19, G. Lou20, 1Fudan University Shanghai Cancer Center, Shanghai, CN, 2Sun
Yat-sen University Cancer Center, Guangzhou, CN, 3Liaoning Cancer Hospital &
Institute, Shenyang, CN, 4Hunan Cancer Hospital, Changsha, CN, 5Henan Cancer
Hospital, Zhengzhou, CN, 6Cancer hospital of the University of Chinese Academy of
Sciences (Zhejiang Cancer Hospital), Hanghou, CN, 7Qilu Hospital of Shandong
University, Jinan, CN, 8The First Hospital of Jilin University, Changchun, CN, 9Chongqing
University Cancer Hospital, Chongqing, CN, 10Anhui Provincial Cancer Hospital aka West
Branch of Anhui Province Hospital, Hefei, CN, 11South West Hospital, Third Military
Medical University, Chongqing, CN, 12TMUCIH - Tianjin Medical University Cancer
Institute and Hospital, Tianjin, CN, 13The Second Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, CN, 14Hubei Cancer Hospital, Wuhan, CN, 15Beijing Cancer
Hospital, Beijing, CN, 16Fujian Provincial Cancer Hospital, Fuzhou, CN, 17The Second
Affiliated Hospital of Dalian Medical University, Dalian, CN, 18The First Affiliated
Hospital of Guangzhou Medical University, Guangzhou, CN, 19Zhongshan Hospital
Xiamen University, Xiamen, CN, 20Harbin Medical University Cancer Hospital, Harbin,
CN
16:10 - 16:20 LBA37 - Atezolizumab (atezo) combined with platinum-based chemotherapy (CT)
and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-
free interval (TFIp) >6 months: Primary analysis of the double-blind placebo
(pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial
A. Gonzalez Martin1, M.J. Rubio Perez2, F. Heitz3, R.D. Christensen4, N. Colombo5, T. Van
Gorp6, A. Oaknin7, A. Leary8, L. Gaba Garcia9, C. Lebreton10, L.M. De Sande González11,
M. Romeo Marin12, A. Redondo13, M.P. Barretina Ginesta14, J.A. Perez Fidalgo15, A.
Santaballa Bertran16, M.J. Bermejo-Pérez17, I. Bruchim18, I. Ray-Coquard19, F. Selle20,
1Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN),
Madrid, ES, 2Reina Sofía University Hospital of Cordoba, Cordoba, ES, 3KEM | Evang.
Kliniken Essen-Mitte gGmbH, Essen, DE, 4Copenhagen University Hospital, Copenhagen,
DK, 5Department of Medicine and Surgery, University of Milan-Bicocca, Milan, IT,
6University Hospital Leuven, Leuven Cancer Institute, Leuven, BE, 7Vall d'Hebron
Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, ES, 8Gustave
Roussy, Villejuif, FR, 9Hospital Clinic and Translational Genomics and Targeted Therapies
in Solid Tumors, IDIBAPS, Barcelona, ES, 10Institut Bergonié – Centre Régional de Lutte
Contre le Cancer (CLCC), Bordeaux, FR, 11Complejo Asistencial Universitario de León -
Hospital de León, León, ES, 12Institut Català d'Oncologia, Badalona, ES, 13Hospital
Universitario La Paz-IdiPAZ, Madrid, ES, 14Institut Català d’Oncologia, IDIBGI, Girona,
ES, 15Hospital Clinico Universitario de Valencia, Valencia, ES, 16Hospital Universitari i
Politècnic La Fe, Valencia, ES, 17Hospitales Universitarios Regional y Virgen Victoria,
Málaga, ES, 18Hillel Yaffe Medical Center Israel, affiliated with the Ruth and Bruce
Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Hadera, IL,

19Centre Léon Bérard, Lyon, FR, 20Groupe Hospitalier Diaconesses Croix Saint-Simon,
Paris, FR

C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB
16:30 - 16:45 Q&A
16:45 - 16:55 LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced
cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-
3047/KEYNOTE-A18 study
D. Lorusso1, Y. Xiang2, K. Hasegawa3, G. Scambia4, M. Leiva Galves5, P. Ramos Elias6, A.

Acevedo7, J. Vizkeleti8, A.J. Gomes9, F. Contreras Mejia10, A. Reiss11, A. Ayhan12, J.-Y.
Lee13, V. Saevets14, F. Zagouri15, K. Li16, K. Ussui Yamada16, S. Toker16, S. Pignata17, L.
Duska18, 1Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic
University of Sacred Heart, Rome, IT, 2Peking Union Medical College Hospital, National
Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, CN, 3Saitama
Medical University International Medical Center, Hidaka, Saitama, JP, 4Fondazione
Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred
Heart, Rome, IT, 5Instituto de Oncologia y Radioterapia Clinica Ricardo Palma, Lima, PE,
6Edificio Integra Medical Center, Guatemala City, GT, 7Oncocentro, Valparaiso, CL,
8Centre of Radiotherapy, Budapest, HU, 9Liga Norte Riograndense Contra o Câncer Rio
Grande do Norte, Natal, BR, 10Instituto Nacional de Cancerologia, Bogota, CO,

11Gyneco-oncology Unit, Haifa, IL, 12Başkent University, Ankara, TR, 13Yonsei University
College of Medicine, Seoul, KR, 14Chelyabinsk Regional Clinical Center Oncology and
Nuclear Medicine, Chelyabinsk, RU, 15Alexandra Hospital, Athens, GR, 16Merck & Co.,
Inc., Rahway, US, 17 Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT,
18University of Virginia School of Medicine, Charlottesville, US
16:55 - 17:05 LBA39 - Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-

3030), a randomised phase 3 trial of first-line atezolizumab (atezo) combined
with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB),
persistent or recurrent cervical cancer (R/M CC)
A. Oaknin1, L. Gladieff2, J. Martinez-Garcia3, G. Villacampa4, M. Takekuma5, U. De

Giorgi6, K. Lindemann7, L. Woelber8, N. Colombo9, L. Duska10, A. Leary11, A. Godoy
Ortiz12, S. Nishio13, A. Angelergues14, M.J. Rubio Perez15, L. Fariñas Madrid16, S.
Yamaguchi17, D. Lorusso18, V. D'Hondt19, L. Randall20, 1Vall d'Hebron Institute of
Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, ES, 2Oncopole
Claudius Regaud, IUCT, Toulouse, FR, 3Hospital Clínico Universitario Virgen de la
Arrixaca, El Palmar, ES, 4Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast
Cancer Research Group, Barcelona, ES, 5Shizuoka Cancer Center, Shizuoka, JP, 6IRCCS
Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, IT, 7Oslo
University Hospital, Oslo, NO, 8Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE,
9Department of Medicine and Surgery, University of Milan-Bicocca, Milan, IT,
10University of Virginia Cancer Center, Charlottesville, US, 11Gustave Roussy, Villejuif,
FR, 12Hospital Regional Universitario Málaga Carlos Haya, Málaga, ES, 13Kurume
University, Kurume, JP, 14Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, FR,
15Hospital Universitario Reina Sofía, Cordoba, ES, 16Vall d'Hebron Institute of Oncology

(VHIO), Barcelona, ES, 17Hyogo Cancer Center, Akashi, JP, 18Fondazione Policlinico
Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, 19Institut du Cancer de
Montpellier, Montpellier, FR, 20VCUHealth, Richmond, US

B. Monk, The University of Arizona, Tucson, US
17:15 - 17:30 Q&A
16:00 - 17:30 Type: Special symposium Bilbao Auditorium - NCC

Title: HER2 positive gastroesophageal cancer
Chair(s): Elizabeth Smyth, GB; Sylvie Lorenzen, DE
16:00 - 16:05 Introduction and scientific background

Oxford, GB
16:05 - 16:20 Novel therapies in HER2 in advanced gastroesophageal cancer

Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
16:20 - 16:35 Targeting HER2 in operable gastroesophageal cancer

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig,
DE
16:35 - 16:50 Lessons from the biology of HER2 positive gastroesophageal cancer
H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL
16:50 - 17:05 HER2 and beyond: What’s next?

K. Shitara, National Cancer Center Hospital East, Kashiwa, JP
17:25 - 17:30 Conclusions and perspectives

S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE
16:00 - 17:20 Type: Proffered Paper session Granada Auditorium -

Title: Proffered Paper session - Genitourinary tumours, Hall 3
prostate
Chair(s): Shahneen Sandhu, AU
16:00 - 16:10 1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final
Results of RADICALS RT Randomised Controlled Trial [NCT00541047]
C. Parker1, N. Clarke2, A. Cook3, H. Kynaston4, P. Meidahl Petersen5, W. Cross6, R.

Persad7, C. Catton8, J. Logue9, H. Payne10, F. Saad11, K. Brasso12, C. Heath13, H.
Lindberg14, R. Raman15, M.A. Røder12, A. Zarkar16, W. Parulekar17, M. Parmar18, M.
Sydes3, 1The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, 2The
University of Manchester, Manchester, GB, 3Medical Research Council Clinical Trials
Unit, London, GB, 4Cardiff & Vale UHB, Cardiff, GB, 5Copenhagen University,
Copenhagen, DK, 6University of Leeds - Leeds Institute of Molecular Medicine (LIMM),
Leeds, GB, 7University Hospitals Bristol NHS Foundation Trust, Bristol, GB, 8Princess
Margaret Cancer Center, Toronto, CA, 9The Christie NHS Foundation Trust, Manchester,
GB, 10University College London Hospitals NHS Foundation Trust, London, GB,
11Hospital St. Luc du CHUM, Montreal, CA, 12Rigshospitalet, Copenhagen, DK,
13Southampton General Hospital - University Hospital Southampton NHS Trust,
Southampton, GB, 14Herlev and Gentofte Hospital, Herlev, DK, 15Kent Oncology Centre -
Maidstone and Tunbridge NHS Trust, Maidstone, GB, 16Heartlands Hospital - University
Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, 17Canadian Cancer
Trials Group, Kingston, CA, 18MRC - Medical Research Council Clinical Trials Unit -
University College London (UCL), London, GB
16:10 - 16:20 1765O - Interim Results From a Phase 1 Study of AMG 509 (xaluritamig), a
STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic
Castration-Resistant Prostate Cancer (mCRPC)
W. Kelly1, D. Danila2, C.-C. Lin3, J.-L. Lee4, N. Matsubara5, P. Ward6, A. Armstrong7, D.

Pook8, M. Kim9, T. Dorff10, S. Fischer11, Y.-C. Lin12, L. Horvath13, C. Sumey14, Z. Yang15,
G. Jurida15, J. Connarn15, H. Penny15, J. Stieglmaier16, L. Appleman17, 1Thomas Jefferson
University, Philadelphia, US, 2MSKCC - Memorial Sloan Kettering Cancer Center, New
York, US, 3NTUH - National Taiwan University Hospital, Taipei City, TW, 4Asan Medical
Center - University of Ulsan College of Medicine, Seoul, KR, 5National Cancer Center
Hospital East, Kashiwa, JP, 6Oncology Hematology Care, Cincinnati, US, 7Duke Cancer
Center, Durham, US, 8Monash Health - Monash Cancer Centre, Bentleigh East, AU,
9SNUH - Seoul National University Hospital, Seoul, KR, 10City of Hope Comprehensive
Cancer Center, Duarte, US, 11Kantonsspital St. Gallen, St. Gallen, CH, 12Chang Gung
Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, 13Chris
O'Brien Lifehouse, Camperdown, AU, 14Sanford Cancer Center, Sioux Falls, US,
15AMGEN (Headquarters) - USA, Thousand Oaks, US, 16AMGEN Research (Munich)
GmbH, Munich, DE, 17UPMC Hillman Cancer Center, Pittsburgh, US
16:20 - 16:30 Invited Discussant 1764O and 1765O

S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU
16:30 - 16:40 Q&A
16:40 - 16:50 LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-

resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP
1901)
L. Emmett1, S. Subramaniam2, M. Crumbaker3, A. Joshua4, A. Weickhardt5, S.T. Lee6, S.

Ng7, R. Francis8, J. Goh9, D. Pattison9, H. Tan10, I. Kirkwood10, S. Sandhu11, A. Nguyen1,
C. Gedye12, N. Rutherford13, M. Hofman14, A. Martin2, M. Stockler15, I. Davis16, 1St.
Vincent's Hospital, Darlinghurst, AU, 2University of Sydney, Sydney, AU, 3The Kinghorn

Cancer Centre, Sydney, AU, 4St Vincents Hospital Sydney, Sydney, AU, 5Austin Health,
Melbourne, AU, 6Austin Health - Austin Hospital, Heidelberg, AU, 7Sir Charles Gairdner
Hospital, Nedlands, AU, 8University of Western Australia, Perth, AU, 9Royal Brisbane and
Women's Hospital, Herston, AU, 10Royal Adelaide Hospital, Adelaide, AU, 11Peter
MacCallum Cancer Centre, Melbourne, AU, 12Calvary Mater Hospital Newcastle,
Newcastle, AU, 13Hunter New England Health Imaging Service, New Lambton, AU,
14Victorian Comprehensive Cancer Centre, Melbourne, AU, 15University of Sydney,
Camperdown, AU, 16Monash University and Eastern Health, Box Hill, AU
16:50 - 17:00 1770O - Refining risk stratification in patients undergoing radiotherapy (RT)
and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-
PC): an individual patient data (IPD) analysis of randomized controlled trials
(RCTs) from the ICECaP consortium
P. Ravi1, W. Xie1, M. Buyse2, S. Halabi3, P. Kantoff4, O. Sartor5, G. Attard6, N. Clarke7, A.

D'Amico1, J. Dignam8, N. James9, K. Fizazi10, S. Gillessen11, W. Parulekar12, H.
Sandler13, D. Spratt14, M. Sydes15, B. Tombal16, S. Williams17, C. Sweeney18, 1Dana
Farber Cancer Institute, Boston, US, 2International Drug Development Institute, Louvain-
la-Neuve, BE, 3Duke University Medical Center, Durham, US, 4Convergent Therapeutics,
Inc., Cambridge, US, 5Mayo Clinic - Rochester, Rochester, US, 6University College
London, London, GB, 7The Christie and Salford Royal NHS Foundation Trusts,
Manchester, GB, 8NRG Oncology Statistics and Data Management Center, Philadelphia,
US, 9ICR - Institute of Cancer Research, London, GB, 10Institut Gustave Roussy, Villejuif,
Cedex, FR, 11EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
Svizzera Italiana (IOSI), Bellinzona, CH, 12Canadian Cancer Trials Group, Kingston, CA,
13Cedars Sinai Medical Center, Los Angeles, US, 14Case Western Reserve University /
University Hospitals, Cleveland, US, 15Medical Research Council Clinical Trials Unit,
London, GB, 16Cliniques Universitaires St. Luc - Université Catholique de Louvain,
Brussels, BE, 17Peter MacCallum Cancer Center, Melbourne, AU, 18The University of
Adelaide, Adelaide, AU
17:00 - 17:10 Invited Discussant LBA84 and 1770O
17:10 - 17:20 Q&A
16:00 - 17:20 Type: Proffered Paper session Burgos Auditorium -

Title: Proffered Paper session - Supportive and Hall 3
palliative care
Chair(s): Christina Ruhlmann, DK
16:00 - 16:10 2030O - Remote symptom monitoring with electronic patient-reported outcomes
(ePROs) during treatment for metastatic cancer: Results from the PRO-TECT
trial (Alliance AFT-39)
E. Basch1, D. Schrag2, J. Jansen3, B. Ginos4, P. Spears5, M. Jonsson3, P. Carr3, A. Deal3, G.

Thanarajasingam6, B. Reeve7, C. Snyder8, D. Bruner9, D. Cella10, V. Blinder11, L.
Kottschade12, J. Perlmutter13, C. Geoghegan13, G. Mazza6, A. Weiss14, A. Dueck4, 1UNC -
The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US,

2MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, 3University of North
Carolina - Chapel Hill, Chapel Hill, US, 4Mayo Clinic Cancer Center, Phoenix, US, 5UNC -
Lineberger Cancer Center, Chapel Hill, US, 6Mayo Clinic - Rochester, Rochester, US,
7Duke Cancer Center - Duke University Medical Center, Durham, US, 8Johns Hopkins
Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, 9Winship
Cancer Institute of Emory University, Atlanta, US, 10Northwestern University, Chicago,
US, 11Memorial Sloan Kettering Cancer Center, Commack, US, 12Mayo Clinic,
Jacksonville, US, 13Independent, Philadelphia, US, 14University of Rochester Cancer
Center, Rochester, US
16:10 - 16:20 2031O - Randomized trial of a telephone-based weight loss intervention in

overweight and obese patients (pts) with breast cancer (BC): the MEDEA trial
I. Vaz Luis1, A. Di Meglio1, E. Martin1, L. Vanlemmens2, C. Segura-Djezzar3, C. Bouleuc4,

O. Tredan5, B. Pistilli1, T. Crane6, D. Soldato1, C. Charles1, A. Barbier1, B. Raynard7, A.
Mangin1, B. Coquet8, G. Jacob9, J. Bonastre10, S. Michiels1, D. Chaltiel1, J. Ligibel11,
1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Centre Oscar Lambret, Lille, FR, 3Centre
Francois Baclesse, Caen, Cedex, FR, 4Institut Curie, Paris, FR, 5Centre Léon Bérard,
Lyon, FR, 6University of Miami, Sylvester Comprehensive Cancer Center, Deerfield
Beach, US, 7Gustave Roussy - Cancer Campus, Villejuif, FR, 8Ligue Nationale Contre le
Cancer, Paris, FR, 9Seintinelles, Paris, FR, 10Institut Gustave Roussy, Villejuif, FR, 11Dana
Farber Cancer Institute, Boston, US
16:30 - 16:40 Q&A
16:40 - 16:50 LBA94 - Effects of short-term fasting on quality of life as an add-on option
during chemotherapy
D. Koppold1, C. Kessler1, M. Wischnewsky2, I.M. Alvarado-Rupflin1, C. Kempter3, M.

Paul4, B. Brueckner3, D. Fischer5, N. Steckhan6, M. Jeitler1, E. Hanslian1, B. Kunz1, A.
Michalsen1, 1Charité - Universitätsmedizin Berlin, Berlin, DE, 2University of Bremen,
Bremen, DE, 3Waldfriede Krankenhaus, Berlin, DE, 4Vivantes Klinikum am Urban, Berlin,
DE, 5Klinikum Ernst von Bergmann, Potsdam, DE, 6Hasso-Plattner-Institut, Potsdam, DE
16:50 - 17:00 LBA95 - Anamorelin and weight gain in patients with advanced Non Small Cell
Lung Cancer (NSCLC) and cachexia: efficacy and safety in the multinational
phase 3 SCALA program
D. Currow1, S. Chessari2, P. Bonomi3, R. Giorgino4, R. Skipworth5, 1University of

Wollongong, Wollongong, AU, 2Helsinn Healthcare SA, Pazzallo-Lugano, CH, 3Rush
University, Chicago, US, 4Triallism GmbH, Allschwill, CH, 5University of Edinburgh,
Edinburgh, GB

J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für
Tumorbiologie, Freiburg im Breisgau, DE

17:10 - 17:20 Q&A
16:00 - 17:30 Type: Proffered Paper session Santander Auditorium - Hall 9

Title: Proffered Paper session - CNS tumours
Chair(s): Dieta Brandsma, NL; Evanthia Galanis, US
16:00 - 16:10 498O - INDIGO: a randomized, double-blinded, Phase 3 study of vorasidenib

versus placebo in IDH1 or IDH2 low-grade glioma
D. Blumenthal1, I. Mellinghoff2, M. Van Den Bent3, M. Touat4, K. Peters5, J. Clarke6, J.

Mendez7, L. Welsh8, W. Mason9, A. Hottinger10, J.M. Sepulveda Sanchez11, W. Wick12, R.
Soffietti13, A. Tron14, D. Zhao14, S. Pandya14, L. Steelman14, I. Hassan14, P. Wen15, T.
Cloughesy16, 1Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, IL, 2Memorial Sloan-
Kettering Cancer Center, New York, US, 3Brain Tumor Center at Erasmus MC Cancer
Institute, Rotterdam, NL, 4Sorbonne Université, Institut du Cerveau, AP-HP, Hôpitaux
Universitaires La Pitié Salpêtrière, Charles Foix, Paris, FR, 5Duke University Medical
Center, Durham, US, 6University of California, San Francisco, US, 7Huntsman Cancer
Institute at the University of Utah, Salt Lake City, US, 8The Royal Marsden Hospital,
London, GB, 9Princess Margaret Cancer Centre, and University of Toronto, Toronto, CA,
10Lundin Family Brain Tumor Research Center, University Hospital of Lausanne, and
University of Lausanne, Lausanne, CH, 11Hospital Universitario 12 de Octubre, Madrid,

ES, 12Universitatsklinikum Heidelberg, Heidelberg, DE, 13University of Turin, Torino, IT,
14Servier Pharmaceuticals, Boston, US, 15Dana-Farber Cancer Institute, Boston, US,
16University of California, Los Angeles, US

D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
16:20 - 16:30 Q&A
16:30 - 16:40 499O - A phase II study to explore the efficacy and safety of FCN-159 in
recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-
activated
W. Li1, Y. Mao2, Z. Kang1, W. Hua2, S. Li1, Z. Wu3, H. Liu4, J. Hu4, J. Guo4, W. Zhong4, X.
Wang5, 1Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, 2Huashan
Hospital, Shanghai Medical College, Fudan University, Shanghai, CN, 3Beijing Fosun
Pharmaceutical Research and Development Co., Ltd., Beijing, CN, 4Beijing Fosun
Pharmaceutical Research and Development Co., Ltd., Shanghai, CN, 5Shanghai Fosun
Pharmaceutical Development Co.,Ltd, Shanghai, CN
16:40 - 16:50 500O - Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ)
plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed
primary glioblastoma (ndGBM): updated results from a phase 1b/2 study
M. Vieito Villar1, J.M. Sepúlveda Sánchez2, V. Moreno Garcia3, G. Lombardi4, A.

Stradella5, R.H. Dahlrot6, C. Haslund7, M. Geurts8, E. Pineda9, P. Brandal10, F. De Vos11,
M.A. Vaz Salgado12, M. Martinez Garcia13, M. Macchini14, B. Amoroso15, T. Sanchez15,
B. Hanna16, X. Li16, Z. Nikolova15, M. Simonelli17, 1Vall d’Hebron Institute of Oncology
(VHIO), Barcelona, ES, 2Hospital Universitario 12 de Octubre, Madrid, ES, 3Hospital
Universitario Fundacion Jimenez Diaz, Madrid, ES, 4Istituto Oncologico Veneto,
Oncologia 1, IOV-IRCCS, Padua, IT, 5Institut Català d'Oncologia, Hospitalet de Llobregat,
Barcelona, ES, 6Odense University Hospital, Odense, DK, 7Aalborg University Hospital,
Aalborg, DK, 8Erasmus MC Cancer Institute, Rotterdam, NL, 9Hospital Clínic de
Barcelona, Barcelona, ES, 10Oslo University Hospital, Oslo, NO, 11University Medical
Center Utrecht, Utrecht, NL, 12Hospital Universitario Ramon y Cajal, Madrid, ES,
13Hospital del Mar, Barcelona, ES, 14IRCCS San Raffaele Scientific Institute, Milan, IT,
15Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb
Company, Seville, ES, 16Bristol Myers Squibb, Princeton, US, 17IRCCS Humanitas
Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan,
IT
16:50 - 17:00 501O - Glasdegib in Combination with Temozolomide and Radiotherapy in

Patients with Newly Diagnosed Glioblastoma: Phase Ib/II GEINO 1602 trial
M.A. Vaz Salgado1, S. Del Barco2, J.M. Sepúlveda3, M. Alonso4, E. Pineda5, C. Balana6,
M. Martínez-García7, R. Gironés8, 1Hospital Universitario Ramón y Cajal, Madrid, ES,
2Institut Català d'Oncologia Girona, Girona, ES, 3Hospital Universitario 12 de Octubre,
Madrid, ES, 4Hospital Virgen del Rocío, Sevilla, ES, 5Hospital Clínic de Barcelona,
Barcelona, ES, 6Institut Català d'Oncologia, Badalona, ES, 7Hospital del Mar, Barcelona,
ES, 8Hospital Universitario y Politécnico la Fe de Valencia, Valencia, ES
17:00 - 17:15 Invited Discussant 499O, 500O and 501O

A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT
17:15 - 17:30 Q&A

16:00 - 17:30 Type: Educational session León Auditorium - Hall 7
Title: Harnessing innate immunity to fight cancer
Chair(s): Adrian Hayday, GB; Daniela Thommen, NL
16:00 - 16:25 Are Gamma Delta T cells the protagonists of cancer attack by the innate immune
system?
A. Hayday, King's College London Guy's Hospital - NHS Foundation Trust, London, GB
16:25 - 16:50 DNA sensing by innate immunity

A. Ablasser, EPFL - Ecole Polytechnique Federale de Lausanne - Interfaculty (EPFL-SV-
IBI), Lausanne, CH
16:50 - 17:15 Do macrophages coordinate anti-cancer activity by the innate immune system
M. Merad, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York,
US

16:00 - 17:30 Type: Patient Advocacy session Cádiz Auditorium -
Title: How to improve access to medicines through patient NCC
engagement?
Chair(s): Jana Pelouchova, CZ; André Deschamps, BE
16:00 - 16:15 The improvement of the regulatory process through the consideration of
patients’ reported outcomes during the medicines’ development
A. Deschamps, Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE
16:15 - 16:30 A gap analysis on access to modern medicines and treatments: A comparison
between West and Eastern Europe
K.E. Morgan, Myeloma Patients Europe AISBL, Brussels, BE
16:30 - 16:45 Incorporating patient organizations’ expertise into the healthcare legislation
J. Pelouchova, Diagnoza leukemie, z.s, Prague, CZ
16:45 - 17:00 Patient engagement and collaboration with national regulatory agencies
L.-L. Eriksson, The Swedish Blood Cancer Association, Sundbyberg, SE
17:00 - 17:15 Leukaemia care and the collaboration with NICE

Z. Pemberton-Whiteley, Leukaemia Care - National Worcester, Worcester, GB

16:00 - 18:00 Type: Special session Ávila
Title: 8th ESMO Designated Centres of Integrated Oncology and Auditorium
Palliative Care Session and Awards: Approaches to the integration of - NCC
palliative care in oncology services
Chair(s): Jayne Wood, GB; Anna Reyners, NL

J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
16:05 - 16:20 Importance of integration of palliative care into mainstream oncology

J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
16:20 - 16:35 Designated centres virtual visits pilot

A. Reyners, UMCG - University Medical Center Groningen, Groningen, NL
16:35 - 16:50 MyPath update and introduction to the JANE network

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO
16:50 - 17:05 Symptom screening with Targeted Early Palliative care (STEP) intervention
C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
17:05 - 17:25 Q&A
17:25 - 17:30 Conclusion and next steps

A. Reyners, UMCG - University Medical Center Groningen, Groningen, NL
17:30 - 18:00 Designated Centres Awards
J. Wood1, A. Reyners2, 1The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust,
London, GB, 2UMCG - University Medical Center Groningen, Groningen, NL

16:00 - 17:30 Type: Young Oncologists session Pamplona Auditorium - Hall 9
Title: YO Mentorship sessions
16:00 - 16:00 Table 1: Clinical research in the general oncology practice setting
J. Cortés1, H. Zhu2, 1Hospital Ruber Internacional, Madrid, ES, 2Fudan University

Shanghai Cancer Center, Shanghai, CN
16:00 - 16:00 Table 2: How to build your own lab and research group in academia
C. Saura Manich1, R. Pihlak2, 1Vall d'Hebron University Hospital, Barcelona, ES, 2St.
Bartholomew's Hospital - Barts Health NHS Trust, London, GB
16:00 - 16:00 Table 3: How to build your own lab and research group in academia
J. Haanen1, M. Moutafi2, 1NKI-AVL - Netherlands Cancer Institute/Antoni van

Leeuwenhoek Hospital, Amsterdam, NL, 2Attikon University Hospital, Haidari, GR
16:00 - 16:00 Table 4: Career opportunities for oncologists in the pharmaceutical industry
L. Mühlenhoff, AstraZeneca GmbH, Wedel, DE
16:00 - 16:00 Table 5: A career in supportive and palliative care
K. Jordan1, D.C. Guven2, 1Ernst von Bergmann Klinikum Potsdam, Potsdam, DE,
2Hacettepe University Oncology Hospital, Ankara, TR
16:00 - 16:00 Table 6: Leadership and management in oncology

R. Sanchez Bayona, Hospital Universitario 12 de Octubre, Madrid, ES
16:00 - 16:00 Table 7: A career in neuro-oncology for medical oncologists
R. Stupp1, A. Starzer2, 1Northwestern University Feinberg School of Medicine, Chicago,

US, 2Medizinische Universitaet Wien, Vienna, AT
16:15 - 17:00 Type: Challenge your Expert Valencia Auditorium

Title: Immunotherapy in colorectal cancer: Where do we - Hall 10
stand and what do we expect?
Chair(s): Chiara Cremolini, IT

G. Argiles Martinez, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

16:15 - 17:00 Type: Challenge your Expert Salamanca
Title: When does targeted therapy outperform Auditorium - Hall
immunotherapy in patients with advanced melanoma? 3
Chair(s): Ryan Sullivan, US

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

R. Sullivan, MGH - Massachusetts General Hospital, Boston, US
16:15 - 17:00 Type: Challenge your Expert Málaga Auditorium -

Title: Is there still a place for anthracyclines in early Hall 10
breast cancer?
Chair(s): Evandro de Azambuja, BE


E. De Azambuja, Institute Jules Bordet, Brussels, BE
16:15 - 17:00 Type: Challenge your Expert Toledo Auditorium - Hall

Title: When can we cure patients with metastatic 3
sarcoma?
Chair(s): Silvia Stacchiotti, IT

W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Amsterdam, NL

S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

16:15 - 17:30 Type: Multidisciplinary session Oviedo Auditorium - Hall 7
Title: Building an academic cell therapy programme
Chair(s): Inge-Marie Svane, DK; Elena Garralda, ES
16:15 - 16:20 Presentation of case/condition

E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES
16:20 - 16:40 Lab requirements and translational opportunities

I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK),
Herlev, DK
16:40 - 17:00 Clinical requirements

A. Furness, The Royal Marsden Hospital - Chelsea, London, GB
17:00 - 17:20 Regulatory requirements

A. Hidalgo-Simon, EMA - European Medicines Agency, Amsterdam, NL
17:30 - 18:30 Type: Young Oncologists session Networking

Title: YO Vesalius talk: Diversity, equity and inclusion: Tips to Hub - NCC
move forward in your career
Chair(s): Kok Haw Jonathan Lim, GB; Elene Mariamidze, GE
17:30 - 17:40 Intorduction by the Chair
K.H.J. Lim1, E. Mariamidze2, 1The Francis Crick Institute, London, GB, 2Todua Clinic,
Tbilisi, GE
17:40 - 18:30 Diversity, equity and inclusion: Tips to move forward in your career
P. Vuylsteke1, P. Garrido Lopez2, S. Peters3, 1University of Botswana, Gaborone, BW,

2Hospital Universitario Ramon y Cajal, Madrid, ES, 3CHUV - Centre Hospitalier
Universitaire Vaudois, Lausanne, CH

Title: AstraZeneca - Clinical Perspectives in mCRPC: Practical Auditorium -
Considerations on Incorporating PARPi plus Next-generation Hall 3
Hormonal Agents into the Clinic
Chair(s): Elena Castro, ES

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES
18:05 - 18:20 Examining the evidence: PARPi plus NHA combination therapy in mCRPC
G. Von Amsberg, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
18:20 - 19:00 Clinical considerations: case-based scenarios for patient selection and AE
management with combination PARPi plus NHAs
E. Castro1, F. Saad2, 1Hospital Universitario 12 de Octubre, Madrid, ES, 2Hospital St.

Luc du CHUM, Montreal, CA
19:00 - 19:25 Exploring the patient perspective: practical approaches for shared decision
making
R. Mckay, University of California San Diego - UCSD, La Jolla, US
19:25 - 19:30 Summary and close


18:00 - 19:30 Type: Industry Satellite Symposium Málaga
Title: Janssen Pharmaceutica N.V. - Targeted therapy optimising Auditorium -
the future of GU cancer care – realising the value, exploring the Hall 10
evidence
Chair(s): Aurelius Omlin, CH; Alison Birtle, GB
18:00 - 18:05 Opening remarks & introduction
A. Omlin1, A. Birtle2, 1OnkoZentrum Zürich, Zurich, CH, 2Royal Preston Hospital,

Preston, GB
18:05 - 18:25 How can we balance efficacy and QoL in mHSPC treatment? Why it’s time to
tailor treatments
F. Schlürmann1, L.-M. Krabbe2, 1CHRU Brest - Hopital Augustin Morvan, Brest, FR,
2UKM - University Hospital Muenster, Muenster, DE
18:25 - 18:45 Germ line testing and genomic profiling - isn’t it time for personalised prostate
cancer care?
D. Olmos1, N. Mehra2, 1Hospital Universitario 12 de Octubre, Madrid, ES, 2Radboud

University Medical Center, Nijmegen, Nijmegen, NL
18:45 - 19:05 Revolutionising urothelial carcinoma care: Discovering the value of targeted
therapy
G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES
19:05 - 19:25 Interactive Q&A session
A. Omlin1, A. Birtle2, F. Schlürmann3, D. Olmos4, N. Mehra5, L.-M. Krabbe6, G.A. De

Velasco Oria4, 1OnkoZentrum Zürich, Zurich, CH, 2Royal Preston Hospital, Preston, GB,
3CHRU Brest - Hopital Augustin Morvan, Brest, FR, 4Hospital Universitario 12 de
Octubre, Madrid, ES, 5Radboud University Medical Center, Nijmegen, Nijmegen, NL,
6UKM - University Hospital Muenster, Muenster, DE
19:25 - 19:30 Closing remarks
A. Omlin1, A. Birtle2, 1OnkoZentrum Zürich, Zurich, CH, 2Royal Preston Hospital,

Preston, GB

Title: Servier - A journey through IDH1mutated Auditorium -
Cholangiocarcinoma - Unveiling clinical and therapeutic Hall 9
perspectives
Chair(s): Michel Ducreux, FR

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR
18:10 - 18:15 Introducing a patient case with IDH1 mutated CCA

T. Macarulla, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
18:15 - 18:35 CCA diagnosis: current practice and challenges
T. Macarulla1, E. Martinelli2, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

Barcelona, ES, 2Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
18:35 - 18:55 Molecular profiling in CCA: where do we stand?
T. Macarulla1, A. Stenzinger2, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,

Barcelona, ES, 2University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
18:55 - 19:15 Treatment landscape in CCA and future perspectives
C.B. Westphalen1, T. Macarulla2, 1LMU Klinikum der Universität München, Munich, DE,
2Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
19:15 - 19:25 Panel discussion Q&A
M. Ducreux1, T. Macarulla2, E. Martinelli3, A. Stenzinger4, C.B. Westphalen5, 1Gustave

Roussy - Cancer Campus, Villejuif, FR, 2Vall d'Hebron Institute of Oncology (VHIO)-Cellex
Center, Barcelona, ES, 3Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT,
4University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, 5LMU Klinikum
der Universität München, Munich, DE

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

18:00 - 19:30 Type: Industry Satellite Symposium Toledo
Title: Bayer - Delivering on the Promise of Precision Oncology: Auditorium -
From the Big Bang to Tangible Impact on Patients’ Lives Hall 3
Chair(s): Vivek Subbiah, US
18:00 - 18:05 Welcome

V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Houston, US
18:05 - 18:10 The Voice That Matters - A Patient Perspective

18:10 - 18:25 The Big Bang of Precision Oncology: Creating Milestones in Medicine
18:25 - 18:40 Theory to Reality: Overcoming Challenges and Raising the Value of Precision
Oncology
V. Subbiah1, J. Hernandez-Losa2, 1The University of Texas M. D. Anderson Cancer Center,

Houston, US, 2Vall d'Hebron University Hospital, Barcelona, ES
18:40 - 19:05 Making It Stick: Implementing the Advances in Precision Oncology into Clinical
Practice
V. Subbiah1, J. Naidoo2, D.S.W. Tan3, 1The University of Texas M. D. Anderson Cancer

Center, Houston, US, 2Beaumont Hospital, Dublin, IE, 3NCCS - National Cancer Centre
Singapore, Singapore, SG
19:05 - 19:15 Open Panel Audience Q&A
V. Subbiah1, J. Naidoo2, D.S.W. Tan3, J. Hernandez-Losa4, 1The University of Texas M. D.

Anderson Cancer Center, Houston, US, 2Beaumont Hospital, Dublin, IE, 3NCCS -
National Cancer Centre Singapore, Singapore, SG, 4Vall d'Hebron University Hospital,
Barcelona, ES
19:15 - 19:25 Impact From Within: Patient Advocacy and the Voices That Bring Progress
A. Moore, LUNGevity Foundation, Chicago, US


Title: Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Auditorium -
Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Hall 7
Cancer
Chair(s): Charles Rudin, US
18:00 - 18:05 Welcome and Introduction of Agenda and Speakers

C. Rudin, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
18:05 - 18:25 Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma

P. Schoeffski, KU Leuven - Laboratory of Experimental Oncology, Leuven, BE
18:25 - 18:50 Improving HER2 Targeting in NSCLC with Selective TKI

18:50 - 19:15 T-cell Engagers: Fighting Solid Tumors from Within

C. Rudin, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
19:15 - 19:30 Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks
C. Rudin1, P. Schoeffski2, Z. Piotrowska3, 1MSKCC - Memorial Sloan Kettering Cancer

Center, New York, US, 2KU Leuven - Laboratory of Experimental Oncology, Leuven, BE,
3MGH - Massachusetts General Hospital, Boston, US

Title: Regeneron Pharmaceuticals, Inc. - Putting the Patient First: Auditorium
The Value of Personalized Medicine for Nonmelanoma Skin Cancers - Hall 7
Chair(s): Vishal Patel, GB

V. Patel, Birmingham City University - City South Campus, Birmingham, GB
18:05 - 18:20 The CSCC and BCC Essentials

D.M. Miller, Beth Israel Deaconess Medical Center, Boston, US
18:20 - 18:50 Navigating the Patient Journey for CSCC
V. Patel1, D.M. Miller2, T. Guo3, 1Birmingham City University - City South Campus,
Birmingham, GB, 2Beth Israel Deaconess Medical Center, Boston, US, 3University of
California San Diego - UCSD, La Jolla, US
18:50 - 19:20 Leveraging the Patient Voice in BCC
V. Patel1, D.M. Miller2, T. Guo3, 1Birmingham City University - City South Campus,
Birmingham, GB, 2Beth Israel Deaconess Medical Center, Boston, US, 3University of
California San Diego - UCSD, La Jolla, US
19:20 - 19:30 Audience Q&A

21.10.2023
08:30 - 09:50 Type: Proffered Paper session Barcelona Auditorium -
Title: Proffered Paper session 1 - Genitourinary Hall 9
tumours, non-prostate
08:30 - 08:40 2359O - Phase 3 THOR Study: Results of Erdafitinib (erda) vs Pembrolizumab
(pembro) in Pretreated Patients (pts) With Advanced or Metastatic Urothelial
Cancer (mUC) With Select Fibroblast Growth Factor Receptor Alterations
(FGFRalt)
A. Siefker-Radtke1, N. Matsubara2, S.H. Park3, R. Huddart4, E. Burgess5, M. Ozguroglu6,

B. Perez Valderrama7, S. Triantos8, S. Akapame8, Y. Kean8, K. Deprince9, S.
Mukhopadhyay10, Y. Loriot11, 1The University of Texas MD Anderson Cancer Center,
Houston, US, 2National Cancer Center Hospital East, Chiba, JP, 3Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul, KR, 4Institute of Cancer
Research and Royal Marsden NHS Foundation Trust, Sutton, GB, 5Levine Cancer
Institute, Charlotte, US, 6Cerrahpaşa Faculty of Medicine, Istanbul University-
Cerrahpaşa, Istanbul, TR, 7Hospital Universitario Virgen del Rocío, Seville, ES, 8Janssen
Research & Development, Spring House, US, 9Janssen Research & Development, Beerse,
BE, 10Janssen Research & Development, Lexington, US, 11INSERM U981, Gustave
Roussy, Université Paris-Saclay, Villejuif, Cedex, FR
08:40 - 08:50 LBA102 - THOR-2 Cohort 1: Results of Erdafitinib (Erda) vs Intravesical

Chemotherapy (Chemo) in Patients (Pts) With High-Risk Non–Muscle-Invasive
Bladder Cancer (HR NMIBC) With Select FGFR Alterations (FGFRalt) Who
Received Prior Bacillus Calmette-Guérin (BCG) Treatment
J. Catto1, B. Tran2, M. Roupret3, J. Gschwend4, Y. Loriot5, H. Nishiyama6, J. Palou7, S.

Daneshmand8, S. Hussain1, H. Cutuli9, G. Procopio10, V. Guadalupi10, N. Vasdev11, V.
Naini12, L. Crow13, S. Triantos13, M. Baig13, G. Steinberg14, 1University of Sheffield;
Sheffield Teaching Hospitals NHS Trust, Sheffield, GB, 2Peter MacCallum Cancer Centre,
Melbourne, AU, 3GRC 5 Predictive Onco-Uro, Hôpital Pitié-Salpêtrière, Sorbonne
University, Paris, Cedex, FR, 4Rechts der Isar Hospital, Technical University of Munich,
Munich, DE, 5INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex,
FR, 6University of Tsukuba, Tsukuba, JP, 7Fundació Puigvert, Universitat Autònoma de
Barcelona, Barcelona, ES, 8Norris Comprehensive Cancer Center, University of Southern
California, Los Angeles, US, 9Sirio Libanes Hospital, Buenos Aires, AR, 10Fondazione
IRCCS Istituto Nazionale dei Tumori, Milan, IT, 11Hertfordshire and Bedfordshire
Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage,
UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, GB,
12Janssen Research & Development, San Diego, US, 13Janssen Research & Development,
Spring House, US, 14Rush University Medical Center, Chicago, US

M. Van Der Heijden, Netherlands Cancer Institute, Amsterdam, NL
09:00 - 09:10 Q&A
09:10 - 09:20 2360O - The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab
govitecan (SG) plus enfortumab vedotin (EV) as ≥ Second line therapy for
metastatic urothelial carcinoma (mUC)
B. Mcgregor1, G. Sonpavde2, L. Kwak1, X. Gao3, C. Mantia1, X. Wei1, J. Berchuck1, P.

Ravi1, M.D. Michaelson4, T. Choueiri1, J. Bellmunt1, 1Dana Farber Cancer Institute,
Boston, US, 2AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US,
3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US,
4MGH - Massachusetts General Hospital, Boston, US
09:20 - 09:30 LBA103 - ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in
metastatic urothelial carcinoma after progression on platinum chemotherapy
and anti-PD-(L)1
S.M.H. Einerhand1, J. Van Dorp1, J. De Feijter1, A. Daletzakis1, S. Oosting2, C. Bruijnen3,

B. Suelmann3, M. Van Der Heijden1, 1NKI-AVL - Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, NL, 2UMCG - University Medical Center Groningen,
Groningen, NL, 3UMC - University Medical Center Utrecht, Utrecht, NL
09:40 - 09:50 Q&A

08:30 - 10:00 Type: Special symposium Sevilla Auditorium - Hall 9
Title: Advancing strategies for cancer
immunotherapy
Chair(s): Inge-Marie Svane, DK; Ignacio Melero, ES

Herlev, DK
08:35 - 08:50 Activation of innate cells through Treg targeting

S. Quezada, University College London, London, GB
08:50 - 09:05 CAR-T and TCR-T approaches for solid cancers

S. Kobold, LMU Klinikum der Universität München, Munich, DE
09:05 - 09:20 Intra-tumoural immunotherapy

I. Melero, Clinica Universidad de Navarra, Pamplona, ES
09:20 - 09:35 New approaches in cancer vaccines

S. Van Der Burg, LUMC - Leids Universitair Medisch Centrum, Leiden, NL
08:30 - 10:00 Type: Mini Oral session Granada Auditorium - Hall 3

Title: Mini oral session 1 - NSCLC, metastatic
Chair(s): Lizza Hendriks, NL; Jordi Remon Masip, FR; Daniel Shao Weng Tan, SG
08:30 - 08:35 LBA68 - FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ±
chemotherapy (CTx) in EGFRm advanced NSCLC
D. Planchard1, P. Jänne2, Y. Cheng3, C. Lee4, K. Laktionov5, T.-Y. Yang 6, Y. Yu7, T. Kato8, L.

Jiang9, B. Chewaskulyong10, S. Lucien Geater11, J.-M. Maurel12, C. Rojas13, L. Havel14,
F.A. Shepherd15, K. Tanaka16, D. Ghiorghiu17, E. Armenteros Monterroso17, X. Huang17,
J.C.-H. Yang18, 1Institut Gustave Roussy, Thoracic Unit, Villejuif, Paris, FR, 2Lowe Center
for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, 3Jilin Cancer Hospital,
Changchun, CN, 4Cancer Care Centre, St. George Hospital, Kogarah, AU, 5Ministry of
Health of the Russian Federation, Moscow, RU, 6Taichung Veterans General Hospital,
Taichung, TW, 7Harbin Medical University Cancer Hospital, Harbin, CN, 8Kanagawa
Cancer Center, Asahi Ward, Yokohama, JP, 9Shanghai Chest Hospital, Shanghai Jiao Tong
University, Shanghai, CN, 10Faculty of Medicine, Chiang Mai University, Chiang Mai, TH,
11Prince of Songkla University, Hat Yai District, Songkhla, TH, 12Cancercare,
Rondebosch Oncology Centre, Rondebosch, Cape Town, ZA, 13Bradford Hill Clinical

Research Center, Santiago, CL, 14First Faculty of Medicine, Charles University,
Thomayer Hospital, Prague, CZ, 15University Health Network, Princess Margaret Cancer
Centre, Toronto, CA, 16Graduate School of Medical Sciences, Kyushu University,
Fukuoka, JP, 17AstraZeneca, Cambridge, GB, 18National Taiwan University Hospital and
National Taiwan University Cancer Center, Taipei, TW
08:35 - 08:40 LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment
in patients with EGFR mutation positive locally advanced or metastatic non-
small cell lung cancer (NSCLC): a randomized multicenter study
Y. Hu1, F. Zhang1, M. Zhao2, Z. Zheng3, H. Zhang4, T. Jiang5, Z. Liu6, J. Wen7, X. Gan8, H.

Wang9, L. Wu10, S. Cang11, J. Zhao12, X. Li13, L. Peng14, Z. Fan15, G. Shen16, Q. Zhou17,
J. Zou18, 1Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, 2The First
Affiliated Hospital of China Medical University, Shenyang, CN, 3General Hospital of
Northern Theater Command, Shenyang, CN, 4Air Force Medical University, xi‘an, CN,
5The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an,
CN, 6The Third Medical Center of Chinese PLA General Hospital, beijing, CN, 7The Sixth
Medical Center of Chinese PLA General Hospital, Beijing, CN, 8The First Affiliated
Hospital of Nanchang University, Nanchang, CN, 9The Affiliated Hospital of Qingdao
University, Qingdao, CN, 10Hunan Cancer Hospital, Changsha, CN, 11Henan Province
People’s Hospital, Zhengzhou, CN, 12Changzhi People's Hospital of Changzhi Medical
College, Changzhi, CN, 13The Seventh Medical Center of Chinese PLA General Hospital,
Beijing, CN, 14The Fourth Medical Center of Chinese PLA General Hospital, Beijing, CN,
15Air Force General Hospital (PLA), Beijing, CN, 16Beijing Fengtai Youanmen Hospital,
Beijing, CN, 17Union Hospital Tongji Medical College Huazhong University of Science
and Technology, Wuhan, CN, 18Renmin Hospital of Wuhan University/ Hubei General
Hospital, Wuhan, CN

D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
08:50 - 08:55 LBA70 - OSIRAM-1: A multicenter, open label, randomized phase II study of
osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy
for EGFR mutation-positive non-squamous non-small cell lung cancer
(TORG1833)
Y. Nakahara1, T. Kato2, R. Isomura2, T. Misumi3, M. Tamiya4, K. Yoh3, N. Furuya5, A.

Ono6, Y. Takiguchi7, K. Koyama8, S. Ikeda9, K. Watanabe10, T. Tokito11, N. Seki12, H.
Imai13, T. Shukuya14, Y. Shibata15, S. Hosokawa16, T. Kozuki17, H. Okamoto18, 1Kitasato
University School of Medicine, Sagamihara, JP, 2Kanagawa Cancer Center, Yokohama, JP,
3National Cancer Center Hospital East, Kashiwa, JP, 4Osaka International Cancer
Institute, Osaka, JP, 5St.Marianna University School of Medicine, Kawasaki, JP, 6Shizuoka
Cancer Center, Shizuoka, JP, 7Chiba University Hospital, Chiba, JP, 8Niigata Cancer
Center Hospital, Niigata, JP, 9Kanagawa Cardiovascular and Respiratory Center,
Yokohama, JP, 10Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome
Hospital, Tokyo, JP, 11Kurume University Hospital, Kurume, JP, 12Teikyo University
Hospital, Tokyo, JP, 13Gunma Prefectural Cancer Center, Ota, JP, 14Juntendo University
Hospital, Tokyo, JP, 15National Hospital Organization Yokohama Medical Center,
Yokohama, JP, 16Japanese Red Cross Okayama Hospital, Okayama, JP, 17National Hospital
Organization Shikoku Cancer Center, Matsuyama, JP, 18Yokohama Municipal Citizen's
Hospital, Yokohama, JP

08:55 - 09:00 LBA71 - A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib
with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC
(RAMOSE trial interim analysis)
X. Le1, J. Patel2, E. Shum3, R. Sanborn4, C. Baik5, C.A. Shu6, C. Kim7, M. Fidler8, R.

Hall9, N. Hanna10, N. Mohindra11, J. Sabari12, S. Heeke13, M. Hernandez14, J. Gray15, J.
Heymach14, A. Saltos15, 1The University of Texas M. D. Anderson Cancer Center,
Houston, US, 2Northwestern University Feinberg School of Medicine, Chicago, US, 3New
York University Medical Center, New York, US, 4Earle A. Chiles Research Institute at the
Robert W. Franz Cancer Center, Portland, US, 5University of Washington Seattle Cancer
Care Alliance, Seattle, US, 6Columbia University Medical Center College of Physicians &
Surgeons - New York Presbyterian Hospital, New York, US, 7Lombardi Cancer Center
Georgetown University, Washington, US, 8Rush Cancer Institute, Chicago, US, 9The
University of Virginia, Charlottesville, US, 10Indiana University Simon Cancer Center,
Indianapolis, US, 11Northwestern University, Chicago, US, 12NYU Langone Health -
Perlmutter Cancer Center - 34th Street, New York, US, 13University of Texas MD
Anderson Cancer Center, Houston, US, 14MD Anderson Cancer Center, Houston, US,
15H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US

Y.-L. Wu, Guangdong Province People's Hospital, Guangzhou, CN
09:10 - 09:15 1312MO - Combining the antigen-presenting cell activator eftilagimod alpha
(soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-
small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)
E. Carcereny1, E. Felip2, M. Majem3, B. Doger De Spéville4, T. Clay5, I. Bondarenko6, J.

Peguero7, M. Cobo Dols8, M. Forster9, G. Ursol10, E. Kalinka11, G. Garcia Ledo12, L. Vila
Martinez13, W. Iams14, M. Krebs15, J. Kefas16, K. Efthymiadis17, S. Perera18, C.
Mueller19, F. Triebel20, 1ICO - Institut Català d'Oncologia Badalona -Hospital Germans
Trias i Pujol, Badalona, ES, 2Vall d'Hebron University Hospital (VHIO), Barcelona, ES,
3Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 4Fundacion Jimenez Díaz, Madrid,
ES, 5Saint John of God Subiaco Hospital, Subiaco, AU, 6City Clinical hospital Nr. 4,
Dnipro, UA, 7Oncology Consultants, Houston, US, 8Hospital Regional Universitario
Málaga Carlos Haya, Malaga, ES, 9University College London Cancer Institute and
University College London Hospital NHS Trust, London, GB, 10St. Luke's Hospital -
Medical and Diagnostic Center "Acinus'', Kropyvnytskyi, UA, 11Instytut Centrum Zdrowia
Matki Polki, Łódź, PL, 12HM Universitario Sanchinarro, Madrid, ES, 13Parc Taulí
Sabadell Hospital Universitari, Barcelona, ES, 14Vanderbilt Ingram Cancer Center,
Nashville, US, 15The University of Manchester and The Christie NHS Foundation Trust,
Manchester, GB, 16University College London Hospitals NHS Trust, London, GB, 17UCLH
NHS Foundation Trust, London, GB, 18Immutep GmbH - Berlin, Berlin, DE, 19Immutep
GmbH, Leipzig, DE, 20Immutep S.A.S, SAINT-AUBIN, FR
09:15 - 09:20 1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody
targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell
lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
B. Besse1, A. Italiano2, S. Cousin2, G. Ruiter3, E. Felip4, E. Castanon Alvarez5, S.

Ramalingam6, C. Rolfo7, D.R. Spigel8, D. Andrew9, S. Cho10, T. Collins9, A. Hansen10, G.

Hawkins9, R. Kurek9, N. Ceaicovscaia10, M. Petruzzelli9, E. Dean9, A. Sacher11, 1Institut
Gustave Roussy, Villejuif, FR, 2Institute Bergonié, Bordeaux, FR, 3The Netherlands
Cancer Institute, Amsterdam, NL, 4Vall d'Hebron Institute of Oncology, Barcelona, ES,
5Clínica Universidad de Navarra, Madrid, ES, 6Emory University - Winship Cancer
Institute, Atlanta, US, 7Mount Sinai Hospital, New York, US, 8Sarah Cannon Research
Institute at Tennessee Oncology, Nashville, US, 9AstraZeneca, Cambridge, GB,
10AstraZeneca, Gaithersburg, US, 11Princess Margaret Cancer Centre, Toronto, CA
09:20 - 09:30 Invited Discussant 1312MO and 1313MO

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL
09:30 - 09:35 1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously

treated non-small cell lung cancer (NSCLC) with actionable genomic alterations
(AGAs)
L. Paz-Ares1, M.-J. Ahn2, A. Lisberg3, S. Kitazono4, B.C. Cho5, G. Blumenschein6, E.

Shum7, E. Pons-Tostivint 8, Y. Goto9, K. Yoh10, R. Heist11, P. Baas12, D. Planchard13, M.
Pérol14, E. Felip15, W.-C. Su16, H. Zebger-Gong17, L. Lan18, C. Liu18, J. Sands19,
1Hospital Universitario 12 de Octubre, Madrid, ES, 2Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, KR, 3JDavid Geffen School of

Medicine at UCLA, Los Angeles, US, 4The Cancer Institute Hospital of JFCR, Tokyo, JP,
5Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, 6University of
Texas MD Anderson Cancer Center, Houston, US, 7NYU Perlmutter Cancer Center, New
York, US, 8University Hospital Nantes, Nantes, FR, 9National Cancer Center Hospital,
Tokyo, JP, 10National Cancer Center Hospital East, Kashiwa, JP, 11Massachusetts General
Hospital Cancer Center, Boston, US, 12The Netherlands Cancer Institute, Amsterdam,
NL, 13Institut Gustave Roussy, Villejuif, FR, 14Léon Bérard Cancer Center, Lyon, FR,
15Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona,
ES, 16National Cheng Kung University Hospital, Tainan City, TW, 17Daiichi Sankyo
Europe GmbH, Munich, DE, 18Daiichi Sankyo, Inc, Basking Ridge, US, 19Dana-Farber
Cancer Institute, Harvard Medical School, Boston, US
09:35 - 09:40 1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific

antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer
(NSCLC)
A. Schram1, K. Goto2, D.-W. Kim 3, A. Hollebecque4, S.Y. Rha5, K. Nishino6, M.

Duruisseaux7, K. Umemoto8, J.O. Park9, N. Leighl10, T. Macarulla11, S. Liu12, M.N. Al-
Hallak13, J. Cleary14, C. Neuzillet15, Y. Goto16, A.K. Joe17, S. Adeyemi17, S. Jauhari17, A.
Drilon18, 1Memorial Sloan Kettering Cancer Center, New York, US, 2National Cancer
Center Hospital East, Kashiwa, JP, 3Seoul National University Hospital and Seoul
National University College of Medicine, Seoul, KR, 4Gustave Roussy Cancer Campus,
Villejuif, FR, 5Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, 6Osaka
International Cancer Institute, Osaka, JP, 7Louis Pradel Hospital, Hospices Civils de Lyon
Cancer Institute; Cancer Research Centre of Lyon, UMR INSERM 1052 CNRS 5286;
Claude Bernard University Lyon 1, University of Lyon, Lyon, FR, 8St. Marianna
University School of Medicine, Kawasaki, JP, 9Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, KR, 10Princess Margaret Cancer Centre, Toronto,
CA, 11Vall d’Hebrón University Hospital, Vall d'Hebrón Institute of Oncology (VHIO),
Barcelona, ES, 12Lombardi Comprehensive Cancer Center, Georgetown University,
Washington, US, 13Barbara Ann Karmanos Cancer Institute, Wayne State University

School of Medicine, Detroit, US, 14Dana-Farber Cancer Institute, Boston, MA, United
States of America, Harvard Medical School, Boston, US, 15Versailles-Saint Quentin
University, Saint-Cloud, FR, 16National Cancer Center Hospital, Tokyo, JP, 17Merus N.V,
Utrecht, NL, 18Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and
Weill Cornell Medical College, New York, US
09:40 - 09:45 1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug

conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from
first-in-human phase 1 study
L. Zhang1, Y. Ma1, Y. Zhao2, W.F. Fang1, H. Zhao1, Y. Huang1, Y. Yang1, X. Hou1, Z. Wen3,
S. Zhang3, J. Wang3, S. Xiao3, H. Wang4, H. Zhu4, M. Olivo4, Y. Zhu4, 1Sun Yat-sen
University Cancer Center, Guangzhou, CN, 2The Affiliated Hospital of Qingdao University,
Qingdao, CN, 3Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., Chengdu, CN, 4SystImmune
Inc., Redmond, US
09:45 - 10:00 Invited Discussant 1314MO, 1315MO and 1316MO

J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR
08:30 - 10:00 Type: Educational session Burgos

Title: Fight the enemy as soon as possible: News and views in the Auditorium -
management of early stages colorectal cancer (CRC) Hall 3
Chair(s): Jenny Seligmann, GB; Dominik Modest, DE
08:30 - 08:50 Screening programmes 20 years later: Lessons learned and how to move on?
M. Van Leerdam, LUMC-Leiden University Medical Center, Leiden, NL
08:50 - 09:05 How do we optimise imaging?

E. Dresen, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
09:05 - 09:25 Current systemic treatment of locally advanced colon cancer

J. Seligmann, The University of Leeds, Leeds, GB
09:25 - 09:45 Future directions neoadjuvant versus adjuvant

D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

08:30 - 10:00 Type: Special symposium Valencia Auditorium - Hall
Title: Open questions in the management of 10
mesothelioma
Chair(s): Jean Yannis Perentes, CH; Kenneth Rosenzweig, US

P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
08:35 - 08:50 When and when not to operate

J.Y. Perentes, UNIL - University of Lausanne, Lausanne, CH
08:50 - 09:05 What is the optimal first-line treatment?

A. Scherpereel, DRC / CHRU of Lille, Lille, FR
09:05 - 09:20 Biomarker-selected therapy: Progress or delusion?

P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
09:20 - 09:35 Preoperative or postoperative radiation for mesothelioma

K. Rosenzweig, Mount Sinai Hospital, New York, US

08:30 - 10:00 Type: Educational session Salamanca
Title: Unravelling choices for adjuvant endocrine therapy Auditorium - Hall 3
in HR+ early breast cancer
Chair(s): Stephen Johnston, GB; Nadia Harbeck, DE
08:30 - 08:50 Risk assessment stratification

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
08:50 - 09:10 ER positive breast cancer: What endocrine therapy is needed in premenopausal
patients?
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL
09:10 - 09:30 ER positive breast cancer: What endocrine therapy is needed in menopausal
patients?
P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
09:30 - 09:50 Beyond chemo and endocrine therapy


08:30 - 10:00 Type: Special symposium Málaga Auditorium - Hall 10
Title: New targets on the horizon
Chair(s): Ruth Plummer, GB; Alexander Drilon, US

A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
08:35 - 08:50 DUBs

A. D'Andrea, Dana Farber Cancer Institute, Boston, US
08:50 - 09:05 Innovative/novel delivery of immunotherapeutics

A. Marabelle, Institut Gustave Roussy, Villejuif, FR
09:05 - 09:20 Peptide-based cancer vaccines

J. Walz, University Clinic Tübingen, Tuebingen, DE
09:20 - 09:35 Mutant specific inhibitors

A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

08:30 - 10:00 Type: Special symposium Santander Auditorium
Title: Protein degrading cancer drugs: The promises of - Hall 9
the new generation
Chair(s): Madelon Maurice, NL; David Spiegel, US
08:35 - 08:50 Superglue: Development of molecular glue degraders (PROTACs)

N. Thomä, Friedrich Miescher Institute for Biomedical Research, Basel, CH
08:50 - 09:05 How to make new drugs to drive protein degradation (PROTACs)
C. Mayor-Ruiz, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, ES
09:05 - 09:20 Degrading cancer targets on the cell surface (SureTACs)

M. Maurice, UMC - University Medical Center Utrecht, Utrecht, NL
09:20 - 09:35 Bifunctional small molecules that mediate the degradation of extracellular
proteins
D. Spiegel, Yale University School of Medicine - Yale Cancer Center, New Haven, US

08:30 - 10:00 Type: Special symposium Oviedo
Title: Next generation diagnostics of blood cancer: An Auditorium -
optimistic view on the future of cancer testing Hall 7
Chair(s): Iñaki Martin Subero, ES

I. Martin Subero, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut
d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES
08:35 - 08:50 Liquid biopsy in lymphoma

D. Kurtz, Stanford University, Stanford, US
08:50 - 09:05 Multi-omic profiling in lymphoid neoplasms

I. Martin Subero, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut
d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES
09:05 - 09:20 Drug sensitivity testing in blood cancer

T. Zenz, USZ - University Hospital Zürich, Zurich, CH
09:20 - 09:35 How novel profiling methods impact trial design

R. Schlenk, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

08:30 - 10:00 Type: Educational session Cádiz Auditorium - NCC
Title: Making essential cancer drugs affordable
Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL
08:30 - 08:50 Insights in essential medicine availability and accessibility from ESMO
antineoplastic medicines study 2.0
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL
08:50 - 09:05 Policy and intellectual property regulatory instruments as tools to enhance
access to expensive essential cancer medicines
E. 'T Hoen, Medicines Law & Policy, Amsterdam, NL
09:05 - 09:20 Governmental policies to control cancer medicine prices

K. Tay-Teo, WHO - World Health Organization, Geneva, CH
09:20 - 09:35 India’s approach to advance access to cancer medicines

M. Sengar, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

08:30 - 10:00 Type: EONS session Alicante Auditorium - Hall
Title: EONS16: Opening session & Keynote 10
lectures
Chair(s): Virpi Sulosaari, FI
08:30 - 08:35 Welcome address

V. Sulosaari, Turku University of Applied Sciences, Turku, FI
08:35 - 08:40 Welcome from Spanish Oncology Nursing Society (Sociedad Española de
Enfermería Oncológica, SEEO)
J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES
08:40 - 08:45 Welcome from ESMO

08:45 - 09:05 Keynote lecture: The effectiveness of nurse-led interventions for cancer
symptom management
D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB
09:05 - 09:25 Keynote lecture: Priorities for future research in cancer nursing
G. Bagcivan, Koc University - School of Nursing, Istanbul, TR
09:25 - 09:40 CN1 - Integrating an electronic Patient Reported Outcome Measure (ePROM)
into a nurse-led rare cancer pathway
J. Ireson1, T. Holch2, D. Greenfield3, K. Singh1, S. Gillett1, S. Rollins1, S. Radley3, J. Tidy1,

G. Jones2, 1Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust,
Sheffield, GB, 2Leeds Beckett University, Leeds, GB, 3Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, GB
09:40 - 09:50 Lifetime Achievement Award, RECaN Award, NRDA Award
09:50 - 10:00 Q&A and discussion
08:45 - 10:00 Type: Proffered Paper session Bilbao Auditorium -

Title: Proffered Paper session 2 - Gynaecological NCC
cancers
Chair(s): Domenica Lorusso, IT
08:45 - 08:55 LBA40 - Phase III double-blind randomized placebo controlled trial of
atezolizumab in combination with carboplatin and paclitaxel in women with
advanced/recurrent endometrial carcinoma.
N. Colombo1, K. Harano2, E. Hudson3, F. Galli4, Y. Antill5, C.H. Choi6, M. Rabaglio7, F.

Marmé8, E. Petru9, C.-H. Lai10, E. Biagioli11, L. Fariñas Madrid12, K. Takehara13, K.

Allan14, Y.C. Lee15, E. Piovano16, C. Zamagni17, G. Tasca18, A. Ferrero19, M.P. Barretina
Ginesta20, 1European Institute of Oncology IRCCS, Milan, IT, 2National Cancer Center
Hospital East, Kashiwa, JP, 3Velindre Cancer Centre, Cardiff, GB, 4Istituto di Ricerche
Farmacologiche Mario Negri IRCCS, Milan, IT, 5Frankston Hospital, Melbourne, AU,
6Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul,
KR, 7Inselspital - Universitatsspital, Bern, CH, 8UMM - Universitaetsklinikum Mannheim

- Medizinische Fakultaet, Mannheim, DE, 9Medical University of Graz Division of
Gynecology, Graz, AT, 10Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City,
TW, 11Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, IT, 12Vall
d'Hebron Institute of Oncology (VHIO), Barcelona, ES, 13National Hospital Organization
Shikoku Cancer Center, Matsuyama, JP, 14University of Glasgow, Glasgow, GB, 15The
University of Sydney, Sydney, AU, 16AOU Città della Salute e della Scienza - Presidio
Sant'Anna, Torino, IT, 17IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna,
IT, 18Istituto Oncologico Veneto IOV, IRCCS, Padova, IT, 19Azienda Ospedaliera Ordine
Mauriziano - Presidio Umberto I, Torino, IT, 20Institut Català d’Oncologia & IDIBGI,
Girona, ES

D.S. Tan, NUHS - National University Health System, Singapore, SG
09:05 - 09:15 Q&A
09:15 - 09:25 LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by

maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly
diagnosed advanced or recurrent endometrial cancer (EC): results from the
Phase III DUO-E/GOG-3041/ENGOT-EN10 trial
S. Westin1, K. Moore2, H.S. Chon3, J.-Y. Lee 4, J. Thomes Pepin5, M. Sundborg6, J. De La

Garza7, S. Nishio8, K. Wang9, K. Mcintyre10, T. Tillmanns11, F. Contreras Mejia12, A. De
Melo13, D. Klasa-Mazurkiewicz14, C. Papadimitriou15, M. Gil Martín16, B. Brasiuniene17,
C. Donnelly18, X. Liu19, E. Van Nieuwenhuysen20, 1The University of Texas MD Anderson
Cancer Center, Houston, US, 2Stephenson Cancer Center, University of Oklahoma
Medical Center, Oklahoma City, US, 3University of South Florida, Tampa, US, 4Yonsei
University College of Medicine, Seoul, KR, 5Minnesota Oncology, Maplewood, US,
6FirstHealth Moore Regional Hospital, Pinehurst, US, 7Texas Oncology-San Antonio
Medical Center, San Antonio, US, 8Kurume University School of Medicine, Kurume, JP,
9Medical University Cancer Institute & Hospital, Tianjin, CN, 10Texas Health
Presbyterian Hospital, Dallas, US, 11West Cancer Center & Research Institute,
Germantown, US, 12National Cancer Institute of Colombia, Bogotá, CO, 13Brazilian
National Cancer Institute, Rio de Janeiro, BR, 14Medical University of Gdańsk, and
PGOG, Gdańsk, PL, 15The National and Kapodistrian University of Athens, and HeCOG,
Athens, GR, 16Catalan Institute of Oncology-Institut d'Investigació Biomèdica de Bellvitge
(IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, and GEICO, Barcelona, ES,
17National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, and
NSGO, Vilnius, LT, 18AstraZeneca, Cambridge, GB, 19AstraZeneca, Gaithersburg, US,

20UZ Leuven, and BGOG, Leuven, BE
09:25 - 09:35 LBA42 - Olaparib vs placebo as maintenance therapy after platinum-based

chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO

randomized phase IIb UTOLA trial
F. Joly Lobbedez1, A. Leary2, I. Ray-Coquard3, B. Asselain4, M. Rodrigues5, L. Gladieff6,

F. Bazan7, S. Abadie Lacourtoisie8, C. Lebreton9, L. Bengrine Lefevre10, K. Leroy11, R.
Leman1, P. Fournel12, R. Largillier13, F. Selle14, J.-S. Frenel15, Y. Fernandez16, C. Foa17,
B. You18, J. Alexandre19, 1Centre Francois Baclesse, Caen, Cedex, FR, 2Gustave Roussy,
Villejuif, FR, 3Centre Léon Bérard and University of Lyon, Lyon, FR, 4ARCAGY-GINECO,
Paris, FR, 5Institut Curie, Paris, FR, 6Institut Claudius Régaud, IUCT Oncopole, Toulouse,
FR, 7CHRU BESANCON - Hôpital Jean Minjoz, BESANCON, FR, 8Institut de
Cancérologie de l’Ouest - ICO - Site Paul Papin, Angers, FR, 9Institut Bergonié, Bordeaux,
FR, 10Centre Georges-François Leclerc, Dijon, FR, 11Université Paris Cité, AP-HP, Hôpital
Européen Georges Pompidou, Paris, FR, 12Centre Hospitalier Universitaire de Saint-
Etienne, pôle de cancérologie, Saint-Étienne, FR, 13Centre Azuréen de Cancérologie,
MOUGINS, FR, 14Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR, 15Institut
de Cancérologie de l’Ouest – Site René Gauducheau, Saint-Herblain, FR, 16Institut de
Cancérologie de Lorraine - Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 17Hôpital
Saint-Joseph, Marseille, FR, 18Hospices Civil de Lyon – Centre Hospitalier Lyon Sud,
PIERRE BENITE, Pierre-Bénite, FR, 19Université de Paris Cité, AP-HP, Cochin Port-Royal,
Paris, FR

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome,
IT
09:45 - 10:00 Q&A

08:45 - 10:00 Type: Multidisciplinary session Toledo Auditorium -
Title: Relieving complex suffering in women with advanced Hall 3
cervical cancer
Chair(s): Snezana Bosnjak, RS; Giovanni Aletti, IT

S. Bosnjak, Institute for Oncology and Radiology of Serbia, Belgrade, RS
08:50 - 09:05 Refractory pain

J. Paice, Northwestern University, Chicago, US
09:05 - 09:20 Ureteral and bowel obstruction, haemorrhage: A surgical perspective

G. Aletti, IEO - Istituto Europeo di Oncologia, Milan, IT
09:20 - 09:35 A psycho-oncologist’s perspective

M. Die-Trill, Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES
09:35 - 09:50 Nausea and vomiting in advanced cervical cancer

A. Baptista Capela, Centro Hospitalar Vila Nova de Gaia / Espinho, Vila Nova de Gaia, PT

08:45 - 10:00 Type: Multidisciplinary session León
Title: Interdisciplinary management of advanced and functional Auditorium -
digestive neuroendocrine tumours Hall 7
Chair(s): Rachel Riechelmann, BR; Stefano Partelli, IT

S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
08:50 - 09:10 Role of surgery in advanced disease

S. Partelli, UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT
09:10 - 09:30 Role of locoregional and ablative therapies

R. Riechelmann, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR
09:30 - 09:50 Role of systemic therapies in the control of hormone-release

S. Singh, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

08:45 - 09:45 Type: Young Oncologists session Ávila Auditorium - NCC
Title: YO Boxing session
Chair(s): Maria Kfoury, FR; Emre Kocakavuk, DE
08:45 - 08:55 Do you need a basic science rotation for your career in oncology? Yes
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES
08:55 - 09:05 Do you need a basic science rotation for your career in oncology? No
S. Pilotto, University of Verona, Verona, IT
09:05 - 09:15 Discussion led by Chairs
09:15 - 09:25 Off-label molecular-guided treatments are a reasonable approach for refractory
advanced solid tumours - Yes
B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna,
AT
09:25 - 09:35 Off-label molecular-guided treatments are a reasonable approach for refractory
advanced solid tumours - No
Y. Metaxas, Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH
09:35 - 09:45 Discussion led by Chairs

10:00 - 11:00 Type: Special session Pamplona
Title: Climate Change Task Force - How to build more Auditorium -
sustainable and environment-friendly oncology care Hall 9
Chair(s): Mathilde Jalving, NL; Rebecca Lee, GB
10:00 - 10:10 Moving towards a sustainable academic society: Update from the ESMO Climate
Change Task Force
R. Lee, The University of Manchester, Manchester, GB
10:10 - 10:20 Climate toxicity of cancer care

S. O'Reilly, CUH - Cork University Hospital, Cork, IE
10:20 - 10:30 A sustainable oncology department: Practical tips and tricks

M. Wolodarski, Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE
10:30 - 10:40 Rationale drug prescribing to reduce environmental impact

R. Van Leeuwen, Erasmus MC - University Medical Center, Rotterdam, NL

Title: Proffered Paper session - Breast cancer, Hall 9
metastatic
Chair(s): Hervé Bonnefoi, FR; Janice Wing-Hang Tsang, HK
10:15 - 10:25 381O - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with
advanced solid tumors
J. Wu1, J. Zhang2, H. Li3, X. Wang4, Q.Y. Zhang5, Y. Shi6, M. Yan7, Y. Pan8, A. Shen9, Q.
Chen10, Q. Rao10, H. Wei11, C. Li11, L. Yang11, Q. Huang11, Z. Cao11, Q. Wu11, 1Fudan
University Cancer Institute, Shanghai, CN, 2Fudan University Shanghai Cancer Center,
Shanghai, CN, 3Peking University Cancer Hospital and Institute, Beijing, CN, 4Zhejiang
Cancer Hospital - Cancer Research Institute, Hangzhou, CN, 53rd Affiliated Hospital of
Harbin Medical University, Harbin, CN, 6TMUCIH - Tianjin Medical University Cancer
Institute and Hospital, Tianjin, CN, 7Henan Cancer Hospital/Affiliated Cancer Hospital of
Zhengzhou University, Zhengzhou, CN, 8Anhui Provincial Hospital, Hefei, CN, 9The First
Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, 10Sun Yat-Sen
Memorial Hospital, Guangzhou, CN, 11Hansoh Pharma Group CO.,LTD., Shanghai, CN
10:25 - 10:35 376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice
(TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast
cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-
Breast04 study
S. Modi1, W. Jacot2, H. Iwata3, Y.H. Park4, M.J. Vidal Losada5, W. Li6, J. Tsurutani7, K.
Zaman8, N. Ueno9, A. Prat10, K. Papazisis11, H. Rugo12, N. Harbeck13, S.-A. Im14, M. De
Laurentiis15, C. Orbegoso16, L. Yung17, F.-C. Cheng17, Y. Cheng17, D. Cameron18,
1Memorial Sloan Kettering Cancer Center, New York, US, 2Institut du Cancer de

Montpellier, Montpellier, FR, 3Aichi Cancer Center Hospital, Nagoya, JP, 4Samsung
Medical Center, Seoul, KR, 5Hospital Clínic de Barcelona, Barcelona, ES, 6The First
Hospital of Jilin University, Changchun, CN, 7Showa University, Shinagawa, JP, 8Lausanne
University Hospital CHUV, Lausanne, CH, 9University of Hawaii Cancer Center,
Honolulu, US, 10Translational Genomics and Targeted Therapies Group, August Pi i
Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, 11Euromedica General
Clinic, Thessaloniki, GR, 12UCSF Helen Diller Family Comprehensive Cancer Center, San
Francisco, US, 13LMU University Hospital, Munich, DE, 14Seoul National University
Hospital, Seoul National University College of Medicine, Seoul, KR, 15Istituto Nazionale
Tumori IRCCS Fondazione G. Pascale, Napoli, IT, 16Daiichi Sankyo, Inc., Rueil-
Malmaison, FR, 17Daiichi Sankyo, Inc., Basking Ridge, US, 18University of Edinburgh,
Edinburgh, GB

G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT
10:45 - 10:55 Q&A
10:55 - 11:05 377O - A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts)
With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain
Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
S. Hurvitz1, S. Modi2, W. Li3, Y.H. Park4, W. Chung5, S.-B. Kim6, J. Cortés7, T. Yamashita8,
J. Pedrini9, S.-A. Im10, L.-M. Tseng11, N. Harbeck12, I. Krop13, G. Curigliano14, E.
Mathias15, J. Cathcart16, A. Cagnazzo15, S. Ashfaque15, A. Egorov15, F. André17, 1David
Geffen School of Medicine at UCLA, Los Angeles, US, 2Memorial Sloan Kettering Cancer
Center, New York, US, 3The First Hospital of Jilin University, Changchun, CN, 4Samsung
Medical Center, Seoul, KR, 5National Cheng Kung University, Tainan City, TW, 6Asan
Medical Center, Seoul, KR, 7International Breast Cancer Center, Barcelona, ES,
8Kanagawa Cancer Center, Yokohama, JP, 9Hospital Nossa Senhora da Conceicao, Porto
Alegre, BR, 10Seoul National University Hospital, Seoul, KR, 11Taipei Veterans General
Hospital, Taipei City, TW, 12LMU University Hospital, Munich, DE, 13Yale Cancer Center,
New Haven, US, 14European Institute of Oncology, IRCCS, and University of Milan,
Milan, IT, 15Daiichi Sankyo, Inc., Basking Ridge, US, 16Daiichi Sankyo Inc., Basking
Ridge, US, 17Institiut Gustave Roussy, Villejuif, FR
11:05 - 11:15 378O - Persistence under abemaciclib and endocrine treatment (ABA+ET) in
patients with advanced breast cancer (aBC) – first results of the randomized
IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching
Tool (MOATT) versus local routine patient coaching (LC).
M. Welslau1, P. Fasching2, L. Mueller3, E. Belleville4, L. Rieger5, M.-O. Zahn6, B. Lex7, L.

Häberle8, H. Tesch1, 1Klinikum Aschaffenburg, Aschaffenburg, DE, 2Universitätsklinikum
Erlangen, Erlangen, DE, 3Onkologie Untere Ems - Leer Papenburg Emden, Leer, DE,
4ClinSol, wuerzburg, DE, 5Praxis Dr. Vehling-Kaiser, Landshut, DE, 6MVZ Onkologische
Kooperation Harz, Goslar, DE, 7Department of Gynecology and Obstetrics, Kulmbach, DE,
8Universitätsklinik Erlangen, Erlangen, DE

J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK
11:25 - 11:35 Q&A
10:15 - 11:45 Type: Special symposium Sevilla

Title: Open questions in immunotherapy for advanced NSCLC: Auditorium -
Duration of IO, combinations and rechallenge Hall 9
Chair(s): Sanjay Popat, GB; Raffaele Califano, GB

R. Califano, The Christie NHS Foundation Trust, Manchester, GB
10:20 - 10:35 Duration of IO treatment

B. Besse, Institut Gustave Roussy, Villejuif, FR
10:35 - 10:50 Immunotherapy re-challenge: Who, when and why

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
CA
10:50 - 11:05 When and how to combine PD-1/PD-L1?

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB
11:05 - 11:20 How to overcome IO resistance: New approaches

E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

10:15 - 11:45 Type: Special symposium Granada Auditorium - Hall 3
Title: Upper GI cancers: From bench to bedside
Chair(s): Nicole van Grieken, NL; Kohei Shitara, JP
10:20 - 10:35 Heterogeneity, evolution, and outcomes in gastroesophageal cancer

S. Klempner, MGH - Massachusetts General Hospital, Boston, US
10:35 - 10:50 ctDNA: From theory to clinical translation

J. Lee, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine,
Seoul, KR
10:50 - 11:05 New directions in pancreas cancer

C. Jorgensen, Cancer Research UK Manchester Institute, Manchester, GB
11:05 - 11:20 Evolving diagnostics in gastroesophageal cancer

N. Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, NL

10:15 - 11:45 Type: Special symposium Burgos
Title: What’s the future in melanoma therapy? Novel targets, Auditorium - Hall
new drugs, reinvented approaches 3
Chair(s): Omid Hamid, US; Joanna Mangana, CH
10:20 - 10:40 Revisiting old friends: New clinical developments of MEKi/BRAFi/NRASi

combinations
R. Sullivan, MGH - Massachusetts General Hospital, Boston, US
10:40 - 11:00 Bispecific T-Cell engagers (TCE) and fusion protein carriers: Ready for prime-
time in melanoma?
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US
11:00 - 11:20 Clinical data, NGS, (x)-omics et al.: What is the ideal mixture to identify and
overcome primary resistance to immune-checkpoint inhibitors?
I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU
10:15 - 11:45 Type: Proffered Paper session Salamanca Auditorium

Title: Proffered Paper session 1 - Basic Science and - Hall 3
Translational research
Chair(s): Federica Di Nicolantonio, IT; Stefan Fröhling, DE
10:15 - 10:25 LBA55 - An ultra-sensitive and specific ctDNA assay provides novel pre-operative
disease stratification in early stage lung cancer
J. Black1, A. Frankell1, S. Veeriah2, M. Colopi2, M. Hill1, C. Abbott3, S. Boyle3, B. Li3, R.

Chen3, M. Al Bakir1, C. Martinez Ruiz2, A. Huebner2, M. Jamal-Hanjani4, N.
Mcgranahan4, C. Swanton1, 1Francis Crick Institute, London, GB, 2University College
London, London, GB, 3Personalis, Inc. - Headquarters (Office and Laboratory), Menlo
Park, US, 4UCL Cancer Institute - Paul O'Gorman Building, London, GB
10:25 - 10:35 1206O - Clinical subtyping of cancer from blood based on comprehensive
epigenomic profiling
S. Baca1, J.-H. Seo2, J. Berchuck1, T. El Zarif1, R. Saliby1, K. Semaan2, B. Fortunato1, M.

Awad1, C. Chau3, J.A. Decaprio2, W.D. Figg3, A. Hata4, F.S. Hodi5, K. Ligon2, K. Ng2, M.
Oser2, S. Tolaney2, P. Wen2, M. Freedman1, T. Choueiri1, 1Dana-Farber Cancer Institute,
Boston, US, 2Dana Farber Cancer Institute, Boston, US, 3NIH - National Institutes of
Health, Bethesda, US, 4MGH - Massachusetts General Hospital, Boston, US, 5Dana

Farber Cancer Institute - Longwood Center, Boston, US
10:35 - 10:45 LBA16 - Primary analysis of efficacy and safety in the CUPISCO trial: A
randomised, global study of targeted therapy or cancer immunotherapy guided
by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy
(CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
L. Mileshkin1, T. Bochtler2, C. Pauli3, G. Durán-Pacheco4, C. Arslan5, F. Bigot6, N.

Chalabi4, N. Cook7, A. Italiano8, F. Losa9, J. Menezes10, C. Michaud4, M. Ozguroglu11, R.
Pazo Cid12, J. Ross13, K.-K. Shiu14, M. Stahl15, M. Thomas4, H. Moch3, A. Krämer2, 1The
University of Melbourne, Melbourne, AU, 2German Cancer Research Center (DKFZ) and
University of Heidelberg, Heidelberg, DE, 3University of Zürich and University Hospital
Zürich, Zurich, CH, 4F. Hoffmann-La Roche Ltd, Basel, CH, 5Medical Park İzmir Hospital,
İzmir, TR, 6Institut de Cancérologie de l'Ouest, Nantes-Angers, FR, 7The University of
Manchester and the Christie NHS Foundation Trust, Manchester, GB, 8Institute
Bergonié, Bordeaux, FR, 9Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet,
Barcelona, ES, 10Centro Pesquisa Integrado em Oncologia, Porto Alegre, BR, 11Istanbul
University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, TR, 12Miguel Servet
University Hospital, Zaragoza, ES, 13Foundation Medicine, Inc./SUNY Upstate Medical
University, Cambridge, US, 14UCL Cancer Institute, London, GB, 15Evang. Kliniken
Essen-Mitte, Essen, DE
10:45 - 10:55 Invited Discussant LBA55, 1206O and LBA16

F. Di Nicolantonio, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT
10:55 - 11:05 Q&A
11:05 - 11:15 1207O - Beyond 100,000 Genomes Project: Whole Genome Sequencing for
cancer patients within NHS Genomic Medicine Service
A. Sosinsky1, S. Walker1, J. Ambrose1, R. Coleran1, O. Yavorska1, A. Hamblin1, N.

Murugaesu1, P. Talley2, S. `Hing2, J. Starczynski2, S. Deans2, S. Hill2, 1Genomics England
Ltd, London, GB, 2NHS England, London, GB
11:15 - 11:25 2231O - Pan-cancer assessment of the impact of intronic variants on cancer
development and progression
A. Safonov1, M. Mehine2, O. Ceyhan-Birsoy2, D. Brown2, C. Bandlamudi1, A. Forbes3, A.

Gazzo2, P. Selenica2, R. Shen2, E. Khurana4, L. Norton5, D. Solit1, S. Chandarlapaty1, P.
Razavi2, M. Robson1, B. Weigelt1, M. Berger2, M. Ladanyi1, J. Reis-Filho1, D. Mandelker2,
1MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, 2Memorial Sloan
Kettering Cancer Center, New York, US, 3Weill Cornell Medical College, New York, US,
4Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, US,
5Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

C. Swanton, Francis Crick Institute, London, GB

11:35 - 11:45 Q&A
10:15 - 11:15 Type: Mini Oral session Málaga Auditorium - Hall 10

Title: Mini oral session - Head and neck cancer
Chair(s): Panagiota Economopoulou, GR; Marc Oliva, ES
10:15 - 10:20 855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer
squamous cell carcinoma (HNSCC): phase 2 trial evaluating the efficacy and the
toxicity of Nivolumab (ADJORL1).
J. Guerlain1, N. Cozic1, A. Daste2, O. Malard3, J. Fayette4, F. Rolland5, O. Mauvais6, A.

Johnson7, S. Salas8, M. Vinches9, A. Bozec10, S. Vergez11, E. De Monès12, I. Breuskin1,
M. Iacob13, B. Archambaud1, F. Janot1, C. Even13, 1Gustave Roussy - Cancer Campus,
Villejuif, FR, 2CHU Bordeaux - Hopital St. André, Bordeaux, FR, 3Chu Nantes Hotel Dieu,
Nantes, FR, 4Centre Léon Bérard, Lyon, FR, 5ICO Institut de Cancerologie de l'Ouest
René Gauducheau, Saint-Herblain, FR, 6CHRU Besancon - Hopital Jean Minjoz,
Besancon, FR, 7Centre Francois Baclesse, Caen, FR, 8AP-HM - CHU La Timone Enfants,
Marseille, FR, 9ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 10Centre
Antoine Lacassagne ( CLCC), Nice, FR, 11IUCT - Institut Universitaire du Cancer de
Toulouse - Oncopole, Toulouse, FR, 12CHU - Centre Universitaire Hospitalier de
Bordeaux, Bordeaux, FR, 13Institut Gustave Roussy, Villejuif, Cedex, FR
10:20 - 10:25 856MO - A Randomized Phase II Study of Concurrent vs. Sequential

Pembrolizumab with Chemoradiation (CRT) in Locally Advanced Head and Neck
Cancer (LA HNSCC): 4-year results and tumor-immune microenvironment
analysis.
D. Zandberg1, D. Clump1, B. Isett1, R. Bao1, H. Wang1, L. Vujanovic1, H. Li1, J. Ohr1, M.

Fenton1, H. Skinner1, R. Seethala1, S. Chiosea1, B. Jonathan2, J. Bauman3, R. Ferris4,
1UPMC Hillman Cancer Center, Pittsburgh, US, 2Winship Cancer Institute of Emory
University, Atlanta, US, 3University of Arizona Cancer Center, Tucson, US, 4University of
Pittsburgh Cancer Institute, Pittsburgh, US
10:25 - 10:30 LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for
recurrent/metastatic Head & Neck Squamous Cell Carcinoma (RMHNSCC)
patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-
ONCO-1, a novel, first in class cell encapsulation-based immunotherapy.
N. Mach1, E. Fernandez1, R. Vernet1, O. Vonrohr1, M. Urwyler1, E. Charrier1, M.-C.

Belkouch1, V. Saingier1, F. Courtout1, C. De Vito1, O. Rubin1, V. Ancrenaz1, J. Grogg2, J.
Renaux3, K. Gysel4, G. Müller4, T. Brezina5, T. Rordorf5, M. Joerger6, O. Michielin1,
1Geneva University Hospital HUG, Geneva, CH, 2MaxiVax SA, Geneva, CH, 3MaxiVAX SA,
Geneva, CH, 4SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, 5University
Hospital Zurich (USZ), Zurich, CH, 6Kantonsspital St. Gallen, St. Gallen, CH
10:30 - 10:45 Invited Discussant 855MO, 856MO and LBA46

P. Economopoulou, Attikon University Hospital, Haidari, GR
10:45 - 10:50 859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory
(R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from
the phase 2 TROPiCS-03 basket trial
L. Michel1, A. Jimeno2, A. Sukari3, T. Beck4, J. Chiu5, E. Ahern6, J. Hilton7, A.
Hollebecque8, S. Zanetta9, J. Patel10, S. Mekan10, T. Wu10, E. Dumbrava11, 1Memorial
Sloan Kettering 64th Street Outpatient Center, New York, US, 2University of Colorado
Cancer Center & Charles C. Gates Center of Stem Cell Biology, Aurora, US, 3Barbara Ann
Karmanos Cancer Institute, Detroit, US, 4Highlands Oncology Group - Rogers,
Fayetteville, US, 5The University of Hong Kong Queen Mary Hospital, Hong Kong, HK,
6Monash Medical Centre, Clayton, AU, 7The Ottawa Hospital Regional Cancer Centre,
Ottawa, CA, 8Gustave Roussy, Villejuif, FR, 9Centre Georges-François Leclerc (Dijon),
Dijon, FR, 10Gilead Sciences, Inc., Foster City, US, 11The University of Texas M. D.
Anderson Cancer Center, Houston, US
10:50 - 10:55 860MO - MRG003, a novel EGFR-targeted antibody-drug conjugant (ADC) for
recurrent/metastatic Nasopharyngeal Carcinoma
F. Han1, F. Wang1, Y.-R. Shi2, Y. Guo3, X.-L. Shu4, S. Pan5, S.-H. Qu6, P. Zhang7, Y. Jiang8,
M.-J. Xu9, K. Lei10, S. Qu11, F. Lei12, X. Lv13, Y.-Q. Xiang1, R.-H. Xu1, 1Sun Yat-sen
University Cancer Center, Guangzhou, CN, 2Hunan Cancer Hospital, Changsha, CN,
3Shanghai East Hospital, Shanghai, CN, 4Chongqing University Cancer Hospital,
Chongqing, CN, 5Yuebei People's Hospital, Shaoguan, CN, 6The People's Hospital of
Guangxi Zhuang Autonomous Region, Nanning, CN, 7West China School of
Medicine/West China Hospital of Sichuan University, Chengdu, CN, 8Cancer Hospital of
Shantou University Medical College, Shantou, CN, 9First Affiliated Hospital of Gannan
Medical university, Ganzhou, CN, 10The Second People's Hospital of Yibin City, YiBin, CN,
11Guangxi Medical University Affiliated Tumour Hospital, Nanning, CN, 12Zhongshan
City People’s Hospital, Zhongshan, CN, 13Sun Yat-Sen University Cancer Center,
Guangzhou, CN
10:55 - 11:00 LBA47 - A phase 2 study evaluating tipifarnib in mHRAS, recurrent or metastatic
(R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
A. Ho1, D. Adkins2, G. Hanna3, J. Bruce4, M.-J. Ahn5, L. Iglesias Docampo6, H. Kang7, D.

Wong8, A. Psyrri9, M. Gillison10, I. Braña11, Y.C. Liu12, C.-Y. Hsieh 13, M.H. Hong14, Z.
Zhang15, B. Balsara15, A. Saunders15, A. Gasco Hernandez15, S. Dale15, R. Haddad3,
1Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, 2Washington
University School of Medicine in St. Louis, St. Louis, US, 3Dana Farber Cancer Institute,
Boston, US, 4University of Wisconsin Carbone Cancer Center, Madison, US, 5Samsung
Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR,
6Hospital Universitario 12 de Octubre, Madrid, ES, 7University of California San
Francisco, San Francisco, US, 8UCLA - David Geffen School of Medicine, Los Angeles,
US, 9Attikon University Hospital, Haidari, GR, 10University of Texas MD Anderson
Cancer Center, Houston, US, 11Vall d'Hebron University Hospital, Barcelona, ES,
12Taichung Veterans General Hospital, Taichung City, TW, 13China Medical University
Hospital, Taichung City, TW, 14Severance Hospital, Yonsei University College of Medicine,
Seoul, KR, 15Kura Oncology, Inc., Boston, US

M. Oliva, Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet),
Barcelona, ES

10:15 - 11:45 Type: Mini Oral session Toledo Auditorium - Hall 3
Title: Mini oral session - Sarcoma
Chair(s): Piotr Rutkowski, PL; Kjetil Boye, NO; Nadia Hindi, ES
10:15 - 10:20 1914MO - The clinico-radiological outcome of desmoid type-fibromatosis after

discontinuing the sorafenib treatment in responders: Single-arm phase II
clinical trial
B. Bharath1, S. Rastogi1, V. Garg2, G. Tansir1, E. Dhamija1, A. Barwad1, S. Kaur1, S.

Gamanagatti1, S. Bhoriwal1, M. Khan1, 1AIIMS - All India Institute of Medical Sciences,
New Delhi, IN, 2Princess Margaret Cancer Centre, Toronto, CA
10:20 - 10:25 1915MO - Fear, anxiety and depression in gastrointestinal stromal tumor (GIST)
patients in the Netherlands: data from a cross-sectional multicenter study
D. Van De Wal1, D. Den Hollander2, I. Desar2, H. Gelderblom3, A. Oosten4, A. Reyners5,

N. Steeghs1, W. Van Der Graaf1, O. Husson1, 1NKI-AVL - Netherlands Cancer
Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 2Radboud University
Medical Center, Nijmegen, NL, 3LUMC - Leids University Medical Center, Leiden, NL,
4Erasmus MC, Rotterdam, NL, 5UMCG - University Medical Center Groningen,
Groningen, NL

P. Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw,
PL
10:35 - 10:40 1916MO - A first-in-human phase 1 trial of NB003, a potent and selective
KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal
tumors (GIST)
P. Chi1, L. Shen2, J. Li3, J. Zhang4, K. Hu5, L. Zhang5, Y. Xu5, 1Memorial Sloan Kettering
Cancer Center, New York, US, 2Peking University Cancer Hospital and Institute, Beijing,
CN, 3Peking University Cancer Hospital and Institute, beijing, CN, 4Fudan University
Shanghai Cancer Center, Shanghai, CN, 5Ningbo Newbay Technology Development Co.,
Ltd., Ningbo, CN
10:40 - 10:45 1917MO - CHAPTER-GIST-101: A phase I study of pimitespib combined with

imatinib in patients with imatinib-refractory gastrointestinal stromal tumor
Y. Naito1, Y. Komatsu2, Y. Kurokawa3, H. Hirano4, T. Nishida5, T. Doi1, 1National Cancer

Center Hospital East, Kashiwa, JP, 2Hokkaido University Hospital, Sapporo, JP, 3Graduate
School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, 4National Cancer
Center Hospital, Tokyo, JP, 5NCCH - National Cancer Center Hospital, Chuo-ku, JP
10:45 - 10:50 1918MO - Circulating tumor DNA in relation to tumor volume in gastro-
intestinal stromal tumors
R. Bleckman1, C. Haag1, R. Mathijssen2, N. Steeghs3, H. Gelderblom4, I. Desar5, A. Ter

Elst1, E. Schuuring1, A. Reyners6, 1UMCG - University Medical Center Groningen,
Groningen, NL, 2Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL,
3Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL,
4LUMC - Leids Universitair Medisch Centrum, Leiden, NL, 5Radboud University Medical
Center, Nijmegen, Nijmegen, NL, 6University Medical Center Groningen, University of

Groningen, Groningen, NL

K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO
11:00 - 11:05 1919MO - Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in
patients (pts) with refractory metastatic sarcoma
B. Wilky1, J. Trent2, M. Gordon3, A. El-Khoueiry4, A. Bullock5, B. Henick6, G. Schwartz6,

M. Agulnik7, D. Mahadevan8, J. Patel9, J. Grossman9, K. Rosenthal9, S. O'Day10, A.M.
Tsimberidou11, 1UCHealth Cancer Care - Anschutz Medical Campus - University of
Colorado Cancer Center, Aurora, US, 2Sylvester Comprehensive Cancer Center -
University of Miami, Miami, US, 3HonorHealth Research Institute, Scottsdale, US, 4USC -
University of Southern California - Keck School of Medicine, Los Angeles, US, 5Beth
Israel Deaconess Medical Center, Boston, US, 6Columbia University Medical Center
College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, 7City
of Hope Comprehensive Cancer Center, Duarte, US, 8UT Health San Antonio MD
Anderson Cancer Center, San Antonio, US, 9Agenus Inc - Corporate HQ, R&D and
Vaccine Manufacturing, Lexington, US, 10Agenus Inc, Lexington, US, 11The University of
Texas MD Anderson Cancer Center, Houston, US
11:05 - 11:10 1920MO - Regomune : a phase II study of regorafenib + avelumab in solid

tumors : results of the advanced or metastatic gastrointestinal stromal tumors
(mGIST) cohort.
S. Cousin1, C. Bellera2, J.-P. Guegan3, T. Valentin4, B. Verret5, J.-P. Metges6, A. Adenis7, P.

Cassier8, F. Bouteiller2, M. Spalato Ceruso1, I. Korakis9, A. Hollebecque10, P.G.
Poureau11, J. Palussiere12, M. Kind2, I. Soubeyran13, A. Bessede3, A. Italiano13, 1Institut
Bergonie, Bordeaux, FR, 2Institut Bergonié, Bordeaux, FR, 3Explicyte, Bordeaux, FR,
4Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, 5Institut Gustave
Roussy, Villejuif, FR, 6CHU Morvan - Institut de Cancerologie et d'Hematologie, Brest,

FR, 7ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, 8Centre Léon
Bérard, Lyon, FR, 9Iuct Oncopole, Toulouse, FR, 10Institut Gustave Roussy, Villejuif,
Cedex, FR, 11CHRU Brest - Hopital Augustin Morvan, Brest, FR, 12Institute Bergonié -
Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, 13Institute Bergonié,
Bordeaux, FR
11:10 - 11:15 1921MO - Patterns of care, outcome and molecular landscape of PATZ1-
rearranged sarcomas identifies two prognostic profiles; a: cohort study from the
French Sarcoma Group (FSG)
H. Vanacker1, F. Le Loarer2, M. Karanian1, A. Meurgey1, A. Dufresne1, S. El Zein3, J.-Y.

Blay1, O. Collard4, I. Ray-Coquard1, W. Waissi1, D. Pissaloux1, S. Paindavoine1, A.
Houlier1, G. Pierron3, P. Meeus1, F. Tirode1, M. Brahmi1, 1Centre Léon Bérard, Lyon, FR,
2Institut Bergonié, Bordeaux, FR, 3Institut Curie, Paris, FR, 4Institute de Cancerologie de
la Loire, Saint-Priest-en-Jarez, FR

N. Hindi, Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,
Madrid, ES

10:15 - 11:45 Type: Special session Oviedo Auditorium -
Title: Bridging the Efficacy-Effectiveness (E-E) gap for Hall 7
cancer therapies
Chair(s): Hendrik van Halteren, NL; John Cairns, GB
10:15 - 10:30 Which factors can cause an E-E gap?

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL
10:30 - 10:45 How often and to which extent does the E-E gap seriously affect treatment
outcome in daily practice?
G. Sonke, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
10:45 - 11:00 Which adaptations in trials and daily practice could bridge the E-E gap?
M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL
11:00 - 11:15 Under which circumstances could effectiveness data be used for clinical
guidelines?
H. Groen, UMCG - University Medical Center Groningen, Groningen, NL
11:15 - 11:30 Should effectiveness data be taken into consideration for drug appraisal by
regulatory authorities?
J. Cairns, London School of Hygiene & Tropical Medicine, London, GB
10:15 - 11:45 Type: Mini Oral session León Auditorium - Hall 7

Title: Mini oral session: CNS tumours
Chair(s): Emeline Tabouret, FR; Joan Seoane, ES; Andreas Hottinger, CH
10:15 - 10:20 502MO - Target therapy matched to genomic alterations in patients with
recurrent IDH wildtype glioblastoma: a real-life cohort analysis from Veneto
Institute of Oncology, Padua (Italy)
G. Cerretti1, M. Padovan1, C. De Toni1, M. Maccari1, A. Bosio1, M. Caccese1, M. Corrà1,

I. Cestonaro1, A. Pittaro1, A. Guerriero2, M. Coppola1, G. Lombardi1, 1IOV - Istituto
Oncologico Veneto IRCCS, Padova, IT, 2Azienda Universitaria Ospedaliera di Padova,
Padova, IT
10:20 - 10:25 503MO - Real-world clinical and genomic characterization of gliomas : predictive
and prognostic insights
O. Mirallas1, G. Velilla2, F. Ruiz-Pace3, J. Yaringaño1, T. Gorria4, D. Gomez-Puerto1, Á.

Martínez5, D. López Valbuena1, M.A. Vaz Salgado6, A. Hernandez Gonzalez7, M. Aguado
Sorolla8, K. Raskina9, M. Gonzalez Rodriguez1, M. Martinez Garcia5, J. Carles Galceran1,
C. Balana10, E. Pineda11, R. Dienstmann12, J.M. Sepúlveda Sánchez13, M. Vieito Villar1,
1Vall d'Hebron University Hospital, Barcelona, ES, 2Instituto de Investigación Sanitaria

Hospital 12 de Octubre (i+12), Madrid, ES, 3Vall d'Hebron Institute of Oncology (VHIO)-
Cellex Center, Barcelona, ES, 4Hospital Clinic of Barcelona, Barcelona, ES, 5Hospital del
Mar - Parc de Salut Mar, Barcelona, ES, 6Hospital Universitario Ramon y Cajal, Madrid,
ES, 7Institut Catala d’Oncologia (ICO) Badalona, Badalona Applied Research Group in
Oncology (B- ARGO Group), Badalona, ES, 8Hospital de la Santa Creu i Sant Pau,
Barcelona, ES, 9VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, 10ICO -
Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol),
Badalona, ES, 11Hospital Clinic y Provincial de Barcelona, Barcelona, ES, 12Grupo
Oncoclinicas, Sao Paulo, BR, 13Hosp. Doce de Octubre, Madrid, ES
10:25 - 10:30 504MO - Validation of a spectroscopic liquid biopsy for the earlier detection of
brain cancer
J. Cameron1, A. Sala1, J. Conn1, G. Antoniou1, D. Palmer1, M. Baker2, 1Dxcover Limited,

Glasgow, GB, 2University of Central Lancashire, Preston, GB

J. Seoane, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES
10:45 - 10:50 505MO - A Phase 0/1b Study of AZD1390 plus Radiotherapy in Recurrent
Glioblastoma Patients
N. Sanai, S. Desai, T. Margaryan, C. Lo Cascio, M. Elliott, J. Molloy, J. Harmon, A. Hong,
E. Luna Melendez, J. Wanebo, K. Braun, W. Kennedy, M. Garcia, W. Yoo, A. Tovmasyan, A.-
C. Tien, S. Mehta, Barrow Neurological Institute, Phoenix, US
10:50 - 10:55 506MO - A phase I dose-expansion cohort of SYHA1813, a vascular endothelial

growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor
(CSF1R) inhibitor, in patients (pts) with recurrent meningioma
W. Li1, Z. Kang1, Z. Wu1, S. Li1, M. Huang1, W. Pu2, X. Yang2, J. Lin2, M. Liu2, 1Beijing
Tiantan Hospital, Capital Medical University, Beijing, CN, 2CSPC Pharmaceutical Group
Limited, Shijiazhuang, CN

A. Hottinger, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
11:10 - 11:15 507MO - REGOMA-OS: a large Italian multicenter, prospective, observational

study analyzing regorafenib efficacy and safety in recurrent glioblastoma
patients
G. Lombardi1, I. Desideri2, V. Villani3, M. Simonelli4, M. Buglione5, S. Chiesa6, E.

Franceschi7, P. Gaviani8, I. Stasi9, C. Caserta10, S. Brugnara11, I.R. Lolli12, E.
Bennicelli13, P. Bini14, A. Cuccu15, S. Scoccianti16, G. Magni17, M. Caccese1, G. De
Salvo1, V. Zagonel1, 1IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 2Università di
Firenze- Dipartimento di Patologia e Oncologia Sperimentali, Firenze, IT, 3IRCCS Istiuto
Nazionale Tumori Regina Elena (IRE), Rome, IT, 4Humanitas University, Milan, IT,
5UNIBS - Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT,
6Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, 7Ospedale
Bellaria Carlo Alberto Pizzardi, Bologna, IT, 8Fondazione IRCCS - Istituto Neurologico
C.Besta, Milan, IT, 9Azienda Toscana Nord-Ovest Livorno, LIvorno, IT, 10Azienda
Ospedaliera Santa Maria di Terni, Terni, IT, 11Ospedale Santa Chiara, Trento, IT, 12IRCCS

Castellana Grotte, Castellana Grotte, IT, 13Ospedale Policlinico San Martino, Genova, IT,
14IRCCS Mondino, Pavia, IT, 15A.O.U di Sassari, Sassari, IT, 16Ospedale Santa Maria
Annunziata (Ponte a Niccheri) - USL Toscana Centro, Bagno a Ripoli, IT, 17Veneto
Institute of Oncology IOV – IRCCS, padua, IT
11:15 - 11:20 508MO - Spatial remodeling of the immune tumor microenvironment after
radiotherapy and CXCL12 inhibition in glioblastoma in the phase 1/2 GLORIA
trial
S. Leonardelli1, J.P. Layer1, L.L. Friker1, R. Turiello1, G. Van Der Voort1, D. Corvino1, C.
Schaub1, W. Müller2, E. Sperk3, L.C. Schmeel21, K. Sahm3, S. Kebir4, P. Hambsch2, T.
Pietsch1, K. Thurley1, M. Glas5, C. Seidel2, U. Herrlinger6, F. Giordano3, M. Hölzel1,
1University Hospital Bonn, Bonn, DE, 2University Hospital Leipzig, Leipzig, DE,
3Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, 4University
Hospital Essen, Essen, DE, 5University Hospital Essen - Westdeutsches

Protonentherapiezentrum, Essen, DE, 6Institute of Experimental Immunology - UKB
University of Bonn, Bonn, DE

E. Tabouret, CHU La Timone Adultes, Marseille, FR
10:15 - 11:45 Type: Educational session Cádiz Auditorium

Title: Do we enter a new era of oncology with big data and - NCC
artificial intelligence?
Chair(s): Rudolf Fehrmann, NL; James McKay, FR
10:15 - 10:30 HMA/EMA Big Data Steering Group: How to use big data and AI to assess the
benefit-risk of medicines across their lifecycle
L. Pinheiro, EMA - European Medicines Agency, Amsterdam, NL
10:30 - 10:45 Wearable medical devices in oncology: Hopes and hypes for patients and health
professionals
H. Martins, UBI - Universidade da Beira Interior - Faculdade de Ciencias da Saude,
Covilha, PT
10:45 - 11:05 AI-based therapeutic algorithms in oncology

L. Verlingue, Centre Léon Bérard, Lyon, FR
11:05 - 11:25 What will the European Health Data Space bring us?

10:15 - 11:45 Type: EONS session Alicante Auditorium - Hall
Title: EONS16: Health promotion, prevention and 10
screening
Chair(s): Constantina Cloconi, CY
10:15 - 10:30 Genetics and cancer nurses prevention

C. Diez De Los Rios De La Serna, University of Glasgow, Glasgow, GB
10:30 - 10:45 PrEvCan – Preventing cancer across Europe

L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE
10:45 - 11:00 Perceptions of health promotion among young people

N. Dodlek, University Hospital Center Osijek, Osijek, HR
11:00 - 11:15 Promoting cancer screening among under-represented populations

S. Mulcahy Symmons, University College Dublin, Dublin, IE
11:15 - 11:25 CN18 - Impact of the medical record-based frailty index on the health outcomes
of elderly patients with colorectal cancer
H. Lee, Yonsei University, Seoul, KR

10:30 - 11:45 Type: Controversy session Bilbao Auditorium -
Title: Adjuvant or neoadjuvant immunotherapy or both in NCC
localised NSCLC
Chair(s): Tony S.K. Mok, HK
10:30 - 10:35 Welcome and “set the scene”

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
10:35 - 10:50 Adjuvant only

10:50 - 11:05 Neo adjuvant only

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL
11:05 - 11:20 Neo adjuvant follow by adjuvant

F. Cappuzzo, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT
11:20 - 11:25 First voting
11:25 - 11:40 Perspective from the Chair

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
11:40 - 11:45 Second voting
10:30 - 11:15 Type: Challenge your Expert Valencia

Title: Immunotherapy in dMMR/MSI-H recurrent/metastatic Auditorium -
endometrial cancer: Monotherapy or combination? Hall 10
Chair(s): Domenica Lorusso, IT

S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

IT

10:30 - 11:15 Type: Challenge your Expert Santander
Title: All you want to know about advanced prostate cancer as Auditorium -
we finally enter the era of biomarker-triggered treatment Hall 9
Chair(s): Silke Gillessen, CH

S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU

S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
11:00 - 11:45 Type: Young Oncologists session Ávila Auditorium -

Title: YO Brunch 1: Caring for the LGBTQ+ cancer NCC
patient
Chair(s): Pawel Sobczuk, PL
11:00 - 11:15 Caring for the LGBTQ+ cancer patient

A. Berner, Private Address - Dr. Alison Berner, Milton Keynes, GB

P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL
11:15 - 12:15 Type: Special session Networking Hub -

Title: Patient Guides: Let’s talk about oesophageal and NCC
stomach cancers
11:15 - 12:15 Patient Guides: Let’s talk about oesophageal and stomach cancers
F. Lordick1, R. Obermannova2, E. Smyth3, T. Gašpert4, Z. Maravic5,

1Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE,
2Masaryk Memorial Cancer Institute, Brno, CZ, 3Oxford University Hospitals NHS
Foundation Trust - Churchill Hospital, Oxford, GB, 4University Hospital KBC Rijeka,
Rijeka, HR, 5DiCE - Digestive Cancers Europe vzw/asbl, Overijse, BE
12:00 - 12:30 Type: Keynote lecture Barcelona Auditorium - Hall 9

Title: The hallmarks of cancer in 2023
Chair(s): Charles Swanton, GB
12:00 - 12:05 Introduction by the Chair

C. Swanton, Francis Crick Institute, London, GB
12:05 - 12:30 The hallmarks of cancer in 2023

D. Hanahan, Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH

12:00 - 13:30 Type: EONS Industry Satellite Symposium Alicante
Title: MSD - Improving health literacy across the patient Auditorium -
pathway from screening and prevention to treatment and care Hall 10
Chair(s): Esra Urkmez Uzel, CH
12:00 - 12:05 Opening remarks

E. Urkmez Uzel, ESGO ENGAGe European Network of Gynecological Cancer Advocacy
Group, Geneva, CH
12:05 - 12:15 Cancer nursing's potential to address the growing cancer burden in Europe
D. Protogiros, National Public Health Organisation, Athens, GR
12:15 - 12:25 Role of cancer nurses in cancer screening and prevention

L. Benito, Barcelona University, Barcelona, ES
12:25 - 12:35 Exploring the conceptual underpinnings of cancer literacy and how it guides
policy and action
K. Sorensen, Global Health Literacy Association, Risskov, DK
12:35 - 13:25 Panel discussion and Q&A
E. Urkmez Uzel1, D. Protogiros2, L. Benito3, K. Sorensen4, 1ESGO ENGAGe European

Network of Gynecological Cancer Advocacy Group, Geneva, CH, 2National Public Health
Organisation, Athens, GR, 3Barcelona University, Barcelona, ES, 4Global Health Literacy
Association, Risskov, DK
13:25 - 13:30 Conclusion remarks

E. Urkmez Uzel, ESGO ENGAGe European Network of Gynecological Cancer Advocacy
Group, Geneva, CH

13:00 - 14:30 Type: Industry Satellite Symposium Burgos
Title: Pfizer Oncology - Focus on Individualised Care With Auditorium -
CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer Hall 3
Chair(s): Javier Cortés, ES
13:00 - 13:05 Welcome and Introductions

13:05 - 13:15 Beyond Therapy: How Can You Identify Women’s Goals For Living with
Metastatic Breast Cancer?
13:15 - 14:25 Leveraging Experience for a Personalised Approach in Patients with HR+/HER2-
Metastatic Breast Cancer: An Interactive Discussion
J. Cortés1, H. Rugo2, P. Fasching3, 1Hospital Ruber Internacional, Madrid, ES, 2UCSF

Helen Diller Family Comprehensive Cancer Center, San Francisco, US, 3University
Hospital Erlangen, Erlangen, DE
14:25 - 14:30 Chair’s sum up and Meeting Close


13:00 - 14:30 Type: Industry Satellite Symposium Valencia
Title: Medscape Oncology Global - Keeping the Outcome in Mind: Auditorium -
Applying Best Practices for Managing HR+/HER2- EBC at High Hall 10
Risk of Recurrence
Chair(s): Sara Hurvitz, US

13:05 - 13:20 Keeping the Outcome in Mind: The Patient With HR-Positive, HER2-Negative
Early Breast Cancer at High Risk of Recurrence
13:20 - 13:40 Latest Developments for Oral Adjuvant Therapy: Analyzing the Latest Data,
Guideline Recommendations and Best Practices
13:40 - 14:00 Managing the Patient at Risk: Which Patients Will Benefit from Adjuvant Oral
Anti-Cancer Therapies?
P. Neven1, S. Hurvitz2, 1University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE,

2UCLA Hematology/Oncology Santa Monica, Santa Monica, US
14:00 - 14:15 How to Approach Nonadherence in Practice: Clinical Pearls for the
Multidisciplinary Team
E. Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, US
14:15 - 14:30 Q&A Session
S. Johnston1, P. Neven2, E. Hamilton3, S. Hurvitz4, 1The Royal Marsden Hospital

(Chelsea) - NHS Foundation Trust, London, GB, 2University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE, 3Sarah Cannon Research Institute-Cancer Centre, Nashville,
US, 4UCLA Hematology/Oncology Santa Monica, Santa Monica, US

Title: Bristol Myers Squibb - Clinical Perspectives on the Auditorium -
Evolution of NSCLC Treatment With I-O and ROS1 TKIs Hall 3
Chair(s): Jürgen Wolf, DE

J. Wolf, University Hospital of Cologne, Cologne, DE
13:10 - 13:30 A Foundation for Survivorship With I-O and Potential New Approaches for
Patients With ROS1+ NSCLC
13:30 - 13:55 Multidisciplinary Approach to Managing the Expanding Options With I-O in Non-
Metastatic NSCLC
T. Cascone1, J.L. Campo Canaveral2, 1The University of Texas MD Anderson Cancer

Center - Main Building, Houston, US, 2University Hospital Puerta de Hierro
Majadahonda, Majadahonda, ES
13:55 - 14:18 We Are NSCLC Clinicians: Ask Us Anything
J. Wolf1, T. Cascone2, J.L. Campo Canaveral3, 1University Hospital of Cologne, Cologne,

DE, 2The University of Texas MD Anderson Cancer Center - Main Building, Houston, US,
3University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES


Title: Sanofi - Novel Targets in Advanced NSCLC: Leveraging Auditorium -
Emerging Biomarkers in an Evolving Treatment Landscape Hall 10
Chair(s): Silvia Novello, IT

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT
13:05 - 13:25 Treatment in Advanced NSCLC: What Have We Learned and Where Are We
Headed?
13:25 - 13:45 Tailor-made: Guiding Treatment Choice With Emerging Biomarkers

A. Ryska, University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ
13:45 - 14:05 What Does the Future Hold? Clinical Update on ADCs in Advanced NSCLC
E. Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals),
L'Hospitalet de Llobregat, ES
14:05 - 14:30 Group Discussion
S. Novello1, E. Nadal2, A. Ryska3, 1Università Degli Studi Di Torino - Orbassano,

Orbassano, IT, 2ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals),
L'Hospitalet de Llobregat, ES, 3University Hospital (Fakultni Nemocnice), Hradec
Kralove, CZ

Title: Servier - Shining the light on colorectal cancer: Auditorium - Hall 9
Advancing treatment strategies in mCRC
Chair(s): Eric Van Cutsem, BE; Julien Taieb, FR

E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg,
Leuven, BE
13:10 - 13:30 New approaches in treating patients with mCRC

13:30 - 13:50 Redefining the meaning of later lines of therapy

J. Taieb, Hopital European George Pompidou, Paris, FR
13:50 - 14:20 Patient cases in mCRC and panel discussion

F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT


Title: Merck Healthcare KGaA - Putting Patients First: Auditorium - Hall
Cultivating Care in Bladder Cancer 3
Chair(s): Joaquim Bellmunt, US
13:00 - 13:10 Chairman’s introduction

J. Bellmunt, Harvard Medical School, Boston, US
13:10 - 13:25 Improving treatment standards in advanced UC: What can we learn from clinical
practice?
P. Grivas, University of Washington, Seattle, US
13:25 - 13:40 Patient needs in UC: How to optimize treatment experience

E. Grande Pulido, MD Anderson Cancer Center Madrid, Madrid, ES
13:40 - 13:55 Open questions in UC: Which gaps can we address today?
V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
13:55 - 14:25 Hot topics in UC: What keeps the faculty awake at night
J. Bellmunt1, E. Grande Pulido2, V. Gruenwald3, P. Grivas4, 1Harvard Medical School,

Boston, US, 2MD Anderson Cancer Center Madrid, Madrid, ES, 3University Hospital
Essen Westdeutsches Tumorzentrum, Essen, DE, 4University of Washington, Seattle, US

13:00 - 14:30 Type: Industry Satellite Symposium Oviedo Auditorium -
Title: Amgen - Targeting advanced GI cancer: new Hall 7
approaches on the horizon?
Chair(s): Fernando Rivera, ES

F. Rivera, Hospital Universitario Marqués de Valdecilla, Santander, ES
13:10 - 13:30 Optimising use of targeted therapy across the RAS WT mCRC continuum
13:30 - 13:50 New therapeutic approaches in GI cancers: targeting KRAS mutations

13:50 - 14:10 The pursuit of further actionable targets in advanced gastric and GEJ cancers
Oxford, GB
F. Rivera1, D. Modest2, C. Cremolini3, E. Smyth4, 1Hospital Universitario Marqués de

Valdecilla, Santander, ES, 2Charité - Universitaetsmedizin Berlin, Berlin, DE, 3AOU
Pisana - Stabilimento di Santa Chiara, Pisa, IT, 4Oxford University Hospitals NHS
Foundation Trust - Churchill Hospital, Oxford, GB

Title: Gilead Sciences Europe Ltd - MILLIONS OF LIVES. ONE Auditorium
MISSION. Exploring the potential of ADCs in multiple solid - Hall 7
tumours
Chair(s): Peter Schmid, GB
13:00 - 13:15 Welcome and introduction: ADCs – A journey across time

13:15 - 13:35 Improving the lives of patients with triple-negative and HR+/HER2- metastatic
breast cancer
S. Tolaney, Dana Farber Cancer Institute, Boston, US
13:35 - 13:55 Unlocking the potential for the treatment of metastatic urothelial cancer
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
13:55 - 14:10 Expanding opportunities in patients with metastatic NSCLC

14:10 - 14:30 Q&A and closing remarks
P. Schmid1, S. Tolaney2, T. Powles3, E. Felip4, 1Cancer Research UK Barts Centre - Barts

and The London School of Medicine and Dentistry, London, GB, 2Dana Farber Cancer
Institute, Boston, US, 3St. Bartholomew's Hospital - Barts Health NHS Trust, London,
GB, 4Vall d'Hebron University Hospital, Barcelona, ES

13:00 - 14:30 Type: Patient Advocacy session Cádiz Auditorium -
Title: New approaches for technologies, therapies, and NCC
surgery
Chair(s): Tanja Spanic, SI; Anne-Marie Baird, IE
13:00 - 13:15 How to decide which mutation to investigate and invest in

M.F. Mosele, Gustave Roussy - Cancer Campus, Villejuif, FR
13:15 - 13:30 The promise of CRISPR for therapeutic applications
13:30 - 13:45 Surgical therapies: What are the new robotic models and how do they support
efficient processes in clinical settings?
S. Sandrucci, AOU Città della Salute e della Scienza Torino, Torino, IT
13:45 - 14:00 Radiation therapies: How do proton beam therapy, stereotactic radiosurgery and
gamma knife surgery treat cancer?
P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk,
Antwerpen, BE
14:00 - 14:15 Identification of new biomarkers in lung cancer

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

14:15 - 15:45 Type: EONS session Alicante Auditorium - Hall 10
Title: EONS16: Supportive care
Chair(s): Eva Pape, BE
14:15 - 14:30 eHealth and digital innovations in supportive care: IBM Watson at your service
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY
14:30 - 14:45 Psychosocial aspects of living long term with advanced cancer and ongoing
systemic treatment
E. Kolsteren, Radboud University Medical Center, Nijmegen, NL
14:45 - 15:00 Cancer nurses roles in a late effect clinic

K. Dieperink, Odense University Hospital, Odense C, DK
15:00 - 15:10 CN35 - Educational interventions and strategies that nurses use to support
women with gynecological cancer: A narrative review
C. Mazzega Fabbro1, C. Pavon2, 1CRO Aviano - Centro di Riferimento Oncologico -

IRCCS, Aviano, IT, 2Azienda Sanitaria Universitaria Friuli Centrale, University Hospital of
Udine, Udine, IT
15:10 - 15:20 CN36 - Current care for patients on oral anticancer therapy through a different
lens: assessment from a patient and healthcare professional perspective
A. Van Hecke1, L.-M. Kinnaer2, V. Foulon3, I. Kenis4, 1Ghent University - University

Centre for Nursing and Midwifery, GENT, BE, 2Ghent University - University Centre for
Nursing and Midwifery, Ghent, BE, 3KU Leuven, Leuven, BE, 4Ghent University, Gent, BE

Title: Proffered Paper session 2 - Genitourinary Hall 9
tumours, non-prostate
14:45 - 14:55 LBA87 - Phase 2 LITESPARK-003 Study of Belzutifan in Combination With

Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
T. Choueiri1, T. Bauer2, J. Merchan3, D. Mcdermott4, R. Figlin5, E. Arrowsmith6, M.D.

Michaelson7, E. Heath8, A. D'Souza9, S. Zhao10, L. Mhamdi11, R. Perini11, D. Vickery11,
S. Tykodi12, 1Dana-Farber Cancer Institute, Boston, US, 2Sarah Cannon Research
Institute and Tennessee Oncology, Nashville, US, 3University of Miami Health System,
Miami, US, 4Beth Israel Deaconess Medical Center, Boston, US, 5Cedars-Sinai Medical
Center, Los Angeles, US, 6Tennessee Oncology, Chattanooga, US, 7Massachusetts
General Hospital, Boston, US, 8Karmanos Cancer Institute, Detroit, US, 9University of
Southern California, Los Angeles, US, 10Swedish Medical Center, Seattle, US, 11Merck &
Co., Inc., Rahway, US, 12University of Washington and Fred Hutchinson Cancer Center,
Seattle, US

14:55 - 15:05 LBA88 - Belzutifan versus everolimus in participants (pts) with previously
treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label
phase 3 LITESPARK-005 study
L. Albiges1, B. Rini2, K. Peltola3, G.A. De Velasco Oria4, M. Burotto5, C. Suarez

Rodriguez6, P. Ghatalia7, R. Iacovelli8, E. Lam9, E. Verzoni10, M. Gumus11, W. Stadler12,
C. Kollmannsberger13, B. Melichar14, B. Venugopal15, A. Wang16, R. Perini17, D.
Vickery18, T. Powles19, T. Choueiri20, 1Institut Gustave Roussy, Villejuif, Cedex, FR,
2Vanderbilt Ingram Cancer Center, Nashville, US, 3Comprehensive Cancer Center -
Helsinki University Central Hospital, Helsinki, FI, 4Hospital Universitario 12 de Octubre,

Madrid, ES, 5Bradford Hill-Clinical Center, Santiago, CL, 6Vall d'Hebron University
Hospital, Barcelona, ES, 7Fox Chase Cancer Center - Main Campus, Philadelphia, US,
8Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, 9UCHealth
Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora,
US, 10Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 11Istanbul Medeniyet
University, Prof.Dr. Suleyman Yalcin City Hospital, Istanbul, TR, 12The University of
Chicago Medical Center, Chicago, US, 13BC Cancer Agency - Vancouver, Vancouver, CA,
14FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, 15BWSCC - Beatson West of
Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, 16Merck & Co.,
Inc., Rahway, US, 17Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station,
US, 18Merck & Co., Inc. - Rahway, Rahway, US, 19St. Bartholomew's Hospital - Barts
Health NHS Trust, London, GB, 20Dana Farber Cancer Institute, Boston, US
15:05 - 15:15 1881O - Safety and Efficacy of Two Doses of Belzutifan in Patients (pts) With
Advanced RCC: Results of the Randomized Phase 2 LITESPARK-013 Study
N. Agarwal1, J. Brugarolas2, P. Ghatalia3, S. George4, J. Haanen5, H. Gurney6, R. Ravilla7,

A. Van Der Veldt8, B. Beuselinck9, I. Pokataev10, B. Suelmann11, M. Tuthill12, D. Vaena13,
F. Zagouri14, J. Wu15, Y. Liu15, R. Perini15, J. Merchan16, M. Atkins17, 1Huntsman Cancer
Institute, Salt Lake City, US, 2University of Texas Southwestern Medical Center, Dallas,
US, 3Fox Chase Cancer Center, Philadelphia, US, 4Roswell Park Cancer Institute, Buffalo,
US, 5Netherlands Cancer Institute, Amsterdam, NL, 6Macquarie University, Sydney, AU,
7New York Oncology Hematology - Albany Cancer Center, Albany, US, 8Erasmus MC,
Rotterdam, NL, 9UZ Leuven, Leuven, BE, 10City Clinical Oncology Hospital No. 1,
Moscow, RU, 11Universitair Medisch Centrum Utrecht, Utrecht, NL, 12Oxford University
Hospitals NHS Foundation Trust, London, GB, 13West Cancer Center and Research
Institute, Germantown, US, 14Alexandra Regional General Hospital, Athens, GR, 15Merck
& Co., Inc., Rahway, US, 16University of Miami Hospital and Clinics, Sylvester Cancer
Center-Cancer Research Services, Miami, US, 17Georgetown University Medical Center,
Washington, US
15:15 - 15:30 Invited Discussant LBA87, LBA88 and 1881O

L. Pickering, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
15:30 - 15:40 Q&A
15:40 - 15:50 1882O - RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in
First-line Treatment of Advanced Renal-Cell Carcinoma (RCC): A randomized,
Open-label, Phase 3 Study

X. Sheng1, M. Ye2, Q. Zou3, P. Chen4, Z. He5, B. Wu6, D. He7, C. He8, X. Xue9, Z. Ji10, H.
Chen11, S. Zhang12, Y. Liu13, W. Zhai14, X. Zhang15, C. Fu16, D. Xu17, M. Qiu18, Y.
Huang14, J. Guo1, 1Peking University Cancer Hospital and Institute, Beijing, CN, 2Hunan
Cancer Hospital, Changsha, CN, 3Jiangsu Cancer Hospital, Nanjing, CN, 4Affiliated
Tumor Hospital of Xinjiang Medical University, Urumqi, CN, 5Peking University First
Hospital, Beijing, CN, 6Shengjing Hospital of China Medical University - Nanhu Campus,
Shenyang, CN, 7First Affiliated of Xian Communication University, Xian, CN, 8Henan
Cacer Hospital, Zhengzhou, CN, 9The First Affiliated Hospital of Fujian Medical
University, Fuzhou, CN, 10Chinese Academy of Medical Sciences and Peking Union
Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, 11Harbin
Medical University Cancer Hospital, Harbin, CN, 12West China School of Medicine/West
China Hospital of Sichuan University, Chengdu, CN, 13The First Hospital of China
Medical University, Shenyang, CN, 14Renji Hospital Affiliated to Shanghai Jiaotong
University School of Medicine, Shanghai, CN, 15Beijing Chaoyang Hospital - Capital
Medical University, Beijing, CN, 16Liaoning Cancer Hospital & Institute, Shenyang, CN,
17Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN,
18Sichuan Academy of Medical Sciences/Sichuan Provincial People's Hospital, Chengdu,
CN

A. Van Der Veldt, Erasmus MC - University Medical Center, Rotterdam, NL
16:00 - 16:10 Q&A
14:45 - 16:15 Type: Proffered Paper session Sevilla Auditorium -

Title: Proffered Paper session 1 - Gastrointestinal tumours, Hall 9
lower digestive
Chair(s): Chiara Cremolini, IT; Rodrigo Dienstmann, BR
14:45 - 14:55 LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus

chemotherapy versus long-course chemoradiotherapy followed by chemotherapy
in locally advanced rectal cancer: a randomized phase III trial (UNION)
T. Zhang1, K. Tao1, Z. Lin1, P. Zhang1, Y. Yin1, P. Chi2, Y. Huang2, Y. Xiao3, Z. Sun3, X. Xu4,
A. Zhang5, X. Qiu6, W. Junxin7, Y. Yuan8, Z. Wang9, X.J. Qu9, F. Zhao10, C. Ma10, F.
Cheng10, Z. Hou10, 1Union Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, CN, 2Fujian Medical University Union Hospital, Fuzhou,
CN, 3Peking Union Medical College Hospital, Beijing, CN, 4Renmin Hospital of Wuhan
University, Wuhan, CN, 5Affiliated Hospital of Hebei University, Baoding, CN, 6Zhongshan
Hospital Xiamen University, Xiamen, CN, 7Fujian Cancer Hospital, Fuzhou, CN, 8The
Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, 9The
First Affiliated Hospital of China Medical University, Shenyang, CN, 10Jiangsu Hengrui
Pharmaceutical Co., Ltd., Shanghai, CN
14:55 - 15:05 LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for
Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT):
Final Results of a Phase III Trial
P.-R. Ding1, X.-Z. Wang2, Y.-F. Li3, Y.-M. Sun4, C.-K. Yang5, Z.-G. Wu6, R. Zhang7, W.

Wang8, Y. Li9, Y.-Z. Zhuang10, J. Lei11, Y. Ren12, X. Wan13, Y. Cheng14, W.-L. Li15, Z.-Q.
Wang16, Z. Pan1, Y.H. Gao1, Z.-F. Zeng17, D.-S. Wan17, 1Sun Yat-sen University Cancer
Center, Guangzhou, CN, 2Shantou Central Hospital, Shantou, CN, 3Yunnan Cancer
Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer
Center, Kunming, CN, 4Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing
Medical University, Nanjing, CN, 5Fujian Cancer Hospital and Fujian Medical University
Cancer Hospital, Fuzhou, CN, 6Meizhou People’s Hospital, Meizhou, CN, 7Liaoning
Cancer Hospital & Institute, Shenyang, CN, 8the First Affiliated Hospital of Guangzhou
University of Chinese Medicine, Guangzhou, CN, 9Guangdong Provincial People’s
Hospital, Guangzhou, CN, 10Cancer Hospital of Shantou University Medical College,
Shantou, CN, 11The First Affiliated Hospital of Guangzhou Medical University,
Guangzhou, CN, 12Henan Cancer Hospital, Zhengzhou, CN, 13Affiliated Cancer Hospital
of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, 14The First Affiliated
Hospital of Chongqing Medical University, Chongqing, CN, 15The First Affiliated Hospital
of Kunming Medical University, Kunming, CN, 16West China School of Medicine/West
China Hospital of Sichuan University, Chengdu, CN, 17State Key Laboratory of Oncology
in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen
University Cancer Center, Guangzhou, CN

K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg,
Leuven, BE
15:15 - 15:25 Q&A
15:25 - 15:35 549O - Adagrasib With or Without Cetuximab in Patients With KRASG12C-
Mutated Colorectal Cancer (CRC): Analysis of Tumor Biomarkers and Genomic
Alterations
M. Pelster1, R. Yaeger2, S. Klempner3, S.-H. Ou4, A. Spira5, P. Jänne6, N. Uboha7, Y.

Gaffar8, G. Newman9, C. Paweletz6, G. Heavey6, L. Alejandro10, T. Kheoh10, K.
Anderes10, H. Der Torossian10, J. Christensen10, J. Weiss11, 1Sarah Cannon Research
Institute, Nashville, US, 2Memorial Sloan Kettering Cancer Center, New York, US,
3Massachusetts General Cancer Center, Boston, US, 4UCI Health Chao Family
Comprehensive Cancer Center, Orange, US, 5Virginia Cancer Specialist, Fairfax, VA; US
Oncology Research, The Woodlands, US, 6Dana Farber Cancer Institute, Boston, US,
7University of Wisconsin, Madison, US, 8Maryland Oncology Hematology, Columbia, US,
9Ridley-Tree Cancer Center, Santa Barbara, US, 10Mirati Therapeutics, Inc., San Diego,
US, 11University of North Carolina-Chapel Hill, Lineberger Comprehensive Cancer

Center, Chapel Hill, US
15:35 - 15:45 550O - Safety and efficacy of D-1553 in combination with cetuximab in KRAS
G12C mutated colorectal cancer (CRC): a phase II study
R.-H. Xu1, Y. Xu2, D. Yan3, P. Munster4, D. Ruan1, Y. Deng5, H. Pan6, C. Underhill7, G.

Richardson8, I. Nordman9, K.-W. Lee 10, S. Wei11, X.-Y. Li 12, J. Shan13, G. Han14, S.
Henderson4, X. Xie15, Z. Xiang15, Z. Shi15, L. Zhang15, 1Sun Yat-sen University Cancer
Center, Guangzhou, CN, 2Fudan University Shanghai Cancer Center, Shanghai, CN,
3Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, CN, 4UCSF, San
Francisco, US, 5The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN,

6Sir Run Run Shaw Hospital School of Medcine Zhejiang University, Hangzhou, CN,
7Border Medical Oncology, Albury, AU, 8Cabrini Hospital - Malvern, Malvern, AU,
9Calvary Mater Newcastle, Waratah, AU, 10Seoul National University College of
Medicine, Seoul National University Bundang Hospital, Seongnam-si, KR, 11Hubei

Cancer Hospital, Wuhan, CN, 12The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, CN, 13The First Affiliated Hospital of Zhejiang University School of Medicine,
Hangzhou, CN, 14Xi'an International Medical Center Hospital, Xi'an, CN, 15InventisBio
Co., Ltd, Shanghai, CN
15:45 - 15:55 551O - Impact of baseline molecular alterations on the efficacy of tucatinib
(TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in
MOUNTAINEER
J. Strickler1, A. Cercek2, K. Ng3, S. Siena4, T. André5, E. Van Cutsem6, C. Wu7, A.

Paulson8, J. Hubbard9, A. Coveler10, C. Fountzilas11, A. Kardosh12, P. Kasi13, H.J. Lenz14,
K. Ciombor15, M.E. Elez Fernandez16, M. Stecher17, P. Cronin17, M. Bieda17, T. Bekaii-
Saab7, 1Duke Cancer Center, Durham, US, 2Memorial Sloan Kettering Cancer Center,
New York, US, 3Dana Farber Cancer Institute, Boston, US, 4Università degli Studi di
Milano, Milan, IT, 5Hopital Saint-Antoine, Paris, FR, 6UZ Leuven - University Hospitals
Leuven - Campus Gasthuisberg, Leuven, BE, 7Mayo Clinic Cancer Center, Phoenix, US,
8Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, 9Mayo Clinic, Rochester,
US, 10Fred Hutchinson Cancer Research Center, Seattle, US, 11Roswell Park
Comprehensive Cancer Center, Buffalo, US, 12OHSU - Oregon Health Science University,
Portland, US, 13Weill Cornell Medicine, New York, US, 14USC - University of Southern
California - Norris Comprehensive Cancer Center, Los Angeles, US, 15Vanderbilt
University Medical Center, Nashville, US, 16Vall d'Hebron University Hospital, Barcelona,
ES, 17Seagen Inc., Bothell, US

R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR
16:05 - 16:15 Q&A

14:45 - 16:15 Type: Educational session Bilbao Auditorium
Title: Optimal treatment sequence in metastatic breast - NCC
cancer (mBC) in 2023
Chair(s): Hervé Bonnefoi, FR; Christoph Thomssen, DE

C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE
14:50 - 15:10 Luminal-like breast cancer

S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR
15:10 - 15:30 HER2+ breast cancer

I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US
15:30 - 15:50 Triple-negative breast cancer
A. Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases
(NCT), Heidelberg, DE

Title: Managing disease progression in oncogene-driven Hall 3
lung cancer
Chair(s): Noemi Reguart Aransay, ES; Ross Soo, SG
14:45 - 15:00 Detection: From technology to clinical practice

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US
15:00 - 15:15 Mechanisms of resistance

A.-M. Baird, St. James's Hospital, Dublin, IE
15:15 - 15:35 Managing progression after EGFR TKIs in EGFR-mutant lung cancer
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of
Medicine, Seoul, KR
15:35 - 15:55 Managing progression after TKIs in oncogenic fusion-driven lung cancer
J. Lin, MGH - Massachusetts General Hospital, Boston, US

14:45 - 16:15 Type: Educational session Valencia Auditorium
Title: Is neoadjuvant immunotherapy a therapeutic - Hall 10
platform for all tumour types?
Chair(s): Myriam Chalabi, NL; Jessica Hassel, DE
14:45 - 15:10 Novel neoadjuvant combination immunotherapies

A. Menzies, Melanoma Institute Australia, Wollstonecraft, AU
15:10 - 15:35 Is chemotherapy plus immunotherapy equal to immunotherapy alone at the

neoadjuvant stage?
T. Cascone, The University of Texas MD Anderson Cancer Center - Main Building,
Houston, US
15:35 - 16:00 How to personalise neoadjuvant immunotherapy

C. Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
14:45 - 16:15 Type: Mini Oral session Salamanca

Title: Mini oral session 1 - Non-metastatic NSCLC and Auditorium - Hall 3
other thoracic malignancies
Chair(s): Andrea Ardizzoni, IT; Kersti Oselin, EE
14:45 - 14:50 1988MO - Recruitment discontinuation in TREASURE trial (Thoracic

RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease)
due to unexpected safety data
F. Bozorgmehr1, F. Weykamp2, T. Overbeck3, N. Maguire4, E. Buchmeier5, M. Hammer-

Hellmig5, T. Gauler6, M. Wermke7, E.G.C. Troost8, M. Ulmer9, A.-C. Mueller10, K.
Kokowski11, B. Röper12, T. Wehler13, S. Hey-Koch14, N.-S. Consdorf15, R. Behnisch16, P.
Christopoulos1, M. Thomas1, S. Rieken17, 1Heidelberg, Germany; Translational Lung
Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research
(DZL), Heidelberg, DE, 2University Hospital Heidelberg, Heidelberg University,
Heidelberg, DE, 3University Medical Center Göttingen, Göttingen University, Goettingen,
DE, 4Barmherzige Brueder Krankenhaus Regensburg, Regensburg, DE, 5Klinikum Köln-
Merheim, Köln, DE, 6WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, 7University
Hospital Dresden, TU Dresden, Dresden, DE, 8Medizinische Fakultät und
Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden; OncoRay -
National Center for Radiation Research in Oncology, Faculty of Medicine and University
Hospital Carl Gustav Carus, TU Dresden, Dresden, DE, 9Klinikum Ludwigsburg
Medizinische Klinik I, Ludwigsburg, DE, 10Klinikum Ludwigsburg, Ludwigsburg, DE,
11Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE,
12Strahlentherapie Klinikum Bogenhausen, München, DE, 13Sana Klinikum Offenbach
GmbH, Offenbach am Main, DE, 14Sana Klinikum Offenbach, Offenbach am Main, DE,
15Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer,
DE, 16Heidelberg University Hospital, Heidelberg, DE, 17Universitätsmedizin Göttingen,

Goettingen, DE

14:50 - 14:55 1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in
relapsed small cell lung cancer (SCLC): the Phase 1/2 LUPER study
A. Calles Blanco1, A. Navarro Mendivil2, B. Doger De Spéville3, E. Álvarez Colomé4, M.J.

De Miguel Luken5, R. Alvarez1, V. Moreno Garcia3, J. Ramon6, M. Arregui Valles7, E.
Corral De La Fuente6, D. Alcalá8, M. Fernández8, J. Rodríguez Morató8, E. Calvo6, R.
Palmero Sanchez9, M. Jové10, E. Felip11, 1Hospital General Universitario Gregorio
Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, ES, 2Vall d
´Hebron Hospital Universitari and Vall d´Hebron Institute of Oncology (VHIO); MEDSIR -
Medica Scientia Innovation Research, Barcelona, ES, 3Hospital Universitario Fundación
Jiménez Díaz, Madrid, ES, 4Vall d´Hebron Hospital Universitari and Vall d´Hebron
Institute of Oncology (VHIO), Barcelona, ES, 5Centro Integral Oncológico Clara Campal,
Hospital Madrid Norte Sanchinarro, Madrid, ES, 6START Madrid-CIOCC, Centro Integral
Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, 7Hospital
General Universitario Gregorio Maranon, Madrid, ES, 8MEDSIR - Medica Scientia
Innovation Research, Barcelona, ES, 9ICO - Institut Català d'Oncologia - Hospital Duran i
Reynals, L'Hospitalet de Llobregat, ES, 10ICO - Institut Català d'Oncologia - Hospital
Duran i Reynals, Hospitalet de Llobregat, ES, 11Vall d'Hebron University Hospital and
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
14:55 - 15:00 1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for
extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the
phase 2 TROPiCS-03 basket trial
A. Dowlati1, A. Cervantes2, S. Babu3, E. Hamilton4, S.F. Wong5, A. Tazbirkova6, I.G.

Sullivan7, C. Van Marcke De Lummen8, A. Italiano9, J. Patel10, S. Mekan10, T. Wu10, A.
Chiang11, 1University Hospitals Seidman Cancer Center and Case Western Reserve
University, Cleveland, US, 2INCLIVA Instituto de Investigación Sanitaria, University of
Valencia, Valencia, ES, 3Fort Wayne Medical Oncology and Hematology, Fort Wayne, Fort
Wayne, US, 4Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US,
5Andrew Love Cancer Centre, Geelong, Geelong, AU, 6Pindara Private Hospital,
Southport, AU, 7Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 8Cliniques
Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE, 9Institute Bergonié, Bordeaux, FR,
10Gilead Sciences, Inc., Foster City, US, 11Yale University School of Medicine, New
Heaven, US

A. Ardizzoni, University of Bologna - Alma Mater Studiorum, Bologna, IT
15:15 - 15:25 LBA99 - First survival data from the NIPU trial; A randomised, open-label, phase
II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as
second line treatment in patients with malignant mesothelioma
A. Helland1, V. Haakensen2, A. Ojlert3, S. Thunold4, A. Nowak5, W.L. Chin5, O.

Grundberg6, S. Farooqi7, M. Lund-Iversen8, W. Szejniuk9, S. Cedres Perez10, J.
Sørensen11, M. Bjaanaes12, 1University of Oslo, Institute of Clinical medicine, Oslo, NO,
2Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, 3Department of
Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, NO, 4Oslo
University Hospital - Radiumhospitalet, Oslo, NO, 5University of Western Australia, Perth,
AU, 6Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE,
7Oslo University Hospital - Ulleval Hospital, Oslo, NO, 8Oslo University Hospital, Oslo,

NO, 9Aalborg University Hospital, Aalborg, DK, 10Vall d'Hebron University Hospital,
Barcelona, ES, 11Rigshospitalet, Copenhagen, DK, 12Oslo University Hospital - Ulleval
Hospital, Oslo, NO
15:25 - 15:35 LBA93 - EXTENTORCH: a randomized, phase III trial of toripalimab versus
placebo, in combination with chemotherapy as a first-line therapy for patients
with extensive stage small cell lung cancer (ES-SCLC)
Y. Cheng1, Y. Liu2, W. Zhang3, L. Wu4, C. Zhou5, D. Wang6, B. Xia7, M. Bi8, X. Fu9, C. Li10,
G. Chen11, D. Lv12, Y. Zhao13, J. Huang14, M. Li15, T. Yi16, X. Huang17, R. Yang18, Z.
Chen19, Y. Wang20, 1Jilin Cancer Hospital, Changchun, CN, 2Jilin Cancer Hospital,
ChangChun, CN, 3The First Affiliated Hospital of Nanchang University, Nanchang, CN,
4Hunan Cancer Hospital, Changsha, CN, 5Shanghai Pulmonary Hospital, Shanghai, CN,
6Chongqing Cancer Hospital, Chongqing, CN, 7Affiliated Hangzhou First People's
Hospital, Zhejiang University School of Medicine, Hangzhou, CN, 8The First Affiliated
Hospital of Bengbu Medical College, Bengbu, CN, 9The Affiliated Hospital of Inner
Mongolia Medical University, Hohhot, CN, 10The Third Affiliated Hospital of Soochow
University (The First People's Hospital of Changzhou), Changzhou, CN, 11Cancer
Hospital Affiliated to Harbin Medical University,, Harbin, CN, 12Affiliated Taizhou
Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, 13Henan
Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN,
14The First Affiliated Hospital Of Soochow University, Suzhou, CN, 15Xiangya Hospital of
Central South University, Changsha, CN, 16Xiangyang Central Hospital, Xiangyang, CN,
17Chongqing University Three Gorges Hospital, Chongqing, CN, 18Yunnan Cancer
Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer
Center, Kunming, CN, 19The Second Affiliated Hospital of Anhui Medical University,
Hefei, CN, 20West China School of Medicine/West China Hospital of Sichuan University,
Chengdu, CN
15:50 - 15:55 1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-

reported outcomes for completely resected non-small cell lung cancer (NSCLC)
in phase III IFCT-0302 trial
G. Eberst1, J. Henriques2, M. Monchatre3, E. Giroux-Leprieur4, E. Kelkel5, A. Bizieux

Thaminy6, P. Ravier7, P. Thomas8, S. Bayle9, C. Audigier Valette10, H. Berard11, F.
Desliers12, A. Lagrange13, P. Bonnefoy14, A. Langlais15, D. Vernerey2, A. Anota2, F.
Morin15, V. Westeel1, 1CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 2CHU
Besançon, Hôpital Jean Minjoz, Besançon, FR, 3Clinique Claude Bernard, Ermont, FR,
4University Paris-Saclay, UVSQ, APHP – Ambroise Paré Hospital, Boulogne-Billancourt,
FR, 5Centre Hospitalier Metropole Savoie - Chambery, Chambéry, FR, 6CHD Vendée, La
Roche-sur-Yon, FR, 7Cabinet de Pneumologie, DIJON, FR, 8CHU Alpes du Sud - Site de
Gap, Gap, FR, 9CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, 10Hopital Sainte
Musse, Toulon, FR, 11Hôpital d'Instruction des Armées Sainte Anne Toulon, Toulon,
Cedex, FR, 12Cabinet de Pneumologie, Lens, FR, 13Centre Hospitalier Louis Pasteur,
Dôle, FR, 14Hôpital de Jonzac, Jonzac, FR, 15French Cooperative Thoracic Intergroup,
Paris, FR
15:55 - 16:00
1263MO - The Impact of PET-CT and Brain MRI for Metastasis Detection among
Patients with T1-Stage Lung Cancer: Findings from a Large Cohort Study
W. Liang, Y. Feng, B. Cheng, J. Li, J. He, The First Affiliated Hospital of Guangzhou
Medical University, Guangzhou, CN

K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla),
Tallinn, EE
14:45 - 16:15 Type: Educational session Málaga Auditorium -

Title: Integrating immunotherapy into the standard of Hall 10
care for cervical cancer
Chair(s): Nicoletta Colombo, IT; Alexandra Leary, FR
14:45 - 15:10 IO in combination with chemoradiation therapy in locally advanced cervical

cancer
S. De Boer, LUMC - Universitair Medisch Centrum, Leiden, NL
15:10 - 15:35 In metastatic and recurrence

N. Colombo, IEO - Istituto Europeo di Oncologia, Milan, IT
15:35 - 16:00 Treatment after progression on immunotherapy

A. Leary, Institut Gustave Roussy, Villejuif, FR
14:45 - 16:15 Type: Proffered Paper session Santander Auditorium

Title: Proffered Paper session 2 - Basic Science and - Hall 9
Translational research
Chair(s): Göran Jönsson, SE
14:45 - 14:55 131O - A composite biomarker for evaluation of homologous recombination

repair deficiency in a pan-cancer cohort
M. Rübsam1, M. Rheinnecker1, B. Hutter1, M. Fröhlich1, C. Heilig1, N. Paramasivam1, M.

Oleś1, C. Ball2, H. Glimm2, M. Hlevnjak1, M. Zapatka1, P. Lichter1, S. Fröhling1, R.
Schlenk3, D. Hübschmann1, 1German Cancer Research Center (DKFZ) and National
Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, 2National Center for
Tumor Diseases (NCT/UCC) Dresden, German Cancer Research Center (DKFZ)
Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische
Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, DE,
3National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research
Center (DKFZ), and Heidelberg University Hospital, Heidelberg, DE
14:55 - 15:05 1O - CircIGF1R_0001 mediates platinum resistance in ovarian cancer that

sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites
L. Ruilin1, Q. Li2, H. Yao3, 12nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun

Yat-Sen University, Guangzhou, CN, 2The Second Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, CN, 32nd Affiliated Hospital of Sun Yat-sen University,
Guangzhou, CN
15:15 - 15:25 Q&A
15:25 - 15:35 2232O - Atezolizumab (atezo) and tumour microenvironment in early triple-
negative breast cancer (eTNBC): Exploratory biomarker analysis from
IMpassion031
N. Harbeck1, C. Duan2, K. Dupree3, C.-W. Chang 3, C. Barrios4, H. Zhang5, S. Saji6, K.

Jung7, M. Telli8, M. Liste Hermoso9, S. Chui3, M. Dieterich9, E. Mittendorf10, L.
Molinero3, 1LMU Klinikum München, Munich, DE, 2Roche (China) Holding Ltd,
Shanghai, CN, 3Genentech, Inc., South San Francisco, US, 4Hospital São Lucas, Porto
Alegre, BR, 5Memorial Sloan Kettering Cancer Center, New York, US, 6Fukushima
Medical University, Fukushima, JP, 7Asan Medical Center - University of Ulsan College of
Medicine, Seoul, KR, 8Stanford University School of Medicine, Stanford, US, 9F.
Hoffmann-La Roche AG, Basel, CH, 10Brigham and Women's Hospital, Boston, US
15:35 - 15:45 2O - PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1+ T cells
with implications for cancer immunotherapy
Y. Wu1, D. Davies1, S. Kamdar1, R. Woolf1, I. Zlatareva1, M.L. Iannito1, C. Morton2, Y.

Haque1, H. Martin3, O. O'Neill3, O. Nussbaumer1, A. Hayday1, 1King's College London,
London, GB, 2Guy’s and St Thomas’ NHS Foundation Trust, London, GB, 3The Francis
Crick Institute, London, GB
15:45 - 15:55 3O - IGSF8 is an Innate Immune Checkpoint and Cancer Immunotherapy Target
K. Benhadji1, Y. Li2, X. Wu2, H. Liu2, X. Xiao2, H. Liu2, Q. Ding2, B. Xie2, C. Sheng2, R.

Zheng2, Q. Yu2, X. Hu1, X.S. Liu1, T. Xiao2, 1GV20 Therapeutics, Cambridge, US, 2GV20
Therapeutics, Shanghai, CN

G. Jönsson, Lund University, Lund, SE
16:05 - 16:15 Q&A
14:45 - 16:15 Type: Mini Oral session Toledo Auditorium - Hall

Title: Mini oral session - Supportive and palliative 3
care
Chair(s): Christina Ruhlmann, DK; Karin Jordan, DE; Camilla Zimmermann, CA
14:45 - 14:50 2032MO - Correlation of safety and efficacy in atezolizumab therapy across

indications
J. Naidoo1, G. Durán-Pacheco2, V. Maiya3, M. Socinski4, G. Sonpavde4, J. Puente5, L.

Essioux6, C. Carter3, J. Cardona2, R. Mohindra7, S. Chandler6, 1Beaumont Hospital,
Dublin, IE, 2F. Hoffmann-La Roche Ltd, Basel, CH, 3Genentech, Inc. - Member of the
Roche Group, South San Francisco, US, 4AdventHealth Medical Group - Internal
Medicine at Orlando, Orlando, US, 5Hospital Clinico Universitario San Carlos, Madrid,
ES, 6F. Hoffmann-La Roche AG, Basel, CH, 7F. Hoffmann-La Roche AG - Elsaessertor II,
Basel, CH
14:50 - 14:55 1843MO - The Effect of Chronic Psychological Stress on the Efficacy of First-line
Therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 Trial)
F. Wu1, Y. Zeng1, Y. Li1, J. Liu1, C. Xiao1, M. Liu2, Z. Qiu1, C. Deng1, F. Ma1, C. Xia1, B.
Zhang3, Z. Xiao4, C. Xu5, Z. Sheng6, P. Liu7, X. Zeng8, Y. Zhao8, J. Zhou1, X. Liu1, C. Hu1,
1The Second Xiangya Hospital of Central South University, Changsha, CN, 2University of
Washington, Seattle, US, 3Hunan Yiyang Central Hospital, Yiyang, CN, 4CHANGDE City
First People's Hoapital, Changsha, CN, 5Xiangxi Tujia and Miao Autonomous Prefecture
People's Hospital, Jishou, CN, 6The Third Hospital of Changsha, Changsha, CN, 7The
First Hospital of Changsha, Changsha, CN, 8Changsha Central Hospital, Changsha, CN
14:55 - 15:00 2033MO - The impact of proton pump inhibitor (PPI) exposure before immune
checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based
study
L. Eng1, S. Saibil2, R. Sutradhar3, V. Aghanya3, Y. Kaliwal3, Y. Niu3, N. Liu3, Y. Liu3, M.

Powis4, G. Liu1, J. Peppercorn5, P. Bedard1, M. Krzyzanowska1, 1UHN - University Health
Network - Princess Margaret Cancer Center, Toronto, CA, 2UHN - University Health
Network - Princess Margaret Cancer Centre, Toronto, CA, 3ICES - Institute for Clinical
Evaluative Sciences, Toronto, CA, 4Princess Margaret Cancer Centre, Toronto, CA,
5Massachusetts General Hospital, Boston, US
15:00 - 15:15 Invited Discussant 2032MO, 1843MO, 2033MO

C. Ruhlmann, OUH - Odense University Hospital, Odense, DK
15:15 - 15:20 LBA96 - Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-
Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III
Study
S. Lu1, J. Wu2, J. Jiang3, Q. Guo4, Y. Yu5, Y. Liu6, H. Zhang7, L. Qian8, X. Dai9, Y. Xie10, T.
Fu11, T. Lee12, Y.(. Lu13, R. Ma13, M. Eisner12, 1Shanghai Chest Hospital, Shanghai, CN,
2Fudan University, Shanghai, CN, 3The First Hospital of Jiaxing, Jiaxing, CN, 4Shandong
First Medical University Cancer Hospital, Jinan, CN, 5Harbin Medical University Cancer
Hospital, Harbin, CN, 6Neijiang Second People's Hospital, Neijiang, CN, 7The First
People's Hospital of Foshan, Foshan, CN, 8Shanghai Fifth People's Hospital, Shanghai,
CN, 9Xuzhou Central Hospital, Xuzhou, CN, 10The People's Hospital of Guangxi Zhuang
Autononous Region, Nanning, CN, 11Zhuzhou Central Hospital, Zhuzhou, CN,
12FibroGen, Inc., San Francisco, US, 13FibroGen (China) Medical Technology
Development Co., Ltd., Shanghai, CN
15:20 - 15:25 LBA97 - Olanzapine for the prevention of Chemotherapy Induced Nausea
Vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC)

regimens - results of a prospective triple blinded phase 3 multicentric study
(OMEC)
V. Ostwal1, S. Mandavkar1, M. Parulekar1, A. Ramaswamy1, P. Bhargava2, S. Srinivas1, D.

Chaugule1, D. Naughane1, A. Kapoor3, A. Gupta4, B. Sansar4, A. Sharma3, R. Rai5, P.
Gupta5, B. Mishra3, V.K. Muddu6, I. Olver7, 1Tata Memorial Hospital - Tata Memorial
Centre, Mumbai, IN, 2Tata Memorial Hospital Centre, Mumbai, IN, 3Mahamana Pandit
Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial
Centre, Varanasi, IN, 4Homi Bhabha Cancer Hospital, Varanasi, IN, 5Mahamana Pandit
Madan Mohan Malviya Cancer Centre, Varanasi, IN, 6AIG Hospitals, Hyderabad, IN,
7University of Adelaide, Adelaide, AU
15:25 - 15:30 1844MO - Association of peripheral blood leukocyte DNA methylation profiles
with the development of depressive symptoms in lung cancer patients
undergoing systemic therapy
A. Starzer, J. Fuerst, E. Tomasich, L. Gottmann, J. Berger, M. Korpan, C. Englisch, M.
Kleinberger, F. Moik, G. Heller, L. Carlberg, M. Preusser, A.S. Berghoff, Medical
University of Vienna, Vienna, AT
15:30 - 15:45 Invited Discussant LBA96, LBA97 and 1844MO

K. Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, DE
15:45 - 15:50 1592MO - Anticancer therapy at the end-of-life; a cluster-randomized trial
M. Hjermstad1, A. Pirnat2, N. Aass3, S. Andersen4, G. Astrup2, O. Dajani1, H. Garresori5,

K.V. Guldhav6, H.M. Hamre7, E. Haukland8, F. Jordal9, E.T. Lohre10, T. Lundeby3, S.
Mjaaland11, Ø. Paulsen12, K.A. Semb13, E.S. Staff14, T.E. Wester2, S. Kaasa3, 1Oslo
University Hospital - Ulleval Hospital, Oslo, NO, 2Oslo University Hospital, Oslo, NO,
3Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, 4University
Hospital of North Norway, Tromso, NO, 5Helse Stavanger HF, Stavanger, NO, 6Health
Forde - Forde Central Hospital, Forde, NO, 7Akershus University Hospital HF, Lorenskog,
NO, 8Nordlandsykehuset Bodoe, Bodoe, NO, 9Sykehuset Ostfold, Fredrikstad, NO, 10St.
Olavs Hospital, Trondheim University Hospital, Trondheim, NO, 11Sorlandet Hospital,
Kristiansand, NO, 12Sykehuset Telemark HF, Skien, NO, 13Sykehuset i Vestfold HF,
Tonsberg, NO, 14Helse More og Romsdal HF, Alesund, NO
15:50 - 15:55 1593MO - Combined Early Palliative Care in Patients with Non-Small-Cell Lung
Cancer: a randomised controlled trial in Chongqing, China
M. Chen, H. Yu, Chongqing Cancer Hospital, Chongqing, CN
15:55 - 16:00 2034MO - EAGER: A Randomized, Controlled, Multicenter Trial of Electro-

Acupuncture in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy
H.-B. Zhang1, Y. Zhu1, J. Mao2, X.-S. Chang1, J.-J. Peng3, X.-Y. Wu 4, W. Wang5, D.-C. Diao1,
Y. Li6, H.-Y. Zhang 7, X.-H. Zhai8, J.-L. Yu9, W. Wang10, J.-X. Zhou 11, Z.-L. Huang12, T.
Zhang13, Y.-H. Liu1, R. Zhou1, H.-C. Ma1, Y.-D. Chen1, 1Guangdong Provincial Hospital of
Traditional Chinese Medicine, Guangzhou, CN, 2MSKCC - Memorial Sloan Kettering
Cancer Center, New York, US, 3The First Affiliated Hospital of Sun Yat-sen University,
Guangzhou, CN, 4Affiliated Hospital of Nanjing University of Traditional Chinese
Medicine, Nanjing, CN, 5the First Affiliated Hospital of Guangzhou University of Chinese
Medicine, Guangzhou, CN, 6Guangdong Provincial People’s Hospital, Guangzhou, CN,

7The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN, 8The Sixth Affiliated
Hospital of Sun Yat-sen University, Guangzhou, CN, 9Zhujiang Hospital of Southern
Medical University, Guangzhou, CN, 10Foshan First People's Hospital, Foshan, CN, 11The
First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN,
12Affiliated Cancer Hospital and Insitute of Guangzhou Medical University, Guangzhou,
CN, 13Yuebei People's Hosptial, Shaoguan, CN

C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
14:45 - 16:15 Type: Special session Oviedo Auditorium - Hall 7

Title: Management of novel treatments’ toxicities
Chair(s): Lazar Popovic, RS; Alice Indini, IT
14:45 - 15:00 Toxicities of novel therapies: Why is that important?

L. Popovic, Oncology Institute of Vojvodina, Sremska Kamenica, RS
15:00 - 15:20 Toxicity of IO + targeted agents

15:20 - 15:40 Management of antibody-drug conjugates toxicities

J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital
Tenon, Paris, FR
15:40 - 16:00 Toxicities of TILs, CAR-Ts and bispecific antibodies

A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
16:00 - 16:15 Discussion and Q&A

A. Indini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
14:45 - 16:10 Type: Mini Oral session León Auditorium - Hall

Title: Mini oral session - Melanoma and other skin 7
tumours
Chair(s): Georgina Long, AU; Omid Hamid, US; Caroline Robert, FR
14:45 - 14:50 1083MO - Brain metastases and survival evaluation in the SECOMBIT trial
P. Ascierto1, M. Mandalà2, P.F. Ferrucci3, M. Guidoboni4, P. Rutkowski5, V. Ferraresi6,

A.M. Arance Fernandez7, M. Guida8, E. Maiello9, H. Gogas10, E. Richtig11, M.T. Fierro12,
C. Lebbe13, H. Helgadottir14, I. Melero15, G. Palmieri16, D. Giannarelli17, A. Grimaldi18,
R. Dummer19, V. Chiarion Sileni20, 1Istituto Nazionale Tumori - IRCCS - Fondazione
Pascale, Napoli, IT, 2Università degli Studi di Perugia, Perugia, IT, 3IEO - Istituto Europeo
di Oncologia, Milan, IT, 4IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei
Tumori IRCCS S.r.l., Meldola, IT, 5Maria Sklodowska-Curie National Research Institute of
Oncology, Warsaw, PL, 6IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT,

7Hospital Clinic y Provincial de Barcelona, Barcelona, ES, 8Istituto Tumori Giovanni
Paolo II, Bari, IT, 9IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni
Rotondo, IT, 10National and Kapodistrian University of Athens - School of Medicine,
Athens, GR, 11Universitätsklinik für Dermatologie und Venerologie, Graz, AT,
12University of Turin, Torino, IT, 13Hopital Saint Louis AP-HP, Paris, FR, 14Karolinska
Institutet - Cancer Center Karolinska (CCK), Solna, SE, 15Clinica Universitaria de

Navarra, Pamplona, ES, 16University of Sassari, Sassari, IT, 17Fondazione Policlinico
Universitario Agostino Gemelli IRCCS, Rome, IT, 18AORN "San Pio", Napoli, IT,
19Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, 20IOV - Istituto
Oncologico Veneto IRCCS, Padova, IT
14:50 - 14:55 1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic
brain metastases: 7-year outcomes and quality of life from the multicenter phase
III NIBIT-M2 trial
A. Di Giacomo1, V. Chiarion Sileni2, M. Del Vecchio3, P.F. Ferrucci4, M. Guida5, P.

Quaglino6, M. Guidoboni7, P. Marchetti8, E. Simonetti9, G. Amato10, A. Covre9, R.
Camerini11, L. Calabro12, M. Valente10, M. Mandalà13, D. Giannarelli14, M. Maio1,
1University of Siena, Center for Immuno-Oncology, University Hospital of Siena, Siena,
IT, 2Veneto Institute of Oncology IOV-IRCCS, Padova, IT, 3Istituto Nazionale dei Tumori,
Milan, IT, 4European Institute of Oncology, IRCCS, Milan, IT, 5IRCCS Istituto Tumori
"Giovanni Paolo II", Bari, IT, 6University of Turin, Torino, IT, 7Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, 8Sapienza
University of Rome, Rome, IT, 9University of Siena, Siena, IT, 10Center for Immuno-
Oncology, University Hospital of Siena, Siena, IT, 11NIBIT Foundation Onlus, Genova, IT,
12University of Ferrara, Ferrara, IT, 13University of Perugia, Santa Maria della
Misericordia, University Hospital of Perugia, Perugia, IT, 14Fondazione Policlinico

Universitario A. Gemelli, IRCCS, Rome, IT

15:10 - 15:15 LBA50 - Three-year survival with tebentafusp in previously untreated metastatic
uveal melanoma in a phase 3 trial
S. Piperno-Neumann1, J. Hassel2, P. Rutkowski3, J.-F. Baurain4, M. Schlaak5, M. Butler6,

R. Sullivan7, R. Dummer8, J. Kirkwood9, M. Orloff10, J. Sacco11, S. Ochsenreither12, A.
Joshua13, L. Gastaud14, B. Curti15, R. Carvajal16, O. Hamid17, L. Collins18, C. Holland19,
P. Nathan20, 1Institut Curie, Paris, FR, 2NCT - Nationales Zentrum für
Tumorerkrankungen, Heidelberg, DE, 3Maria Sklodowska-Curie National Research
Institute of Oncology, Warsaw, PL, 4Cliniques Universitaires Saint-Luc (UCLouvain Saint-
Luc), Woluwe-Saint-Lambert, BE, 5Charité - Universitaetsmedizin Berlin, Berlin, DE,
6UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA,
7MGH - Massachusetts General Hospital, Boston, US, 8Universitätsspital Zürich - Klinik
für Dermatologie, Zurich, CH, 9UPMC Hillman Cancer Center, Pittsburgh, US, 10Thomas
Jefferson Univ Hospital, Philadelphia, US, 11Clatterbridge Cancer Center - NHS
Foundation Trust, Wirral, GB, 12Charité - Universitätsmedizin Berlin, Berlin, DE, 13The
Kinghorn Cancer Centre, Sydney, AU, 14Centre Anticancer Antoine Lacassagne, Nice, FR,
15Portland Providence Medical Center, Portland, US, 16Columbia University Medical
Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York,
US, 17The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US,

18Immunocore Limited, Abingdon-on-Thames, GB, 19Immunocore LLC, Conshohocken,
US, 20Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB
15:15 - 15:20 1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients
(pts) with advanced mucosal melanoma after progression on immune checkpoint
inhibitors (ICI): Results from the phase 2 C-144-01 study
G.-U. Grigoleit1, H. Kluger2, S. Thomas3, J. Chesney4, E. Domingo-Musibay5, M.F.

Sanmamed6, T. Medina7, M. Ziemer8, E. Whitman9, F. Graf Finckenstein10, J. Chou10, X.
Wu10, G. Sulur10, W. Shi10, A. Sarnaik11, 1Helios Klinikum Duisburg, Duisburg, DE, 2Yale
Cancer Center, New Haven, US, 3Orlando Health Cancer Institute, Orlando, US, 4Brown
Cancer Center University of Louisville, Louisville, US, 5University of Minnesota,
Minneapolis, US, 6Clinica Universidad de Navarra, Pamplona, ES, 7University of
Colorado Cancer Center, Aurora, US, 8Universitätsklinikum Leipzig - Klinik und Poliklinik
für Frauenheilkunde, Leipzig, DE, 9Atlantic Health System, Morristown, US, 10Iovance
Biotherapeutics, Inc., San Carlos, US, 11H. Lee Moffitt Cancer Center & Research
Institute - Magnolia Campus, Tampa, US
15:20 - 15:25 LBA51 - Unraveling relatlimab (RELA)-specific biology using biomarker analyses
in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or
NIVO alone in RELATIVITY-047
E. Lipson1, S. Dolfi2, H. Tang2, H. Gogas3, H. Tawbi4, F.S. Hodi5, P. Ascierto6, E.

Gutierrez7, D. Schadendorf8, F. Medina Soto9, P. Rutkowski10, E. Murillo Ramirez11, M.
Maio12, Y. Xu2, K. Desai2, A. Yu2, K. Demers2, K. Miller-Moslin2, G. Long13, C. Garnett-
Benson2, 1The Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel
Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine,
Baltimore, US, 2Bristol Myers Squibb, Princeton, US, 3National and Kapodistrian
University of Athens - School of Medicine, Athens, GR, 4The University of Texas MD
Anderson Cancer Center, Houston, US, 5Dana Farber Cancer Institute, Boston, US,
6Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, IT, 7FAICIC Clinical
Research, Veracruz, MX, 8University Hospital Essen Westdeutsches Tumorzentrum,

Essen, DE, 9Axis Heilsa S. de R.L. de C.V, Monterrey, Nuevo León, MX, 10Maria
Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, 11iBiomed
Clinical Research, Guadalajara, MX, 12Center for Immuno-Oncology, University Hospital
of Sienadelle Scotte, Siena, IT, 13Melanoma Institute Australia, University of Sydney,
Royal North Shore and Mater Hospitals, Wollstonecraft, AU
15:25 - 15:40 Invited Discussant LBA50, 1086MO and LBA51
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US
15:40 - 15:45 1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity
and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous
squamous cell carcinoma – First results from the AliCe study
J. Becker1, B. Schilling2, U. Leiter-Stoppke3, L. Zimmer4, J. Hassel5, I. Von Wasielewski6,

M. Ziemer7, M. Fluck8, F. Meier9, A. Spillner10, A. Gesierich2, T. Eigentler11, E.
Livingstone12, M. Albers10, Y. Angela13, R. Gutzmer14, 1German Cancer Consortium
(DKTK), Essen, DE, 2UKW - University Hospital Würzburg, Würzburg, DE,
3Universitaetsklinik Tuebingen, Tuebingen, DE, 4Universitätsklinikum Essen, Essen, DE,
5NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, 6MHH -
Medizinische Hochschule Hannover, Hannover, DE, 7Universitätsklinikum Leipzig - Klinik

und Poliklinik für Frauenheilkunde, Leipzig, DE, 8Fachklinik Hornheide, Münster, DE,
9Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, 10Alcedis GmbH,
Giessen, DE, 11Charité - Universitätsmedizin Berlin, Berlin, DE, 12University Hospital

Essen Westdeutsches Tumorzentrum, Essen, DE, 13Johannes Weseling Klinikum, Minden,
DE, 14Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE
15:45 - 15:50 1088MO - A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV

Cutaneous Squamous Cell Carcinoma (CSCC): One-year Follow-up
N. Gross1, D.M. Miller2, N. Khushalani3, V. Divi4, E. Ruiz5, E. Lipson6, F. Meier7, Y.B. Su8,
P.L. Swiecicki9, J.L. Atlas10, J.L. Geiger11, A. Hauschild12, J.H. Choe13, B. Hughes14, S.-Y.
Yoo15, M. Mathias15, H. Han15, M. Fury15, D. Rischin16, 1The University of Texas M. D.
Anderson Cancer Center, Houston, US, 2Beth Israel Deaconess Medical Center, Boston,
US, 3Moffitt Cancer Centre, Tampa, US, 4Stanford University School of Medicine,
Stanford, US, 5Brigham and Women’s Hospital, Harvard Medical School, Boston, US,
6Johns Hopkins, Baltimore, US, 7Universitaetsklinikum Carl Gustav Carus Dresden,
Dresden, DE, 8Nebraska Cancer Specialists - Midwest Cancer Center-Legacy, Omaha,

US, 9University of Michigan, Ann Arbor, US, 10Carolinas HealthCare System/Atrium
Health, Charlotte, US, 11Cleveland Clinic, Cleveland, US, 12Schleswig-Holstein
University Hospital, Kiel, DE, 13Duke Cancer Institute, Durham, US, 14Royal Brisbane
and Women's Hospital and University of Queensland, Herston, AU, 15Regeneron
Pharmaceuticals, Inc., Tarrytown, US, 16Peter MacCallum Cancer Centre and University
of Melbourne, Melbourne, AU
15:50 - 15:55 LBA52 - A randomized Phase Ib/II study of the selective small molecule AXL
inhibitor bemcentinib in combination with either dabrafenib/trametinib or
pembrolizumab in patients with metastatic melanoma
O. Straume1, C. Schuster1, S. Aziz2, K. Davidsen1, J. Karlsen3, A.J. Rayford4, M.I. Siraji4,

H. Løvendahl Svendsen2, L. Reisæter2, B.T. Gjertsen4, L. Akslen4, J. Lorens4, 1Haukeland
Universitetssykehus, Bergen, NO, 2Helse Bergen - Haukeland University Hospital,
Bergen, NO, 3NTNU - Norwegian University of Science and Technology, Trondheim, NO,
4University of Bergen, Bergen, NO

14:45 - 16:15 Type: Proffered Paper session Cádiz Auditorium -

Title: Proffered paper session: Policy and preventive NCC
strategie
14:45 - 14:55 1687O - PRIMCAT: A novel approach to informing Health Technology Assessment
decision making in Australia
F. Franchini1, K. Trapani1, J. Soon1, B. Daniels2, P. Gillett1, K. Degeling1, M. Alexander3,

Y.H. To4, S. O'Haire5, O. Yang3, S. Fox6, J. Desai5, Y. Zhang3, B. Solomon5, P. Gibbs4, G.
Mcarthur7, S. Pearson2, M. Ijzerman8, 1University of Melbourne, Parkville, AU,
2University of New South Wales, Kensington, AU, 3The University of Melbourne,
Parkville, AU, 4WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU,
5Peter MacCallum Cancer Center, Melbourne, AU, 6Peter MacCallum Cancer Centre,
Melbourne, AU, 7University of Melbourne and Peter MacCallum Cancer Centre,

Melbourne, AU, 8Erasmus University, Rotterdam, NL
14:55 - 15:05 1688O - Informative censoring of surrogate end-point data in FDA-approved

cancer drugs
T. Meirson1, J. Ofer2, G. Markel1, Y. Pras3, S. Gilboa4, 1Rabin Medical Center, Petah

Tikva, IL, 2Davidoff Cancer Center - Rabin Medical Center, Petah Tikva, IL, 3Tel Aviv
University, Tel Aviv, IL, 4Tel Aviv University-Sackler Faculty of Medicine, Tel Aviv, IL
15:05 - 15:15 1689O - Comprehensive mapping review of real-world evidence publications

focusing on targeted therapies in solid tumors: a collaborative work from ESMO
Real World Data and Digital Health Working Group
A. Pellat1, T. Grinda2, A. Prelaj3, P. Cresta4, A. Valachis5, I. Zerdes6, D. Martins Branco7,

L. Provenzano3, A. Spagnoletti3, G. Nader Marta7, B. Wilson8, F. Montemurro9, L.
Castelo-Branco10, G. Pentheroudakis10, S. Delaloge11, M. Koopman12, 1Hôpital Cochin,
Paris, FR, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3Fondazione IRCCS - Istituto
Nazionale dei Tumori, Milan, IT, 4VHIO - Vall d'Hebron Institute of Oncology, Barcelona,
ES, 5Faculty of Medicine & Health, Örebro University, Örebro, SE, 6Karolinska Institutet
- Bioclinicum, Solna, SE, 7Université Libre de Bruxelles (ULB), Hôpital Universitaire de
Bruxelles (HUB), Institut Jules Bordet, Brussels, BE, 8Queen's University, Kingston, CA,
9IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, 10ESMO - European Society for Medical
Oncology, Lugano, CH, 11Institut Gustave Roussy, Villejuif, FR, 12UMC - University
Medical Center Utrecht, Utrecht, NL

A. Cortellini, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
15:25 - 15:35 Q&A
15:35 - 15:45 1690O - Impact of the Sars-Cov-2 outbreak on the initial clinical presentation of
new solid cancer diagnoses: a systematic review and meta-analysis
S. Marty1, G. Lamé2, E. Guével3, S. Priou2, G. Chatellier4, C. Tournigand1, E. Kempf1,

1Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR, 2CentraleSupélec -
Paris-Saclay campus, Gif sur Yvette, FR, 3Assistance Publique - Hopitaux De Paris AP-HP,
Paris, FR, 4Assistance Publique - Hopitaux De Paris, Paris, FR
15:45 - 15:55 1691O - Trends in new patient consultations during the COVID-19 pandemic at a
comprehensive cancer centre in a public healthcare system
C. Barron1, T. Pittman2, W. Xu2, M. Madunic1, J. Brierley1, M. Krzyzanowska1, 1UHN -

University Health Network - Princess Margaret Cancer Center, Toronto, CA, 2Princess
Margaret Cancer Centre, Toronto, CA

L. Castelo-Branco, ESMO - European Society for Medical Oncology, Lugano, CH
16:05 - 16:15 Q&A

15:00 - 16:00 Type: Controversy session Burgos Auditorium - Hall 3
Title: Pregnancy after breast cancer: Is it safe?
Chair(s): Ann H. Partridge, US

A.H. Partridge, Dana Farber Cancer Institute, Boston, US
15:05 - 15:20 Yes

15:20 - 15:35 No
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

15:00 - 16:00 Type: Young Oncologists session Pamplona Auditorium - Hall

Title: ESMO for medical students and young 9
physicians
Chair(s): Kok Haw Jonathan Lim, GB; Andres Cervantes, ES
15:00 - 15:15 ESMO-ESO Medical Students Course

15:15 - 15:30 Developing a successful career in medical oncology

15:30 - 16:00 Guided poster walk

16:15 - 17:45 Type: EONS Industry Satellite Symposium Alicante Auditorium - Hall
Title: AstraZeneca - Wellbeing in cancer nursing 10
workforce
Chair(s): Virpi Sulosaari, FI

16:20 - 16:45 Healthy work environment – what does it stand for in cancer care setting and
how to apply the principles into practice
16:45 - 17:10 The role of cancer nursing leadership in support of well-being at work
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE
17:10 - 17:35 Factors contributing to well-being at work – cancer nurse’s experience

M. Cable, University Hospital Coventry - University Hospitals Coventry and Warwickshire
NHS Trust, Coventry, GB
17:35 - 17:45 Q&A and Conclusion remarks
V. Sulosaari1, H. Ullgren2, M. Cable3, 1Turku University of Applied Sciences, Turku, FI,

2Karolinska University Hospital-Solna, Solna, SE, 3University Hospital Coventry -
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB
16:30 - 18:10 Type: Mini Oral session Bilbao Auditorium -

Title: Mini oral session 1 - Gastrointestinal tumours, NCC
upper digestive
Chair(s): Lorenza Rimassa, IT; Tania Fleitas, ES
16:30 - 16:35 945MO - AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab

(OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS +
BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)
Z. Ren1, Y. Huang2, Y. Guo3, M.M. Hou4, W. Wang5, M. Kuang6, C. Hao7, W. Wang8, Y.

Zhang9, T. Song10, C. Dai11, K. Hsing-Tao 12, V. Li13, R. Abdrashitov14, L. Wang13, J.
Fan15, 1Zhongshan Hospital Fudan University, Shanghai, CN, 2Mengchao Hepatobiliary
Hospital of Fujian Medical University, Fuzhou, CN, 3Nanfang Hospital, Southern Medical
University, Guangzhou, CN, 4Chang Gung Medical Foundation - Linkou Chang Gung
Memorial Hospital, Taoyuan City, TW, 5Hunan Cancer Hospital, Changsha, CN, 6The First
Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, 7Beijing Cancer Hospital,
Beijing, CN, 8West China Hospital Sichuan University, Sichuan, CN, 9Harbin Medical
University Cancer Hospital, Harbin, CN, 10HCC Research Center for Prevention and
Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, 11Shengjing
Hospital of China Medical University - Huaxiang Campus, Shenyang, CN, 12Chi Mei
Medical Center - Chiali, Tainan City, TW, 13BeiGene (Beijing) Co. Ltd, Beijing, CN,
14BeiGene USA, Inc., Fulton, US, 15Liver Cancer Institute, Zhongshan Hospital - Fudan
University, Shanghai, CN

16:35 - 16:40 94MO - Advanced extrahepatic cholangiocarcinoma: post-hoc analysis of the
ABC-01, -02 and -03 clinical trials.
A. Lamarca1, P. Ross2, H. Wasan3, R. Hubner4, M. Mcnamara4, A. Lopes5, D. Palmer6, J.

Valle4, J. Bridgewater7, 1Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES,
2Guy's Hospital, London, GB, 3Hammersmith Hospital - Imperial College Healthcare NHS
Trust, London, GB, 4The Christie NHS Foundation Trust, Manchester, GB, 5CRUK & UCL
Cancer Trials Centre, London, GB, 6University of Liverpool - Imaging Centre at
Liverpool, ICaL (formerly NiCaL), Liverpool, GB, 7UCL Cancer Institute - Paul O'Gorman
Building, London, GB
16:40 - 16:45 95MO - Tinengotinib in Patients with Advanced, Fibroblast Growth Factor
Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma
M. Javle1, L. Kankeu Fonkoua2, A. Mahipal3, C.-Y. Liao 4, C. Fountzilas5, D. Li6, M.

Pelster7, S. Goel8, P. Peng9, C. Sun9, H. Wang9, K. Hennessy10, X. Fu11, L. Neo9, Y.
Shan9, P. Huang9, D. Wu9, F. Wu9, J. Fan12, S.A. Piha-Paul13, 1MD Anderson Cancer
Center, Houston, US, 2Mayo Clinic, Rochester, US, 3University Hospitals Cleveland
Medical Center, Cleveland, US, 4University of Chicago – Department of Medicine,
Chicago, US, 5Roswell Park Comprehensive Cancer Center, Buffalo, US, 6City of Hope
Comprehensive Cancer Center, Duarte, US, 7Sarah Cannon Research Institute,
Tennessee Oncology, Nashville, US, 8Rutgers Cancer Institute of New Jersey, New
Brunswick, US, 9TransThera Sciences (Nanjing), Inc., Nanjing, CN, 10TransThera
Sciences (US), Inc., Gaithersburg, US, 11TransThera Sciences (Nanjing), Inc., nanjing,
CN, 12TransThera Sciences (US), Inc, Gaithersburg, US, 13The University of Texas MD
Anderson Cancer Center - Main Building, Houston, US

L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
17:00 - 17:05 LBA78 - Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin

with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced
Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2
Gastrectomy: An Updated Analysis of RESOLVE Trial
X. Zhang1, Z. Li1, H. Liang2, Y. Xue3, Y. Wang4, Z. Zhou5, J. Yu6, L. Chen7, Y. Du8, G. Li9,
G. Xiao10, D. Wu11, Y. Zhou12, C. Dang13, Y. He14, Z. Zhang15, Y. Sun16, Y. Li17, L. Shen1,
J. Ji1, 1Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, 2Tianjin
Medical University Cancer Institute & Hospital, Tianjin, CN, 3Harbin Medical University
Cancer Hospital, Harbin, CN, 4Fudan University Shanghai Cancer Center, Shanghai, CN,
5Sun Yat-sen University Cancer Center, Guangzhou, CN, 6The First Affiliated Hospital,
Zhejiang University School Of Medicine, Hangzhou, CN, 7Chinese PLA General Hospital
(301 Military Hospital), Beijing, CN, 8Zhejiang Cancer Hospital, Hangzhou, CN, 9East
theater General Hospital of PLA, Nanjing, CN, 10Beijing Hospital, Beijing, CN, 11The
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN,
12The Affiliated Hospital of Qingdao University, Qingdao, CN, 13The First Affiliated
Hospital of Xi'an Jiaotong University, Xi'an, CN, 14The First Affiliated Hospital, Sun Yat-
sen University, Guangdong, CN, 15Beijing Friendship Hospital, Capital Medical
University, Beijing, CN, 16Zhongshan Hospital Fudan University, Shanghai, CN, 17The
Fourth Hospital of Hebei Medical University, Shijiazhuang, CN

17:05 - 17:10 1512MO - Perioperative camrelizumab (C) combined with rivoceranib (R) and
chemotherapy (chemo) versus chemo for locally advanced resectable gastric or
gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of
a randomized, phase 3 trial (DRAGON IV)
C. Li1, Y. Zheng1, Z. Shi2, L. Yang3, B. Zhang1, Z. Wang1, H. Chen4, X. Wang5, P. Zhao6, J.

Dong7, C. Lian8, Q. Zhao9, Z. Zheng10, A. Zhang11, S. Xu12, K. Wang13, F. Yuan1, Y. Tian3,
K. Yin2, Z. Zhu1, 1Ruijin Hospital, Shanghai Jiaotong University School of Medicine,
Shanghai, CN, 2Changhai Hospital of Shanghai, Shanghai, CN, 3Cancer Hospital Chinese
Academy of Medical Sciences, Beijing, CN, 4Lanzhou University Second Hospital,
Lanzhou, CN, 5Yantai Yuhuangding Hospital, Yantai, CN, 6Sichuan Provincial Cancer
Hospital, Chengdu, CN, 7Shanxi Provincial Cancer Hospital, Taiyuan, CN, 8Heping
Hospital Affiliated to Changzhi Medical College, Changzhi, CN, 9The Fourth Hospital of
Hebei Medical University, Shijiazhuang, CN, 10Liaoning Cancer Hospital & Institute,
Shenyang, CN, 11Affiliated Hospital of Hebei University, Baoding, CN, 12Affiliated
Hospital of Jiangsu University, Zhenjiang, CN, 13Sichuan Provincial People's Hospital,
Chengdu, CN
17:10 - 17:20 Invited Discussant LBA78 and 1512MO
17:20 - 17:25 LBA79 - GEMSTONE-303: prespecified progression-free survival (PFS) and

overall survival (OS) final analyses of a phase 3 study of sugemalimab plus
chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced
gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
X. Zhang1, J. Wang2, G. Wang3, Y. Zhang4, Q. Fan5, L. Chuangxin6, C. Hu7, M.L. Sun8, Y.

Wan9, S. Sun10, J. Wang11, L. Zhang12, Y. Shu13, J. Luo14, D. Zhu14, H. Wang14, Y. Xu14,
Q. Shi14, J. Yang14, L. Shen1, 1Beijing Cancer Hospital, Beijing, CN, 2Henan Cancer
Hospital, Zhengzhou, CN, 3Anhui Provincial Hospital, Hefei, CN, 4Harbin Medical
University Cancer Hospital, Harbin, CN, 5The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, CN, 6Henan Provincial People's Hospital, Zhengzhou, CN, 7Anhui
Provincial Cancer Hospital, Hefei, CN, 8Jinan Central Hospital, Jinan, CN, 9Jiangxi
Cancer Hospital, Nanchang, CN, 10Xuzhou Central Hospital, Xuzhou, CN, 11Affiliated
Hospital of Jining Medical University, Jining, CN, 12Chongqing University Three Gorges
Hospital, Chongqing, CN, 13Jiangsu Province Hospital, Nanjing, CN, 14CStone
Pharmaceuticals Co. Ltd., Shanghai, CN
17:25 - 17:30 LBA80 - Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus
Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal
Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-
305 Study
R.-H. Xu1, D.-Y. Oh 2, K. Kato3, T. Arkenau4, J. Tabernero5, M. Cruz-Correa6, A. Zimina7, Y.

Bai8, J. Shi9, K.-W. Lee 10, H. Hirano3, D.R. Spigel11, L. Wyrwicz12, R. Pazo Cid13, L. Li14,
Y. Xu15, M.B. Mchenry16, S. Yang14, M. Moehler17, 1Sun Yat-sen University Cancer
Center State Key Laboratory of Oncology in South China, Collaborative Innovation
Center of Cancer Medicine, Guangzhou, CN, 2Seoul National University Hospital Cancer
Research Institute, Seoul National University College of Medicine, Seoul, KR, 3National
Cancer Center Hospital, Tokyo, JP, 4Sarah Cannon Research Institute, London, GB, 5Vall
d’Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, ES, 6University
of Puerto Rico, San Juan, PR, 7BIH Of Omsk Region, Omsk Oblast, RU, 8Harbin Medical

University Cancer Hospital, Harbin, CN, 9Linyi Cancer Hospital, Linyi, CN, 10Seoul
National University Bundang Hospital, Seoul National University College of Medicine,
Seongnam, KR, 11Tennessee Oncology, Nashville, US, 12Maria Sklodowska-Curie
National Research Institute of Oncology, Warsaw, PL, 13Hospital Universitario Miguel
Servet, Zaragoza, ES, 14BeiGene (Beijing) Co., Ltd., Beijing, CN, 15BeiGene (Shanghai)
Co., Ltd., Shanghai, CN, 16BeiGene USA, Inc., Cambridge, US, 17Johannes Gutenberg-
University Clinic, Mainz, DE
17:30 - 17:35 1513MO - A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line
therapy in patients with advanced gastric or esophago-gastric junction MSI-H
tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
K. Muro1, H. Kawakami2, S. Kadowaki1, A. Makiyama3, M. Tsuda4, K. Hirata5, N.

Sugimoto6, N. Machida7, H. Hara8, H. Hirano9, T. Esaki10, Y. Komatsu11, S. Hironaka12,
1Aichi Cancer Center Hospital, Nagoya, JP, 2Kindai University Faculty of Medicine,
Osakasayama, JP, 3Gifu University Hospital, Gifu, JP, 4Hyogo Cancer Center, Akashi, JP,
5Keio University School of Medicine, Shinjuku-ku, JP, 6Osaka International Cancer
Institute, Osaka, JP, 7Kanagawa Cancer Center, Yokohama, JP, 8Saitama Cancer Center,
Ina, JP, 9National Cancer Center Hospital, Chuo-ku, JP, 10National Hospital Organization
Kyushu Cancer Center, Fukuoka, JP, 11Hokkaido University Hospital, Sapporo, JP,
12Kyorin University Faculty of Medicine, Mitaka, JP
17:35 - 17:50 Invited Discussant LBA79, LBA80 and 1513MO

17:50 - 17:55 LBA81 - Updated efficacy and safety results from phase 3 GLOW study
evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with
claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA)
unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ)
adenocarcinoma
F. Lordick1, M. Shah2, K. Shitara3, J. Ajani4, Y.-J. Bang5, P. Enzinger6, D. Ilson7, E. Van

Cutsem8, J. Gallego Plazas9, J. Huang10, L. Shen11, S.C. Oh12, P. Sunpaweravong13,
H.H.F. Soo14, H. Türk15, J.W. Park16, D. Moran16, P. Bhattacharya16, Y. Cao17, R.-H. Xu18,
1University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, DE,
2Weill Cornell Medical College, New York, US, 3National Cancer Center Hospital East,
Kashiwa, JP, 4The University of Texas MD Anderson Cancer Center, Houston, US, 5Seoul
National University College of Medicine, Seoul, KR, 6Dana Farber Cancer Institute,
Boston, US, 7Memorial Sloan Kettering Cancer Center, New York, US, 8University
Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE, 9Hospital General
Universitario de Elche, Elche, ES, 10National Cancer Center / National Clinical Research
Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking
Union Medical College, Beijing, CN, 11Key Laboratory of Carcinogenesis and
Translational Research (Ministry of Education/Beijing), Peking University Cancer
Hospital and Institute, Beijing, CN, 12Korea University Guro Hospital, Seoul, KR,
13Prince of Songkla University, Amphoe Hat Yai, TH, 14Penang Hospital, Penang, MY,
15BezmialemVakif University, Istanbul, TR, 16Astellas Pharma Global Development, Inc.,
Northbrook, US, 17Astellas Pharma USA, Northbrook, US, 18Sun Yat-sen University
Cancer Center State Key Laboratory of Oncology in South China, Collaborative
Innovation Center of Cancer Medicine, Guangzhou, CN
17:55 - 18:00 LBA82 - Updated efficacy and safety results from phase 3 SPOTLIGHT study
evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients
with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA)
unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ)
adenocarcinoma
J. Ajani1, F. Lordick2, Y.-J. Bang3, P. Enzinger4, D. Ilson5, M. Shah6, E. Van Cutsem7, R.-H.
Xu8, G. Aprile9, J. Xu10, R. Pazo Cid11, Y.-K. Kang12, J. Yang13, D. Moran13, P.
Bhattacharya13, M. Matsangou14, A. Arozullah13, J.W. Park13, K. Shitara15, 1The
University of Texas MD Anderson Cancer Center, Houston, US, 2University Cancer
Center Leipzig, University of Leipzig Medical Center, Leipzig, DE, 3Seoul National
University College of Medicine, Seoul, KR, 4Dana-Farber Cancer Institute, Boston, US,
5Memorial Sloan Kettering Cancer Center, New York, US, 6Weill Cornell Medical College,
New York, US, 7University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE,
8Sun Yat-sen University Cancer Center, Guangzhou, CN, 9Azienda ULSS 8 Berica,
Vicenza, IT, 10The Fifth Medical Center of the PLA General Hospital, Beijing, CN,
11Hospital Universitario Miguel Servet, Zaragoza, ES, 12Asan Medical Center, University
of Ulsan, Seoul, KR, 13Astellas Pharma Global Development, Inc., Northbrook, US,
14Astellas Pharma Inc., Northbrook, US, 15National Cancer Center Hospital East,
Kashiwa, JP
S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE
16:30 - 18:00 Type: Educational session Granada

Title: Biomarkers in metastatic colorectal cancer: What has Auditorium - Hall
changed in the last few years? 3
Chair(s): Myriam Chalabi, NL; Hans Prenen, BE
16:30 - 16:55 Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS
G12C, NTRK)
M. Chalabi, Netherlands Cancer Institute, Amsterdam, NL
16:55 - 17:20 Biomarkers in 2023: What, how and when to test?

H. Prenen, UZA - University Hospital Antwerp, Edegem, BE
17:20 - 17:45 Biomarkers in the near future: What to expect?

F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

16:30 - 17:45 Type: Multidisciplinary session Burgos Auditorium - Hall 3
Title: Bladder preservation strategies
Chair(s): Elizabeth Plimack, US
16:30 - 16:35 Presentation of case/condition: Non-muscle invasive bladder cancer (NMIBC)

progressing to MIBC
16:35 - 16:55 Organ preservation for refractory NMIBC: A surgeon's perspective

J. Boormans, Erasmus MC, Rotterdam, NL
16:55 - 17:15 Radiotherapy in bladder preservation

R. Huddart, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB
17:15 - 17:35 The role of systemic therapy in bladder preservation

E. Plimack, Fox Chase Cancer Center - Main Campus, Philadelphia, US
16:30 - 18:15 Type: Proffered Paper session Madrid Auditorium - Hall 6

Title: Presidential 1
Chair(s): Solange Peters, CH
16:30 - 16:42 LBA1 - CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO)
plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by
surgery and adjuvant NIVO or placebo for previously untreated, resectable stage
II–IIIB NSCLC
T. Cascone1, M. Awad2, J. Spicer3, J. He4, S. Lu5, B. Sepesi1, F. Tanaka6, J. Taube7, R.

Cornelissen8, L. Havel9, J. Kuzdzal10, L. Petruzelka11, L. Wu12, J.-L. Pujol13, H. Ito14, C.
Coronado Erdmann15, P. Sathyanarayana15, S. Meadows-Shropshire15, M. Provencio
Pulla16, 1The University of Texas MD Anderson Cancer Center, Houston, US, 2Dana-
Farber Cancer Institute, Boston, US, 3McGill University Health Center, Montreal, CA,
4National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijng, CN,
5Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University,
Shanghai, CN, 6University of Occupational and Environmental Health, Kitakyushu, JP,

7The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University
School of Medicine, Baltimore, US, 8Erasmus MC Cancer Institute, Rotterdam, NL,

9Thomayer Hospital, Prague, CZ, 10John Paul II Hospital, Krakow, PL, 11Charles
University, Prague, CZ, 12Hunan Cancer Hospital, Changsha, CN, 13Montpellier Regional
University Hospital, Montpellier, FR, 14Kanagawa Cancer Center, Yokohama, JP, 15Bristol
Myers Squibb, Princeton, US, 16Hospital Universitario Puerta de Hierro, Madrid, ES
16:42 - 16:54 LBA2 - ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in
patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
B. Solomon1, J.S. Ahn2, R. Dziadziuszko3, F. Barlesi4, M. Nishio5, D.H. Lee6, J.-S. Lee7, W.-

Z. Zhong8, H. Horinouchi9, W. Mao10, M. Hochmair11, F. De Marinis12, M.R. Migliorino13,
I. Bondarenko14, T. Lohmann15, T. Xu16, A. Cardona Gavaldon15, W. Bordogna15, T. Ruf15,
Y.-L. Wu8, 1Peter MacCallum Cancer Center, Melbourne, AU, 2Samsung Medical Center,
Seoul, KR, 3Medical University of Gdansk, Gdańsk, PL, 4International Center for Thoracic
Cancers (CICT), Villejuif, FR, 5Japanese Foundation for Cancer Research, Tokyo, JP,
6Asan Medical Center, Seoul, KR, 7Seoul National University Bundang Hospital,
Seongnam, KR, 8Guangdong Provincial People’s Hospital (Guangdong Academy of

Medical Sciences), Southern Medical University, Guangzhou, CN, 9National Cancer
Center Hospital, Tokyo, JP, 10Chinese Academy of Sciences, Zhejiang, CN, 11Klinik
Floridsdorf, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology,
Vienna, AT, 12European Institute of Oncology (IRCSS), Milan, IT, 13San Camillo Forlanini
Hospital, Roma, IT, 14Dnipropetrovsk Medical Academy, Dnipro, UA, 15F. Hoffmann-La
Roche Ltd, Basel, CH, 16Roche (China) Holding Ltd, Shanghai, CN

M. Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, US
17:04 - 17:10 Q&A
17:10 - 17:22 LBA3 - Randomized Phase 3 Study of Selpercatinib versus Cabozantinib or

Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid
Cancer
J. Hadoux1, R. Elisei2, M. Brose3, A. Hoff4, B. Robinson5, M. Gao6, B. Jarzab7, P. Isaev8,

K. Kopeckova9, J. Wadsley10, D. Führer11, B. Keam12, E. Sherman13, M. Tahara14, M.
Hu15, Y. Lin16, P. Maeda16, L. Wirth17, J. Capdevila Castillon18, 1Gustave Roussy, Villejuif,
Cedex, FR, 2University of Pisa - DAM, Pisa, IT, 3Sidney Kimmel Cancer Center - Thomas
Jefferson University, Philadelphia, US, 4Instituto do Câncer do Estado de São Paulo,
Universidade de São Paulo, São Paulo, BR, 5University of Sydney, Sydney, AU, 6Tianjin
Medical University Cancer Institute & Hospital, Tianjin, CN, 7Maria Sklodowska-Curie
National Research Institute of Oncology, Gliwice Branch, Gliwice, PL, 8A. Tsyb MRRC,
Obninsk, RU, 9Motol University Hospital, Prague, CZ, 10Weston Park Hospital - Sheffield
Teaching Hospitals NHS Foundation Trust, Sheffield, GB, 11University Hospital, Essen,
University of Duisburg-Essen, Endocrine Tumour Center at West German Cancer Center,
Essen, DE, 12Seoul National University Hospital, Seoul, KR, 13MSKCC - Memorial Sloan
Kettering Cancer Center, New York, US, 14National Cancer Center Hospital East,
Kashiwa, JP, 15The University of Texas M. D. Anderson Cancer Center, Houston, US, 16Eli
Lilly and Company, Indianapolis, US, 17MGH - Massachusetts General Hospital, Boston,
US, 18Vall Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO),
Barcelona, ES

L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano,
Milan, IT
17:30 - 17:35 Q&A

17:35 - 17:47 LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus
Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC
H.H.F. Loong1, K. Goto2, B. Solomon3, K. Park4, M. Pérol5, E. Arriola6, S. Novello7, Y.

Cheng8, A. Ardizzoni9, M. Mak10, F. Santini11, Y. Elamin12, A. Drilon13, J. Wolf14, B.
Han15, H. Han16, M. Uh16, T. Puri16, V. Ilaria17, C. Zhou18, 1The Chinese University of
Hong Kong - Prince of Wales Hospital, Sha Tin, HK, 2National Cancer Center Hospital
East, Kashiwa, JP, 3Peter MacCallum Cancer Center, Melbourne, AU, 4Samsung Medical
Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, 5Centre Léon
Bérard, Lyon, FR, 6HOSPITAL DEL MAR, BARCELONA, ES, 7Università Degli Studi Di
Torino - Orbassano, Orbassano, IT, 8Jilin Cancer Hospital, Changchun, CN, 9University of
Bologna - Alma Mater Studiorum, Bologna, IT, 10ICESP - Instituto do Cancer do Estado
de Sao Paulo, Sao Paulo, BR, 11Hospital Sirio Libanes - Complexo Hospitalar Bela Vista,
Sao Paulo, BR, 12The University of Texas M. D. Anderson Cancer Center, Houston, US,
13Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, 14University
Hospital of Cologne, Cologne, DE, 15Shanghai Chest Hospital, Shanghai Jiao Tong
University, Shanghai, CN, 16Eli Lilly and Company, Indianapolis, US, 17Eli Lilly and
Company - Global Headquarters, Indianapolis, US, 18Shanghai Pulmonary Hospital,
Shanghai, CN
17:47 - 17:59 LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line

Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung
Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global
Study
N. Girard1, K. Park2, K. Tang3, B.C. Cho4, L. Paz-Ares5, S. Cheng6, S. Kitazono7, M.

Thiagarajan8, J. Goldman9, J. Sabari10, R. Sanborn11, A. Mansfield12, J.-Y. Hung 13, S.
Popat14, J. Dias15, A. Bhattacharya16, T. Agrawal17, M. Shreeve18, R. Knoblauch17, C.
Zhou19, 1Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University,
UVSQ, Versailles, FR, 2Sungkyunkwan University School of Medicine, Seoul, Korea,
Republic of, (current affiliation: MD Anderson Cancer Center), Houston, US, 3The First
Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, 4Yonsei Cancer Center,
Yonsei University College of Medicine, Seoul, KR, 5Hospital Universitario 12 de Octubre,
Madrid, ES, 6Sunnybrook Odette Cancer Centre, Toronto, CA, 7Japanese Foundation for
Cancer Research, Tokyo, JP, 8General Hospital Kuala Lumpur, Kuala Lumpur, MY,
9University of California Los Angeles, Los Angeles, US, 10NYU Langone Health, New
York, US, 11Providence Cancer Institute, Portland, US, 12Mayo Clinic, Rochester, US,
13Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, TW, 14The Institute of Cancer Research, London, GB,
15Barretos Cancer Hospital, Barretos, BR, 16Janssen R&D, High Wycombe, GB, 17Janssen
R&D, Spring House, US, 18Janssen R&D, San Diego, US, 19Tongji University School of
Medicine, Shanghai, CN
18:09 - 18:15 Q&A

16:30 - 18:00 Type: Special symposium Salamanca
Title: New mechanisms and drugs for the treatment of Auditorium - Hall 3
patients with sarcomas
Chair(s): Kjetil Boye, NO; Marta Sbaraglia, IT
16:35 - 16:50 Targeting fusion driven sarcomas

C. Kadoch, Dana Farber Cancer Institute, Boston, US
16:50 - 17:05 Targeting proapoptotic pathways: MDM2 and beyond

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
17:05 - 17:20 Multi-facets of antiangiogenic agents

T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW
17:20 - 17:35 Novel combinations

R. Jones, The Royal Marsden Hospital - Chelsea, London, GB
16:30 - 17:50 Type: Mini Oral session Málaga Auditorium - Hall

Title: Mini oral session - Investigational 10
immunotherapy
Chair(s): Alessandra Curioni-Fontecedro, CH; María José De Miguel, ES
16:30 - 16:35 1020MO - AdvanTIG-203: Phase 2 Randomized, Multicenter Study of

Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Unresectable,
Locally Advanced, Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
(ESCC) and Programmed Cell Death-Ligand 1 (PD-L1) Positivity
F. Wang1, C.-Y. Lin 2, J.-M. Sun3, C.-H. Lu4, X. Zhu5, Z. Chen6, I.-H. Kim7, Y. Pan8, J.
Zhang9, Z. Chen10, D. Tougeron11, S.-B. Kim12, E. Van Cutsem13, R. Abdrashitov14, R.
Ge15, J. Sun15, J. Zhou15, R.-H. Xu1, 1Sun Yat-Sen University Cancer Center, Guangzhou,
CN, 2China Medical University Hospital, Taiwan, CN, 3Samsung Medical Center, Seoul,
KR, 4Chiayi Chang Gung Memorial Hospital, Taiwan, CN, 5Sichuan Provincial People’s
Hospital, Chengdu, CN, 6The Second Affiliated Hospital of Anhui Medical University,
Hefei, CN, 7Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, KR,
8Anhui Provincial Hospital, Hefei, CN, 9Liaoning Cancer Hospital & Institute, Shenyang,
CN, 10People's Hospital of Deyang City, Deyang, CN, 11Poitiers University Hospital,
Poitiers, FR, 12Asan Medical Center, Seoul, KR, 13University Hospitals Gasthuisberg
Leuven and University of Leuven (KUL), Leuven, BE, 14BeiGene USA, Inc., Fulton, US,

15BeiGene (Beijing) Co., Ltd., Beijing, CN
16:35 - 16:40 1021MO - Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-
PD1) in recurrent/advanced solid tumors
M. Mckean1, E. Dumbrava2, O. Hamid3, P. Merriam4, J. Call5, W. Feely6, A. Green7, U.

Vaishampayan8, K. Moore9, S. Weroha10, S. Krishnan6, A. George11, 1Sarah Cannon
Research Institute, Nashville, US, 2M. D. Anderson Cancer Center, Houston, US, 3The
Angeles Clinic and Research Institute, Los Angeles, US, 4Dana Farber Cancer Institute,
Boston, US, 5START Mountain Region, West Valley City, US, 6OncoMed Pharmaceuticals,
Inc. - Mereo BioPharma Group plc, Redwood City, US, 7Memorial Sloan Kettering Cancer
Center, New York, US, 8Michigan Medicine University of Michigan, Ann Arbor, US,
9Oklahoma University, Oklahoma City, US, 10Mayo Clinic, Rochester, US, 11The Royal
Marsden Foundation Trust, London, GB

A. Curioni-Fontecedro, Cantonal Hospital Fribourg, Villar sur Glane, CH
16:55 - 17:00 1022MO - Predicting overall survival of patients with melanoma and NSCLC
treated with immunotherapy using AI combining total tumor volume and tumor
heterogeneity on CT-Scans.
L. Dawi1, S. Ammari2, Y. Belkouchi3, J. Hadchiti4, L. Lawrance2, F. Wirth4, A. Bertin4, S.

Morer4, N. Billet4, C. Balleyguier5, P.-H. Cournede2, H. Talbot3, N. Lassau2, 1Gustave
Roussy, Bourg-la-reine, FR, 2Gustave Roussy - Cancer Campus, Villejuif, FR,
3CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, 4Gustave Roussy, Paris, FR,
5Institut Gustave Roussy, Villejuif, Cedex, FR
17:00 - 17:05 1023MO - Decoding Immunotherapy Resistance: A Novel Multiparametric

Magnetic Resonance Imaging Approach to Stratify Cancer Patient Outcomes
K. Bernatowicz1, F. Grussu1, C. Tozzi1, A. Voronova1, M. Sanz2, M. Vieito Villar2, G.

Alonso Casal2, V. Galvao2, A. Oberoi2, I. Braña2, O. Saavedra Santa Gadea2, E. Muñoz
Couselo2, G. Serna1, A.B. Moreno1, M. Rotxes2, J. Tabernero2, R. Toledo1, P. Nuciforo1, E.
Garralda2, R. Perez Lopez1, 1Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center,
Barcelona, ES, 2Vall d'Hebron University Hospital, Barcelona, ES
17:05 - 17:10 1024MO - Interpretable AI-identified spatial tumor microenvironment (TME)

neighborhoods associate with severe immune-related adverse events (irAE) and
progressive disease (PD) in patients with melanoma treated with anti-PD-1-
based therapy
D. Jimenez-Sanchez1, E.M. Will1, J. Lai1, G. Warrier2, E. Lipson2, J. Deutsch1, A.S.

Szalay1, J. Taube3, 1Johns Hopkins Hospital, Baltimore, US, 2Johns Hopkins Medicine -
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, 3Johns Hopkins Sidney
Kimmel Cancer Center, Baltimore, US
17:25 - 17:30 1025MO - Preliminary safety, pharmacokinetics and immunomodulatory activity

of RBS2418, an oral ENPP1 inhibitor, alone and in combination with
pembrolizumab in patients with solid tumors
T. Marron1, J. Misleh2, C. Chen3, Z. Wainberg4, J. Powderly5, R. Boccia6, M. Gordon7, J.

Segar8, I. Csiki9, J. Schanzer9, L. O'Toole9, N. Huang9, J. Seppa9, J. Glenn10, K. Klumpp11,
A. Spira12, 1The Mount Sinai Hospital - Icahn School of Medicine, New York, US,
2Christiana Care Health System - Helen F. Graham Cancer Center and Research
Institute, Newark, US, 3Stanford Cancer Center Palo Alto, Palo Alto, US, 4UCLA - David
Geffen School of Medicine, Los Angeles, US, 5Carolina BioOncology Institute,
Huntersville, US, 6AOP, Bethesda, US, 7HonorHealth Research Institute, Scottsdale, US,
8The University of Arizona, Tucson, US, 9Riboscience LLC, Sunnyvale, US, 10Stanford
Health Care, Stanford, US, 11Riboscience, Sunnyvale, US, 12Virginia Cancer Specialist,
Fairfax, US
17:30 - 17:35 1026MO - A phase 1b/2 study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII

agent) in combination with bevacizumab (BEV) in patients with advanced solid
tumors
R.-H. Xu1, L. Huiyan1, H. Zhao1, W. Wei1, D. Ma2, X. Yin3, Y. Ni4, Y. Wang5, Y. Zhang6, J.
Zhou7, H. Pan8, Z. Niu9, J. Zhang10, H. Ren11, M. Kang12, W. Jia13, S. Gu14, P. Liu15, Z.
Zhang15, S. Wang16, 1Sun Yat-sen University Cancer Center, Guangzhou, CN, 2Henan
Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN,
3Hunan Cancer Hospital, Changsha, CN, 4Shanxi Provincial Hospital of Traditional
Chinese Medicine, Taiyuan, CN, 5Shanxi Provincial Cancer Hospital, Taiyuan, CN,
6Harbin Medical University Cancer Hospital, Harbin, CN, 7Sichuan Cancer Hospital,
Chengdu, CN, 8Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, CN, 9Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN,
10Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, 11The
Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, 12Affiliated

Hospital of Guilin Medical University, Guilin, CN, 13The First Affiliated Hospital of
USTC/Anhui Provincial Hospital, Hefei, CN, 14Hunan Cancer Hospital & The Affiliated
Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN,
15Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN, 16Jiangsu Hengrui
Pharmaceuticals Co., Ltd., Shenyang, CN

M.J. De Miguel Luken, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico
Clara Campal, Madrid, ES

16:30 - 18:00 Type: Patient Advocacy session Cádiz
Title: The importance of secondary prevention: Early detection Auditorium -
and screening programmes NCC
Chair(s): Eva-Maria Strömsholm, FI; Barbara Moss, GB
16:30 - 16:45 Improving early diagnosis through screening programme guidelines: The case of
lung cancer
J. Van Meerbeeck, UZA - University Hospital Antwerp, Edegem, BE
16:45 - 17:00 The importance of harmonizing screening programmes across different levels of
healthcare systems: Europe, national, regional
R. Giuliani, The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB
17:00 - 17:15 Cancer screening, another ground of health equity

G. Gorgoni, Agenzia Strategica Regionale per la Salute e il Sociale, Bari, IT
17:15 - 17:30 The case of colon cancer

B. Moss, DiCE - Digestive Cancers Europe - EuropaColon LTD, Salisbury, GB
17:30 - 17:45 The case of dental screening programmes

M. Heffernan, Dr. Heffs, London, GB

Title: GSK - Convergence of evidence and experience in first-line Auditorium
advanced ovarian cancer Experts debate considerations and options - Hall 3
for optimized clinical management
Chair(s): Antonio Gonzalez Martin, ES
18:30 - 18:40 The evidence nexus: Treatment evolution in first-line advanced ovarian cancer
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES
18:40 - 19:25 Not too little, not too much: What is the best 1L maintenance treatment
approach for patients with HRd tumors?
A. Leary1, J. Ledermann2, 1Institut Gustave Roussy, Villejuif, FR, 2UCL Cancer Institute -
UCL - London's Global University, London, GB
19:25 - 19:50 What’s next: Novel strategies to address unmet needs in advanced ovarian
cancer
A. Leary1, J. Ledermann2, 1Institut Gustave Roussy, Villejuif, FR, 2UCL Cancer Institute -
UCL - London's Global University, London, GB
19:50 - 19:55 Conclusions and thoughts


Title: Pfizer Oncology - Understanding novel PARPi Auditorium - Hall
combination mechanisms in mCRPC 10
Chair(s): Josep Maria Piulats Rodriguez, ES

J.M. Piulats Rodriguez, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i
Reynals), Hospitalet de Llobregat, ES
18:35 - 19:00 Molecular rationale behind PARPi and ARPi combinations in mCRPC
19:00 - 19:20 Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: Findings from
Clinical Trials
A. Azad, Peter MacCallum Cancer Centre, Melbourne, AU
19:20 - 19:40 Role of novel PARPi + ARPi therapeutic combinations in evolving clinical
practice
P. Barthelemy, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR
19:40 - 19:55 Q&A



18:30 - 20:00 Type: ESMO Colloquium Salamanca
Title: ESMO Colloquium supported by Eisai Europe Ltd.: Auditorium -
Optimising outcomes for patients with advanced renal cancer Hall 3
Chair(s): Toni Choueiri, US; Thomas Powles, GB

18:40 - 18:55 Current and emerging clinicopathologic and molecular prognostic schemes for
patients with advanced renal cell carcinoma
V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
18:55 - 19:10 State-of-the-art combination therapies for patients with advanced RCC
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR
19:10 - 19:25 Do all patients need combination therapy? De-escalation and patient selection
19:25 - 19:40 Research insights in enhancing treatment efficacy: Escalation, sequencing and
prediction
19:55 - 20:00 Concluding remarks


18:30 - 20:00 Type: Industry Satellite Symposium Málaga Auditorium
Title: AstraZeneca - Keeping abreast of a dynamic disease: - Hall 10
Considerations in HR+ mBC
Chair(s): Rebecca Dent, SG
18:30 - 18:35 Welcome and brief introduction to a dynamic disease

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG
18:35 - 19:00 Adapting to a dynamic disease: Optimising endocrine therapy and the role for
genomic medicine
F.C. Bidard, Institut Curie, Paris, FR
19:00 - 19:25 Responding to a dynamic disease: Utilising ADCs

I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US
19:25 - 19:50 Managing a dynamic disease: Tailoring treatment strategies

K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
19:50 - 19:58 The future of a dynamic disease: What’s on the horizon for HR+ mBC?
R. Dent1, F.C. Bidard2, I. Krop3, K. Jhaveri4, 1NCCS - National Cancer Centre Singapore,
Singapore, SG, 2Institut Curie, Paris, FR, 3Yale University School of Medicine - Yale
Cancer Center, New Haven, US, 4Memorial Sloan Kettering Evelyn H. Lauder Breast
Center, New York, US
19:58 - 20:00 Meeting summary and close


Title: MSD - Oncologists at the Helm of Translating Auditorium - Hall
Biomarker Insights into Actionable Patient Care 9
Chair(s): Maria Alsina Maqueda, ES

M. Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, ES
18:35 - 18:55 How have clinical Biomarkers changed the treatment of cancer patients and
what may the future look like?
18:55 - 19:05 Q&A
M. Alsina Maqueda1, K. Pantel2, C. Eloy3, 1Hospital Universitario de Navarra, Pamplona,

ES, 2UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, 3IPATIMUP -
Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT
19:05 - 19:30 Emerging role of NGS and ctDNA in transforming the clinical utility of
biomarkers
K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
19:30 - 19:45 How will the use of Digital pathology and AI tools lead to better patient care
(Panel discussion)
C. Eloy, IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do
Porto, Porto, PT
19:45 - 19:55 Q&A
M. Alsina Maqueda1, K. Pantel2, C. Eloy3, 1Hospital Universitario de Navarra, Pamplona,

ES, 2UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, 3IPATIMUP -
Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT


18:30 - 20:00 Type: Industry Satellite Symposium Toledo Auditorium -
Title: Ipsen - aRCC and mCRPC: is your decision-making Hall 3
up-to-date?
Chair(s): Joaquim Bellmunt, US
18:30 - 18:37 Welcome & introduction

18:37 - 18:49 Keeping pace in aRCC Description: A presentation highlighting the rapid
advances in treatment landscape as well as biological understanding of aRCC,
and what this means for patients in the real world.
D. Heng, Tom Baker Cancer Centre, Calgary, CA
18:49 - 19:01 Spoilt for choice in 1L aRCC? Or not Really? Description: A presentation
discussing the clinical endpoints that are considered when selecting first-line
treatment for patients with aRCC.
S. Pal, City of Hope Comprehensive Cancer Center, Duarte, US
19:01 - 19:10 Panel Discussion
J. Bellmunt1, S. Pal2, D. Heng3, C. Suarez Rodriguez4, A. Merseburger5, 1Harvard

Medical School, Boston, US, 2City of Hope Comprehensive Cancer Center, Duarte, US,
3Tom Baker Cancer Centre, Calgary, CA, 4Vall d'Hebron University Hospital, Barcelona,
ES, 5UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE
19:10 - 19:35 Putting theory into practice Description: A simulated multi-disciplinary tumour
board considering the first- and second-line treatment choices for a patient with
aRCC.
C. Suarez Rodriguez1, D. Heng2, 1Vall d'Hebron University Hospital, Barcelona, ES, 2Tom
Baker Cancer Centre, Calgary, CA
19:35 - 19:55 Direction of travel in mCRPC Description: A presentation reflecting on the

similar rapid changes that are occurring in mCRPC and changes anticipated in
the near-term, and considering the data available to help clinicians select and
sequence treatments.
A. Merseburger, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck,
Lübeck, DE


Title: Merck - Exploring SCCHN: insight into an evolving Hall 7
treatment landscape
Chair(s): Hisham Mehanna, GB

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham,
GB
18:35 - 18:47 Treatment of LA SCCHN: challenges and unmet needs

S. Rieken, Universitätsmedizin Göttingen, Goettingen, DE
18:47 - 18:59 A matter of life and cell death: resistance to apoptosis in SCCHN
J. Schoenfeld, Dana-Farber Cancer Institute, Boston, US
18:59 - 19:11 Looking ahead: ongoing developments in LA SCCHN

C. Le Tourneau, Institut Curie, Paris, FR

GB
19:26 - 19:38 Reviewing the evidence: treatment sequencing in R/M SCCHN

N. Baste Rotllan, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

GB

GB

Title: Gilead Sciences Europe Ltd - Lines of progress: Continuing Auditorium -
to improve outcomes in metastatic breast cancer Hall 7
Chair(s): Eva Ciruelos, ES
18:30 - 18:45 Metastatic Breast Cancer: A journey of progress through innovations

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES
18:45 - 19:10 Expanding possibilities in HR+/HER2- mBC

H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
19:10 - 19:35 Improving outcomes for patients with metastatic TNBC

A. Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases
(NCT), Heidelberg, DE
19:35 - 19:55 Audience Q&A
A. Schneeweiss1, H. Rugo2, S. Tolaney3, 1German Cancer Research Center - National

Center for Tumor Diseases (NCT), Heidelberg, DE, 2UCSF Helen Diller Family
Comprehensive Cancer Center, San Francisco, US, 3Dana Farber Cancer Institute,
Boston, US


22.10.2023
08:30 - 10:00 Type: Special symposium Barcelona Auditorium - Hall 9
Title: Circulating tumour DNA: A perfect fit?
Chair(s): Clara Montagut Viladot, ES; Julien Taieb, FR

08:35 - 08:50 ctDNA assessment: How and when?

K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
08:50 - 09:05 ctDNA in mCRC: Monitoring response and guiding treatment

C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES
09:05 - 09:20 ctDNA in early-stage CRC: Tailoring the adjuvant therapy

09:20 - 09:35 ctDNA clearance: Surrogacy for cure and organ-sparing approaches
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES
08:30 - 10:00 Type: Mini Oral session Sevilla Auditorium - Hall 9

Title: Mini oral session 2 - NSCLC, metastatic
Chair(s): Martin Reck, DE; Jessica Lin, US; Tetsuya Mitsudomi, JP
08:30 - 08:35 1317MO - Updated study results of pelcitoclax (APG-1252) combined with
osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer
(NSCLC)
Y. Ma1, H. Zhao1, Y. Zhao2, Y. Cheng3, J. Cui4, G. Liu5, D. Xiong5, J. Zhang5, L. Xu5, J. Yu5,
L. Men5, E. Liang6, D. Yang5, L. Zhang1, Y. Zhai6, 1State Key Laboratory of Oncology in
South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen
University Cancer Center, Guangzhou, CN, 2Henan Cancer Hospital/Affiliated Cancer
Hospital of Zhengzhou University, Zhengzhou, CN, 3Jilin Cancer Hospital, Changchun,
CN, 4The First Hospital of Jilin University, Changchun, CN, 5Ascentage Pharma (Suzhou)
Co., Ltd., Suzhou, CN, 6Ascentage Pharma Group, Inc., Rockville, US
08:35 - 08:40 1318MO - First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–

Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in
Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
J. Rotow1, S.N. Waqar2, K. Papadopoulos3, J.-Y. Hung 4, A. Spira5, H. Gan6, T. Yoshida7, C.-

H.S. Kuo8, B. Doger De Spéville9, E. Felip10, K. Yoh11, G. Morrison-Thiele 12, R.
Robinson13, N. Rudraganguly13, R. Saab13, B.C. Cho14, 1The Lowe Center for Thoracic
Oncology at Dana-Farber Cancer Institute, Boston, US, 2Washington University School of
Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, 3South Texas Accelerated
Research Therapeutics (START), San Antonio, US, 4Kaohsiung Municipal Ta-Tung
Hospital, Kaohsiung Medical University, Kaohsiung City, TW, 5Virginia Cancer Specialists,
US Oncology Research, Fairfax, US, 6Austin Health - Austin Hospital, Heidelberg, AU,
7National Cancer Center Hospital, Tokyo, JP, 8Chang Gung Memorial Hospital, Chang
Gung University, Taipei, TW, 9START Madrid Hospital Universitario, Madrid, ES, 10Vall
d'Hebron University Hospital, Barcelona, ES, 11National Cancer Center Hospital East,
Kashiwa, JP, 12Abbvie Inc. - Headquarters, North Chicago, US, 13AbbVie, Inc., San
Francisco, US, 14Yonsei University, Seoul, KR
08:40 - 08:45 1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung
cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a
Phase I study with BAY 2927088
H.H.F. Loong1, G. Daniele2, T.-Y. Yang 3, T. Leal4, K. Goto5, Y. Shinno6, K. Nishino7, T.

Sakamoto8, E. Felip9, J.C. Ruffinelli10, N. Gallot11, Z. Wang12, C. Chen13, B. Brennan14,
S.-F. Pu14, M. Kornacker15, P. Grassi16, X. Le17, D.S.W. Tan18, B.-C. Goh19, 1The Chinese
University of Hong Kong, Hong Kong, CN, 2Fondazione Policlinico Universitario Agostino
Gemelli IRCCS, Rome, IT, 3Taichung Veterans General Hospital, Taichung City, TW,
4Emory University, Atlanta, US, 5National Cancer Center Hospital East, Kashiwa, JP,
6National Cancer Center Hospital, Tokyo, JP, 7Osaka International Cancer Institute,
Osaka, JP, 8Tottori University, Yonago, JP, 9Vall d'Hebron University Hospital, Barcelona,
ES, 10ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals),
L'Hospitalet de Llobregat, ES, 11ClinBAY Ltd., Limassol, CY, 12Bayer HealthCare
Pharmaceuticals, Inc., Cambridge, US, 13Bayer HealthCare Pharmaceuticals Inc.,
Whippany, US, 14Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, 15Bayer
Consumer Care, Basel, CH, 16Bayer S.p.A., Milan, IT, 17MD Anderson Cancer Center,
Houston, US, 18National Cancer Centre Singapore, Singapore, SG, 19National University
Cancer Institute, Singapore, SG
09:00 - 09:05 1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated
advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01
M. Johnson1, P. Jänne2, Y. Goto3, K. Yoh4, S.-H. Lee5, L. Paz-Ares6, B. Besse7, S. Novello8,

H. Hayashi9, D.-W. Kim 10, T. John11, S. Kao12, E. Felip13, J.C.-H. Yang14, M. Reck15, Q.
Dong16, A. Sporchia16, D. Sternberg16, H.A. Yu17, 1Sarah Cannon Research Institute,
Nashville, US, 2Dana-Farber Cancer Institute, Boston, US, 3National Cancer Center
Hospital, Chuo-ku, JP, 4National Cancer Center Hospital East, Kashiwa, JP, 5Department
of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
and Department of Health Sciences and Technology, Samsung Advanced Institute for
Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, 6Spanish National
Cancer Research Center, Universidad Complutense and Ciberonc, Madrid, ES, 7Gustave
Roussy, Villejuif, FR, 8University of Turin, Orbassano, IT, 9Kindai University, Osaka, JP,
10Seoul National University College of Medicine and Seoul National University Hospital,
Seoul, KR, 11Peter MacCallum Cancer Centre, Melbourne, AU, 12Sydney Medical School,

The University of Sydney, Sydney, AU, 13Vall d’Hebron University Hospital and Vall
d’Hebron Institute of Oncology, Barcelona, ES, 14National Taiwan University Hospital,
Taipei City, TW, 15Airway Research Center North, German Center for Lung Research,
Grosshansdorf, DE, 16Daiichi Sankyo, Inc, Basking Ridge, US, 17Medical Oncology,
Memorial Sloan Kettering Cancer Center, New York, US
09:05 - 09:10 1321MO - Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2
(ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC)
With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-
Lung01 and DESTINY-Lung02
B. Li1, D. Planchard2, K. Goto3, E. Smit4, J. De Langen5, Y. Goto6, K. Ninomiya7, T. Kubo7,

M. Pérol8, E. Felip9, H. Hayashi10, K. Nakagawa10, J. Shimizu11, M. Nagasaka12, K.
Pereira13, A. Taguchi14, A. Ali15, M. Karnoub13, R. Yonemochi13, P. Jänne16, 1Memorial
Sloan Kettering Cancer Center, New York, US, 2Gustave Roussy, Villejuif, Cedex, FR,
3National Cancer Center Hospital East, Kashiwa, JP, 4LUMC-Leiden University Medical
Center, Leiden, NL, 5Netherlands Cancer Institute, Amsterdam, NL, 6National Cancer
Center Hospital, Tokyo, JP, 7Okayama University Hospital, Okayama, JP, 8Léon Bérard
Cancer Center, Lyon, FR, 9Vall d'Hebron University Hospital, Barcelona, ES, 10Kindai
University Hospital, Osakasayama, JP, 11Aichi Cancer Center Hospital, Nagoya, JP,
12University of California Irvine School of Medicine, Orange, US, 13Daiichi Sankyo, Inc.,
Basking Ridge, US, 14Daiichi Sankyo Co., Ltd., Chuo-ku, JP, 15Daiichi Sankyo Europe
GmbH, Munich, DE, 16Dana-Farber Cancer Institute, Boston, US
09:10 - 09:15 1324MO - CNS Outcomes of Lazertinib vs Gefitinib in EGFR-mutated Advanced

NSCLC: A LASER301 Subset Analysis
R. Soo1, B.C. Cho2, J.-H. Kim3, M.-J. Ahn4, K.H. Lee5, A. Zimina6, S. Orlov7, I.
Bondarenko8, Y.-G. Lee9, L. Yueh Ni10, S.S. Lee11, K.H. Lee12, Y.K. Pang13, C.H. Fong14,
J.H. Kang15, C.S. Lim16, P. Danchaivijitr17, H. Lee18, S. Park18, I. Cicin19, 1National
University Cancer Institute Singapore, Singapore, SG, 2Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, KR, 3CHA Bundang Medical Center, Seongnam,
KR, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR,
5Chungbuk National University Hospital, Chungbuk National University College of
Medicine, Cheongju, KR, 6State Budgetary Healthcare Institution of Omsk Region, Omsk,
RU, 7Pavlov State Medical University, Saint-Petersburg, RU, 8Dnipropetrovsk Medical
Academy, Dnipro, UA, 9Kangbuk Samsung Hospital, Sungkyunkwan University School of
Medicine, Seoul, KR, 10Hospital Umum Sarawak, Sarawak, MY, 11IInje University
Haeundae Paik Hospital, Inje University College of Medicine, Busan, KR, 12Yeungnam
Univeristy Medical Center, Daegu, KR, 13University Malaya Medical Centre, Kuala
Lumpur, MY, 14Hospital Pulau Pinang, Georgetown, MY, 15Seoul St. Mary’s Hospital,
College of Medicine, The Catholic University of Korea, Seoul, KR, 16Hospital Sultan
Ismail, Johor Bahru, MY, 17Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, TH, 18Yuhan Corporation, Seoul, KR, 19Trakya University Medical Faculty,
Edirne, TR

J. Lin, MGH - Massachusetts General Hospital, Boston, US
09:30 - 09:35 1322MO - Insights into Tumour Dissemination and Progression using

Longitudinal Imaging and ctDNA in the TRACERx Lung Cancer Study
W.K. Liu1, B. Ding2, S. Hessey1, C. Martinez Ruiz3, J. Kittel1, C. Lombardelli1, H. Lee2, C.

Veiga2, C. Richard1, A. Huebner3, A. Hackshaw4, C. Abbosh5, G. Royle2, A. Frankell6, C.
Swanton6, M. Jamal-Hanjani1, 1University College London Cancer Institute, London, GB,
2UCL - University College London, London, GB, 3UCL Cancer Institute - Paul O'Gorman
Building, London, GB, 4Cancer Research UK & University College London Cancer Trials
Centre, London, GB, 5Cancer Research UK, London, GB, 6Francis Crick Institute,
London, GB
09:35 - 09:40 LBA72 - DARWIN II: Deciphering Anti-tumour Response and Resistance to
immunotherapy With INtratumour Heterogeneity in NSCLC
C. Hiley1, S. Saghafinia1, T. Ahmad2, M. Krebs3, D. Fennell4, S. Baijal5, N. Steele6, G.

Price7, C. Lombardelli8, W.K. Liu9, C. Castignani10, K. Enfield10, B. Chain8, S. Quezada11,
G. Kassiotis12, K. Litchfield13, N. Mcgranahan9, A. Hackshaw14, M. Jamal-Hanjani1, C.
Swanton10, 1UCL Cancer Institute - Paul O'Gorman Building, London, GB, 2University
College London Hospitals NHS Foundation Trust, London, GB, 3The Christie NHS
Foundation Trust, Manchester, GB, 4Leicester Royal Infirmary - University Hospitals of
Leicester NHS Trust, Leicester, GB, 5Heartlands Hospital - University Hospitals
Birmingham NHS Foundation Trust, Birmingham, GB, 6BWSCC - Beatson West of
Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, 7Aberdeen
Royal Infirmary - NHS Grampian, Aberdeen, GB, 8UCL - University College London,
London, GB, 9University College London Cancer Institute, London, GB, 10Francis Crick
Institute, London, GB, 11UCL Cancer Institute, London, GB, 12The Francis Crick
Institute, London, GB, 13UCL Cancer Institute - UCL - London's Global University,
London, GB, 14Cancer Research UK & University College London Cancer Trials Centre,
London, GB
09:40 - 09:45 1323MO - Immune evasion across space and time in patients with lung cancer
enrolled in the PEACE autopsy study
S. Hessey1, W.K. Liu1, O. Pich2, A. Huebner1, A. Bunkum1, C. Richard1, C. Puttick2, C.

Lombardelli1, D. Moore1, N. Mcgranahan1, S. Zaccaria1, C. Hiley2, C. Swanton2, M.
Jamal-Hanjani1, 1University College London Cancer Institute, London, GB, 2Francis Crick
Institute, London, GB
09:45 - 10:00 Invited Discussant 1322MO, LBA72 and 1323MO
08:30 - 09:55 Type: Mini Oral session Bilbao Auditorium - NCC

Title: Mini oral session - Breast cancer, metastatic
Chair(s): Barbara Pistilli, FR; Christoph Thomssen, DE; Hervé Bonnefoi, FR
08:30 - 08:35 379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line

(1L) treatment for unresectable locally advanced/metastatic triple-negative
breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
P. Schmid1, P. Wysocki2, C. Ma3, Y.H. Park4, R. Fernandes5, S. Lord6, R. Baird7, C.

Prady8, K. Jung9, J. Asselah10, R. Huisden11, R. Stewart11, K. Heider11, P. Vukovic11, N.
Denduluri12, Z. Nowecki13, 1Barts Cancer Institute, Queen Mary University of London,
London, GB, 2Jagiellonian University Medical College, Krakow, PL, 3Washington

University School of Medicine, St. Louis, US, 4Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, KR, 5Schulich School of Medicine & Dentistry,
Western University, London Health Sciences Centre, London, CA, 6University of Oxford,
Oxford, GB, 7Cancer Research UK Cambridge Centre, Cambridge, GB, 8Sherbrooke
University, Centre intégré de Cancérologie de la Montérégie, CISSS Montérégie Centre,
Greenfield Park, Quebec, CA, 9Asan Medical Center, University of Ulsan, College of
Medicine, Seoul, KR, 10McGill University Health Centre, Montreal, CA, 11AstraZeneca,
Cambridge, GB, 12AstraZeneca, Gaithersburg, US, 13Maria Skłodowska-Curie National
Research Institute of Oncology, Warsaw, PL
08:35 - 08:40 380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive

(HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II,
single-arm, basket trial
Q. Ouyang1, Y. Yin2, L. Song3, M. Yan4, X. Wu5, Z. Tong6, Y. Liu7, X. Wang8, X. Jin9, Y.

Diao9, G. Liu9, J. Ge9, J. Li10, 1Hunan Cancer Hospital, Changsha, CN, 2Jiangsu Province
Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN,
3Shandong Cancer Hospital and Institute, Jinan, CN, 4Henan Cancer Hospital,
Zhengzhou, CN, 5Hubei Cancer Hospital, Tongji Medical College, Huazhong University of
Science and Technology and Hubei Provincial Clinical Research Center for Breast
Cancer, Wuhan, CN, 6TMUCIH - Tianjin Medical University Cancer Institute and Hospital,
Tianjin, CN, 7The First Hospital of China Medical University, Shenyang, CN, 8Sir Run Run
Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, 9Sichuan
Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, CN, 10Shanghai East Hospital,
Shanghai, CN
08:40 - 08:55 Invited Discussant 379MO, 380MO

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR
08:55 - 09:00 382MO - Updated results from the phase 1/2 study of OP-1250, an oral complete
estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD )
in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast
cancer.
N. Lin1, V. Borges2, M.R. Patel3, M. Okera4, J. Meisel5, R. Wesolowski6, T. Pluard7, K.

Miller8, N. Mccarthy9, A. Conlin10, R. Mahtani11, D. Sabanathan12, K. Mccann13, E.
Roesch14, G. Mathauda-Sahota15, J. Schroeder15, E. Hamilton16, 1Dana Farber Cancer
Institute, Boston, US, 2UCHealth Cancer Care - Anschutz Medical Campus - University of
Colorado Cancer Center, Aurora, US, 3Florida Cancer Specialists/Sarah Cannon Research
Institute, Fort Myers, US, 4Cancer Research SA, Adelaide, AU, 5Winship Cancer Institute,
Emory University, Atlanta, US, 6The Ohio State University Comprehensive Cancer Center,
Columbus, US, 7Saint Luke's Hospital of Kansas City - Saint Luke's Health System,
Kansas City, US, 8Indiana University Melvin and Bren Simon Cancer Center, Indianapolis,
US, 9ICON Cancer Center - Wesley Medical Centre, Auchenflower, AU, 10Providence
Cancer Institute, Portland, US, 11Miami Cancer Institute - Baptist Health South Florida,
Miami, US, 12Macquarie University, Macquarie Park, AU, 13Jonsson Comprehensive
Cancer Center, University of California Los Angeles, Los Angeles, US, 14Cleveland Clinic,
Taussig Cancer Center, Cleveland, US, 15Olema Pharmaceuticals, Inc., San Francisco,
US, 16Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US
09:00 - 09:05 383MO - Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-
advanced breast cancer (aBC): Results from the phase 1a/b EMBER study
K. Jhaveri1, R. Jeselsohn2, C. Ma3, E. Lim4, K. Yonemori5, E. Hamilton6, K. Harnden7, S.-
A. Im8, T. Beck9, S. Sammons10, M. Bhave11, P. Kaufman12, C. Saura Manich13, T.
Meniawy14, F. Bacchion15, R. Ismail-Khan15, Y. Li16, S. Estrem15, B. Nguyen15, M.
Beeram17, 1Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US,
2Dana Farber Cancer Institute, Boston, US, 3Washington University School of Medicine,
St. Louis, US, 4Garvan Institute of Medical Research, Darlinghurst, AU, 5National Cancer
Center Hospital, Tokyo, JP, 6Sarah Cannon Research Institute, Nashville, US, 7Inova
Schar Cancer Institute, Fairfax, US, 8Seoul National University Hospital, Seoul, KR,
9Highlands Oncology Group - Rogers, Fayetteville, US, 10Duke Cancer Institute, Boston,
US, 11Winship Cancer Institute of Emory University, Atlanta, US, 12University of Vermont
- Larner College of Medicine, Burlington, US, 13Vall d'Hebron University Hospital,
Barcelona, ES, 14Sir Charles Gairdner Hospital and Linear Research Institute, Subiaco,
AU, 15Loxo@Lilly, Lilly Corporate Center, Indianapolis, US, 16Eli Lilly and Company, New
York, US, 17South Texas Accelerated Research Therapeutics (START), San Antonio, US
09:05 - 09:10 384MO - Final overall survival analysis for fulvestrant vs anastrozole in
endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast
cancer (FALCON)
J. Robertson1, Z. Shao2, S. Noguchi3, S. Singh4, S. Subramaniam5, M. Ellis6, 1University

of Nottingham, School of Medicine, Nottingham, GB, 2University Shanghai Cancer
Center, Shanghai, CN, 3Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP,
4AstraZeneca Netherlands, Zoetermeer, NL, 5AstraZeneca India, Bangalore, IN,
6AstraZeneca Pharmaceuticals LP, Gaithersburg, US

C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE
09:25 - 09:30 385MO - A multicenter, open-label, dose escalation and expansion study of
DP303c in patients with HER2-positive pre-treated advanced solid tumors
J. Zhang1, X. Hu1, Y. Du1, Y. Meng1, Y. Liu2, Y. Shi3, J. Wang4, A. Zang5, S. Gu6, T. Liu7, H.
Zhou8, H. Guo9, S. Xiang10, X. Zhang11, S. Wu10, M. Li12, 1Fudan University Shanghai
Cancer Center, Shanghai, CN, 2The First Hospital of China Medical University, Shenyang,
CN, 3Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, 4Henan
Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN,
5Affiliated Hospital of Hebei University, Baoding, CN, 6Hunan Cancer Hospital & The
Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,

Changsha, CN, 7Zhongshan Hospital Fudan University, Shanghai, CN, 8The First
Affiliated Hospital of Bengbu Medical College, Bengbu, CN, 9Nanjing Drum Tower
Hospital, Nanjing, CN, 10CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Beijing,
CN, 11CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shijiazhuang, CN, 12CSPC
Zhongqi Pharmaceutical Technology Co., Ltd., Shanghai, CN
09:30 - 09:35 386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-
treated HER2-positive metastatic breast cancer: final results of the phase III
TULIP trial
P. Aftimos1, N. Turner2, J. O'Shaughnessy3, E. Van Den Tweel4, M. Oesterholt4, S.

Escrivá-De-Romaní5, N. Quenel Tueux6, T. Tan7, J. Lim8, S. Ladoire9, A. Armstronh10, A.
Stradella11, G. Bianchi12, M. Colleoni13, E. Kaczmarek14, K. Punie15, X. Song16, N.

Koper4, C. Saura Manich5, 1Institute Jules Bordet, Anderlecht, BE, 2The Royal Marsden
Hospital - Chelsea, London, GB, 3Texas Oncology - Baylor Sammons Cancer Center,
Dallas, US, 4Byondis B.V., Nijmegen, NL, 5Vall d'Hebron University Hospital, Barcelona,
ES, 6Institute Bergonié, Bordeaux, FR, 7NCCS - National Cancer Centre Singapore,
Singapore, SG, 8NUHS - National University Health System, Singapore, SG, 9Centre
Georges-François Leclerc (Dijon), Dijon, FR, 10The Christie NHS Foundation Trust,
Manchester, GB, 11ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i
Reynals), L'Hospitalet de Llobregat, ES, 12SC Oncologia Medica 1 Fondazione IRCCS
Istituto Nazionale Tumori Milano, Milan, IT, 13IEO - Istituto Europeo di Oncologia, Milan,
IT, 14Centre Oscar Lambret, Lille, FR, 15Leuven Cancer Institute, University Hospitals
Leuven, Leuven, BE, 16The Ottawa Hospital Regional Cancer Centre, Ottawa, CA
09:35 - 09:40 387MO - First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular
Screening Program in Advanced Breast Cancer
T. Pascual1, E. Segui Solis2, R. Olivera-Salguero3, J.M. Cejalvo4, M. Oliveira5, P. Tolosa

Ortega6, M.J. Vidal Losada7, M. Malumbres8, J. Gavilá-Gregori9, C. Saura Manich5, S.
Pernas Simon10, M. Margeli Vila11, E. Ciruelos6, E. Galve-Calvo12, P. Galván13, E.
Sanfeliu Torres7, R. Olmos14, M. Forns15, A. Casas Fernandez Tejerina16, A. Prat17,
1SOLTI/Hospital Clinic y Provincial de Barcelona/IDIBAPS, Barcelona, ES, 2Hospital
Clinic y Provincial de Barcelona/SOLTI/IDIBAPS, Barcelona, ES, 3SOLTI Cancer Research

Group, Barcelona, ES, 4Hospital Clinico Universitario de Valencia/INCLIVA/SOLTI,
Valencia, ES, 5Vall d'Hebron University Hospital, Barcelona, ES, 6Hospital Universitario
12 de Octubre, Madrid, ES, 7Hospital Clinic of Barcelona, Barcelona, ES, 8Vall d'Hebron
Institute of Oncology (VHIO), Barcelona, ES, 9IVO - Fundación Instituto Valenciano de
Oncología, Valencia, ES, 10ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i
Reynals), L'Hospitalet de Llobregat, ES, 11ICO - Institut Català d'Oncologia Badalona
(Hospital Universitario Germans Trias i Pujol), Badalona, ES, 12Hospital Universitario de
Basurto, Bilbao, ES, 13IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut
d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES, 14Asociación Española
de Cáncer de Mama Metastásico (CMM), Oviedo, ES, 15Asociación Española de Cáncer
de Mama Metastásico, Oviedo, ES, 16Fundación Actitud Frente al Cáncer, Seville, ES,
17Hospital Clinic y Provincial de Barcelona, Barcelona, ES

H. Bonnefoi, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC),
Bordeaux, FR
08:30 - 09:35 Type: Mini Oral session Granada Auditorium - Hall

Title: Mini oral session - Genitourinary tumours, 3
prostate
Chair(s): Boris Hadaschik, DE; Himisha Beltran, US
08:30 - 08:35 1766MO - Health-related quality of life (HRQoL) in nonmetastatic hormone-

sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical
recurrence (BCR) from the EMBARK study
S. Freedland1, M. Gleave2, U. De Giorgi3, A. Rannikko4, C. Pieczonka5, R. Tutrone6, B.

Venugopal7, H. Woo8, M. Ramirez Backhaus9, S. Supiot10, A. Lantz11, A. Ganguli12, J.
Ivanova13, P. Kral14, S.-P. Huang15, F. Saad16, N. Shore17, 1Samuel Oschin
Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, US,

2University of British Columbia Faculty of Medicine, Vancouver, CA, 3IRCCS Istituto
Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, IT, 4Helsingin
yliopistollinen keskussairaala, Helsinki, FI, 5PLLC, Syracuse, US, 6Chesapeake Urology
Research Associates, Towson, US, 7BWSCC - Beatson West of Scotland Cancer Centre -
NHS Greater Glasgow and Clyde, Glasgow, GB, 8Australian National University,
Canberra, AU, 9Instituto Valenciano de Oncologia IVO, Valencia, ES, 10ICO Institut de
Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 11Karolinska University
Hospital, Solna, SE, 12Astellas Pharma USA, Northbrook, US, 13Pfizer, New York, US,
14IQVIA, Bratislava, SK, 15Kaohsiung Medical University Hospital, Kaohsiung City, TW,
16Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Montreal, CA,
17Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, US
08:35 - 08:40 1767MO - External validation of a digital pathology-based multimodal artificial

intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1)
prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the
docetaxel (Doc) or abiraterone (AAP) phase 3 STAMPEDE trials
C. Parker1, L. Mendes1, E. Grist1, V. Liu2, D. Van Der Wal2, J. Griffin2, E. Chen2, P. Tran3,
D. Spratt4, L. Murphy5, A. Sachdeva6, S. Lall1, M. Parmar5, M. Sydes7, L. Brown5, A.
Esteva2, F. Feng8, N. Clarke6, N. James9, G. Attard10, 1UCL Cancer Institute - Paul
O'Gorman Building, London, GB, 2ArteraAI, Los Altos, US, 3Maryland Proton Treatment
Center, Baltimore, US, 4Case Western Reserve University / University Hospitals,
Cleveland, US, 5MRC - Medical Research Council Clinical Trials Unit - University College
London (UCL), London, GB, 6The Christie & Salford NHS Foundation Trust, Manchester,
GB, 7Medical Research Council Clinical Trials Unit, London, GB, 8UCSF Medical Center
at Mission Bay, San Francisco, US, 9Institute of Cancer Research and Royal Marsden
Hospital, London, GB, 10University College London, London, GB
08:40 - 08:45 1768MO - Incidence of fracture related hospitalisations in men with de novo
high risk localised and metastatic hormone sensitive prostate cancer: analysis of
routinely collected healthcare data from the STAMPEDE docetaxel and
zoledronic acid comparisons
C. Jones1, P. Dutey-Magni2, L. Murphy2, M. Murray2, J. Brown3, E. Mccloskey3, M.

Parmar4, N. James5, M. Sydes6, L. Brown2, N. Clarke7, A. Sachdeva1, 1The Christie NHS
Foundation Trust, Manchester, GB, 2MRC - Medical Research Council Clinical Trials Unit
- University College London (UCL), London, GB, 3University of Sheffield Medical School,
Sheffield, GB, 4Institute of Clinical Trials and Methodology-UCL, London, GB, 5ICR -
Institute of Cancer Research, London, GB, 6Medical Research Council Clinical Trials
Unit, London, GB, 7The Christie and Salford Royal NHS Foundation Trusts, Manchester,
GB

B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
09:00 - 09:05 1771MO - Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts)
with metastatic castration-resistant prostate cancer (mCRPC): randomized
double-blind phase 3 KEYNOTE-641 study
J. Graff1, M. Burotto2, P. Fong3, D. Pook4, B. Zurawski5, R. Manneh Kopp6, J. Salinas7, K.

Bylow8, G. Kramer9, R. Ratta10, M. Kwiatkowski11, M. Retz12, C. Kwak13, J. Arranz
Arija14, H. Gurney15, N. Matsubara16, L.W. Liang17, J. Todoric17, K. Imai17, A. Stenzl18,

1OHSU - Oregon Health Science University, Portland, US, 2Bradford Hill-Clinical Center,
Recoleta, CL, 3Auckland City Hospital, Auckland, NZ, 4Monash Health - Monash Medical
Centre, Clayton, AU, 5Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, PL,
6Sociedad de Oncologia y Hematologia Del Cesar, Valledupar, CO, 7Hospital Provincial de
Córdoba, Cordoba, ES, 8Froedtert Hospital & Medical College of Wisconsin, Milwaukee,
US, 9Medical University of Vienna, Vienna, AT, 10Hopital Foch, Suresnes, FR, 11Szpital
Wojewódzki im. Mikolaja Kopernika w Koszalinie, Koszalin, PL, 12Rechts der Isar Medical
Center, Technical University Munich, Munich, DE, 13Seoul National University - College
of Medicine - Yeongeon Medical Campus, Seoul, KR, 14Hospital General Universitario
Gregorio Maranon, Madrid, ES, 15Macquarie University - Faculty of Medicine, Health and
Human Sciences, Sydney, AU, 16National Cancer Center Hospital East, Kashiwa, JP,
17Merck & Co., Inc., Rahway, US, 18Crona Kliniken - Universitätsklinikum Tübingen,
Tübingen, DE
09:05 - 09:10 1772MO - Pembrolizumab (pembro) plus enzalutamide (enza) and androgen
deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive
prostate cancer (mHSPC): randomized double-blind phase 3 KEYNOTE-991 study
C. Gratzke1, M. Ozguroglu2, A. Peer3, M.A.N. Sendur4, M. Retz5, J. Goh6, W.C. Loidl7, G.

Jayram8, S.-S. Byun9, C. Kwak10, M. Kwiatkowski11, R. Manneh Kopp12, J.C. Vazquez
Limon13, J.F. Escobar Penagos14, U. De Giorgi15, K.M.D. Trindade16, C. Niu17, Y. Liu18, C.
Poehlein19, J.M. Piulats Rodriguez20, 1University Medical Center Freiburg, Freiburg im
Breisgau, DE, 2Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine,
Istanbul, TR, 3Rambam Health Care Center, Haifa, IL, 4Ankara Yıldırım Beyazıt
University Faculty of Medicine and Ankara Bilkent City Hospital, Ankara, TR, 5Rechts der
Isar Medical Center, Technical University Munich, Munich, DE, 6Fiona Stanley Hospital,
Murdoch, AU, 7Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, 8Urology
Associates, P.C, Nashville, US, 9Seoul National University Bundang Hospital, Seongnam,
KR, 10Seoul National University - College of Medicine - Yeongeon Medical Campus,
Seoul, KR, 11Szpital Wojewódzki im. Mikolaja Kopernika w Koszalinie, Koszalin, PL,
12Sociedad de Oncologia y Hematologia Del Cesar, Valledupar, CO, 13Antiguo Hospital
Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, MX, 14Hospital San Lucas
Cardiologica del Sureste, Tuxtla Gutierrez, MX, 15IRST - Istituto Romagnolo per lo Studio
dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, 16Oncocentro Ceara, Fortaleza, BR,
17MSD China - One Merck Campus Beijing, Beijing, CN, 18Merck & Co. Inc., Rahway, US,
19Merck & Co., Inc., Rahway, US, 20ICO - Institut Català d'Oncologia l'Hospitalet
(Hospital Duran i Reynals), Hospitalet de Llobregat, ES
09:10 - 09:15 LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as
first-line (1L) therapy in patients (pts) with metastatic castration-resistant
prostate cancer (mCRPC) and homologous recombination repair (HRR) gene
alterations: Three-year update and final analysis (FA) of MAGNITUDE
K.N. Chi1, E. Castro2, G. Attard3, M.R. Smith4, S. Sandhu5, E. Efstathiou6, G. Roubaud7,

E.J. Small8, A.J. Gomes9, D. Rathkopf10, M. Saad11, H. Gurney12, W. Jung13, G. Mason14,
S. Dibaj14, D. Wu14, B. Diorio14, A. Lopez-Gitlitz14, W. Kim14, D. Olmos2, 1University of
British Columbia, Vancouver, CA, 2Hospital Universitario 12 de Octubre, Madrid, ES,
3UCL Cancer Institute, London, GB, 4Harvard Medical School, Boston, US, 5Peter
MacCallum Cancer Centre, Melbourne, AU, 6Houston Methodist Cancer Center, Houston,
US, 7Institute Bergonié, Bordeaux, FR, 8University of California San Francisco Medical
Center, San Francisco, US, 9Liga Norte Riograndense Contra o Câncer, Natal, BR,

10Memorial Sloan Kettering Cancer Center, New York, US, 11University of Malaya
Medical Centre, Kuala Lumpur, MY, 12Macquarie University, Sydney, AU, 13Keimyung
University Dongsan Hospital, Daegu, KR, 14Research & Development, Raritan, US
09:15 - 09:20 LBA86 - Androgen receptor pathway inhibitors or taxanes for patients with
metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a
randomized, outcome-adaptive, biomarker-driven platform trial
H. Grönberg1, J. Lindberg1, B. De Laere1, A. Crippa1, A. Discacciati1, C. Karlsson2, A.

Ullén3, E. Jänes4, A. Mortezavi5, P. Ost6, G. Enblad7, J. Oldenburg8, J. Sandzén9, L.
Pettersson10, M. Vigmostad11, M. Hjälm-Eriksson12, M. Olsson13, P. Schatteman14, C.
Ghysel15, M. Eklund1, 1Karolinska Institutet, Stockholm, SE, 2Umea University, Umea,
SE, 3Karolinska University Hospital-Solna, Solna, SE, 4Sundsvall Hospital, Sundsvall, SE,
5University Hospital Basel, Basel, CH, 6UZ Gent - University Hospital Ghent, Gent, BE,
7Akademiska Sjukhuset Uppsala, Uppsala, SE, 8Akershus University Hospital (Ahus),
Lorenskog, NO, 9Centralsjukhuset i Karlstad, Karlstad, SE, 10Ryhov County Hospital,

Jonkoping, SE, 11Stavanger University Hospital - Helse Stavanger HF, Stavanger, NO,
12Capio St. Görans Hospital, Stockholm, SE, 13Växjö lasarett, xx, SE, 14Onze-Lieve-
Vrouw Clinic - Campus Aalst, Aalst, BE, 15AZ Sint-Jan Brugge-Oostende AV, Brugge, BE
09:20 - 09:35 Invited Discussant 1771MO, 1772MO, LBA85 and LBA86

H. Beltran, Dana Farber Cancer Institute, Boston, US
08:30 - 10:00 Type: Proffered Paper session Valencia Auditorium - Hall 10

Title: Proffered Paper session - Sarcoma
Chair(s): Silvia Stacchiotti, IT; Sebastian Bauer, DE
08:30 - 08:40 1913O - A randomised, multicenter phase-III study comparing doxorubicin (dox)
alone versus dox with trabectedin (trab) followed by trab in non-progressive
patients (pts) as first-line therapy, in pts with metastatic or unresectable
leiomyosarcoma (LMS): Final results of the LMS-04 study
P. Pautier1, A. Italiano2, S. Piperno-Neumann3, C. Chevreau4, N. Penel5, N. Firmin6, P.

Boudou Rouquette7, F. Bertucci8, V. Le Brun-Ly9, I. Ray-Coquard10, E. Kalbacher11, E.
Bompas12, O. Collard13, N. Isambert14, C. Guillemet15, M. Rios16, A. Le Cesne17, B.
Archambaud17, F. Duffaud18, 1Gustave Roussy Cancer Campus, VILLEJUIF, FR, 2Institute
Bergonié, Bordeaux, FR, 3Institut Curie, Paris, FR, 4Institut Universitaire du Cancer -
Toulouse- Oncopole, Toulouse, FR, 5Centre Oscar Lambret, Lille, FR, 6Icm Val D Aurelle,
Montpellier, FR, 7Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, 8IPC - Institut Paoli-
Calmettes, Marseille, FR, 9CHU Limoges - Hopital Dupuytren, Limoges, FR, 10Centre
Léon Bérard, Lyon, FR, 11CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, 12ICO
Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 13Institute de
Cancerologie de la Loire, Saint-Priest-en-Jarez, FR, 14CHU Poitiers - Jean Bernard
Hôpital, Poitiers, FR, 15Centre Henri Becquerel, Rouen, FR, 16Institut de Cancérologie de
Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 17Gustave Roussy - Cancer Campus,
Villejuif, FR, 18CHU La Timone Adultes, Marseille, FR

D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

08:50 - 08:55 Q&A
08:55 - 09:05 LBA89 - Efficacy and safety findings from MANTRA – a global, randomized,
multicenter, phase 3 study of the MDM2 inhibitor milademetan vs trabectedin in
patients with dedifferentiated liposarcomas
R. Jones1, R. Sanfilippo2, S. Schuetze3, A. Sebio4, R. Alvarez5, N. Bui6, A. Wagner7, S.

Chawla8, T.W.-W. Chen 9, D. Pink10, A. Le Cesne11, A. Italiano12, B. Vincenzi13, I.
Kiladze14, S. Patel15, R. Bryce16, F. Xu17, R. Doebele17, G. Schwartz18, M. Gounder19,
1The Royal Marsden Hospital and Institute of Cancer Research, London, GB, 2Fondazione
IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 3University Hospital - Michigan
Medicine, Ann Arbor, US, 4Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 5Hospital
General Universitario Gregorio Maranon, Madrid, ES, 6Stanford Cancer Center Palo Alto,
Palo Alto, US, 7Dana-Farber Cancer Institute, Boston, US, 8Keck Medical Center of USC,
Santa Monica, US, 9NTU - National Taiwan University - College of Medicine, Taipei City,
TW, 10HELIOS Klinikum Bad Saarow, Bad Saarow, DE, 11Gustave Roussy - Cancer
Campus, Villejuif, FR, 12Institute Bergonié, Bordeaux, FR, 13Policlinico Universitario
Campus Bio-Medico, Rome, IT, 14CMC - Caucasus Medical Centre, Tbilisi, GE, 15The
University of Texas M. D. Anderson Cancer Center, Houston, US, 16Rain Oncology, Inc.,
Newark, US, 17Rain Oncology Inc, Newark, US, 18Case Comprehensive Cancer Center,
Cleveland, US, 19Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York,
US

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
09:15 - 09:20 Q&A
09:20 - 09:30 LBA90 - A randomized phase II study of durvalumab and tremelimumab

compared to doxorubicin in patients with advanced or metastatic soft tissue
sarcoma (MEDISARC, AIO-STS-0415)
V. Gruenwald, University Hospital Essen, Essen, DE
09:30 - 09:40 LBA91 - TOMAS2: a randomized phase 2 study from the Italian Sarcoma Group
(ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced,
metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard
treatments.
L. D'Ambrosio1, A. Merlini1, A. Brunello2, V. Ferraresi3, A. Paioli4, B. Vincenzi5, M.

Pantaleo6, T. De Pas7, L. Gurrieri8, R. Sanfilippo9, A. Buonadonna10, G.G. Baldi11, G.
Badalamenti12, C. Marchiò13, Y. Pignochino1, G. Manessi1, S. Aliberti14, A.P. Dei Tos15, S.
Stacchiotti9, G. Grignani16, 1University of Turin, Torino, IT, 2IOV - Istituto Oncologico
Veneto IRCCS, Padova, IT, 3IRCCS Regina Elena National Cancer Institute (IRE), Rome,
IT, 4IOR - Istituto Ortopedico Rizzoli - IRCCS, Bologna, IT, 5Policlinico Universitario
Campus Bio-Medico, Rome, IT, 6University of Bologna - Alma Mater Studiorum, Bologna,
IT, 7IEO - Istituto Europeo di Oncologia, Milan, IT, 8IRST - Istituto Romagnolo per lo
Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, 9Fondazione IRCCS - Istituto
Nazionale dei Tumori, Milan, IT, 10CRO Aviano - Centro di Riferimento Oncologico -

IRCCS, Aviano, IT, 11Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana
Centro, Prato, IT, 12University of Palermo, Palermo, IT, 13IRCCS - Istituto di Candiolo -
FPO, Candiolo, IT, 14Istituto di Candiolo - FPO, Candiolo, IT, 15University of Padua -
School of Medicine, Padua, IT, 16Istituto di Candiolo - FPO, IRCCS, Candiolo, IT
09:50 - 10:00 Q&A
08:30 - 10:00 Type: Special symposium Salamanca Auditorium

Title: Immunotherapy for head and neck cancer: What, - Hall 3
when and how long?
Chair(s): Sjoukje Oosting, NL; Melvin Lee Kiang Chua, SG

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL
08:35 - 08:50 Perioperative immunotherapy for head and neck squamous cell carcinoma
(HNSCC)
A. Argiris, Hygeia Hospital, Marousi, GR
08:50 - 09:05 Incorporating immunotherapy into the approach to locally advanced HNSCC
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London,
GB
09:05 - 09:20 Novel combinations in the non-curative HNSCC setting

B. Ma, The Chinese University of Hong Kong, Sha Tin, HK
09:20 - 09:35 Patient selection is crucial to improve immunotherapy effectiveness

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG
08:30 - 10:00 Type: Proffered Paper session Málaga Auditorium - Hall

Title: Proffered Paper session - Developmental 10
therapeutics
Chair(s): Lillian Siu, CA; Elena Garralda, ES
08:30 - 08:40 652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective,

tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic
ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
K. Arbour1, S. Punekar2, I. Garrido-Laguna3, D. Hong4, B. Wolpin5, M. Pelster6, M.

Barve7, A.N. Starodub8, D. Sommerhalder9, S. Chang10, Y. Zhang10, Z. Salman10, X.
Wang10, C. Gustafson10, A. Spira11, 1Memorial Sloan Kettering Cancer Center, New York,
US, 2New York University Medical Center, New York, US, 3University of Utah Health -
Huntsman Cancer Institute, Salt Lake City, US, 4The University of Texas MD Anderson
Cancer Center, Houston, US, 5Dana Farber Cancer Institute, Boston, US, 6Sarah Cannon
Research Institute, Nashville, US, 7Mary Crowley Cancer Research Center, Dallas, US,
8The Christ Hospital - Hematology & Oncology, Cincinnati, US, 9NEXT OncologyTM, San
Antonio, US, 10Revolution Medicines, Inc., Redwood City, US, 11Virginia Cancer
Specialists, Fairfax, US
08:40 - 08:50 653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2
inhibitor) in Patients with KRAS p.G12C mutated solid tumors.
J. Wang1, J. Zhao2, J. Zhong1, X. Li3, J. Fang2, Y. Yu4, X. Li5, X. Fang6, J. Chang7, Z. Liu8, Y.
Zhao9, Q. Song10, C. Bai11, A. Wang-Gillam12, Y. Ding13, Z. Rao13, C. Bi13, 1Chinese
Academy of Medical Sciences and Peking Union Medical College - National Cancer
Center, Cancer Hospital, Beijing, CN, 2Beijing Cancer Hospital, Beijing, CN, 3Beijing
Tiantan Hospital, Capital Medical University, Beijing, CN, 4Harbin Medical University
Cancer Hospital, Harbin, CN, 5The First Affiliated Hospital of Zhengzhou University,
Zhengzhou, CN, 6The Second Affiliated Hospital of Zhejiang University School of
Medicine, Hangzhou, CN, 7Cancer Hospital Chinese Academy of Medical Sciences,
Shenzhen Center, Shenzhen, CN, 8Beijing Chest Hospital, Capital Medical University,
Beijing, CN, 9Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,
Zhengzhou, CN, 10Renmin Hospital of Wuhan University/ Hubei General Hospital,
Wuhan, CN, 11Peking Union Medical College Hospital, Chinese Academy of Medical
Sciences & Peking Union Medical College, Beijing, CN, 12Jacobio (US) Pharmaceuticals,
Inc, Boston, US, 13Jacobio Pharmaceuticals Co., Ltd., Beijing, CN
08:50 - 09:00 LBA33 - A first-in-human phase 1 study of a novel KRAS G12D inhibitor HRS-
4642 in patients with advanced solid tumors harboring KRAS G12D mutation
C. Zhou1, W. Li1, Z. Song2, Y. Zhang2, Y. Zhang3, D. Huang4, Z. Yang5, M. Zhou6, R. Mao7,

C. Huang7, X. Li7, J. Wang7, 1Shanghai Pulmonary Hospital, Tongji University School of
Medicine, Shanghai, CN, 2Zhejiang Cancer Hospital, Hangzhou, CN, 3West China
Hospital, Sichuan University, Chengdu, CN, 4Tianjin Medical University Cancer Institute
& Hospital, Tianjin, CN, 5The Second Affiliated Hospital of Chongqing Medical
University, Chongqing, CN, 6Ruijin Hospital, Shanghai Jiaotong University School of
Medicine, Shanghai, CN, 7Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN
09:00 - 09:10 Invited Discussant 652O, 653O and LBA33

E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES
09:10 - 09:20 Q&A
09:20 - 09:30 654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts)

with solid tumors harboring specific HER2-activating mutations (HER2m):
primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01)
study
B. Li1, F. Meric-Bernstam2, A. Bardia3, Y. Naito4, S. Siena5, P. Aftimos6, I. Anderson7, G.

Curigliano8, M.J. De Miguel Luken9, M. Kalra10, D.-Y. Oh 11, J.O. Park12, S. Postel-Vinay 13,
S.Y. Rha14, T. Satoh15, I. Spanggaard16, F. Michelini17, A. Smith18, K. Kalil Machado19, C.
Saura Manich20, 1Memorial Sloan Kettering Cancer Center, New York, US, 2MD
Anderson Cancer Center, University of Texas, Houston, US, 3Massachusetts General
Hospital Cancer Center, Boston, US, 4National Cancer Center Hospital East, Kashiwa, JP,
5Università degli Studi di Milano, Milan, IT, 6Institute Jules Bordet, Anderlecht, BE,
7Providence Medical Group, Santa Rosa, US, 8European Institute of Oncology IRCCS,
Division of New Drugs and Early Drug Development for Innovative Therapies., Milan, IT,
9Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid,
ES, 10LifeBridge Health, Baltimore, US, 11Seoul National University Hospital, Seoul, KR,
12Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR,
13Institut Gustave Roussy, Villejuif, FR, 14Yonsei Cancer Center, Yonsei University Health
System, Seoul, KR, 15Osaka University, Suita, JP, 16Rigshospitalet, Copenhagen, DK,
17AstraZeneca, Waltham, US, 18AstraZeneca UK, Royston, GB, 19AstraZeneca,
Gaithersburg, US, 20SOLTI/Vall d'Hebron University Hospital/Vall d’Hebron Institute of

Oncology, Barcelona, ES
09:30 - 09:40 655O - Phase 1b Study of Cofetuzumab Pelidotin, an Anti-PTK7 Antibody-Drug

Conjugate, in Patients with PTK7-Expressing Recurrent Non-Small Cell Lung
Cancer (rNSCLC)
B.C. Cho1, M. Johnson2, J. Bar3, E. Schaefer4, K. Yoh5, A. Zer6, M. Moskovitz7, S.-H. Lee8,
V. Moreno Garcia9, M.J. De Miguel Luken10, Y. Okuma11, J.-H. Kim12, C.-H. Lee13, P.
Ansell14, C. Biesdorf De Almeida15, R. Saab15, K. Freise15, D. Ramies16, E. Jeng17, D.
Camidge18, 1Yonsei University, Seoul, KR, 2Sarah Cannon Research Institute-Cancer
Centre, Nashville, US, 3Chaim Sheba Medical Center, Ramat Gan, IL, 4HOG - Highlands
Oncology Group, Rogers, US, 5National Cancer Center Hospital East, Kashiwa, JP,
6Rambam Health Care Campus, Haifa, IL, 7Rambam Health Care Campus, Haifa, IL,
8Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, and Department of Health Sciences and Technology, Samsung Advanced

Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR,
9Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, 10Hospital Madrid Norte
San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, 11NCCH - National
Cancer Center Hospital, Chuo-ku, JP, 12CHA Bundang Medical Center, Seongnam, KR,
13NCKUH - National Cheng Kung University Hospital, Tainan City, TW, 14AbbVie Inc USA,
North Chicago, US, 15Abbvie Inc. - Headquarters, North Chicago, US, 16AbbVie, Inc.,
North Chicago, US, 17Abbvie, Mettawa, US, 18University of Colorado Denver - Anschutz
Medical Campus, Aurora, US

A.A. Adjei, Cleveland Clinic Main Campus, Cleveland, US
09:50 - 10:00 Q&A
08:30 - 10:00
Type: Mini Oral session Santander Auditorium -
Title: Mini oral session - Basic science & translational Hall 9
research
Chair(s): Caterina Marchiò, IT; Sanjay Aneja, US
08:30 - 08:35 132MO - Molecular profiling of 991 prospectively recruited rare cancers patients
in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
M. Morfouace1, J. Oliveira2, N. Penel3, J. Peron4, M. Pracht5, B. Brasiuniene6, A. Capela

Marques7, C. Gennigens8, L. Greillier9, M.-S. Robert1, H.J. Klumpen10, R. Peeters11, L.
Licitra12, N. Girard13, J. Gietema14, W. De Herder15, E. Kapiteijn16, A. Idbaih17, I. Ray-
Coquard18, J.-Y. Blay 18, 1EORTC AISBL/IVZW - European Organisation for Research and
Treatment of Cancer, Brussels, BE, 2Instituto Portugues de Oncologia do Porto Francisco
Gentil, EPE (IPO-Porto), Porto, PT, 3Centre Oscar Lambret, Lille, FR, 4Ch Lyon Sud,
Pierre Benite, FR, 5Centre Eugene - Marquis, Rennes, FR, 6National Cancer Institute,
Vilnius, LT, 7CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1 -
EPE-SNS, Vila Nova de Gaia, PT, 8Centre Hospitalier Universitaire Sart Tilman, Liège,
BE, 9Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR,
10Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL,
11Erasmus MC - University Medical Center, Rotterdam, NL, 12Fondazione IRCCS -
Istituto Nazionale dei Tumori, Milan, IT, 13Institut Curie, Paris, FR, 14UMCG - University
Medical Center Groningen, Groningen, NL, 15Erasmus MC - Erasmus University
Rotterdam, Rotterdam, NL, 16Leiden University Medical Center (LUMC), Leiden, NL,
17Hopital Pitié Salpetrière AP-HP, Paris, FR, 18Centre Léon Bérard, Lyon, FR
08:35 - 08:40 LBA100 - CUP-ONE Trial: A prospective double-blind validation of molecular

classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcomes
H. Wasan1, J. Wang2, E.M. Elaine Mccartney3, H. Soifer4, K. Treuner4, Y. Zhang4, C.

Schnabel4, K. Carty3, L. Mcmahon3, T.R.J. Evans3, M. Nicolson5, H. Thygesen3, J.R.
Roche3, K. Oien3, 1Hammersmith Hospital - Imperial College Healthcare, London, GB,
2UCLH - University College London Hospital, London, GB, 3University of Glasgow,
Glasgow, GB, 4Biotheranostics, A Hologic Company, San Diego, US, 5NHS Highland,
Inverness, GB
08:40 - 08:45 1208MO - A randomized phase III trial of site-specific therapy guided by the 90-
gene expression assay versus empiric chemotherapy in patients with cancer of
unknown primary
Z. Luo1, X. Liu1, X. Zhang1, S. Jiang1, M. Mo1, Q. Wang1, Y. Wang1, L. Zhou1, S. Hu1, H.

Yang1, Y. Hou1, Y. Chen1, X. Lu1, X. Zhou1, W. Li1, X. Yang1, K. Chen1, J. Cao1, Q. Xu2, X.
Hu1, 1Fudan University Shanghai Cancer Center, Shanghai, CN, 2The Canhelp Genomics
Research Center, Canhelp Genomics Co., Ltd., Hangzhou, China, 311000, Shanghai, CN
08:45 - 08:50 LBA101 - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for
germline genetic testing and non-inferiority of digitally-delivered information in
women with breast cancer.
B. Torr1, S. Choi1, S. Allen1, M. Hamill1, G. Kavanaugh1, S. Macmahon2, E. Poyastro-

Pearson2, L. Yuan2, M. Valganon-Petrizan2, A. George3, V. Jenkins4, L. Fallowfield4, R.
Manchanda5, A. Gandhi6, G. Evans6, Z. Kemp7, M. Hubank1, C. Turnbull1, 1ICR - The
Institute of Cancer Research - North Site, Sutton, GB, 2The Royal Marsden Hospital
(Sutton), Sutton, GB, 3The Institute of Cancer Research and Royal Marsden Hospital,

Sutton, GB, 4Brighton and Sussex Medical School - University of Sussex, Brighton, GB,
5Wolfson Institute of Population Health, London, GB, 6Manchester University NHS
Foundation Trust, Manchester, GB, 7The Royal Marsden Hospital - NHS Foundation
Trust, London, GB
08:50 - 09:05 Invited Discussant 132MO, LBA100, 1208MO and LBA101

C. Marchiò, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT
09:05 - 09:10 1209MO - Computer-Aided HCC Lesion Detection Based on Deep Learning and
CT Images
O. Lucidarme1, T. Broussaud1, S. Bodard2, V. Paradis3, I. Brocheriou1, C. Guettier4, L.

Ayache5, C. Bougharka1, A. O'Keane2, S. Poullot6, J. Shen6, V.K. Le6, E. Geremia6, V.
Groza6, Q. Renault6, M. Macrez6, T. Foriel6, Y. Liu6, M. Lewin-Zeitoun4, V. Vilgrain7,
1Sorbonne Université, Paris, FR, 2GH Necker - Enfants Malades, Paris, FR, 3Campus
hospitalo-universitaire Grand Paris-Nord, Paris, FR, 4CentraleSupélec - Paris-Saclay

campus, Gif sur Yvette, FR, 5Institut Necker Enfant Malades, Paris, FR, 6Median
Technologies, Valbonne, FR, 7Beaujon Hospital APHP, Clichy, FR
09:10 - 09:15 1210MO - Comparison of Clinical and Radiological Features-based and

Radiomics Features-based Models for Pulmonary Nodule Malignancy Prediction
on CT Images
F. Zeng1, B. Wang2, M. Peng2, J. Tao2, X. Tu2, H. Lu3, X. Qiu2, Y. Yang2, Q. Zeng1, J.-B.
Fan4, Q. Liu1, 1The First Affiliated Hospital of Guangzhou Medical University,
Guangzhou, CN, 2Anchordx Medical Co., Ltd, Guangzhou, CN, 3AnchorDX Medical Co.,
Ltd, Guangzhou, CN, 4Southern Medical University, Guangzhou, CN

S. Aneja, Yale University School of Medicine, New Heaven, US
09:25 - 09:30 2233MO - CDC7 inhibition constrains lineage plasticity and prevents resistance
and neuroendocrine transformation in the lung and prostate
Á. Quintanal-Villalonga 1, S. Zaidi1, W.R. Karthaus1, Y.A. Zhan1, M. Shafer1, J. Qiu1, E. De

Stanchina1, M.C. Haffner2, C.L. Sawyers1, C. Rudin1, 1MSKCC - Memorial Sloan
Kettering Cancer Center, New York, US, 2Fred Hutchinson Cancer Research Center,
Seattle, US
09:30 - 09:35 133MO - Differentiation of Malignant and Benign Lung Nodules using
Epigenetically Modified Nucleosomes in Plasma
P.-H. Chen1, T.-M. Tsai2, D. Pamart3, T. Bygott3, M. Herzog3, J. Micallef3, J.-S. Chen2,
1National Taiwan University Hospital Hsin - Chu Branch, Hsinchu City, TW, 2NTUCC -
National Taiwan University Cancer Center, Taipei City, TW, 3Belgian Volition SRL, Isnes,
BE

L. Montuenga, FIMA-UNAV-CUN, PAMPLONA, ES

08:30 - 10:00 Type: Proffered Paper session Toledo Auditorium -
Title: Proffered Paper session - NETs and endocrine Hall 3
tumours
Chair(s): Marianne Pavel, DE
08:30 - 08:40 723O - Cabozantinib plus Atezolizumab in Advanced and Progressive Neoplasms
of the Endocrine System: A multi-cohort Basket Phase II Trial (CABATEN /
GETNE-T1914)
J. Capdevila Castillon1, J. Molina-Cerrillo2, M. Benavent Viñuales3, R. Garcia-Carbonero4,

A. Teule5, A. Custodio6, P. Jimenez-Fonseca7, C. López8, C. Hierro9, A. Carmona-
Bayonas10, J. Martínez-Trufero 11, M. Llanos12, I. Sevilla13, J. Hernando1, T. Alonso-
Gordoa2, I. Gallego Jimenez3, J. Gallego14, B. Antón Pascual4, E. Grande Pulido15, 1Vall
Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES,
2Hospital Universitario Ramón y Cajal, Madrid, ES, 3University Hospital Virgen del
Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, 4Hospital Universitario 12

de Octubre, Imas12, UCM, Madrid, ES, 5Institut Català d´Oncologia (ICO) - IDIBELL, L
´Hospitalet de Llobregat, ES, 6Hospital Universitario La Paz, IdiPAZ, Madrid, ES,
7Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, 8Hospital Universitario
Marqués de Valdecilla, IDIVAL, Santander, ES, 9Catalan Institute of Oncology (ICO-

Badalona) Germans Trias i Pujol University Hospital, Badalona, ES, 10Hospital
Universitario Morales Meseguer. UMI. IMIB., Murcia, ES, 11Instituto Aragonés de
Investigación Sanitaria, Hospital Universitario Miguel Servet, Zaragoza, ES, 12Hospital
Universitario de Canarias, San Cristobal de la Laguna, ES, 13Investigación Clínica y
Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) /
Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, ES,
14General Universitario de Elche Hospital, Alicante, ES, 15MD Anderson Cancer Center
Madrid, Madrid, ES
08:40 - 08:50 LBA53 - Alliance A021602: Phase III, Double-Blinded Study of Cabozantinib
Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression
on Prior Therapy (CABINET)
J. Chan1, S. Geyer2, F.-S. Ou2, M. Knopp3, S. Behr4, T. Zemla2, J. Acoba5, A. Shergill6, E.

Wolin7, T. Halfdanarson8, N. Trikalinos9, B. Konda10, N. Vijayvergia11, N.A. Dasari12, J.
Strosberg13, E. Kohn14, M. Kulke15, E. O'Reilly16, J. Meyerhardt1, 1Dana-Farber Cancer
Institute, Boston, US, 2Mayo Clinic, Rochester, US, 3University of Cincinnati, Cincinnati,
US, 4UCSF - University of California San Francisco, San Francisco, US, 5University of
Hawaii Cancer Center, Honolulu, US, 6University of Chicago, Chicago, US, 7Icahn School
of Medicine at Mount Sinai, New York, US, 8Mayo Clinic - Rochester, Rochester, US,
9Washington University School of Medicine in St. Louis - Siteman Cancer Center, St.
Louis, US, 10The Ohio State University Comprehensive Cancer Center, Columbus, US,
11Fox Chase Cancer Center - Main Campus, Philadelphia, US, 12MD Anderson Cancer
Center, Houston, US, 13H. Lee Moffitt Cancer Center & Research Institute - Magnolia
Campus, Tampa, US, 14National Cancer Institute, Bethesda, US, 15Boston University and
Boston Medical Center, Boston, US, 16Memorial Sloan Kettering Cancer Center, New
York, US

M. Pavel, Universitätsklinik Erlangen - Medizinische Klinik 1, Erlangen, DE
09:00 - 09:10 Q&A

09:10 - 09:20 LBA54 - Alkylating agent-based vs oxaliplatin-based chemotherapy in
neuroendocrine tumours according to the O6-methylguanine-DNA
methyltransferase (MGMT) status: a randomized phase II study (MGMT-NET) on
behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN
network
T. Walter1, T. Lecomte2, J. Hadoux3, P. Niccoli4, L. Saban-Roche5, E. Gaye6, R.

Guimbaud7, M. Baconnier8, V. Hautefeuille9, C. Do Cao10, C. Petorin11, O. Hentic
Dhome12, M. Perrier13, T. Aparicio14, J.-Y. Scoazec 15, C. Lombard Bohas16, S. Bin1, V.
Hervieu1, M. Barritault1, L. Gerard17, 1Hospices Civiles de Lyon - HCL - Lyon University
Hospital Center, Lyon, FR, 2CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR,
3Institut Gustave Roussy, Villejuif, Cedex, FR, 4IPC - Institut Paoli-Calmettes, Marseille,
Cedex, FR, 5Institut cancerologie de la loire, Saint etienne, FR, 6Centre Oscar Lambret,
Lille, FR, 7Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR,
8CH Annecy Genevois, Annecy, FR, 9CHU Amiens-Picardie - Site Nord, Amiens, FR,
10Centre Hospitalier Régional Universitaire de Lille, Lille, FR, 11CHU Estaing, Clermont-
Ferrand, FR, 12Beaujon Hospital APHP, Clichy, FR, 13Reims University Hospital, Reims,
FR, 14Hopital Saint Louis AP-HP, Paris, FR, 15Institut Gustave Roussy, Villejuif, FR,
16Hopital Edouard Herriot Pav. E bis, Lyon, FR, 17Hospices Civils de Lyon, Bron, FR
09:20 - 09:30 1182O - Temozolomide treatment induces an MMR-dependent hypermutator

phenotype in well differentiated pancreatic neuroendocrine tumors
L. De Mestier Du Bourg1, D. Cohen2, J. Masliah-Planchon3, S. Sivakumar4, O. De Rycke5,

O. Hentic Dhome1, Z. Fleischmann6, E. Sokol6, B. Decker7, A. Couvelard1, P.
Ruszniewski1, I. Bieche3, J. Cros8, 1Beaujon Hospital APHP, Clichy, FR, 2INSERM, Paris,
FR, 3Institut Curie, Paris, FR, 4Foundation Medicine, Inc., Morrisville, US, 5Assistance
Publique - Hopitaux De Paris AP-HP, Paris, FR, 6Foundation Medicine, Inc., Cambridge,
US, 7Foundation Medicine, Boston, US, 8Beaujon Hospital APHP, Saint Maur des Fosses,
FR
09:30 - 09:40 724O - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical
carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP);
EOADR1-19/SPENCER
E. Baudin1, S. Grisanti2, C. Menke-Van Der Houven Van Oordt 3, H. Haak4, J. Capdevila

Castillon5, M. Fassnacht6, V. Subbiah7, C. Jimenez7, C. De La Fouchardiere8, J. Yachnin9,
D. Granberg9, M. Kroiss10, K.G. Daugaard11, D. Cosentini2, L. Lamartina1, J.-M.
Paillarse12, L. Aubergeon12, J. Fagerberg12, L. Chêne12, A. Berruti2, 1Gustave Roussy,
Villejuif, FR, 2Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili,
Brescia, IT, 3Amsterdam UMC, Amsterdam, NL, 4Maxima Medish Centrum, Eindhoven,
NL, 5Hospital Universitari Vall d'Hebron, Barcelona, ES, 6University Hospital Würzburg,
Würzburg, DE, 7The University of Texas MD Anderson Cancer Center (MDACC),
Houston, US, 8Centre Léon Bérard, Lyon, FR, 9Karolinska Institutet, Karolinska
University Hospital, Stockholm, SE, 10LMU - Ludwig Maximilians University of Munich,
Munich, DE, 11Rigshospitalet, Copenhagen, DK, 12Enterome, Paris, FR
09:40 - 09:50 Invited Discussant LBA54, 1182O and 724O

N. Fazio, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

09:50 - 10:00 Q&A
08:30 - 10:00 Type: Educational session Cádiz

Title: Current issues in primary prevention and screening to Auditorium -
block the onset or development of cancer NCC
Chair(s): Wendy Tse Yared, BE; Mary Gospodarowicz, CA
08:30 - 08:50 Processed meat, sugar, exercise: Prevention opportunities for oncologists
J. Schüz, IARC - International Agency for Research on Cancer, Lyon, FR
08:50 - 09:10 Structural and behavioural interventions: Applying the latest insights from
implementation science to cancer prevention
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES
09:10 - 09:30 Commercial drivers of cancer medicines and non-pharmaceutical technologies in

cancer care
R. Sullivan, Institute of cancer policy, London, GB
09:30 - 09:50 False dichotomies and going beyond screening

M. Gospodarowicz, University of Toronto - St. George Campus, Toronto, CA

08:30 - 10:00 Type: Young Oncologists session Ávila
Title: YO Fellowship Session: Fellowships in Europe: Educational Auditorium -
opportunities for young oncologists NCC
Chair(s): Teresa Amaral, DE
08:30 - 08:45 Introduction & On ESMO Fellowship programme

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE
08:45 - 09:00 Practical tips from a former fellow

A. Matikas, Karolinska Institutet, Huddinge, SE
09:00 - 09:15 Best Fellowship project

F. Papaccio, University of Salerno, Naples, IT
09:15 - 09:30 Best Paper project

M.-J. Devlin, QMUL - Queen Mary University of London - Charterhouse Square, London,
GB
09:30 - 09:40 Conclusions

09:40 - 10:00 Awards: Presentation of the 2023 fellows and Best Exam

Title: Pfizer - Perspectives on adverse events and healthcare Auditorium - Hall
needs management in kidney cancer 10
Chair(s): Daniel Kelly, GB

08:35 - 08:55 Anticancer therapies and adverse events profile in kidney cancer – A medic’s
perspective
F. Schlürmann, CHRU Brest - Hopital Augustin Morvan, Brest, FR
08:55 - 09:15 Adverse events management in kidney cancer: Seeing the whole person – A
nurse’s perspective
S. Smith, East & North Hertfordshire NHS Trust, Stevenage, GB
09:15 - 09:35 Living with and being treated for kidney cancer – A patient’s perspective
S. Pointon, Action Kidney Cancer, Manchester, GB
09:35 - 09:50 RCC4Nurses – interactive education program

G. Kotronoulas, University of Glasgow, Glasgow, GB
09:50 - 10:00 Q&A and Conclusion remarks


09:00 - 10:00 Type: Controversy session Burgos
Title: All patients with resected stage IIB/IIC should be Auditorium - Hall
treated with adjuvant anti-PD1 therapy 3
Chair(s): Georgina Long, AU

09:05 - 09:20 Yes

D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
09:20 - 09:35 No
R. Lee, The University of Manchester, Manchester, GB

09:00 - 09:45 Type: Challenge your Expert Oviedo

Title: Management of IMDC favourable-risk patients in Auditorium - Hall
metastatic renal cell carcinoma (RCC) 7
Chair(s): Laurence Albiges, FR

M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna,
AT

L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

09:00 - 10:00 Type: Special session León Auditorium
Title: Emerging issues in Adolescent and Young Adult (AYA) - Hall 7
patients with malignant diseases
Chair(s): Andrea Ferrari, IT; Ivana Bozovic Spasojevic, RS

I. Bozovic Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
09:02 - 09:17 Setting priorities for AYA patients with sarcoma

A. Ferrari, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
09:17 - 09:32 Short- and long-term side effects in AYA patients, with a focus on patients with
breast cancer
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul
Cancro, Genova, IT
09:32 - 09:47 AYA oncology: The importance of research, with a focus on patients with
melanoma
S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB
10:00 - 11:00 Type: Special session Pamplona

Title: Resilience Task Force - Caring for caregivers: How to Auditorium - Hall
build a sustainable oncology workforce 9
Chair(s): Kok Haw Jonathan Lim, GB

K.H.J. Lim, The Francis Crick Institute, London, GB
10:10 - 11:00 Moderated discussion and Q&A
K. Punie1, M. O'Connor2, M.E. Elez Fernandez3, C. Hardy4, I. Vaz Luis5, J.-Y. Blay 6, 1UZ
Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, 2University
Hospital Waterford, Waterford, IE, 3Vall d'Hebron University Hospital, Barcelona, ES,
4Lancaster University Division of Health Research, Lancaster, GB, 5Institut Gustave
Roussy, Villejuif, Cedex, FR, 6Centre Léon Bérard, Lyon, FR

tumours, upper digestive
10:15 - 10:25 1616O - Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-

IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a
multicenter, randomized, open-label, three-arm, phase 2/3 trial
A. Ohba1, M. Ozaka2, G. Ogawa1, T. Okusaka1, S. Kobayashi3, T. Yamashita4, M. Ikeda5, I.

Yasuda6, K. Sugimori7, N. Sasahira2, K. Ikezawa8, I. Miki9, N. Okano10, N. Mizuno11, M.
Furukawa12, H. Shirakawa13, Y. Sano1, H. Katayama1, J. Furuse3, M. Ueno3, 1National
Cancer Center Hospital, Tokyo, JP, 2Cancer Institute Hospital of Japanese Foundation for
Cancer Research, Tokyo, JP, 3Kanagawa Cancer Center, Yokohama, JP, 4Kanazawa
University, Kanazawa, JP, 5National Cancer Center Hospital East, Kashiwa, JP, 6University
of Toyama, Toyama, JP, 7Yokohama City University Medical Center, Yokohama, JP, 8Osaka
International Cancer Institute, Osaka, JP, 9Hyogo Cancer Center, Hyogo, JP, 10Kyorin
University Faculty of Medicine, Tokyo, JP, 11Aichi Cancer Center Hospital, Nagoya, JP,
12National Hospital Organization, Kyushu Cancer Center, Fukuoka, JP, 13Tochigi Cancer
Center, Utsunomiya, JP
10:25 - 10:35 LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant

gemcitabine-based chemoradiotherapy for borderline resectable and resectable
pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial
B. Groot Koerkamp1, Q. Janssen1, J. Van Dam1, B. Bonsing2, H. Bos3, K. Bosscha4, B.

Haberkorn5, I. De Hingh6, T. Karsten7, M. Van Der Kolk8, M. Liem9, O. Loosveld10, G.
Patijn11, H.C. Van Santvoort12, J. De Vos-Geelen13, B. Van Der Holt14, M. Homs1, G. Van
Tienhoven15, M.G. Besselink15, H. Wilmink15, 1Erasmus MC Cancer Institute, Rotterdam,
NL, 2LUMC-Leiden University Medical Center, Leiden, NL, 3Ziekenhuis De
Tjongerschans, Heerenveen, NL, 4Jeroen Bosch Hospital, 's-Hertogenbosch, NL,
5Maasstad Ziekenhuis, Rotterdam, NL, 6Catharina Hospital Eindhoven, Eindhoven, NL,
7OLVG Hospital, Amsterdam, NL, 8Radboud University Medical Center, Nijmegen,
Nijmegen, NL, 9Medisch Spectrum Twente, Enschede, NL, 10Amphia Ziekenhuis-location

Molengracht, Breda, NL, 11Isala Hospital, Zwolle, NL, 12UMC - University Medical
Center Utrecht, Utrecht, NL, 13Maastricht University Medical Center (MUMC),
Maastricht, NL, 14Erasmus MC Cancer Institue, Rotterdam, NL, 15Amsterdam UMC -
University of Amsterdam, Amsterdam, NL

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES
10:50 - 11:05 Q&A
11:05 - 11:15 LBA76 - The primary results of an intergroup phase III randomized controlled
trial comparing ramucirumab plus irinotecan with irinotecan in the third or
later line treatment beyond progression after ramucirumab for advanced gastric
cancer (RINDBeRG Trial).
S. Kadowaki1, D. Sakai2, R. Kawabata3, H. Hara4, H. Yasui5, M. Takahashi6, M. Hirao7,

H. Imai8, K. Minashi9, T. Kawakami10, H. Satake11, J. Matsuyama12, Y. Sakamoto13, K.
Sawada14, M. Kataoka15, H. Kawakami16, T. Shimokawa17, N. Boku18, T. Satoh19, 1Aichi
Cancer Center Hospital, Nagoya, JP, 2Osaka International Cancer Institute, Osaka, JP,
3Osaka Rosai Hospital, Sakai, JP, 4Saitama Cancer Center, Saitama, JP, 5Kobe City
Medical Center General Hospital, Kobe, JP, 6Yokohama Municipal Citizen's Hospital,
Yokohama, JP, 7National Hospital Organization Osaka National Hospital, Osaka, JP,
8Tohoku University Hospital, Sendai, JP, 9Chiba Cancer Center Hospital, Chiba, JP,
10Shizuoka Cancer Center, Shizuoka, JP, 11Kansai Medical University Hospital, Hirakata,
JP, 12Higashiosaka City Medical Center, Higashiosaka, JP, 13Osaki Citizen Hospital, Osaki,
JP, 14Kushiro Rosai Hospital, Kushiro, JP, 15National Hospital Organization, Nagoya

Medical Center, Nagoya, JP, 16Kindai University Faculty of Medicine, Osakasayama, JP,
17Wakayama Medical University, Faculty of Medicine, Wakayama, JP, 18IMS Hospital,
Institute of Medical Science, University of Tokyo, Tokyo, JP, 19Osaka University Hospital,
Suita, JP
11:15 - 11:25 LBA77 - 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line
treatment of HER2 negative locally advanced (LA) unresectable or metastatic
gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-
PRODIGE 51): a randomized phase 3 trial sponsored by the FFCD
A. Zaanan1, O. Bouche2, C. De La Fouchardiere3, E. Samalin-Scalzi4, K. Le Malicot5, S.

Pernot6, P. Artru7, V. Ly Lebrun8, K. Aldabbagh9, F. Khemissa Akouz10, H. Castanie11, M.
Laly12, D. Botsen13, M. Muller14, G. Roth15, T. Lecomte16, J.M. Phelip17, C. Lepage18, C.
Louvet19, 1Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, 2CHU de Reims -
Hôpital Robert Debré, Reims, Cedex, FR, 3Centre Léon Bérard, Lyon, FR, 4ICM - Institut
du Cancer de Montpellier, Montpellier, Cedex, FR, 5Fédération Francophone de
Cancérologie Digestive, Dijon, FR, 6Institut Bergonié, Bordeaux, FR, 7Hôpital privé Jean
Mermoz, Lyon, FR, 8CHU Limoges - Hopital Dupuytren, Limoges, FR, 9Polyclinique Saint
Côme, Compiegne, FR, 10Centre Hospitalier de Perpignan - Hôpital Saint Jean,
Perpignan, Cedex, FR, 11Centre Catherine de Sienne, Nantes, FR, 12CHD Vendee -
Hopital Les Oudairies, La Roche-sur-Yon, FR, 13Institut Jean Godinot, Reims, FR,
14CHRU Nancy, Nancy, FR, 15CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital
Michallon, La Tronche, FR, 16CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR,

17CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, 18CHU Dijon, Dijon, FR, 19IMM -
Institut Mutualiste Montsouris, Paris, FR

R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ
11:40 - 11:55 Q&A
10:15 - 11:45 Type: Mini Oral session Sevilla Auditorium -

Title: Mini oral session - Genitourinary tumours, non- Hall 9
prostate
Chair(s): Patrizia Giannatempo, IT; Ursula Vogl, CH; Deborah Mukherji, AE
10:15 - 10:20 2361MO - Impact of Positron Emission Tomography (PET) Imaging on Staging of
Muscle-Invasive Bladder Cancer (MIBC) [PET-MUSE]
S. Sridhar1, S. Mukherjee2, N. Power3, R. Breau4, S. Cheng5, P. Chung6, G. Pond7, U.

Metser6, M. Levine8, 1Princess Margaret Cancer Center, Toronto, CA, 2JCC - Juravinski
Cancer Centre - Hamilton Health Sciences, Hamilton, CA, 3London Health Sciences
Centre (LHSC) - London Regional Cancer Program (LRCP), London, CA, 4University of
Ottawa Faculty of Medicine, Ottawa, CA, 5Sunnybrook Health Sciences Centre - Odette
Cancer Centre, Toronto, CA, 6Princess Margaret Cancer Centre, Toronto, CA, 7McMaster
University Medical Centre - Hamilton Health Sciences, Hamilton, CA, 8McMaster
University, Hamilton, CA
10:20 - 10:25 2362MO - Erdafitinib (erda) vs Chemotherapy (chemo) in Patients (pts) With

Advanced or Metastatic Urothelial Cancer (mUC) With Select FGFR Alterations
(FGFRalt): Subgroups From the Phase 3 THOR Study
Y. Loriot1, N. Matsubara2, R. Huddart3, N. Houede4, B. Laguerre5, V. Guadalupi6, J.H.

Ku7, S. Triantos8, S. Akapame8, K. Deprince9, S. Mukhopadhyay10, A. Siefker-Radtke11,
1INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR, 2National
Cancer Center Hospital East, Chiba, JP, 3Institute of Cancer Research and Royal Marsden
NHS Foundation Trust, Sutton, GB, 4Institut de Cancérologie du Gard - CHU Caremeau,
Nîmes, France and Montpellier University, Nimes, FR, 5Centre Eugene Marquis, Rennes,
FR, 6Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, IT, 7Seoul National
University Hospital, Seoul, KR, 8Janssen Research & Development, Spring House, US,
9Janssen Research & Development, Beerse, BE, 10Janssen Research & Development,
Lexington, US, 11The University of Texas MD Anderson Cancer Center, Houston, US

P. Giannatempo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
10:35 - 10:40 2363MO - A phase II study investigating the safety and efficacy of neoadjuvant
atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)
B. Szabados1, E. Nogueron Martinez2, F.J. Alvarez Marquez3, D. Castellano Gauna4, A.

Rodriguez-Vida 5, M.C. Garcias De Espana6, S. Hussain7, C. Alvarez Fernandez8, M.
Linch9, T. Bonfill Abella10, M. Gross Goupil11, J. Kelly12, R. Jones13, S. Crabb14, L.
Beltran15, R. Garonce-Hediger16, N.J. Rakebrandt17, R. Georgescu 18,18, C. Ackerman18,
T. Powles19, 1Barts Cancer Institute, London, GB, 2Complejo Hospitalario Universitario
de Albacete, Albacete, ES, 3Hospital General Juan Ramon Jimenez, Huelva, ES, 4Hospital
Universitario 12 de Octubre, Madrid, ES, 5Hospital del Mar IMIM Research Institute,
Barcelona, ES, 6Hospital Universitario Son Espases, Palma de Mallorca, ES, 78. Sheffield
Teaching Hospitals NHS Trust, Sheffield, GB, 8Hospital Universitario Central de Asturias,
Oviedo, ES, 9UCL Cancer Institute - Paul O'Gorman Building, London, GB, 10Hospital de
Sabadell Corporacis Parc Tauli, Sabadell, ES, 11CHU Bordeaux - Hopital St. André,
Bordeaux, FR, 12UCLH - University College London Hospitals NHS Foundation Trust,
London, GB, 13MVLS - Medical, Veterinary and Life Sciences College - University of
Glasgow, Glasgow, GB, 14Southampton General Hospital, Southampton, GB, 15Barts
Hospital NHS Trust, London, GB, 16F. Hoffmann-La Roche AG, Basel, CH, 17Oncology
Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, CH, 18Barts ECMC, London,
GB, 19St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
10:40 - 10:45 2364MO - Durvalumab (D) +/- tremelimumab (T) in combination with dose-
dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-
invasive bladder carcinoma (MIBC): results of NEMIO, a randomized phase I-II
trial
C. Thibault1, M. Bennamoun2, A. Flechon3, G. Gravis4, D. Pouessel5, P.-F. Combe6, D.

Borchiellini7, Y. Loriot8, B. Laguerre9, P. Barthelemy10, M. Gross Goupil11, C. Helissey12,
O. Huillard13, M. Cancel14, L. Campedel15, F. Audenet1, H. Belhouari16, S. Kotti16, Y.
Tran16, S. Oudard1, 1HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR,
2Institute Mutualiste Montsouris, Paris, FR, 3Centre Leon Berard, Lyon, FR, 4IPC -
Institut Paoli-Calmettes, Marseille, Cedex, FR, 5Oncopole Claudius Regaud - Institut

Universitaire du Cancer Toulouse, Toulouse, FR, 6Pôle Santé Léonard de Vinci,
Chambray-lès-Tours, FR, 7Centre Anticancer Antoine Lacassagne, Nice, FR, 8Institut

Gustave Roussy, Paris Saclayrsité ar, Villejuif, Cedex, FR, 9Centre Eugene - Marquis,
Rennes, FR, 10ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR,
11CHU Bordeaux - Hopital St. André, Bordeaux, FR, 12Military Hospital Begin, Saint-
Mandé, FR, 13Hopital Cochin AP-HP, Paris, FR, 14University hospital of Tours, Tours,
cedex, FR, 15Hôpital Pitié Salpêtrière, Paris, FR, 16ARTIC - Association pour la
Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, cedex, FR
10:45 - 10:50 2365MO - Study EV-103 Cohort L: Perioperative treatment w/ enfortumab

vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle
invasive bladder cancer (MIBC)
S. Sridhar1, P. O'Donnell2, T. Flaig3, J. Rosenberg4, C. Hoimes5, M. Milowsky6, S.

Srinivas7, S. George8, R. Mckay9, D. Petrylak10, P.M. Coelho Barata11, C. Hwang12, M.
Cruz-Correa13, M. Iafolla14, M. Mckean15, R. Dreicer16, S. Brancato17, J. Lukas18, Y.
Yu18, H. Moon19, 1Princess Margaret Cancer Center, Toronto, CA, 2The University of
Chicago, Chicago, US, 3UCHealth Cancer Care - Anschutz Medical Campus - University
of Colorado Cancer Center, Aurora, US, 4MSKCC - Memorial Sloan Kettering Cancer
Center, New York, US, 5Duke Cancer Institute, Durham, US, 6University of North
Carolina - Chapel Hill, Chapel Hill, US, 7Stanford Comprehensive Cancer Institute,
Stanford, US, 8Roswell Park Comprehensive Cancer Center, Buffalo, US, 9University of
California San Diego - UCSD, La Jolla, US, 10Yale University School of Medicine, New
Heaven, US, 11Case Western Reserve University / University Hospitals, Cleveland, US,
12Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, 13Hospital Oncologico
Isaac Gonzalez Martinez, San Juan, PR, 14University Health Network - Princess Margaret
Cancer Center, Toronto, CA, 15Sarah Cannon Research Institute, Nashville, US,
16University of Virginia Cancer Center, Charlottesville, US, 17Astellas Pharma USA,
Northbrook, US, 18Seagen Inc., Bothell, US, 19Kaiser Permanente - Riverside Medical
Center, Riverside, US

U. Vogl, IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, CH
11:05 - 11:10 LBA104 - First safety and efficacy results of the TAR-210 erdafitinib (erda)
intravesical delivery system in patients (pts) with non–muscle-invasive bladder
cancer (NMIBC) with select FGFR alterations (alt)
A. Vilaseca1, G. Jayram2, C. Raventos3, N. Shore4, D. Zainfeld5, T.W. Kang6, J.H. Ku7, J.

Meeks8, Ó. Rodríguez Faba9, F. Roghmann10, S. Daneshmand11, N. Beeharry12, C.
Cost12, A. Kalota12, J. Lauring12, M. Peterson13, M. Quiroz12, N. Stone12, W. Zhu13, F.
Guerrero-Ramos14, 1Hospital Clínic de Barcelona, Barcelona, ES, 2Urology Associates,
Nashville, US, 3Vall d'Hebron, Barcelona, ES, 4Carolina Urologic Research Center, Myrtle
Beach, US, 5Urology San Antonio, San Antonio, US, 6Chonnam National University
Medical School, Chonnam National University Hospital, Gwangju, KR, 7Seoul National
University Hospital, Seoul National University College of Medicine, Seoul, KR,
8Northwestern University, Feinberg School of Medicine, Chicago, US, 9Fundació
Puigvert, Universitat Autònoma de Barcelona, Barcelona, ES, 10Ruhr-University Bochum,

Marien Hospital, Herne, DE, 11University of Southern California Norris Comprehensive
Cancer Center, Los Angeles, US, 12Janssen Research & Development, Spring House, US,
13Janssen Research & Development, Raritan, US, 14University Hospital 12 de Octubre,
Madrid, ES

11:10 - 11:15 LBA105 - Results From SunRISe-1 in Patients (Pts) With Bacillus Calmette–
Guérin (BCG)-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR
NMIBC) Receiving TAR-200 Monotherapy
A. Necchi1, J. Jacob2, S. Daneshmand3, G. Simone4, E. Xylinas5, D. Morris6, P.

Spiegelhalder7, D. Zainfeld8, T.W. Kang9, J. Matulay10, L. Belkoff11, K. Decaestecker12, H.
Arentsen13, S. Hampras14, C. Cutie15, H. Sweiti16, K. Stromberg14, J. Martin17, A.
Shukla15, M. Van Der Heijden18, 1Vita-Salute San Raffaele University, IRCCS San
Raffaele Hospital and Scientific Institute, Milan, IT, 2Upstate Medical University,
Syracuse, US, 3University of Southern California Norris Comprehensive Cancer Center,
Los Angeles, US, 4'Regina Elena' National Cancer Institute, Rome, IT, 5Bichat-Claude
Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris,
FR, 6Urology Associates, Nashville, US, 7Urologie Neandertal, Gemeinschaftspraxis für
Urologie, Mettmann, DE, 8Urology San Antonio, San Antonio, US, 9Chonnam National
University Medical School, Chonnam National University Hospital, Gwangju, KR,
10Atrium Health Levine Cancer Institute, Charlotte, US, 11MidLantic Urology/Solaris
Health, Bala Cynwyd, US, 12Ghent University Hospital; AZ Maria Middelares, Ghent, BE,
13AZ Sint-Jan Hospital Brugge-Oostende, Oostende, BE, 14Janssen Research &
Development, Raritan, US, 15Janssen Research & Development, Lexington, US, 16Janssen
Research & Development, Spring House, US, 17Janssen Research & Development, High
Wycombe, GB, 18Netherlands Cancer Institute, Amsterdam, NL
11:25 - 11:30 1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in

the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal
cell carcinoma (aRCC)
M. Voss1, B. Garmezy2, S.H. Kim3, J.P. Maroto Rey4, A. Mansinho5, A. Rodriguez-Vida 6, J.

Oliveira7, M. Van Dongen8, L. Medina Rodríguez9, S. Negrier10, B. Tran11, B. Carneiro12,
E. Castanon Alvarez13, S.Y. Rha14, Y. Wang15, S. Gainer15, Z. Tang15, I. Achour15, J.
Asare15, L. Albiges16, 1Memorial Sloan Kettering Cancer Center and Weill Medical
College, New York, US, 2Sarah Cannon Research Institute at Tennessee Oncology,
Nashville, US, 3Seoul National University Bundang Hospital, Seongnam, KR, 4Santa Creu
i Sant Pau Hospital, Barcelona, ES, 5Centro Hospitalar Universitário Lisboa Norte,
Hospital de Santa Maria, Lisbon, PT, 6Hospital del Mar, IMIM Research Institute,
Barcelona, ES, 7Portuguese Oncology Institute of Porto (IPO Porto) / Porto
Comprehensive Cancer Center (Porto.CCC), Porto, PT, 8The Netherlands Cancer
Institute, Amsterdam, NL, 9Unidad de Gestión Clínica Intercentros de Oncología Médica,
Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación
Biomédica de Málaga (IBIMA), Málaga, ES, 10Centre Léon Bérard, Lyon I University,
Lyon, FR, 11Peter MacCallum Cancer Centre, Melbourne, AU, 12Legorreta Cancer Center
at Brown University, The Warren Alpert Medical School, Lifespan Cancer Institute,
Providence, US, 13Clínica Universidad de Navarra, Madrid, ES, 14Yonsei Cancer Center,
Yonsei University Health System, Seoul, KR, 15AstraZeneca, Gaithersburg, US, 16Institut
Gustave Roussy, Villejuif, Cedex, FR
11:30 - 11:35 1884MO - Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in
previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
The TIDE-A study.
R. Iacovelli1, C. Ciccarese1, M. Bersanelli2, P. Zucali3, E. Fantinel4, D. Bimbatti5, E.

Verzoni6, C. Accettura7, L. Bonomi8, C. Buttigliero9, G. Fornarini10, S. Pipitone11, F.
Atzori12, C. Masini13, F. Massari14, F. Primi15, S. Buti16, M. Perrino17, S. Pafumi18, G.
Tortora1, 1Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT,
2University Hospital of Parma, Parma, IT, 3Humanitas University, Pieve Emanuele, IT,
4AOU Integrata di Verona - Ospedale Borgo Trento, Verona, IT, 5IOV - Istituto Oncologico
Veneto IRCCS, Padova, IT, 6Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT,
7Ospedale Vito Fazzi - ASL Lecce, Lecce, IT, 8ASST Papa Giovanni XXIII, Bergamo, IT,
9Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, 10IRCCS Ospedale
Policlinico San Martino, Genova, IT, 11Azienda Ospedaliero - Universitaria Policlinico di

Modena, Modena, IT, 12Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT,
13Azienda Ospedaliera - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT,
14AOU Policlinico S. Orsola-Malpighi, Bologna, IT, 15Ospedale Belcolle - ASL Viterbo,
Viterbo, IT, 16University of Parma, Parma, IT, 17IRCCS Humanitas Research Hospital,
Rozzano, IT, 18AOU Integrata di Verona - University of Verona, Verona, IT

D. Mukherji, Clemenceau Medical Center, Dubai, AE

10:15 - 11:45 Type: Special session Bilbao Auditorium - NCC
Title: ESMO Clinical Practice Guidelines 1
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR
10:15 - 10:25 Early breast cancer case presentation

F. Giugliano, IEO - Istituto Europeo di Oncologia, Milan, IT
10:25 - 10:35 Early breast cancer case discussion

S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE
10:35 - 10:45 Q&A
10:45 - 10:55 Oncogene-addicted metastatic NSCLC case presentation

M. Brandão, Institute Jules Bordet, Brussels, BE
10:55 - 11:05 Oncogene-addicted metastatic NSCLC discussion

11:05 - 11:15 Q&A
11:15 - 11:25 Advanced pancreatic cancer case presentation

E. Mariamidze, Todua Clinic, Tbilisi, GE
11:25 - 11:35 Advanced pancreatic cancer discussion

T. Conroy, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy,
FR

10:15 - 11:45 Type: Educational session Granada
Title: Dissecting metastatic castration-sensitive prostate Auditorium - Hall
cancer (mCSPC) for optimal patient benefit 3
Chair(s): Karim Fizazi, FR; Dana Rathkopf, US
10:15 - 10:35 Evidence from trials: Summary of a fantastic decade

D. Rathkopf, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
10:35 - 10:55 Next generation imaging: How does it change the evidence seen in trials?
B. Tombal, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-
Lambert, BE
10:55 - 11:15 How to best integrate biology

G. Attard, University College London, London, GB
11:15 - 11:35 Tolerance and long-term side-effects

A. Morgans, Dana Farber Cancer Institute, Boston, US
10:15 - 11:45 Type: Educational session Burgos Auditorium -

Title: Liquid biopsies development and application: Hall 3
Where do we stand?
Chair(s): Scott Bratman, CA; Naureen Starling, GB
10:15 - 10:32 Detection of HPV circulating tumour DNA

S. Bratman, Princess Margaret Cancer Centre, Toronto, CA
10:32 - 10:49 Incorporating liquid biopsies into clinical trials

S. Marsoni, IFOM-IEO Campus, Milan, IT
10:49 - 11:06 Standardisation of liquid biopsy approaches

E. Heitzer, Medical University of Graz, Graz, AT
11:06 - 11:23 Genome-wide cell-free DNA fragmentation in cancer

V. Velculescu, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer
Center, Baltimore, US
10:15 Type: Mini Oral session Valencia Auditorium - Hall 1

- Title: Mini oral session - Gynaecological cancers
11:55

Chair(s): Christian Marth, AT; Alexandra Leary, FR; Kosei Hasegawa, JP
10:15 LBA43 - Updated Response Data and Analysis of Progression Free Survival by Mechanism of Mismatc
- Repair Loss in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus
10:20 carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
R. Eskander1, M. Sill2, A. Miller2, L. Beffa3, R. Moore4, J. Hope5, F. Musa6, R. Mannel7, M. Shahin8, G.

Canturia9, E. Girda10, C. Mathews11, J. Kavecansky12, C. Leath Iii13, L. Gien14, E. Hinchcliff15, S. Lele
Powell17, C. Aghajanian18, 1University of California San Diego - UCSD, La Jolla, US, 2NRG Oncology Statistics
and Data Management Center, Philadelphia, US, 3Case Western Reserve University / University Hospitals,
Cleveland, US, 4URMC - University of Rochester Medical Center, Rochester, US, 5Alaska Women’s Cancer Care
Anchorage, US, 6Pacific Cancer Care, Monterey, US, 7Stephenson Cancer Center, Oklahoma University Health
Science Center, Oklahoma City, US, 8Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia,
US, 9Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, US, 10Rutgers
Cancer Institute of New Jersey, New Brunswick, US, 11Women & Infants Hospital - Warren Alpert Medical Scho
of Brown Univ, Providence, US, 12The Permanente Medical Group, San Jose, US, 13University of Alabama at
Birmingham, Birmingham, US, 14Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA,
15Northwestern Medical Group, Chicago, US, 16Roswell Park Comprehensive Cancer Center, Buffalo, US,
17National Cancer Institute Sponsored NRG Oncology, Washington University School of Medicine, Philadelphia,
US, 18Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
10:20 740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent
- endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS)
10:25 outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
M.R. Mirza1, S. Sharma2, J. Herrstedt3, M. Shahin4, D. Cibula5, E. Fleming6, F. Raspagliesi7, J. Buscema

Hanker9, R. Coleman10, I. Boere11, K. Schneider12, L. Gilbert13, B. Slomovitz14, M.G. Teneriello15, M.A.
Powell16, S. Ghosh17, S. Stevens18, K. Ring19, A. Stuckey20, 1Rigshospitalet, Copenhagen University Hospital,
Copenhagen, and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, 2AMITA
Adventist Hinsdale Hospital, Hinsdale, US, 3Zealand University Hospital Roskilde, Roskilde, DK, 4Hanjani
Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney
Kimmel Medical College of Thomas Jefferson University, Willow Grove, US, 5General University Hospital in
Prague, First Faculty of Medicine, Charles University, Prague, CZ, 6Norris Cotton Cancer Center, Dartmouth-
Hitchcock Medical Center, Lebanon, US, 7Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, 8Arizona
Oncology, Tucson, US, 9University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, and AGO Study Group
Wiesbaden, DE, 10Sarah Cannon Research Institute, Nashville, US, 11Erasmus MC Cancer Centre, Rotterdam,
NL, 12Norvant Health Cancer Institute – Elizabeth, Charlotte, US, 13McGill University Health Centre, Montreal
CA, 14Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International
University, Miami Beach, US, 15US Oncology Research, The Woodlands, US, 16National Cancer Institute
Sponsored NRG Oncology, Washington University School of Medicine, St. Louis, US, 17GSK, Waltham, US,
18GSK, London, GB, 19University of Virginia, Charlottesville, US, 20Women and Infants Hospital, Providence, US
10:25 742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer
-
10:30
M. De Bruyn1, A. Eerkens1, K. Brummel1, A. Vledder1, S. Paijens2, M. Requesens1, D. Loiero3, N. Van Rooij

Plat1, P. Klok1, F.-J. Haan1, D. Church4, R. Wardenaar1, F. Foijer1, V. Koelzer3, T. Bosse5, J. Bart1, M. Jalving
Reyners1, H. Nijman1, 1UMCG - University Medical Center Groningen, Groningen, NL, 2Erasmus MC,
Rotterdam, NL, 3USZ - Universitätsspital Zürich, Zurich, CH, 4University of Oxford, Oxford, GB, 5Leiden
University Medical Center, Leiden, NL

10:30 741MO - Luveltamab Tazevibulin (STRO-002), an anti-Folate Receptor Alpha (FolRα) Antibody Drug
- Conjugate (ADC), Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial
10:35 Cancer (EEC): STRO-002-GM1 Phase 1 Dose Expansion
B. Pothuri1, R. Naumann2, L. Martin3, D. O'Malley4, D. Uyar5, J. Moroney6, J. Diaz7, J. Garcia-Donas8,

Redondo9, A. Gonzalez Martin10, D. Illescas11, L. Liu12, C. Berman13, A. Oaknin11, 1NYU Langone Laura and
Isaac Perlmutter Cancer Center, New York, US, 2Levine Cancer Institute, Charlotte, US, 3Fox Chase Cancer
Center - Main Campus, Philadelphia, US, 4OSUCCC - The Ohio State University Comprehensive Cancer Center
James, Columbus, US, 5Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, 6University of
Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, 7Miami Cancer Institute -
Baptist Health South Florida, Miami, US, 8Hospital Madrid Norte San Chinarro - Centro Integral Oncologico
Clara Campal, Madrid, ES, 9Hospital Universitario La Paz, Madrid, ES, 10Clinica Universidad de Navarra,
Madrid, ES, 11Vall d'Hebron University Hospital, Barcelona, ES, 12Sutro Biopharma - Headquarters, San
Francisco, US, 13Sutro Biopharma, Inc., South San Francisco, US
10:35 Invited Discussant LBA43, 740MO, 742MO and 741MO

-
10:50
C. Marth, Innsbruck Medical University, Innsbruck, AT
10:50 743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Be
- as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase
10:55 study
N. Liu1, Z. Yang2, D. Tang3, H. Lou4, K. Zhang3, H. Cao5, D. Zou6, X. Zhang7, S. Xue7, X. Kang7, D. Wang
1Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, 2Cancer Hospital of China Medical
University,Liaoning Cancer Hospital & Institute, Shenyang, CN, 3The Affiliated Tumor Hospital of Xiangya
Medical School of Central South University, Changsha, CN, 4Cancer Hospital of the University of Chinese
Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, 5Guizhou Provincial People's Hospital, Medical
College of Guizhou University, Guiyang, CN, 6Chongqing University Cancer Hospital, Chongqing, CN,
Pharmaceutical Co., Ltd., Jinan, CN
10:55 744MO - AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS)
- With or Without Ociperlimab (OCI) in Patients (pts) With Previously Treated Recurrent/Metastatic
11:00 (R/M) Cervical Cancer (CC)
J.-Y. Lee 1, L. Wu2, S. Boonyapipat3, H.S. Kim4, J.-W. Lee 5, L. Wang6, T. Wang7, D. Wang8, D. Yao9, H. Liu
Andabekov11, X. Zhang12, W. Wang13, Y.M. Kim14, K. Wang15, Y. Gao15, X. Mu16, I. Volodymyrovych
Sinielnikov17, 1Severance Hospital Yonsei University Health System, Seoul, KR, 2Cancer Hospital Chinese
Academy of Medical Sciences, Beijing, CN, 3Songklanagarind Hospital (Prince of Songkhla University),
Songkhla, TH, 4Seoul National University Hospital, Seoul, KR, 5Samsung Medical Center, Seoul, KR,
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, 7The First
Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, 8Liaoning Cancer Hospital & Institute, Xi’an, CN,
Tumor Hospital Affiliated to Guangxi Medical University, Nanning, CN, 10Anhui Provincial Cancer Hospital AKA
West Branch of Anhui Province Hospital, Hefei City, CN, 11Oncological Scientific Center LLC, Moscow, RU,
12Zhejiang Cancer Hospital, Hangzhou, CN, 13Second Hospital of Shanxi Medical University, Taiyuan, CN,
14Asan Medical Center, Seoul, KR, 15BeiGene (Beijing) Co. Ltd, Beijing, CN, 16BeiGene (Shanghai) Co. Ltd,
Shanghai, CN, 17Volyn Regional Medical Center of Oncology, Lutsk, UA
11:00 LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of
- chemotherapy in women with recurrent or metastatic cervical cancer
11:05

X. Wu1, L. Xia1, K. Zhang2, Y. Tang3, G.N. Zhang4, D. Wang5, H. Lou6, N. Liu7, H. Zhang8, H. Chen9, K. Wang
S. Wei11, L. Wang12, K. Gao13, G. Li14, H. Zhang15, Y. Hu16, X. Zhou17, Y. Wang17, Q. Wang17, 1Fudan Universit
Shanghai Cancer Center, Shanghai, CN,
2Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Universit
Changsha, CN, 3Chongqing University Cancer Hospital, Chongqing, CN, 4Sichuan Cancer Hospital & Institute,
Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu,
CN, 5Liaoning Cancer Hospital & Institute, Shenyang, CN, 6Zhejiang Cancer Hospital, Hangzhou, CN,
7Shandong Cancer Hospital & Institute, Jinan, CN, 8Yunnan Cancer Hospital & The Third Affliated Hospital of
Kunming Medical University, Kunming, CN, 9The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN
10Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, 11Shanxi Cancer Hospital, Taiyuan, CN
12The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN,
Medical University Cancer Hospital, Nanning, CN, 14Cancer Center Union Hospital Tongji Medical College
Huazhong University of Science and Technology, Wuhan, CN, 15Hubei Cancer Hospital, Wuhan, CN, 16
Central Hospital of Gynecology Obstetrics, Tianjin, CN, 17Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai,
CN
11:05 Invited Discussant 743MO, 744MO and LBA44

-
11:15
A. Leary, Institut Gustave Roussy, Villejuif, FR
11:15 LBA45 - Overall Survival (OS) Outcomes from NRG-GY004, a Phase III Study Comparing Single-Agen
- Olaparib or Combination Cediranib and Olaparib to Platinum (Plat) Based Chemotherapy in Recurren
11:20 Plat Sensitive Ovarian Cancer (OvCa)
J. Liu1, M. Brady2, U. Matulonis1, A. Miller2, E. Kohn3, E. Swisher4, W. Tew5, N. Cloven6, C. Muller7, D. Bender
R. Moore9, D. Michelin10, S. Waggoner11, M. Geller12, K. Fujiwara13, S. D'Andre14, M. Carney15, A. Secord
Walker17, M. Bookman18, 1Dana Farber Cancer Institute, Boston, US, 2Roswell Park Comprehensive Cancer
Center, Buffalo, US, 3National Cancer Institute, Bethesda, US, 4University of Washington, Seattle, US,
Sloan Kettering Cancer Center, New York, US, 6Texas Oncology, Fort Worth, US, 7University of New Mexico,
Albuquerque, US, 8University of Iowa Hospitals and Clinics, Iowa City, US, 9URMC - University of Rochester
Medical Center, Rochester, US, 10Cancer Research Consortium of West Michigan, Grand Rapids, US,
Western Reserve University / University Hospitals, Cleveland, US, 12University of Minnesota, Minneapolis, US,
13Saitama Medical University International Medical Center, Saitama, JP, 14Sutter Institute for Medical Research
Sacramento, US, 15University of Hawaii Cancer Center, Honolulu, US, 16Duke University, Durham, US,
17University of Oklahoma Health Sciences Center, Oklahoma City, US, 18Kaiser Permanente Medical Center, Sa
Francisco, US
11:20 746MO - Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC)
- compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care
11:25 chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
J.-M. Lee1, A. Miller2, P. Rose3, M. Alhilli3, C. Washington4, V. John5, C. Shah6, K. Matsuo7, J. Siedel8,
J. Chan10, E. Hopp11, E. Kohn1, K. Moore4, J. Liu12, 1National Cancer Institute, Bethesda, US, 2NRG Oncology,
Buffalo, US, 3Case Western Reserve University / University Hospitals, Cleveland, US, 4Stephenson Cancer
Center/University of Oklahoma, Oklahoma City, US, 5Northwell Health Cancer Institute, Lake Success, US,
6Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, 7Keck School of Medicine - University of
Southern California USC, Los Angeles, US, 8University of Michigan Hospital, Ann Arbor, US, 9UTSW - Universit
of Texas Southwestern Medical Center, Dallas, US, 10Sutter Cancer Center, Sacramento, US, 11Froedtert
Hospital & Medical College of Wisconsin, Milwaukee, US, 12Dana Farber Cancer Institute, Boston, US
11:25 Invited Discussant LBA45 and 746MO

-
11:35
K. Hasegawa, Saitama Medical University International Medical Center, Saitama, JP
11:35 745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated
- ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study
11:40
K. Moore1, A. Philipovskiy2, K. Harano3, B. Rini4, K. Sudo5, S. Kitano6, D.R. Spigel7, J. Lin8, M. Kundu
Bensmaine9, Y. Myobatake8, E. Hamilton10, 1Oklahoma University, Oklahoma City, US, 2Florida Cancer
Specialists, Lake Mary, US, 3National Cancer Center Hospital East, Kashiwa, JP, 4Vanderbilt-Ingram Cancer
Center, Nashville, US, 5National Cancer Center Hospital, Tokyo, JP, 6Japanese Foundation for Cancer Research,
Tokyo, JP, 7Tennessee Oncology, PLLC, Nashville, US, 8Daiichi Sankyo, Inc., Basking Ridge, US, 9Daiichi Sankyo
France SAS, Rueil-Malmaison, FR, 10Sarah Cannon Research Institute, Nashville, US
11:40 747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed

- platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for
11:45 persistent/recurrent rare epithelial ovarian cancer (eOC)
I. Ray-Coquard1, S. Pignata2, J.-Y. Lee 3, R. Coleman4, J. Brown5, J.-W. Kim 6, F. Selle7, D. Lorusso8, M.J. Bermejo-
Pérez9, P. Pautier10, C. Gourley11, A. Ayhan12, G. Richardson13, D. Cibula14, L. Yauch15, M. Dieterich16
Krishnan15, O. Calas-Zeroug17, P. Harter18, D. Gershenson19, 1Centre Léon Bérard and University of Lyon, Lyon
FR, 2Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, 3Yonsei University College of
Medicine, Seoul, KR, 4The US Oncology Network, The Woodlands, US, 5Levine Cancer Institute at Atrium
Health, Charlotte, US, 6Seoul National University College of Medicine, Seoul, KR, 7Groupe Hospitalier
Diaconesses Croix Saint-Simon, Paris, FR, 8Fondazione Policlinico Universitario Agostino Gemelli, IRCCS and
Catholic University of Sacred Heart, Rome, IT, 9Hospitales Universitarios Regional y Virgen Victoria, IBIMA,
Málaga, ES, 10Gustave Roussy, Villejuif, FR, 11Cancer Research UK Edinburgh Centre, Western General
Hospital, Edinburgh, GB, 12Baskent University Hospital, Ankara, TR, 13Cabrini Hospital, Malvern, AU,
Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, CZ, 15Genentech,
South San Francisco, US, 16F. Hoffmann-La Roche Ltd, Basel, CH, 17Cytel Inc - Clinical Research Services,
Geneva, CH, 18Evang. Kliniken Essen-Mitte, Essen, DE, 19The University of Texas MD Anderson Cancer Center,
Houston, US
11:45 Invited Discussant 745MO and 747MO

-
11:55
M.R. Mirza, Rigshospitalet, Copenhagen, DK

10:15 - 11:45 Type: Special symposium Salamanca
Title: Cutting edge diagnostics and innovation in the Auditorium - Hall 3
treatment of brain tumours
Chair(s): Roger Stupp, US; Slavka Lukacova, DK
10:20 - 10:35 New treatment targets: From bench to bedside

M. Sanson, Hopital Pitié Salpetrière AP-HP, Paris, FR
10:35 - 10:50 Immunotherapy
M. Platten, Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE
10:50 - 11:05 Opening the blood-brain barrier (BBB)

A. Sonabend, Northwestern University Feinberg School of Medicine, Chicago, US
11:05 - 11:20 Methylation profiling: Hype or progress?

H.-K. Ng, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

10:15 - 11:45 Type: Multidisciplinary session Toledo
Title: A young female with limited stage classic Hodgkin’s Auditorium -
lymphoma and large mediastinal mass Hall 3
Chair(s): Olivier Casasnovas, FR; Ramon Garcia-Sanz, ES

O. Casasnovas, CHU Dijon, Dijon, FR
10:20 - 10:40 How to select the chemotherapy

P. Borchmann, University Hospital Cologne, Köln, DE
10:40 - 11:00 How to guide treatment with PET

11:00 - 11:20 When or when not to irradiate

U. Ricardi, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT
11:20 - 11:40 Preserving fertility in female patients

R. Garcia-Sanz, University Hospital of Salamanca, Salamanca, ES

10:15 - 11:45 Type: Special session León Auditorium - Hall 7
Title: More intelligent trial design
Chair(s): Mahesh Parmar, GB; Ian Tannock, CA

I. Tannock, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
10:20 - 10:35 Multi-arm multi-stage (MAMS) trials

M. Parmar, Institute of Clinical Trials and Methodology-UCL, London, GB
10:35 - 10:50 Pragmatic trials

J. Bogaerts, EORTC AISBL/IVZW - European Organisation for Research and Treatment of
Cancer, Brussels, BE
10:50 - 11:05 De-escalation trials

L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine,
Chapel Hill, US
11:05 - 11:20 Trials in low-and middle-income countries (LMIC)

C. Pramesh, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

M. Parmar, Institute of Clinical Trials and Methodology-UCL, London, GB

Title: Transnational cancer policies: EU and WHO projects Auditorium -
driving improvements in national cancer plans NCC
Chair(s): Bente Mikkelsen, CH; Tit Albreht, SI
10:15 - 10:35 EBCP and implementation plans at the EU level

P. Roux, European Commission - Directorate General Health and Food Safety,
Luxembourg City, LU
10:35 - 10:55 The joint development of policies through Joint Actions as policy projects, and
the arising EU guide for National Cancer Control Programmes
T. Albreht, National Institute of Public Health of Slovenia - Nacionalni institut za javno
zdravje, Ljubljana, SI
10:55 - 11:15 Perspectives from the European Parliament
11:15 - 11:35 WHO/IARC national cancer control plan tool and case studies
B. Mikkelsen, WHO - World Health Organization, Geneva, CH

Title: EONS16: Symptom management
Chair(s): Tugba Pehlivan Sarıbudak, TR
10:15 - 10:30 Prevalence and predictors of unmet needs among lymphoma cancer survivors
V. Boland, Trinity College Dublin, Dublin, IE
10:30 - 10:45 PROMS in patients with advanced RCC and advanced hepatocellular carcinoma
G. Kotronoulas, University of Glasgow, Glasgow, GB
10:45 - 11:00 Digital innovation in cancer care: Symptom assessment and management
E. Furlong, National University of Ireland - University College Dublin, Dublin, IE
11:00 - 11:10 CN3 - Patient adherence to digital patient-reported outcome monitoring (PROM)
in cancer immunotherapies
J. Lijnsvelt1, S.G. Aanes2, S. Iivanainen3, M.G. Vitale4, S. Mentu5, R. Arokoski5, P. Mohr6,

A. Addeo7, P. Ascierto4, J. Koivunen3, E. Haukland8, C. Blank1, 1NKI-AVL - Netherlands
Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, 2Nordlandsykehuset
HF, Bodoe, NO, 3OYS - Oulu University Hospital, Oulu, FI, 4Istituto Nazionale Tumori -
IRCCS - Fondazione Pascale, Napoli, IT, 5Kaiku Health, Helsinki, FI, 6Elbe-Kliniken,
Buxtehude, DE, 7HUG - Hopitaux Universitaires de Geneve, Geneva, CH, 8University of
Stavanger, Stavanger, NO
11:10 - 11:20 CN59 - The comparison between two types of educational information in
reducing nausea and vomiting in patients undergoing chemotherapy:
randomized controlled trial
C. Mazzega Fabbro1, J. Polesel1, M. Manicone1, L. Brusutti1, E. Malnis1, F. Puglisi2, 1CRO

Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, 2Centro di Riferimento
Oncologico (CRO), IRCCS, Aviano, IT

10:30 - 11:45 Type: Multidisciplinary session Málaga
Title: Is stereotactic radiotherapy a valid alternative to Auditorium - Hall
surgery for patients with stage I NSCLC? 10
Chair(s): Gaetano Rocco, US
10:30 - 10:45 Characteristics and treatment outcomes of screening-detected early NSCLC

W. Rzyman, Medical University of Gdansk, Gdansk, PL
10:45 - 11:00 A radiation oncologist’s perspective

M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH
11:00 - 11:15 A surgeon's perspective

G. Rocco, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
11:15 - 11:30 Opportunities for immunotherapy in stage I NSCLC

10:30 - 11:15 Type: Challenge your Expert Santander

Title: How do we manage patients with complicated Auditorium - Hall 9
toxicity to immunotherapy?
Chair(s): John Haanen, NL

M. Postow, Memorial Sloan Kettering 60th Street Outpatient Center, New York, US

J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL

10:30 - 11:45 Type: Multidisciplinary session Oviedo Auditorium - Hall 7
Title: Management of retroperitoneal sarcoma
Chair(s): Winan Van Houdt, NL; Claudia María Valverde Morales, ES

H. Kosela Paterczyk, Maria Sklodowska-Curie National Research Institute of Oncology,
Warsaw, PL
10:35 - 10:50 A pathologist’s perspective

M. Sbaraglia, Ospedale Regionale di Treviso S.Maria di Cà Foncello - ULSS2, Treviso, IT
10:50 - 11:05 A surgeon’s perspective

D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

A. Miah, The Royal Marsden Hospital - Chelsea, London, GB
11:20 - 11:35 A medical oncologist’s perspective

C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES
11:00 - 11:45 Type: Young Oncologists session Ávila

Title: YO Brunch 2: How to tell a compelling story in scientific Auditorium -
articles and presentations NCC
Chair(s): Rille Pihlak, GB
11:00 - 11:15 How to tell a compelling story in scientific articles and presentations

R. Pihlak, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

12:00 - 12:30 Type: Keynote lecture Barcelona Auditorium - Hall 9
Title: Healthcare in times of crises
Chair(s): Jose Martin-Moreno, ES

12:05 - 12:30 Healthcare in times of crises

B. Mikkelsen, WHO - World Health Organization, Geneva, CH

Title: MSD - The Role of Cancer Nurses in the Management Auditorium - Hall
of gBRCAm HER2- Breast Cancer 10
Chair(s): Julio de la Torre-Montero, ES

12:05 - 12:20 Genetic risk/surgical management

S. González-Santiago, Hospital San Pedro De Alcantara, Caceres, ES
12:20 - 12:25 Q&A
J. De La Torre-Montero1, S. González-Santiago2, Y. Hanhauser3, E. Schumacher-Wulf 4,

1Universidad Pontificia Comillas, Madrid, ES, 2Hospital San Pedro De Alcantara,
Caceres, ES, 3St James's Hospital, Dublin, IE, 4Mamma MIA - The Breast Cancer
Magazine, Köln, DE
12:25 - 12:40 Decision-making in BRCA+ risk management

Y. Hanhauser, St James's Hospital, Dublin, IE
12:40 - 12:45 Q&A

Magazine, Köln, DE
12:45 - 13:00 Nursing considerations related to PARP inhibitors

S. González-Santiago, Hospital San Pedro De Alcantara, Caceres, ES
13:00 - 13:05 Q&A
J. De La Torre-Montero1, S. González-Santiago2, E. Schumacher-Wulf 3, Y. Hanhauser4,

Caceres, ES, 3Mamma MIA - The Breast Cancer Magazine, Köln, DE, 4St James's
Hospital, Dublin, IE

13:05 - 13:20 Patient experience of care
E. Schumacher-Wulf, Mamma MIA - The Breast Cancer Magazine, Köln, DE
13:20 - 13:25 Q&A

Magazine, Köln, DE

13:00 - 14:30 Type: Industry Satellite Symposium Burgos Auditorium -

Title: AstraZeneca - Transforming care in Early stage Hall 3
Lung cancer
Chair(s): Sanjay Popat, GB

13:05 - 13:20 Optimising resectable NSCLC outcomes in patients with actionable mutations
R.S. Herbst, Yale University School of Medicine, New heaven, US
13:20 - 13:35 Improving outcomes in unresectable NSCLC: from clinical trial to clinical
practice
S. Formenti, Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US
13:35 - 13:50 Leveraging the MDT to navigate early-stage disease

13:50 - 14:25 Panel discussion and audience Q&A


Title: Novartis - Expanding Horizons: Clinical and Patient Auditorium -
Perspectives on CDK4/6 Inhibitors in HR+/HER2- Early Breast Hall 10
Cancer
Chair(s): Michael Gnant, AT
13:00 - 13:10 Unmet Need in HR+/HER2- Early Breast Cancer

M. Gnant, MedUni Wien - Medical University of Vienna, Vienna, AT
13:10 - 13:20 Efficacy of CDK4/6i in HR+/HER2- Early Breast Cancer
M. Piccart, Institute Jules Bordet, Brussels, BE
M. Gnant1, M. Piccart2, 1MedUni Wien - Medical University of Vienna, Vienna, AT,

2Institute Jules Bordet, Brussels, BE
13:30 - 13:40 Safety and QoL with CDK4/6i in HR+/HER2- Early Breast Cancer
M. Gnant, MedUni Wien - Medical University of Vienna, Vienna, AT

13:50 - 14:00 Key Takeaways and Live Q&A

14:00 - 14:10 QOL and Treatment Adherence in Early Breast Cancer: The Patient Perspective
R. Haidinger, Brustkrebs Deutschland e.V., Hohenbrunn, DE

14:20 - 14:30 Live Q&A and Closing
M. Gnant1, M. Piccart2, R. Haidinger3, 1MedUni Wien - Medical University of Vienna,

Vienna, AT, 2Institute Jules Bordet, Brussels, BE, 3Brustkrebs Deutschland e.V.,
Hohenbrunn, DE

13:00 - 14:30 Type: Industry Satellite Symposium Salamanca Auditorium -
Title: MSD - Treatment Modalities in Early-Stage Hall 3
Resectable NSCLC
Chair(s): Delvys Rodriguez Abreu, ES
13:00 - 13:05 Welcome & opening comments
D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo

Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES
13:05 - 13:25 Current early-stage resectable disease data

H. Wakelee, Standford University, Stanford, US
13:25 - 13:45 Surgical considerations in early-stage disease

J. Spicer, McGill University, Montreal, CA
13:45 - 14:05 Integrating treatment strategies into practice

14:05 - 14:25 Panel Q&A
D. Rodriguez Abreu1, H. Wakelee2, J. Spicer3, B. Besse4, 1Hospital Universitario Insular

de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria,
ES, 2Standford University, Stanford, US, 3McGill University, Montreal, CA, 4Institut
Gustave Roussy, Villejuif, FR


Title: Janssen Pharmaceutica N.V. - Transforming treatment Auditorium -
approaches for patients with EGFR-mutant NSCLC Hall 10
Chair(s): Luis Paz-Ares, ES; Natasha Leighl, CA
13:00 - 13:05 Welcome and introductions

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES
13:05 - 13:20 Strategies for overcoming EGFR resistance in NSCLC patient management
A. Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT
L. Paz-Ares1, N. Leighl2, N. Girard3, J. Sabari4, A. Passaro5, 1Hospital Universitario 12 de

Octubre, Madrid, ES, 2UHN - University Health Network - Princess Margaret Cancer
Center, Toronto, CA, 3Institut Curie, Paris, FR, 4NYU Langone Health - Perlmutter Cancer
Center - 34th Street, New York, US, 5IEO - Istituto Europeo di Oncologia IRCCS, Milan,
IT
13:32 - 13:47 Expanding our horizons: Novel frontline approaches in EGFR-mutant NSCLC
N. Girard, Institut Curie, Paris, FR

IT
13:59 - 14:14 Current and future directions for EGFR exon 20 insertion mutations in NSCLC
J. Sabari, NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US

IT
14:26 - 14:30 Key learnings/closing remarks

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
CA

Title: Astellas Pharma Europe Ltd - Putting the patient first: Auditorium -
Considering treatment choice and maximising quality of life in Hall 9
mHSPC
Chair(s): Christopher Sweeney, AU

C. Sweeney, The University of Adelaide, Adelaide, AU
13:05 - 13:20 Reinforcing standard of care: The benefits of early treatment intensification in
patients with mHSPC
H. Payne1, C. Sweeney2, J. Puente3, 1University College London Hospitals NHS

Foundation Trust, London, GB, 2The University of Adelaide, Adelaide, AU, 3Hospital
Clinico Universitario San Carlos, Madrid, ES
13:20 - 13:35 The importance of first-line treatment choice in patients with mHSPC

13:35 - 13:50 Maintaining quality of life: Holistic approaches in the management of patients
with mHSPC

13:50 - 13:55 Q&A


C. Sweeney, The University of Adelaide, Adelaide, AU

13:00 - 14:30 Type: ESMO Colloquium Toledo
Title: ESMO Colloquium supported by Daiichi Sankyo, Europe in Auditorium
collaboration with AstraZeneca: The impact of antibody-drug - Hall 3
conjugates (ADCs) in the changing treatment landscape of advanced
NSCLC
Chair(s): Enriqueta Felip, ES; Pasi Jänne, US

13:10 - 13:30 Emerging data on the role of ADCs in the clinical care pathways for advanced
NSCLC patients
P. Jänne, Dana Farber Cancer Institute, Boston, US
13:30 - 13:50 Improving the safety profiles of ADCs: Early detection and optimal management
of toxicities
M. Pérol, Centre Léon Bérard, Lyon, FR
13:50 - 14:10 Antibody-drug conjugates: Novel combinations with precision therapeutics and
the quest for biomarkers
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

P. Jänne, Dana Farber Cancer Institute, Boston, US

Title: F. Hoffmann-La Roche LTD - Redefining Lung Cancer Auditorium - Hall
Together: A New Era for Patients 7
Chair(s): Stephen Liu, US

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US
13:05 - 13:25 Optimising the patient journey: from lung cancer detection to biomarker testing
S. Liu1, L. Pijuan2, 1Lombardi Cancer Center Georgetown University, Washington, US,

2Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES
13:25 - 13:45 Evolving treatment decisions in resectable NSCLC
M. Reck1, N. Altorki2, 1Krankenhaus Grosshansdorf, Grosshansdorf, DE, 2NewYork-

Presbyterian Hospital/ Weill Cornell Medical Center, New York, US
13:45 - 13:55 A look at the patient journey through the lens of the nurse
A. Silverio Pons, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES
S. Liu1, M. Reck2, N. Altorki3, L. Pijuan4, A. Silverio Pons5, 1Lombardi Cancer Center

Georgetown University, Washington, US, 2Krankenhaus Grosshansdorf, Grosshansdorf,
DE, 3NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US,
4Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, 5Vall d'Hebron Institut
de Recerca (VHIR), Barcelona, ES


13:00 - 14:30 Type: Industry Satellite Symposium León Auditorium -
Title: GSK - The breakthrough era in endometrial cancer Hall 7
treatment
Chair(s): Ana Oaknin, ES
13:00 - 13:10 Three ways EC management is changing

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES
13:10 - 13:35 Anti–PD-(L)1s plus chemotherapies continue to evolve: Updates from 2023
congresses
I. Colombo, EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH
13:35 - 13:55 Synergy: Is it more than a buzzword for IO plus PARPi or TKI?
K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
13:55 - 14:15 Surge in molecular-based targets brings new hope for EC treatment
A. Oaknin1, I. Colombo2, K. Moore3, 1Vall d'Hebron University Hospital, Barcelona, ES,

2EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH,
3Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US
14:15 - 14:30 Full discussion/Q&A
A. Oaknin1, K. Moore2, I. Colombo3, 1Vall d'Hebron University Hospital, Barcelona, ES,

2Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, 3EOC -
Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH

13:00 - 14:30 Type: Patient Advocacy session Cádiz Auditorium - NCC
Title: Living with and after cancer
Chair(s): André Deschamps, BE; Natacha Bolanos Fernandez, ES
13:00 - 13:15 Resilience is key after diagnosis, during treatment, and after treatment
N. Bolanos Fernandez, Lymphoma Coalition, Madrid, ES
13:15 - 13:30 Behavioural changes in daily life: A cross-cutting approach for daily wellbeing
J. Kufel-Grabowska, Wielkopolskie Centrum Onkologii, Poznan, PL
13:30 - 13:45 Quality of life and survivorship

M. Die-Trill, Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES
13:45 - 14:00 Palliative and supportive care

C. Ostgathe, Universität Erlangen-Nürnberg, Nürnberg, DE
14:00 - 14:15 Reducing inequalities in Europe through robust national cancer control plans
that include palliative care

14:45 - 16:15 Type: Special symposium Barcelona Auditorium -
Title: Finding the positive in triple negative breast Hall 9
cancer
Chair(s): Andrew Tutt, GB; Eva Ciruelos, ES

14:50 - 15:05 Integrative multiomics analysis to dissect TNBC

S.J. Sammut, CRUK - Cancer Research UK Cambridge Institute - University of
Cambridge, Cambridge, GB
15:05 - 15:20 Targeting DNA damage response

A. Tutt, ICR - Institute of Cancer Research, London, GB
15:20 - 15:35 Predicting response or resistance to IO

G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT
15:35 - 15:50 Emerging targets in TNBC

M. Arnedos, Institute Bergonié, Bordeaux, FR

A. Tutt, ICR - Institute of Cancer Research, London, GB

14:45 - 16:15 Type: Special symposium Sevilla Auditorium
Title: Molecular profiling of gynaecological cancers for - Hall 9
therapeutic stratification
Chair(s): David SP Tan, SG

14:50 - 15:05 Molecular profiling of gynaecological cancers: A pathologist's view

G. Mccluggage, Royal Victoria Hospital - Belfast Health and Social Care Trust HSC,
Belfast, GB
15:05 - 15:20 Endometrial cancer

V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US
15:20 - 15:35 Ovarian and rare gynaecological cancers

C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU
15:35 - 15:50 Cervical cancer

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES


14:45 - 16:15 Type: Special session Bilbao Auditorium - NCC
Title: ESMO Clinical Practice Guidelines 2
Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR
14:45 - 14:55 Non-oncogene-addicted metastatic NSCLC case presentation

M. Tagliamento, Gustave Roussy - Cancer Campus, Villejuif, FR
14:55 - 15:05 Non-oncogene-addicted metastatic NSCLC discussion

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
15:05 - 15:15 Q&A
15:15 - 15:25 Recurrent/metastatic squamous cell carcinoma of the head and neck
C. Gurizzan, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT
15:25 - 15:35 Recurrent/metastatic squamous cell carcinoma of the head and neck
C. Even, Institut Gustave Roussy, Villejuif, Cedex, FR
15:35 - 15:45 Q&A
15:45 - 15:55 Prostate cancer case presentation

C. Oing, Newcastle University, Newcastle upon Tyne, GB
15:55 - 16:05 Prostate cancer discussion

K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

14:45 - 16:15 Type: Educational session Granada Auditorium - Hall 3
Title: Managing stage III NSCLC in the era of IO
Chair(s): Rafal Dziadziuszko, PL; Kersti Oselin, EE

J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
14:50 - 15:15 Who should and shouldn't get surgery?

J. Spicer, McGill University, Montreal, CA
15:15 - 15:40 IO and chemotherapy before or after surgery?

15:40 - 16:05 IO after or with chemoradiotherapy? For how long?

J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
14:45 - 16:20 Type: Mini Oral session Burgos Auditorium -

Title: Mini oral session - Gastrointestinal tumours, lower Hall 3
digestive
Chair(s): Gunnar Folprecht, DE; Raghav Sundar, SG; Jeanne Tie, AU
14:45 - 14:50 LBA30 - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable

metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type
(WT) tumor status from circulating DNA (cirDNA). First results of the
randomised phase II PANIRINOX-UCGI28 study
T. Mazard1, F. Ghiringhelli2, A. Winter1, C. De La Fouchardiere3, D. Botsen4, T. André5, J.

Vanbockstael6, M. Dos Santos7, J. Martin-Babau8, Y. Rinaldi9, L. Evesque10, S. Ellis11, C.
Gavoille12, D. Smith13, M. Fonck14, D. Sefrioui15, V. Pezzella16, S. Nougaret1, A.R.
Thierry1, O. Bouche17, 1ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR,
2Centre Georges-François Leclerc (Dijon), Dijon, FR, 3IPC - Institut Paoli-Calmettes,
Marseille, Cedex, FR, 4Institut Jean Godinot, Reims, FR, 5Hopital Saint-Antoine, Paris,
FR, 6ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, 7Centre
Francois Baclesse, Caen, FR, 8Hôpital Privé des Côtes d'Armor, Plérin, FR, 9Marseille
European Hospital, Marseille, FR, 10Centre Anticancer Antoine Lacassagne, Nice, FR,
11Centre Catalan d'Oncologie Clinique St. Pierre, Perpignan, FR, 12Institut de
Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 13Hopital Haut

Leveque, Pessac, FR, 14Institute Bergonié - Centre Régional de Lutte Contre le Cancer
(CLCC), Bordeaux, FR, 15Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR,
16Unicancer, Paris, Cedex, FR, 17CHU de Reims - Hôpital Robert Debré, Reims, Cedex,
FR
14:50 - 14:55 554MO - Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-
type patients with initially unresectable colorectal liver metastases: The TRICE
randomized clinical trial

Y. Li1, D. Wang1, C. Ren1, S.-S. Li2, W. Pat Fong1, X. Wu1, J. Xiao2, Y. Yuan1, B.-K. Li1, P.-R.
Ding1, Z. Wang1, F. Wang1, Z. Pan1, G. Chen1, X.-Z. Wang3, L.-Y. Wang 4, T. Chen4, T. Liu5,
Y. Yuan6, R.-H. Xu1, 1Sun Yat-sen University Cancer Center, Guangzhou, CN, 2The 6th
Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, 3Shantou Central Hospital,
Shantou, CN, 4Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN,
5Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, 6The Second Affiliated
Hospital, Zhejiang University School of Medicine, Hangzhou, CN
14:55 - 15:00 555MO - Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive
clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal
cancer (mCRC): the DEEPER trial (JACCRO CC-13)
Y. Sunakawa1, M. Shiozawa2, T. Watanabe3, H. Ota4, H. Yasui5, M. Kochi6, D. Manaka7,

H. Ohori8, T. Yamaguchi9, M. Matsuura10, Y. Shinohara11, T. Miyake12, T. Sagawa13, C.
Tanaka14, S. Okamura15, M. Takeuchi16, W. Ichikawa17, M. Fujii18, A. Tsuji19, 1St.
Marianna University School of Medicine, Kawasaki, JP, 2Kanagawa Cancer Center,
Yokohama, JP, 3Japanese Red Cross Society Himeji Hospital, Himeji, JP, 4Ikeda City
Hospital, Ikeda, JP, 5Kobe City Medical Center General Hospital, Kobe, JP, 6Nihon
University School of Medicine, Tokyo, JP, 7Kyoto-Katsura Hospital, Kyoto, JP, 8Japanese
Red Cross Ishinomaki Hospital, Miyagi, Miyagi, JP, 9Tokyo Metropolitan Cancer and
Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, 10Kobe City Nishi-Kobe
Medical Center, Kobe, JP, 11JCHO - Japan Community Healthcare Organization Kyushu
Hospital, Kitakyushu, JP, 12Shiga University of Medical Science, Otsu, JP, 13Hokkaido
Cancer Center, Sapporo, JP, 14Gifu Prefectural General Medical Center, Gifu, JP, 15Suita
Municipal Hospital, Suita, JP, 16The University of Tokyo, Tokyo, JP, 17Showa University
Fujigaoka Hospital, Yokohama, JP, 18Japan Clinical Cancer Research Organization,
TOKYO, JP, 19Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki,
JP
15:00 - 15:15 Invited Discussant LBA30, 554MO and 555MO

G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE
15:15 - 15:20 LBA31 - Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced
MMR-deficient colon cancers: the NICHE-3 study
Y. Verschoor1, J. Van Den Berg1, S. Balduzzi1, J. Van Blijderveen1, S. Oosterling2, P.

Burger3, T. Aukema4, T. Vogten5, S. Dokter1, R. Beets-Tan 6, A. Lent7, G. Beets1, M. Van
Leerdam1, J. Haanen1, M. Chalabi1, 1NKI-AVL - Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital, Amsterdam, NL, 2Spaarne Hospital Hoofddorp, Hoofddorp, NL,
3Catharina Hospital Eindhoven, Eindhoven, NL, 4Hagaziekenhuis, Den Haag, NL,
5Tergooi Ziekenhuizen, Blaricum, NL, 6Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, 7OLVG Hospital, Amsterdam, NL
15:20 - 15:25 556MO - A phase II clinical trial of sintilimab plus chidamide combined with or
without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer
F. Wang1, Y. Jin1, H.-Y. Luo 1, W.-L. Guan1, Y. Li1, F. Wang1, M. Qiu1, L.-L. Liu2, X. Hu3, Y.
Zhang4, W. Fang2, Z.-X. Wang 1, C. Ren1, D. Wang1, R.-H. Xu1, 1Sun Yat-sen University
Cancer Center, State Key Laboratory of Oncology in South China, Collaborative
Innovation Center of Cancer Medicine, Guangzhou, CN, 2The First Affiliated Hospital,
Zhejiang University School Of Medicine, Hangzhou, CN, 3The First Affiliated Hospital of
Guangxi Medical University, Nanning, CN, 4Cancer Hospital Affiliated to Harbin Medical

University, Harbin, CN
15:25 - 15:30 LBA32 - Pembrolizumab versus chemotherapy in microsatellite instability-high

(MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer
(mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study
K.-K. Shiu1, T. André2, T.W. Kim3, B. Vittrup Jensen4, L.H. Jensen5, C. Punt6, D. Smith7, R.
Garcia-Carbonero8, J. Alcaide-Garcia9, P. Gibbs10, C. De La Fouchardiere11, F. Rivera12,
M.E. Elez Fernandez13, D. Le14, T. Yoshino15, Y. Zuo16, D. Fogelman17, D. Adelberg17, L.
Diaz18, 1University College Hospital, NHS Foundation Trust, London, GB, 2Sorbonne
University, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, FR,
3Asan Medical Center, University of Ulsan, Seoul, KR, 4Herlev and Gentofte Hospital,
Herlev, DK, 5University Hospital of Southern Denmark, Vejle, DK, 6Amsterdam University
Medical Center, University of Amsterdam, Amsterdam Netherlands, and Julius Center for
Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht
University, Utrecht, NL, 7Bordeaux University Hospital, Bordeaux, FR, 8Hospital
Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, 9Hospitales Universitarios
Regional y Virgen de la Victoria IBIMA, Malaga, ES, 10Western Health, St. Albans, AU,
11Centre Léon Bérard, Lyon, FR, 12Hospital Universitario Marqués de Valdecilla, IDIVAL,
Santander, ES, 13Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of
Oncology, Barcelona, ES, 14Sydney Kimmel Comprehensive Cancer Center at Johns
Hopkins University, Baltimore, US, 15National Cancer Center Hospital East, Kashiwa, JP,
16MSD China, Beijing, CN, 17Merck & Co., Inc., Rahway, US, 18Memorial Sloan Kettering
Cancer Center, New York, US
15:30 - 15:35 557MO - Phase II trial evaluating the efficacy of pembrolizumab combined with
vorinostat in patients with recurrent and/or metastatic anal squamous cell
carcinoma – subgroup analysis of the PEVOsq basket trial
C. Coutzac1, F. Bigot2, D. Vansteene3, M. Dos Santos4, F. Ghiringhelli5, B. You6, A.

Lambert7, C. Gomez-Roca8, C. Abdeddaim9, C. Neuzillet10, E. Jeannot10, E. Guerini
Rocco11, G. Frige12, L. Mazzarella12, C. Dupain10, M. Kamal10, F. Legrand13, M.
Jimenez14, T. Filleron15, C. Le Tourneau2, 1Centre Léon Bérard, Lyon, FR, 2ICO - Institut
de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, 3ICO Institut de Cancerologie
de l'Ouest René Gauducheau, Saint-Herblain, FR, 4Centre Francois Baclesse, Caen, FR,
5Centre Georges-François Leclerc (Dijon), Dijon, FR, 6Lyon Sud Hospital Center - HCL,
Pierre-Bénite, FR, 7Capsule Corp, Nancy, FR, 8Institut Universitaire du Cancer -Toulouse-
Oncopole, Toulouse, FR, 9Centre Oscar Lambret, Lille, FR, 10Institut Curie, Paris, FR,
11IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, 12IEO - Istituto Europeo di
Oncologia, Milan, IT, 13Unicancer, Paris, Cedex, FR, 14Unicancer, Paris, FR, 15Institut
Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR
15:35 - 15:50 Invited Discussant LBA31, 556MO, LBA32 and 557MO

R. Sundar, NUHS - National University Health System, Singapore, SG
15:50 - 15:55 558MO - Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts)
with resected colorectal cancer (CRC): an updated 24 months (mos) disease free
survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)
Y. Nakamura1, D. Kotani2, M. Saori2, H. Yukami3, J. Watanabe4, N. Akazawa5, K.

Kataoka6, K. Hirata7, K. Yamazaki8, K.-H. Yeh9, G. Laliotis10, V. Aushev10, A. Jurdi10, M.

Kotaka11, H. Bando2, H. Taniguchi12, I. Takemasa13, T. Kato14, T. Yoshino1, E. Oki15,
1National Cancer Center Hospital East, 柏市柏の葉--, JP, 2National Cancer Center Hospital
East, Kashiwa, JP, 3Osaka Medical and Pharmaceutical University Hospital, Takatsuki, JP,
4Yokohama City University Medical Center, Yokohama, JP, 5Sendai City Medical Center
Sendai Open Hospital, Sendai, JP, 6Hyogo College of Medicine, Nishinomiya, JP,
7University of Occupational and Environmental Health, Kitakyushu, JP, 8Shizuoka Cancer
Center, Shizuoka, JP, 9NTUH - National Taiwan University Hospital, Taipei City, TW,
10Natera, Inc., San Carlos, US, 11Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP,
12Aichi Cancer Center Hospital, Nagoya, JP, 13Sapporo Medical University School of
Medicine, Sapporo, JP, 14National Hospital Organization Osaka National Hospital, Osaka,
JP, 15Kyushu University - Graduate School of Medical Sciences - Faculty of Medical
Sciences, Fukuoka, JP
15:55 - 16:00 559MO - Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type
refractory metastatic colorectal cancer: individual patients’ data pooled analysis
from 4 phase II trials.
D. Ciardiello1, G. Mauri2, D. Rossini3, V. Famiglietti4, G. Martini5, S. Napolitano5, S. Del

Tufo4, M.G. Zampino6, A. Avallone7, F. Pietrantonio8, S. Lonardi9, D. Santini10, G. Masi11,
S. Siena12, A. Bardelli13, F. Ciardiello5, C. Cremolini11, A. Sartore Bianchi14, T. Troiani5,
E. Martinelli5, 1IEO, Milan, IT, 2IFOM, Milan, IT, 3Università di Pisa, Pisa, IT, 4Università
degli Studi della Campania Luigi Vanvitelli, Caserta, IT, 5Università degli Studi della
Campania Luigi Vanvitelli, Napoli, IT, 6IEO - Istituto Europeo di Oncologia, Milan, IT,
7Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, 8Fondazione
IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 9IOV - Istituto Oncologico Veneto
IRCCS, Padova, IT, 10Università degli Studi di Roma la Sapienza - Facoltà di Medicina,
Latina, IT, 11AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, 12UNIMI - Università
degli Studi di Milano Statale, Milan, IT, 13IRCCS - Istituto di Candiolo - FPO, Candiolo, IT,
14Università degli Studi di Milano, Milan, IT
16:00 - 16:05 560MO - Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-
Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in
2nd line metastatic colorectal cancer (mCRC): the randomized AFEMA trial
P. García Alfonso1, M.E. Elez Fernandez2, J. Soto Alsar1, D. Paez3, A. Fernandez Montes4,
B. Grana Suarez5, A. Salud6, A. Yubero Esteban7, M.A. Gomez España8, I. Macias
Declara9, G.A. Quintero Aldana10, C. Lopez Lopez11, T. Fernandez Rodriguez12, M.C.
Gravalos Castro13, E. González-Flores14, M. Guix Arnau15, B. García Paredes16, J.J. Reina
Zoilo17, J. Sastre Varela16, E. Aranda Aguilar8, 1Gregorio Marañon General University
Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad
Complutense, Madrid, ES, 2Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron
Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC,
Barcelona, ES, 3Hospital de la Santa Creu i Sant Pau, Barcelona, ES, 4Complexo
Hospitalario Universitario de Ourense, Ourense, ES, 5Hospital Universitario de A Coruña.
Instituto Investigación Biomédica INIBIC, A Coruña, ES, 6Hospital de Lleida Arnau de
Vilanova, Lleida, ES, 7Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES,
8Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III. Hospital
Universitario Reina Sofía, Cordoba, ES, 9Hospital Parc Taulí de Sabadell, Barcelona, ES,
10Hospital Universitario Lucus Augusti (HULA), Lugo, ES, 11Hospital Marqués de
Valdecilla, IDIVAL, UNICAN, Santander, ES, 12Hospital Son Llatzer, Palma de Mallorca,
ES, 13Hospital Universitario 12 de Octubre, Madrid, ES, 14Hospital Universitario Virgen
de las Nieves, Granada, ES, 15Hospital del Mar, Barcelona, ES, 16Hospital Clínico San

Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad
Complutense, Madrid, ES, 17Complejo Hospitalario Virgen de la Macarena, Seville, ES

J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU
14:45 - 16:15 Type: Multidisciplinary session Valencia

Title: Pancreatic cancer: Evidence based options to improve Auditorium - Hall
quality of life and extend survival 10
Chair(s): Stephen Chan, HK; Radka Obermannova, CZ
14:45 - 14:50 Case/Condition presentation

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
14:50 - 15:05 Endoscopic management of obstructive jaundice: What clinicians should know?
R. Tang, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
15:05 - 15:20 Pain management and palliative care

A. Epstein, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
15:20 - 15:35 Malignant ascites

J. Herre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB
15:35 - 15:50 Nutrition and exercise

R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ
15:50 - 16:05 Radiotherapy

L. Dawson, Princess Margaret Cancer Centre, Toronto, CA

14:45 - 16:15 Type: Educational session Salamanca Auditorium -
Title: Neoadjuvant and adjuvant therapy in Hall 3
genitourinary cancers
Chair(s): Srikala Sridhar, CA; Michiel van der Heijden, NL
14:45 - 15:05 State-of-the-art in adjuvant treatment of renal cell carcinoma

G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES
15:05 - 15:25 State-of-the-art in adjuvant treatment of urothelial cancer

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE
15:25 - 15:45 Interpretation of current peri-operative trial designs and endpoints

S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
15:45 - 16:05 Global access considerations in systemic treatment of genitourinary cancers

F.A. Barros Schutz, Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo, BR

14:45 - 16:15 Type: Multidisciplinary session Málaga Auditorium -
Title: Early-stage (II/III) melanoma: Risk stratification and Hall 10
treatment decisions
Chair(s): Mathilde Jalving, NL; Dirk Schadendorf, DE

14:50 - 15:05 A pathologist’s perspective: What to look for and how to report it
B. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
15:05 - 15:20 A dermatologist’s perspective: Secondary prevention and risk stratifications

strategies
15:20 - 15:35 Further development of the clinical case: A surgeon’s perspective – Do we still
need surgery in the era of risk scores stratification and systemic therapy?
A. Van Akkooi, Melanoma Institute Australia, Wollstonecraft, AU
15:35 - 15:50 Further development of the clinical case: A medical oncologist’s perspective – Do
all patients need adjuvant systemic therapy and how does this influences therapy
in advanced setting?
M. Jalving, UMCG - University Medical Center Groningen, Groningen, NL
14:45 - 16:15 Type: Educational session Santander

Title: Intensification vs descalation of therapy in H&N Auditorium - Hall 9
cancer: When and for whom?
Chair(s): Amanda Psyrri, GR; Jens Peter Klussmann, DE
14:45 - 15:10 Novel strategies to de-escalate surgery

R. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, US
15:10 - 15:35 De-escalation in radiation and systemic therapy

A. Psyrri, Attikon University Hospital, Haidari, GR
15:35 - 16:00 Which patients need more intensive treatment?

J. Bourhis, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

14:45 - 16:15 Type: Special symposium Oviedo Auditorium -
Title: Advances in our understanding of paraganglioma / Hall 7
pheochromocytoma
Chair(s): Margot Tesselaar, NL; Patricia Dahia, US

M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
14:50 - 15:05 The genetics of paraganglioma (PPGL) and implications for testing and
screening
M. Robledo, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES
15:05 - 15:20 Perioperative considerations and management of localised disease

M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL
15:20 - 15:35 Targeted radionuclide therapy for advanced disease/theranostics

J. Kunikowska, University of Warsaw, Warsaw, PL
15:35 - 15:50 The treatment landscape for metastatic PPGL: Are we making progress?
P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San
Antonio, US

P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San
Antonio, US

14:45 - 16:15 Type: Special session León
Title: In collaboration with the MASCC - The multiple faces of Auditorium -
fatigue in the cancer ecosystem Hall 7
Chair(s): Christina Ruhlmann, DK; Florian Scotté, FR
14:45 - 15:05 The epidemiology, biology and aetiology of cancer-related fatigue

F. Scotté, Institut Gustave Roussy, Villejuif, FR
15:05 - 15:25 Fatigue in health care professionals: Another term for burnout?
K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
15:25 - 15:45 Systemic anticancer therapy-related fatigue: Causes and management

15:45 - 16:05 Fatigue related to emerging targeted anticancer therapeutics
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
16:05 - 16:15 Panel discussion / Q&A
14:45 - 16:15 Type: Educational session Cádiz Auditorium -

Title: Oncology drug trials: How can we bring true value for NCC
patients?
Chair(s): Ian Tannock, CA; E.G. Elisabeth de Vries, NL
14:45 - 15:05 Challenges, pitfalls and the way forward: Investigator’s perspective
I. Tannock, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
15:05 - 15:25 Walking the tightrope without losing sight of the patient
K. Yonemori, National Cancer Center - Tsukiji Campus, Chuo-ku, JP
15:25 - 15:40 Clinical trials in oncology: What really matters to patients?

T. Lang, Myeloma Patients Europe AISBL, Brussels, BE
15:40 - 16:00 “Value” and what it really means for new cancer drugs
A. Fojo, Columbia University, New York, US

Title: YO Masterclass: Tackling new challenges facing young NCC
investigators
Chair(s): Kok Haw Jonathan Lim, GB
14:45 - 15:10 Bridging the gap between basic science and clinical research
15:25 - 15:50 Investigator-initiated trials: From design to activation

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE
16:05 - 16:25 Coffee break
16:25 - 16:50 Preprints from medRxiv and bioRxiv: Should I trust them?
L. Rowett, ESMO - European Society for Medical Oncology, Lugano, CH
17:05 - 17:30 Interpreting clinical trial data: How to understand subgroup analyses
S. Brown, University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB

Title: The control centre in immune defence: The tertiary Auditorium - Hall
lymphoid structure in tumours 3
Chair(s): Daniela Thommen, NL

C. Sautes-Fridman, Centre de Recherche des Cordeliers, Paris, FR

D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL

Title: EONS16: Palliative and end-of-life care
Chair(s): Tugba Pehlivan Sarıbudak, TR
15:00 - 15:15 Co-design of a web-based resource for head and neck cancer patients using the
person-based approach
C. Semple, Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB
15:15 - 15:30 Managing Cancer and Living Meaningfully (CALM) for oncology nurses
M. Van Klinken, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-
AVL), Amsterdam, NL
15:30 - 15:45 The journey of persons with genitourinary malignancies: Nurses' perspective on
supportive and palliative care
S. Terzoni, Ospedale San Paolo - ASST Santi Paolo e Carlo, Milan, IT
15:45 - 15:55 CN25 - Psycho-education and telephone counselling on the quality of life of
advanced cancer patients undergoing chemotherapy in Indonesia.
N. Huda, W.N. Dewi, H. Deli, Universitas Riau, Pekanbaru, ID
15:55 - 16:05 CN26 - Healthcare professionals’ perceptions on palliative care in onco-

haematological area: validation of the Palliative Care Perception instrument
T. Buttiron Webber1, G. Pegoraro2, I. Lima2, G. Catania2, M. Calzolari2, M. Zanini2, L.

Sasso2, A. Bagnasco2, 1Ente Ospedaliero Ospedali Galliera, Genova, IT, 2University of
Genoa, Genova, IT
16:05 - 16:15 CN27 - Pain in men with metastatic castration-resistant prostate cancer
(mCRPC) starting their first-line of life prolonging treatment- a cross sectional
study in Sweden
U. Rönningås1, M. Holm2, P. Fransson3, L. Beckman4, A. Wennman-Larsen1, 1Karolinska

Institutet, Stockholm, SE, 2Sophiahemmet Universty, Stockholm, SE, 3Umea University,
Umea, SE, 4Sundsvalls sjukhus, Sundsvall, SE
16:30 - 18:00 Type: Mini Oral session Burgos Auditorium - Hall

Title: Mini oral session - NETs and endocrine 3
tumours
Chair(s): Mauro Cives, IT; Sara De Dosso, CH; Jaydira Del Rivero, US
16:30 - 16:35 2211MO - Uncovering the Mechanisms of Persistent Disease in RET-altered

Thyroid Cancers: Insights from Patient-Derived Xenograft Models treated with
Selective RET Inhibitors.
A. Garcia Alvarez1, J. Hernando2, I. Chicote2, J. Martínez-Quintanilla3, A. Carmona3, C.

Iglesias1, X. Serres Créixams1, J. Jimenez4, P. Nuciforo4, S. Aguilar Izquierdo1, J.

Gonzalo4, A. Vivancos1, H.G. Palmer3, J. Capdevila Castillon1, 1Vall d'Hebron University
Hospital, Barcelona, ES, 2Hospital Universitario Vall d'Hebron, Vall d´Hebron Institut of
Oncology (VHIO), Barcelona, ES, 3VHIO - Vall d'Hebron Institute of Oncology, Barcelona,
ES, 4Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
16:35 - 16:40 1183MO - Molecular characterization of rectal neuroendocrine tumors (NETs)

with unfavorable prognosis by multiomics analysis: A multicenter retrospective
cohort study (GARNET)
T. Shibuki1, N. Mizuno2, N. Kobayashi3, H. Hirano4, T. Tsuchikawa5, S. Matsumoto6, H.

Okuyama7, E. Sasaki8, K. Shinjo9, R. Yamaguchi10, T. Kawata11, W. Hosoda2, 1National
Cancer Center Hospital East, Chiba, JP, 2Aichi Cancer Center Hospital, Aichi, JP,
3Yokohama City University Hospital, Kanagawa, JP, 4National Cancer Center Hospital,
Tokyo, JP, 5Hokkaido University Hospital, Hokkaido, JP, 6Kyoto University Hospital, Kyoto,
JP, 7Kagawa University Hospital, Kagawa, JP, 8Fukushima Medical University Hospital,
Fukushima, JP, 9Nagoya University Graduate School of Medicine, Aichi, JP, 10Aichi
Cancer Center Research Institute, Aichi, JP, 11Novartis Pharma K.K., Tokyo, JP

M. Cives, Università degli Studi di Bari Aldo Moro, Bari, IT
16:55 - 17:00 1184MO - Safety and efficacy of everolimus (EVE) as second–line treatment in
neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC)
M. Pavel1, L. Fischer Von Weikersthal2, G. Klöppel3, K. Krause4, L. Apostolidis5,

1Universitätsklinik Erlangen, Erlangen, DE, 2Klinikum St. Marien Amberg, Amberg, DE,
3Technical University Munich, München, DE, 4AIO-Studien-gGmbH, Berlin, DE, 5National
Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE
17:00 - 17:05 1185MO - Activity and safety of avelumab alone or in combination with
cabozantinib in patients with advanced high grade neuroendocrine neoplasias
(NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter
AVENEC and CABOAVENEC trials.
M.M. Weber1, L. Apostolidis2, S. Krug3, A. Rinke4, B. Gruen2, P. Michl5, T. Gress4, D.

Wagner1, W. Roth1, E. Mettler1, C. Ruckes1, P. Galle1, C. Fottner6, 1Universitätsmedizin
der Johannes Gutenberg-Universität Mainz, Mainz, DE, 2National Center for Tumor
Diseases (NCT) Heidelberg, Heidelberg, DE, 3UKH - Universitätsklinikum Halle (Saale),
Halle (Saale), DE, 4UKGM - Uniklinikum Giessen und Marburg - Standort Marburg,
Marburg, DE, 5UKHD - Universitätsklinikum Heidelberg, Heidelberg, DE,
6Universitätsmedizin Mainz, Mainz, DE
17:05 - 17:10 725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in
patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine
carcinomas
V. Gambardella1, J. Capdevila Castillon2, Y. Kuboki3, O. Alese4, D. Morgensztern5, C.M.

Sayehli6, M.F. Sanmamed7, E. Arriola8, Z. Oum'Hamed9, E. Song10, M. Studeny11, M.
Wermke12, 1Hospital Clínico Universitario, INCLIVA Biomedical Research Institute,
University of Valencia, Valencia, ES, 2Vall d'Hebron University Hospital and Vall d'Hebron
Institute of Oncologyology, Barcelona, ES, 3National Cancer Center Hospital East,
Kashiwa, JP, 4Winship Cancer Institute of Emory University, Atlanta, US, 5Washington

University School of Medicine, St. Louis, US, 6Medical Clinic and Polyclinic II of the
University Hospital, Würzburg, DE, 7Clínica Universidad de Navarra, Pamplona, ES,
8Hospital del Mar - CIBERONC (Centro de Investigación Biomédica en Red de
Oncología), Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions
Mèdiques), Barcelona, ES, 9Boehringer Ingelheim France SAS, Paris, FR, 10Boehringer
Ingelheim (China) Investment Co., Shanghai, CN, 11Boehringer Ingelheim International
GmbH, Ingelheim, DE, 12NCT/UCC Early Clinical Trial Unit, Dresden, DE

S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della
17:25 - 17:30 1186MO - A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide

Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE Followed by
Surgery for Pancreatic Neuroendocrine Tumors (NeoLuPaNET)
S. Partelli1, L. Landoni2, M. Bartolomei3, A. Zerbi4, C. Grana5, U. Boggi6, G. Butturini7, R.

Casadei8, C. Bassi2, M. Falconi9, 1UniSR - Università Vita e Salute San Raffaele Milano,
Milan, IT, 2AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, 3Arcispedale
Sant'Anna - AOU di Ferrara, Ferrara, IT, 4Department of Biomedical Sciences, Humanitas
University, Milan, IT, 5IEO - Istituto Europeo di Oncologia, Milan, IT, 6Azienda
Ospedaliero-Universitaria Pisana, Pisa, IT, 7Ospedale P. Pederzoli Casa di Cura Privata
Spa, Peschiera Del Garda, IT, 8University of Bologna - Alma Mater Studiorum, Bologna,
IT, 9IRCCS Ospedale San Raffaele, Milan, IT
17:30 - 17:35 2212MO - Major secondary outcomes in the multicentre noninferiority

randomised trial IoN: Is ablative radiOiodine Necessary for low risk
differentiated thyroid cancer patients?
A. Hackshaw1, K. Newbold2, M. Beasley3, K. Garcez4, J. Wadsley5, S. Johnson6, T.

Stephenson7, M. Gaze8, A. Goodman9, S. Jeffries10, D. Wilkinson11, E. Macias12, D.
Power13, T. Roques14, L. Speed15, G. Gerrard16, S. Forsyth1, E. Chang1, K. Farnell17, U.
Mallick18, 1Cancer Research UK & University College London Cancer Trials Centre,
London, GB, 2The Royal Marsden Hospital (Sutton), Sutton, GB, 3BHOC - Bristol
Haematology and Oncology Centre, Bristol, GB, 4The Christie NHS Foundation Trust,
Manchester, GB, 5Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation
Trust, Sheffield, GB, 6Newcastle General Hospital Northern Centre for Cancer
Treatment, Newcastle-upon-Tyne, GB, 7Northern General Hospital-Sheffield Teaching
Hospitals NHS Foundation Trust, Sheffield, GB, 8University College London Hospitals
NHS Foundation Trust, London, GB, 9RD&E - Royal Devon and Exeter Hospital
(Wonford), Exeter, GB, 10Addenbrooke's Hospital, Cambridge, GB, 11The James Cook
University Hospital, Middlesbrough, GB, 12Kent and Canterbury Hospital, Canterbury,
GB, 13St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, 14Norfolk
and Norwich University Hopsital NHS Foundation Trust, Norwich, GB, 15Leicester Royal
Infirmary, Leicester, GB, 16Leeds Cancer Centre, Leeds, GB, 17Butterfly Thyroid Cancer
Trust, Newcastle, GB, 18Newcastle Freeman Hospital - Newcastle Upon Tyne Hospitals
NHS Foundation Trust, Newcastle-upon-Tyne, GB
17:35 - 17:40 1187MO - Does the ENDOCAN-COMETE network improves the survival of
adrenocortical carcinomas in France?

R. Libe1, G. Coureau2, A.-S. Foucan2, M. Haissaguerre3, D. Drui4, S. Grunenwald5, F.
Castinetti6, S. Laboureau7, C. Docao8, F. Borson-Chazot9, B. Goichot10, L. Lamartina11,
O. Chabre12, S. Moog11, J. Bertherat13, A. Tabarin14, M. Faron15, E. Baudin11, 1Hopital
Cochin - Site Port-Royal AP-HP, Paris, FR, 2CHU - Centre Universitaire Hospitalier de
Bordeaux, Bordeaux, FR, 3CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, 4CHU de
Nantes, Hôtel Dieu, Nantes, FR, 5Centre Hospitalier Universitaire de Toulouse - Hopital
Larrey, Toulouse, FR, 6Aix-Marseille University - Faculté de Médecine - Timone,
Marseille, FR, 7CHU Angers, Angers, Cedex, FR, 8CHU Lille - Centre Hospitalier
Régional Universitaire de Lille, Lille, FR, 9Hospices Civils de Lyon, Bron, FR, 10Hopital
de Hautepierre - Hopitaux Universitaires de Strasbourg, Strasbourg, FR, 11Gustave
Roussy - Cancer Campus, Villejuif, FR, 12CHU Grenoble Alpes - Site Nord (La Tronche),
La Tronche, FR, 13Institut Cochin, Paris, FR, 14University of Bordeaux, Bordeaux, FR,
15Institut Gustave Roussy, Villejuif, FR

J. Del Rivero, NIH - National Institutes of Health, Bethesda, US
16:30 - 18:00 Type: Educational session Valencia Auditorium -

Title: ESMO Guideline updates on supportive and Hall 10
palliative care
Chair(s): Florian Scotté, FR; Christina Ruhlmann, DK
16:30 - 16:55 Antiemetics

J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjaelland, Roskilde, DK
16:55 - 17:20 Anxiety, depression and insomnia

L. Grassi, Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT
17:20 - 17:45 Prognostication in advanced cancer: Navigating the uncertainty

P. Stone, University College London, London, GB
16:30 - 18:00 Type: Proffered Paper session Toledo Auditorium - Hall

Title: Proffered paper session - Haematological 3
malignancies
Chair(s): Davide Rossi, CH
16:30 - 16:40 822O - Activation of γ9δ2 T Cells by ICT01 as a Novel Immunotherapeutic

Approach for Relapsed/Refractory Hematologic Cancers (EVICTION Trial)
S. Garciaz1, S. Champiat2, P. Peterlin3, K. Lemmens4, A. De Gassart4, P. Brune4, E.

Valentin4, C. Leparquier5, M. Iche5, D. Olive6, N. Vey7, P. Frohna4, 1Institut Paoli-
Calmettes, Aix-Marseille University, Marseille, FR, 2Gustave Roussy - Cancer Campus,
Villejuif, FR, 3University Hospital of Nantes (Hôtel-Dieu - CHU de Nantes), Nantes, FR,
4ImCheck Therapeutics SAS, Marseille, Cedex, FR, 5Ilife Consulting, Argenteuil, FR,
6Centre de Recherche en Cancérologie de Marseille, Marseille, FR, 7IPC - Institut Paoli-

Calmettes, Marseille, Cedex, FR
16:40 - 16:50 823O - Preliminary Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis
of the CD123 NK Cell Engager (NKCE) SAR443579 in Patients (pts) with
Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute
Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)
M. Jongen-Lavrencic1, A. Bajel2, S. Garciaz3, A. Maiti4, S. Fleming5, S. De Button6, G. A

Huls7, K. Jensen8, S. Ziti-Ljajic9, D. Draganov8, F. Rotolo10, C. Palu11, J. Courta9, W.
Passe-Coutrin9, K. Traudtner12, T. Wagenaar8, G. Abbadessa8, A. Selwyn Stein13,
1Erasmus University Medical Center, Rotterdam, NL, 2Peter MacCallum Cancer Center
and Royal Melbourne Hospital, Melbourne, AU, 3Institut Paoli-Calmettes, Aix-Marseille

University, Marseille, FR, 4MD Anderson Cancer Center, Houston, US, 5Alfred Health,
Melbourne, AU, 6Institut Gustave Roussy, Paris, FR, 7University Medical Center
Groningen, Groningen, NL, 8Sanofi, Cambridge, US, 9Sanofi, Chilly-Mazarin, FR,
10Sanofi, Montpellier, FR, 11Sanofi, Cambridge, GB, 12Sanofi, Amsterdam, NL, 13City of
Hope National Medical Center, Duarte, US

D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH
17:00 - 17:10 Q&A
17:10 - 17:20 824O - Treatment and survival in patients with localized primary ocular adnexal
MALT lymphoma: A large bicentric cohort study
L.-R. Gao1, X. Li2, X. Wang1, Y. Wu1, L. Wang2, S. Qi1, Y. Li1, 1National Cancer
Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy
of Medical Sciences and Peking Union Medical College, Beijing, CN, 2Beijing TongRen
Hospital, Capital Medical University, Beijing, CN
17:20 - 17:30 825O - Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral
T-cell lymphoma
N. Lou1, M. Yang1, X. Han2, 1Chinese Academy of Medical Sciences and Peking Union
Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, 2CAMS-PUMC -
Chinese Academy of Medical Sciences and Peking Union Medical College - Dongdan
Campus, Dongcheng-qu, CN
17:30 - 17:40 826O - A single-arm, multicenter clinical study of radiotherapy combined with
toripalimab in stage I/II extranodal NK/T cell lymphoma
M. Jiang, L. Liang, West China School of Medicine/West China Hospital of Sichuan
University, Chengdu, CN

17:50 - 18:00 Q&A

16:30 - 18:00 Type: Patient Advocacy session Cádiz Auditorium
Title: How does digitalisation help personalised care - NCC
throughout the patient journey?
Chair(s): Tanja Spanic, SI; Gregor Cuzak, SI
16:30 - 16:45 Patients at the centre of the new digital solutions: HealthDay and personalised
care
T. Spanic, Europa Donna Slovenia, Ljubljana, SI
16:45 - 17:00 New solutions for cancer patients

G. Cuzak, Trokot d.o.o., Ljubljana, SI
17:00 - 17:15 Saving life trough tracking symptoms and early detection of cancer recurrence:
The importance of collecting data in registries
R. Cordoba Mascunano, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES
17:15 - 17:30 Virtual nursing services: Data for healthier patient lives
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE
17:30 - 17:45 New technologies in hospitals, improving patient experience

L. Kornowska, Polish Federation of Hospitals, Warsaw, PL

Chair(s): Andres Cervantes, ES; Silke Gillessen, CH
16:30 - 16:42 One LBA TBC
16:42 - 16:54 LBA7 - Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone

for previously untreated unresectable or metastatic urothelial carcinoma: results
from the phase 3 CheckMate 901 trial
M. Van Der Heijden1, G. Sonpavde2, T. Powles3, A. Necchi4, M. Burotto5, M. Schenker6,

J.P. Sade7, A. Bamias8, P. Beuzeboc9, J. Bedke10, J. Oldenburg11, Y. Urun12, D. Ye13, Z.
He14, B. Perez Valderrama15, Y. Tomita16, J. Filian17, D. Purcea18, F. Nasroulah17, M.
Galsky19, 1Netherlands Cancer Institute, Amsterdam, NL, 2Dana-Farber Cancer Institute,
Harvard Medical School, Boston, US, 3Barts Cancer Institute, Queen Mary University of
London, London, GB, 4Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT,

5Bradford Hill-Clinical Center, Santiago, CL, 6Sf. Nectarie Oncology Center Craiova,
Craiova, RO, 7Alexander Fleming Institute, Buenos Aires, AR, 8National & Kapodistrian
University of Athens, ATTIKON University Hospital, Athens, GR, 9Hopital Foch, Suresnes,
FR, 10Eberhard Karls University Tübingen, Tübingen, DE, 11Akershus University
Hospital (Ahus), Lorenskog, NO, 12Ankara University, Ankara, TR, 13Fudan University
Shanghai Cancer Center, Shanghai, CN, 14Peking University First Hospital, Beijing, CN,
15Hospital Universitario Virgen del Rocio, Seville, ES, 16Niigata University Graduate
School of Medical and Dental Sciences, Niigata, JP, 17Bristol Myers Squibb, Princeton,
US, 18Bristol Myers Squibb, Boudry, CH, 19Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai, New York, US
16:54 - 17:04 Invited Discussant one LBA TBC and LBA7

A. Apolo, National Cancer Institute, Bethesda, US
17:04 - 17:10 Q&A
17:10 - 17:22 LBA8 - A randomised phase III trial of induction chemotherapy followed by
chemoradiation compared with chemoradiation alone in locally advanced
cervical cancer. The GCIG INTERLACE trial
M. Mccormack1, D. Gallardo Rincón2, G. Eminowicz3, P. Diez4, L. Farrelly5, C. Kent6, E.

Hudson7, M. Panades8, T. Mathews9, A. Anand10, M. Persic11, J. Forrest12, R. Bhana13, N.
Reed14, A. Drake15, H. Stobart16, A. Mukhopadhyay17, A.M. Hacker18, A. Hackshaw5, J.
Ledermann19, 1University College London Hospital, London, GB, 2The National Cancer
Institute, Ciudad de Mexico, MX, 3UCH - University College Hospital, London, GB,
4Mount Vernon Cancer Centre, Northwood, GB, 5Cancer Research UK & University
College London Cancer Trials Centre, London, GB, 6Leicester Royal Infirmary -
University Hospitals of Leicester NHS Trust, Leicester, GB, 7Velindre Cancer Centre -
Velindre NHS University Trust - NHS Wales, Cardiff, GB, 8United Lincolnshire Hospitals -
Lincoln County Hospital, Lincoln, GB, 9Northern General Hospital-Sheffield Teaching
Hospitals NHS Foundation Trust, Sheffield, GB, 10Nottingham City Hospital, Nottingham,
GB, 11Royal Derby Hospital - University Hospitals of Derby and Burton NHS Foundation
Trust, Derby, GB, 12Royal Devon and Exeter NHS Hospital (Wonford) - Royal Devon and
Exeter Foundation Trust, Exeter, GB, 13Royal Stoke University Hospital, Stoke-on-Trent,
GB, 14BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and
Clyde, Glasgow, GB, 15Belfast City Hospital - Belfast Health & Social Care Trust, Belfast,
GB, 16Independent Cancer Patients Voice, London, GB, 17CNCI - Chittaranja National
Cancer Institute, Kolkata, IN, 18UCL - University College London, London, GB, 19UCL
Cancer Institute - UCL - London's Global University, London, GB
17:22 - 17:34 LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-

Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of
Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer
I. Vergote1, A. Gonzalez Martin2, K. Fujiwara3, E. Kalbacher4, A. Bagameri5, S.

Ghamande6, J.-Y. Lee 7, S. Banerjee8, F. Maluf9, D. Lorusso10, K. Yonemori11, E. Van
Nieuwenhuysen1, L. Manso Sanchez12, L. Woelber13, A. Westermann14, A. Covens15, E.
Whalley16, M.S.L. Teng16, I. Soumaoro17, B. Slomovitz18, 1Universitaire Ziekenhuizen
Leuven, Katholieke Universiteit Leuven, and Belgium and Luxembourg Gynaecological

Oncology Group, Belgium, European Union, Leuven, BE, 2Cancer Center Clinica
Universidad de Navarra, Madrid, Spain and GEICO, Madrid, ES, 3Saitama Medical
University International Medical Center, Saitama, JP, 4Centre Hospitalier Universitaire de
Besançon, Besancon, FR, 5Országos Onkológiai Intézet, Budapest, HU, 6Georgia Cancer
Center, August University, Augusta, US, 7Yonsei University College of Medicine, Seoul,
KR, 8The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
London, GB, 9Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR,
10Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome and Catholic
University of Sacred Heart, Rome, IT, 11National Cancer Center - Tsukiji Campus, Chuo-
ku, JP, 12Hospital Universitario 12 de Octubre, Madrid, ES, 13Arbeitsgemeinschaft
Gynäkologische Onkologie Study Group and University Medical Center Hamburg-
Eppendorf, Hamburg, DE, 14Amsterdam University Medical Centres, Amsterdam, NL,
15Sunnybrook Research Institue, Toronto, CA, 16Seagen Inc., Bothell, US, 17Genmab,
Princeton, US, 18Mount Sinai Medical Center, Miami Beach, US
17:44 - 17:50 Q&A
17:50 - 18:02 LBA10 - Sotorasib plus panitumumab versus standard-of-care for

chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC):
CodeBreak 300 phase 3 study
F. Pietrantonio1, L. Salvatore2, T. Esaki3, D. Modest4, D. Paez5, J. Taieb6, M. Karamouzis7,

E. Ruiz8, T.W. Kim9, Y. Kuboki10, F. Meriggi11, D. Cunningham12, K.-H. Yeh13, E. Chan14,
J. Chao15, N. Strydom16, Y. Saportas17, Q. Tran17, C. Cremolini18, M. Fakih19,
1Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, 2Fondazione Policlinico
Universitario Agostino Gemelli IRCCS, Rome, IT, 3National Hospital Organization Kyushu
Cancer Center, Fukuoka, JP, 4Charité - Universitaetsmedizin Berlin, Berlin, DE, 5Hospital
de la Santa Creu i Sant Pau, Barcelona, ES, 6Hopital European George Pompidou, Paris,
FR, 7National and Kapodistrian University of Athens - School of Medicine, Athens, GR,
8INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, 9Asan Medical
Center - University of Ulsan College of Medicine, Seoul, KR, 10National Cancer Center
Hospital East, Kashiwa, JP, 11Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT,
12The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, 13NTUH -
National Taiwan University Hospital, Taipei City, TW, 14Amgen, Thousand Oaks, US,
15AMGEN - USA, Seattle, US, 16Amgen Inc - SSF, South San Francisco, US, 17AMGEN
(Headquarters) - USA, Thousand Oaks, US, 18AOU Pisana - Stabilimento di Santa Chiara,
Pisa, IT, 19City of Hope Comprehensive Cancer Center, Duarte, US
18:10 - 18:15 Q&A

16:45 - 17:45 Type: EONS session Alicante
Title: ECL/EONS collaborative session – Let’s break the taboo Auditorium -
around cancer and sexuality: Improving communication and care Hall 10
Chair(s): Johan De Munter, BE
16:45 - 17:00 How to improve communication and care for sexual wellbeing?
Recommendations and tools for oncology professionals
H. Neefs, Kom op tegen Kanker, Brussels, BE
17:00 - 17:15 Cancer and sexuality in adolescents and young adults (AYAs)
S. Sleeman, Association of European Cancer Leagues, Brussels, BE
17:15 - 17:25 CN37 - Perceptions and attitudes of healthcare providers towards discussing
sexuality and sexual problems in cancer patients (from LGBTQ+ backgrounds)
C. Beyts1, J. Verhelle1, E. Pape2, G. Van Ramshorst2, 1Ghent University - Campus Ufo,

Gent, BE, 2UZ Gent - Universitair Ziekenhuis Gent, Gent, BE
17:00 - 18:00 Type: Controversy session Salamanca

Title: PARP inhibitors for castration-resistant prostate cancer Auditorium -
combined with an AR pathway inhibitor: One approach for all Hall 3
Chair(s): Elena Castro, ES

17:05 - 17:20 Pro

N. Clarke, The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB
17:20 - 17:35 Contra

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES


Title: Sanofi Regeneron - Overcoming Therapeutic Challenges in Auditorium -
Non-melanoma Skin Cancer: A Multidisciplinary Approach Hall 3
Chair(s): Paolo Ascierto, IT

P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
18:35 - 18:55 Multidisciplinary management of non-melanoma skin cancer: Dermatological

Standpoint
18:55 - 19:15 Multidisciplinary management of non-melanoma skin cancer: Oncological

Approach
19:15 - 19:35 Multidisciplinary management of non-melanoma skin cancer: Surgical

Perspective
W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
19:35 - 19:55 Multidisciplinary management of non-melanoma skin cancer: Radiological

Viewpoint
S. Billan, Rambam Health Care Campus, Haifa, IL


18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium - Hall 10
Title: Seagen - ADCs’ Potential Across Tumors
Chair(s): Josep Tabernero, ES

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES
18:33 - 18:43 ADC Technologies in Oncology

18:43 - 19:03 Emerging ADCs in Non-Small Cell Lung Cancer

D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR
19:03 - 19:23 Advances in ADCs for Head and Neck Cancer

L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano,
Milan, IT
19:23 - 19:43 Future Directions for ADCs in Urothelial Cancer
19:43 - 19:58 Panel Discussion and Audience Q&A
J. Tabernero1, D. Planchard2, L. Locati3, T. Powles4, 1Vall d'Hebron University Hospital,

Barcelona, ES, 2Institut Gustave Roussy, Villejuif, Cedex, FR, 3ICS Maugeri: Pazienti e
Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT, 4St. Bartholomew's Hospital
- Barts Health NHS Trust, London, GB


Title: AstraZeneca - Assessing therapeutic options for patients Auditorium -
with hepatobiliary cancers: the role of immunotherapy-based Hall 3
regimens
Chair(s): Stephen Chan, HK

18:35 - 18:55 Plenary: Integration of immunotherapy-based approaches in HCC and BTC

B. Sangro, Clinica Universidad de Navarra, Pamplona, ES
18:55 - 19:10 Panel discussion 1: Assessing long-term survivorship and prognostic factors in
patients with hepatobiliary cancers
19:10 - 19:25 Case study discussion 1: Assessing patient outcomes in unresectable / advanced
HCC
19:25 - 19:40 Case study discussion 2: Navigating clinical decision-making in advanced BTC
A. Casadei Gardini, IRCCS Ospedale San Raffaele, Milan, IT
19:40 - 19:55 Panel discussion 2: Current management of immune-mediated adverse events in

patients with hepatobiliary cancers
S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG
19:55 - 20:00 Audience Q&A
S. Chan1, S.P. Choo2, B. Sangro3, A. Casadei Gardini4, 1The Chinese University of Hong
Kong - Sino Building, Sha Tin, HK, 2NCCS - National Cancer Centre Singapore,
Singapore, SG, 3Clinica Universidad de Navarra, Pamplona, ES, 4IRCCS Ospedale San
Raffaele, Milan, IT

Title: Illumina - Detection of homologous recombination Auditorium -
deficiency (HRD): Role of HRD testing and impact on patient Hall 10
management
Chair(s): Frederique Penault-Llorca, FR
18:30 - 18:35 Introduction & Welcome

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR
18:35 - 18:55 The clinical value of HRD testing in ovarian cancer

IT
18:55 - 19:15 The value of biomarker testing for homologous recombination deficiency in
prostate cancer
D. Olmos, Hospital Universitario 12 de Octubre, Madrid, ES
19:15 - 19:35 The role of HRD and related tests in cancer care
19:35 - 19:55 The utility of HRD testing – current status and future trends
F. Barve1, F. Penault-Llorca2, D. Lorusso3, D. Olmos4, 1CRUK - Cancer Research UK

Cambridge Institute - University of Cambridge, Cambridge, GB, 2Jean Perrin Center,
Clermont-Ferrand, FR, 3Fondazione Policlinico Universitario Agostino Gemelli - IRCCS
Rome, Rome, IT, 4Hospital Universitario 12 de Octubre, Madrid, ES


Title: PeerVoice - The Science and the Art of Modern Prostate Auditorium
Cancer Care: Improving Patient Outcomes Through Intensification - Hall 9
and Individualisation of Treatment
Chair(s): Karim Fizazi, FR

18:33 - 19:03 State of the Science, State of the Art: Are We Implementing Individualised and
Evidence-Based Treatment Plans for mHSPC?
C. Gratzke1, A. Morgans2, K. Fizazi3, 1University Medical Center Freiburg, Freiburg im

Breisgau, DE, 2Dana Farber Cancer Institute, Boston, US, 3Institut Gustave Roussy,
Villejuif, Cedex, FR
19:03 - 19:15 Audience Q&A: What’s on Your Mind in mHSPC?
K. Fizazi1, A. Morgans2, C. Gratzke3, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Dana
Farber Cancer Institute, Boston, US, 3University Medical Center Freiburg, Freiburg im
Breisgau, DE
19:15 - 19:45 Mastering the Science and the Art: Are We Taking Advantage of Opportunities to
Optimise Care and Outcomes in nmCRPC?
K. Fizazi1, A. Morgans2, C. Gratzke3, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Dana
Farber Cancer Institute, Boston, US, 3University Medical Center Freiburg, Freiburg im
Breisgau, DE
19:45 - 19:57 Audience Q&A: Sharing Challenges and Solutions in nmCRPC
A. Morgans1, K. Fizazi2, C. Gratzke3, 1Dana Farber Cancer Institute, Boston, US, 2Institut
Gustave Roussy, Villejuif, Cedex, FR, 3University Medical Center Freiburg, Freiburg im
Breisgau, DE
19:57 - 20:00 Final Remarks and Closing


Title: Takeda - Navigating Treatment Choices In ALK+ mNSCLC: Auditorium -
A Focus on Patient-Centered Decision Making Hall 3
Chair(s): Stephen Liu, US
18:30 - 18:35 Chair Introduction

18:35 - 18:55 Optimizing Molecular Testing and Diagnosis of NSCLC

R. Califano, The Christie NHS Foundation Trust, Manchester, GB
18:55 - 19:15 Quality of Life and Impact on Individuals Living With ALK+ mNSCLC
L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
19:15 - 19:35 Current and Emerging Treatment Landscape in ALK+ mNSCLC

19:35 - 19:45 Panel Q&A
S. Liu1, R. Califano2, L. Mezquita3, 1Lombardi Cancer Center Georgetown University,

Washington, US, 2The Christie NHS Foundation Trust, Manchester, GB, 3Hospital Clinic y
Provincial de Barcelona, Barcelona, ES
19:45 - 20:00 A Conversation With an Individual Living With Lung Cancer: Perspectives on
Testing and Quality of Life
S. Liu1, Y. Diaz2, 1Lombardi Cancer Center Georgetown University, Washington, US,

2ALK+ International, London, GB

18:30 - 20:00 Type: ESMO Colloquium Oviedo
Title: ESMO Colloquium supported by Eli Lilly and Company: Auditorium
Integrating molecular oncology in the care of patients with rare - Hall 7
oncogene-driven non-small cell lung cancer
Chair(s): Noemi Reguart Aransay, ES; Jürgen Wolf, DE

18:40 - 19:00 The importance of next-generation sequencing (NGS) testing in non-small cell
lung cancer: Science, implementation and timing
A. Stenzinger, University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
19:00 - 19:20 The availability of molecular testing in Europe and its implications for state-of-
the-art care for patients with lung cancer
A. Bayle, Institut Gustave Roussy, Villejuif, Cedex, FR
19:20 - 19:40 Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for
efficacy and ongoing research


18:30 - 20:00 Type: Industry Satellite Symposium León Auditorium -
Title: Daiichi Sankyo - The Multi-Tumor Toolkit: ADCs in Hall 7
Cancer Therapy
Chair(s): Benjamin Levy, US
18:30 - 18:40 ADC technology in cancer therapy

B. Levy, Johns Hopkins University, Baltimore, US
18:40 - 19:05 The role of ADCs in the lung treatment landscape

M. Thomas, Thoraxklinik Heidelberg gGmbH, Heidelberg, DE
19:05 - 19:25 The impact of ADCs on the breast cancer treatment landscape
C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES
19:25 - 19:40 The current state and future potential of ADCs in other tumor types
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP
19:40 - 20:00 Multi-tumor panel roundtable discussion and Q&A
B. Levy1, M. Thomas2, C. Saura Manich3, K. Shitara4, 1Johns Hopkins University,

Baltimore, US, 2Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, 3Vall d'Hebron
University Hospital, Barcelona, ES, 4National Cancer Center Hospital East, Kashiwa, JP

23.10.2023
tumours, lower digestive
Chair(s): Clara Montagut Viladot, ES; Dominik Modest, DE
08:30 - 08:40 552O - FOxTROT: results of embedded phase II evaluating the addition of
panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt
colon cancer (CC) with extended biomarker panel
J. Seligmann1, D. Morton2, M. Seymour3, F. Elliott3, K. Handley4, B. Glimelius5, C.

Williams3, G. Hemmings6, D. Bottomley7, R. Gray8, P. Quirke3, L. Magill4, A. Beggs2, N.
West9, 1University of Leeds, leeds, GB, 2The University of Birmingham - Medical School,
leeds, GB, 3UL - University of Leeds, leeds, GB, 4The University of Birmingham - Institute
for Cancer Studies, leeds, GB, 5Akademiska Sjukhuset Uppsala, leeds, GB, 6University of
Leeds - Institute of Cancer and Pathology (LICAP), Leeds, GB, 7UL - University of Leeds,
Leeds, GB, 8University of Oxford, leeds, GB, 9St. James's University Hospital - Leeds
Teaching Hospitals NHS Trust, leeds, GB
08:40 - 08:50 LBA27 - First-line systemic treatment in patients with initially unresectable
colorectal cancer liver metastases (CRLM): overall survival of the phase III
CAIRO5 study of the Dutch Colorectal Cancer Group
C. Punt1, M. Bond1, K. Bolhuis2, O. Loosveld3, J.W. De Groot4, H. Droogendijk5, H.

Helgason6, M. Hendriks7, J. Klaase8, G. Kazemier9, M. Liem10, A. Rijken3, C. Verhoef11, J.
De Wilt12, K. De Jong8, M. Van Amerongen13, B. De Valk14, E. Kerver15, A. Komurcu16,
R.-J. Swijnenburg9, 1University Medical Center Utrecht, Utrecht, NL, 2The Netherlands
Cancer Institute, Amsterdam, NL, 3Amphia Ziekenhuis, Breda, NL, 4Isala, Zwolle, NL,
5Bravis Ziekenhuis, Roosendaal, NL, 6Haaglanden Medisch Centrum, Den Haag, NL,
7Noordwest Ziekenhuisgroep, Alkmaar, NL, 8University Medical Center Groningen,
Groningen, NL, 9Amsterdam UMC, Amsterdam, NL, 10Medisch Spectrum Twente,

Enschede, NL, 11Erasmus MC, Rotterdam, NL, 12Radboud University Medical Center,
Nijmegen, NL, 13Sint Maartenskliniek, Woerden, NL, 14Spaarne Gasthuis, Hoofddorp,
NL, 15OLVG Hospital, Amsterdam, NL, 16IKNL - Netherlands Comprehensive Cancer
Organisation, Utrecht, NL

09:00 - 09:10 Q&A
09:10 - 09:20 LBA28 - The PEGASUS trial: post-surgical liquid biopsy-guided treatment of
stage III and high-risk stage II colon cancer patients
S. Lonardi1, F. Pietrantonio2, N. Tarazona Llavero3, C. Montagut Viladot4, A. Sartore

Bianchi5, M.G. Zampino6, M.E. Elez Fernandez7, C. Santos Vivas8, M. Mandalà9, S.
Tamberi10, M.S. Sciallero11, S. Muñoz12, L. Lazzari13, P. Luraghi13, V. Torri14, A.
Cervantes3, A. Bardelli13, J. Tabernero7, S. Siena5, S. Marsoni13, 1IOV - Istituto
Oncologico Veneto IRCCS, Padova, IT, 2Fondazione IRCCS - Istituto Nazionale dei
Tumori, Milan, IT, 3INCLIVA Biomedical Research Institute, University of Valencia,

Valencia, ES, 4Hospital del Mar - Parc de Salut Mar, Barcelona, ES, 5Università degli
Studi di Milano "La Statale", ASST Grande Ospedale Metropolitano Niguarda, Milan, IT,
6IEO - Istituto Europeo di Oncologia, Milan, IT, 7Vall d'Hebron University Hospital,
Barcelona, ES, 8ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals),
L'Hospitalet de Llobregat, ES, 9University of Perugia, Santa Maria della Misericordia,
University Hospital of Perugia, Perugia, IT, 10Ospedale degli Infermi - AUSL Romagna,
Faenza, IT, 11IRCCS Ospedale Policlinico San Martino, Genova, IT, 12Vall d'Hebron
Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, 13IFOM - the AIRC Institute of
Molecular Oncology, Milan, IT, 14Istituto Di Ricerche Farmacologiche Mario Negri -
IRCCS, Milan, IT
09:20 - 09:30 LBA29 - Aspirin After Standard Adjuvant Therapy for Colorectal Cancers
(ASCOLT) - An International, Phase III, Randomised, Placebo-controlled Trial
J. Chia1, E. Segelov2, Y. Deng3, W. Wang4, G.F. Ho5, A. Sharma6, K. Ding7, G. Chen8, G.M.
Jeffery9, L. Nott10, R. Zielinski11, J.B. Ahn12, T.-Y. Chao 13, T. Yau14, S. Nabilah15, M.
Gandhi15, P. Rothwell16, J. Simes17, R. Ali18, H.C. Toh19, 1CURIE Oncology, Singapore,
SG, 2University of Bern, Bern, CH, 3The Sixth Affiliated Hospital, Sun Yat-sen University,
Guangzhou, CN, 4Foshan First People's Hospital, Foshan, CN, 5Pusat Perubatan
Universiti Malaya (PPUM), Kuala Lumpur, MY, 6AIIMS - All India Institute of Medical
Sciences, New Delhi, IN, 7The Second Affiliated Hospital of Zhejiang University School of
Medicine - East Gate 1, Hangzhou, CN, 8Sun Yat-sen University Cancer Center,
Guangzhou, CN, 9Christchurch Hospital, Christchurch, NZ, 10Department of Health -
Australia, Canberra, AU, 11Orange Health Service, Orange, AU, 12Yonsei University,
Seoul, KR, 13Shuang Ho hospital, New Taipei City, CN, 14The University of Hong Kong -
Queen Mary Hospital, Hong Kong, HK, 15CRIS - Consortium for Clinical Research and
Innovation Singapore, Singapore, SG, 16Wolfson Institute of Preventive Medicine - Barts
and The London School of Medicine, London, GB, 17University of Sydney, Sydney, AU,
18Cambridge Clinical Trials Unit - Cambridge University Hospitals NHS Foundation
Trust, Cambridge, GB, 19NCCS - National Cancer Centre Singapore, Singapore, SG
09:30 - 09:40 553O - Prognostic value of KRAS and BRAF mutations in microsatellite stable
(MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled
analysis of 7 trials.
J. Taieb1, L. Pederson2, F. Sinicrope3, S. Lonardi4, S. Alberts2, T. George5, L. Saltz6, G.

Yothers7, R. Goldberg8, R. Kerr9, T. Yoshino10, E. Van Cutsem11, S. Ogino12, T. André13, P.
Laurent-Puig14, Q. Shi3, 1Hopital European George Pompidou, Paris, FR, 2Mayo Clinic -
Rochester, Rochester, US, 3Mayo Clinic, Rochester, US, 4IOV - Istituto Oncologico Veneto
IRCCS, Padova, IT, 5UF - University of Florida Health, Gainesville, US, 6Memorial Sloan
Kettering Cancer Center, New York, US, 7University of Pittsburgh, Pittsburgh, US, 8West
Virginia University, Morgantown, US, 9Churchill Hospital, Oxford, GB, 10National Cancer
Center Hospital East, Kashiwa, JP, 11UZ Leuven - University Hospitals Leuven - Campus
Gasthuisberg, Leuven, BE, 12Harvard Medical School, Boston, US, 13Hopital Saint-
Antoine, Paris, FR, 14Université Paris Cité, Paris, FR

09:50 - 10:00 Q&A

08:30 - 10:00 Type: Multidisciplinary session Sevilla Auditorium - Hall
Title: Management of oligometastatic disease in 9
NSCLC
Chair(s): Anne-Marie Dingemans, NL
08:30 - 08:45 Introduction and definition of oligometastatic disease(s) + Case presentation

A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL
08:45 - 09:05 The role of systemic therapy in patients with or without molecular alterations
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG
09:05 - 09:25 The role of surgery

G. Veronesi, IRCCS Ospedale San Raffaele, Milan, IT
09:25 - 09:45 The role of radiation therapy

C. Le Pechoux, Institut Gustave Roussy, Villejuif, Cedex, FR
08:30 - 10:00 Type: Educational session Bilbao Auditorium

Title: How to navigate the different treatment options for - NCC
hepatobiliary cancers
Chair(s): Angela Lamarca, ES; Jeroen Dekervel, BE
08:30 - 08:50 Immunotherapy for liver cancer

A. Vogel, University Health Network - Toronto General Hospital Research Institute
(TGHRI), Toronto, CA
08:50 - 09:10 Immunotherapy for biliary cancer

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES
09:10 - 09:30 Personalised medicine and targeted agents for biliary tract cancer
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
09:30 - 09:50 Personalised treatment for HCC: Where are we now?


08:30 - 10:00 Type: Special symposium Granada Auditorium - Hall 3
Title: Molecular targets and related treatments
Chair(s): Himisha Beltran, US; Daniel Heinrich, NO
08:30 - 08:45 How to interpret a genomic testing report

H. Beltran, Dana Farber Cancer Institute, Boston, US
08:45 - 09:00 PSMA targeting

D. Heinrich, Sykehuset Innlandet HF, Brumunddal, NO
09:00 - 09:15 PARP inhibition

09:15 - 09:30 Third generation AR targeting

A. Bernard-Tessier, Institut Gustave Roussy, Villejuif, Cedex, FR
09:30 - 09:45 Checkpoint inhibitors and Pi3K inhibitors

N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL
08:30 - 09:55 Type: Proffered Paper session Burgos Auditorium - Hall

Title: Proffered Paper session - Head and neck 3
cancer
Chair(s): Paolo Bossi, IT; Silke Tribius, DE
08:30 - 08:40 853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC)
patients with 1-3 oligometastases using stereotactic ablative radiotherapy
(SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial
J. Thariat1, M. Bosset2, A. Falcoz3, D. Vernerey4, Y. Pointreau5, S. Racadot6, J.C. Faivre7,

J. Castelli8, S. Guihard9, F. Huguet10, S. Chapet11, Y. Tao12, J. Bourhis13, X.S. Sun14,
1Centre Francois Baclesse, caen, FR, 2Marie Curie Radiotherapy Center, valence, FR,
3CHRU Besancon - Hopital Jean Minjoz, besancon, FR, 4MSD, besancon, FR, 5Jean
Bernard Center, Le Mans, FR, 6Centre Léon Bérard, Lyon, FR, 7Institut de Cancérologie
de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 8Centre Eugene - Marquis,
Rennes, FR, 9Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR,
10Hopital Tenon AP-HP, Paris, Cedex, FR, 11CHRU Bretonneau, Tours, FR, 12Institut
Gustave Roussy, Villejuif, Cedex, FR, 13CHUV - Centre Hospitalier Universitaire Vaudois,
Lausanne, CH, 14Hôpital Nord Franche-Comté - HNFC, Belfort, FR
08:40 - 08:45 857O - MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR
monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA)

squamous cell carcinomas of head and neck (SCCHN)
P. Blanchard1, M. Cheugoua-Zanetsie2, I. Deneche2, D. Rosenthal3, M. Gillison4, J.

Eriksen5, K. Prabhash6, J. Giralt7, J.A. Bonner8, M.G. Ghi9, H. Mehanna10, L. Siu11, M.
Gebre Medhin12, D. Rischin13, A. Dietz14, R. Mesia Nin15, Y. Pointreau16, T. Crombet17,
A. Auperin18, 1Institut Gustave Roussy, Villejuif, FR, 2Gustave Roussy, Villejuif, FR, 3The
University of Texas MD Anderson Cancer Center, Houston, US, 4University of Texas MD
Anderson Cancer Center, Houston, US, 5Aarhus University Hospital, Aarhus, DK, 6Tata
Memorial Hospital - Tata Memorial Centre, Mumbai, IN, 7Vall d'Hebron University
Hospital, Barcelona, ES, 8University of Alabama at Birmingham Hospital, Birmingham,
US, 9IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 10The University of Birmingham
- Institute for Cancer Studies, Birmingham, GB, 11Princess Margaret Cancer Centre,
Toronto, CA, 12Lund University, Lund, SE, 13Peter MacCallum Cancer Centre,
Melbourne, AU, 14Universitätsklinikum Leipzig, Leipzig, DE, 15ICO - Institut Català
d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, 16Centre Jean
Bernard, Le Mans, FR, 17Center of Molecular Immunology, Havana, CU, 18Gustave
Roussy - Cancer Campus, Villejuif, FR

S. Tribius, Asklepios Klinik St. Georg, Hamburg, DE
08:55 - 09:05 Q&A
09:05 - 09:10 858O - Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic
circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced
(LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease
relapse and survival.
N. Honoré1, C. Van Marcke De Lummen2, R. Galot2, R. Helaers3, A. Van Maanen4, J.

Ambroise5, A. Mendola1, H. Dahou1, E. Marbaix2, P. Van Eeckhout2, E. Longton2, M.
Magremanne2, S. Schmitz2, N. Limaye3, J.-P. Machiels2, 1UCLouvain -IREC/MIRO,
Woluwe-Saint-Lambert, BE, 2Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc),
Woluwe-Saint-Lambert, BE, 3De Duve Institute UCLouvain, Woluwe-Saint-Lambert, BE,
4Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE, 5UCLouvain -
Université Catholique de Louvain, Woluwe-Saint-Lambert, BE

J.P. Klussmann, Universitätsklinikum Köln (AöR), Köln, DE
09:25 - 09:30 Q&A
09:30 - 09:40 854O - INTERLINK-1: Phase 3 study of cetuximab (CTX) ± monalizumab (M) in
participants (pts) with recurrent/metastatic head and neck squamous cell
carcinoma (R/M HNSCC) with disease progression on/after platinum
chemotherapy (CT) and previously treated with an immune checkpoint inhibitor
(ICI)
J. Fayette1, L. Licitra2, K. Harrington3, R. Haddad4, L. Siu5, Y.C. Liu6, M. Tahara7, J.-P.

Machiels8, D. Rischin9, T. Seiwert10, R. Ferris11, U. Keilholz12, A. Psyrri13, B. Keam14, P.
Bossi15, R. Metcalf16, O. Serrano17, P. Kaur18, D. Ruscica19, R. Cohen20, 1Lyon-I
University, Lyon, FR, 2Milan and University of Milan, Milan, IT, 3The Royal Marsden/The
Institute of Cancer Research NIHR Biomedical Research Centre, London, GB, 4Dana-
Farber Cancer Institute, Boston, US, 5Princess Margaret Cancer Centre, Toronto, CA,
6Taichung Veterans General Hospital, Taichung City, TW, 7Hospital East, Kashiwa, JP,
8Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institute for Experimental
and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain, Brussels,
BE, 9Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, AU,
10Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore,
US, 11University of Pittsburgh Cancer Institute, Pittsburgh, US, 12Charité

Comprehensive Cancer Center, Berlin, DE, 13Attikon University Hospital, National
Kapodistrian University of Athens, Athens, GR, 14Seoul National University Hospital,
Seoul, KR, 15Radiological Sciences and Public Health, University of Brescia, Brescia, IT,
16The Christie NHS Foundation Trust, Manchester, GB, 17AstraZeneca & Cytel Inc, Paris,
FR, 18Formerly AstraZeneca, Cambridge, GB, 19AstraZeneca, Cambridge, GB,

20University of Pennsylvania School of Medicine, Philadelphia, US
09:40 - 09:50 Invited Discussant 854MO

C. Le Tourneau, Institut Curie, Paris, FR
09:50 - 09:55 Q&A
08:30 - 10:00 Type: Proffered Paper session Valencia Auditorium -

Title: Proffered Paper session - Melanoma and other Hall 10
skin tumours
Chair(s): Teresa Amaral, DE; Enrique Espinosa, ES
08:30 - 08:40 LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant

versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma
from SWOG S1801
S. Patel1, M. Othus2, P. Wright3, J. Hyngstrom4, C. Lao5, T.-G. Truong6, S. Chandra7, K.

Kendra8, C. Devoe9, A. Hegde10, A. Mangla11, M. Lowe12, E. Buchbinder13, J.
Kirkwood14, E. Sharon15, L. Korde15, J. Moon2, V. Sondak16, A. Ribas17, V. Prieto1, 1The
University of Texas MD Anderson Cancer Center, Houston, US, 2Fred Hutchinson Cancer
Research Center, Seattle, US, 3Spectrum Health, Grand Rapids, US, 4University of Utah
Health - Huntsman Cancer Institute, Salt Lake City, US, 5University of Michigan
Comprehensive Cancer Center, Ann Arbor, US, 6Kaiser Permanente Vallejo Medical
Center, Vallejo, US, 7Robert. H. Lurie Cancer Center of Northwestern University,
Chicago, US, 8OSUCCC - The Ohio State University Comprehensive Cancer Center -
James, Columbus, US, 9Northwell Health Cancer Institute, Lake Success, US, 10The
University of Alabama at Birmingham, Birmingham, US, 11Case Western Reserve
University / University Hospitals, Cleveland, US, 12Emory University, Atlanta, US, 13Dana
Farber Cancer Institute, Boston, US, 14UPMC Hillman Cancer Center, Pittsburgh, US,
15National Cancer Institute, Bethesda, US, 16H. Lee Moffitt Cancer Center & Research
Institute - Magnolia Campus, Tampa, US, 17Jonsson Comprehensive Cancer Center at

UCLA, Los Angeles, US
08:40 - 08:50
LBA49 - mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab
vs pembrolizumab in high-risk resected melanoma: clinical efficacy and
correlates of response
J. Weber1, A. Khattak2, M. Carlino3, R. Sullivan4, J. Luke5, T. Meniawy6, M. Taylor7, G.

Ansstas8, K. Kim9, M. Mckean10, M. Faries11, T. Tran12, C.L. Cowey13, A. Pecora14, T.
Medina15, V. Atkinson16, G. Gibney17, E. Buchbinder18, R. Meehan19, G. Long20, 1Laura
and Isaac Perlmutter Cancer Center, New York City, US, 2Hollywood Private Hospital &
Edith Cowan University, Perth, AU, 3Crown Princess Mary Cancer Centre Westmead,
Westmead, AU, 4MGH - Massachusetts General Hospital, Boston, US, 5University of
Pittsburgh Cancer Institute, Pittsburgh, US, 6Saint John of God Subiaco Hospital,
Subiaco, AU, 7Providence Cancer Institute, Southfield, US, 8Washington University
School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, 9California Pacific
Medical Center Research Institute, San Francisco, US, 10Sarah Cannon Research
Institute, Nashville, US, 11The Angeles Clinic and Research Institute, Los Angeles, US,
12Yale University School of Medicine - Yale Cancer Center, New Haven, US, 13Texas
Oncology - Baylor Sammons Cancer Center, Dallas, US, 14John Theurer Cancer Center -
Hackensack University Medical Center, Hackensack, US, 15University of Colorado
Cancer Center Anschutz Cancer Pavilion, Aurora, US, 16Princess Alexandra Hospital -
Metro South Health, Woolloongabba, AU, 17Georgetown Lombardi Comprehensive
Cancer Center, Washington DC, US, 18Dana Farber Cancer Institute, Boston, US,
19Moderna, Inc. - Global Headquarters, Cambridge, US, 20Melanoma Institute Australia,
Wollstonecraft, AU
08:50 - 09:00 1081O - ctDNA reduction and clinical efficacy of the darovasertib + crizotinib
(Daro + Crizo) combination in metastatic uveal melanoma (MUM)
M. Mckean1, B. Chmielowski2, M. Butler3, R. Carvajal4, J. Rodon5, M. Carlino6, K. Kim7,

T. Wise-Draper8, S. Khan9, A. Salama10, J. Moser11, J. Reeves12, K. Wilner13, M.
Maurer14, M. Abed14, B. Mitchell14, D. Beaupre15, M. Orloff16, 1Sarah Cannon Research
Institute, Nashville, US, 2Jonsson Comprehensive Cancer Center, University of California
Los Angeles, Los Angeles, US, 3UHN - University Health Network - Princess Margaret
Cancer Centre, Toronto, CA, 4Northwell Health Cancer Institute, Lake Success, US, 5The
University of Texas MD Anderson Cancer Center, Houston, US, 6Crown Princess Mary
Cancer Centre Westmead, Westmead, AU, 7California Pacific Medical Center Research
Institute, San Francisco, US, 8Vontz Center for Molecular Studies, Cincinnati, US,
9HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York,
US, 10Duke University, Durham, US, 11HonorHealth Research Institute, Scottsdale, US,
12Sarah Cannon Research Institute at Florida Cancer Specialists, Cape Coral, US,
13Pfizer Inc., San Diego, US, 14IDEAYA Biosciences, South San Francisco, US, 15Biosplice
Therapeutics, Inc., San Diego, US, 16Thomas Jefferson Univ Hospital, Philadelphia, US

09:10 - 09:20 Q&A
09:20 - 09:30 1082O - Concurrent Intrathecal (IT) and Intravenous (IV) nivolumab (N) for
melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

I. Glitza1, S. Phillips1, I. John1, R. Bassett2, R. Lin2, M. Rohlfs1, J. Richard1, M. Iqbal1, T.
Hennegan1, I. Mccutcheon3, S. Ferguson3, B. O'Brien3, S. Tummala3, N. Guha-Thakurta 1,
M. Debnam1, H. Tawbi1, E. Burton1, M. Davies1, 1The University of Texas M. D. Anderson
Cancer Center, Houston, US, 2MD Anderson Cancer Center, Houston, US, 3The
University of Texas MD Anderson Cancer Center, Houston, US
09:30 - 09:40 1085O - ATezolizumab, bevAcizumab, and Cobimetinib (TACo) in patients (pts)
with PD1 refractory melanoma brain metastases (MBM)
E. Burton1, V. Honaker2, D. Milton3, I. Glitza1, R. Amaria4, S. Patel2, A. Diab3, M. Wong3,

J. Mcquade1, C. Chung2, J. Wefel3, J. Li5, M. Davies3, H. Tawbi3, 1The University of Texas
M. D. Anderson Cancer Center, Houston, US, 2MD Anderson Cancer Center, Houston,
US, 3The University of Texas MD Anderson Cancer Center, Houston, US, 4The M.D.
Anderson Cancer Center, Houston, US, 5The University of Texas MD Anderson Cancer
Center - Main Building, Houston, US

R. Dummer, USZ - University Hospital Zürich, Zurich, CH
09:50 - 10:00 Q&A
08:30 - 10:00 Type: Educational session Santander Auditorium - Hall 9

Title: Diffuse large B-cell lymphoma
Chair(s): Hervé Tilly, FR; Laurie Sehn, CA
08:30 - 08:55 Molecular classification

P. Johnson, University of Southampton, Southampton, GB
08:55 - 09:20 First-line therapy

H. Tilly, Centre Henri Becquerel, Rouen, FR
09:20 - 09:45 Therapy at relapse

L. Sehn, UBC - The University of British Columbia, Vancouver, CA

08:30 - 10:00 Type: Special symposium León Auditorium - Hall 7
Title: Cancer-related central and peripheral
neuropathy
Chair(s): Maryam Lustberg, US; Jorn Herrstedt, DK

M. Lustberg, Yale University School of Medicine, New Heaven, US
08:35 - 08:50 Antineoplastic drug-induced central neuropathy
A. Argyriou, University Hospital Patras, Patras, GR
08:50 - 09:05 Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN)

S. Nielsen, Sjællands Universitets Hospital, Naestved, DK
09:05 - 09:20 Treatment of established CIPN

R. Geva, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL
09:20 - 09:35 Unmet needs

M. Lustberg, Yale University School of Medicine, New Heaven, US

J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjaelland, Roskilde, DK

Title: ESMO-WHO review of innovation in cancer therapeutics: Auditorium -
Does the pipeline meet the need? NCC
Chair(s): Rosa Giuliani, GB; André Ilbawi, CH

A. Ilbawi, WHO - World Health Organization, Geneva, CH
08:35 - 08:50 Evaluating innovative products in breast cancer: Characteristics, impact and
market share
R. Giuliani, The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB
08:50 - 09:05 Horizon scanning of emerging therapeutics in the next decade: What does the
future hold?
09:05 - 09:20 Innovation in the EU Cancer Mission: Delivering solutions?

C. Chomienne, Hopital Saint Louis AP-HP, Paris, FR
09:20 - 09:50 Panel Discussion

W. Tse Yared, Association of European Cancer Leagues, Brussels, BE
09:50 - 10:00 Q&A and closing remarks

Title: YO Forum: Preparing future-proof (young) NCC
oncologists
Chair(s): Maria Kfoury, FR; Rodrigo Sanchez Bayona, ES
08:30 - 08:50 How to put together a great CV and make a standout application
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR
08:50 - 09:10 How to write a successful research grant/protocol

R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB
09:10 - 09:30 The dos and don’ts of research project management

09:30 - 09:50 Empowerment and resilience: A toolbox to foster your well-being and personal
development
C. Hardy, Lancaster University Division of Health Research, Lancaster, GB

Title: EONS16: Person centred care in cancer
Chair(s): Paz Fernández Ortega, ES
08:30 - 08:30 Novice Research Dissemination Award

A. Kolstrøm, Home nursing care, Kristiansund, NO
08:30 - 08:40 CN28 - FROM DIFFICULTY TO MEANING. Palliative cancer patients experience
on advance care planning conversation and having a palliative plan.
A. Kolstrøm, Kristiansund Municipality/ NTNU, Kristiansund, NO
08:40 - 09:00 Person-centred care for older people with cancer

N. Farrington, Southampton General Hospital Southampton University Hospitals NHS
Trust, Southampton, GB
09:00 - 09:25 Survivorship through the eyes of a cancer nurse
V. Sulosaari1, J. De Munter2, 1Turku University of Applied Sciences, Turku, FI, 2UZ Gent -
Universitair Ziekenhuis Gent, Gent, BE
09:25 - 09:35 CN76 - Consensus views on research priorities for cancer survivorship in older
adulthood: A Delphi study
A. Drury1, A. O'Brien2, L. O'Connell3, S. Cosgrave4, M. Hannan5, C. Smyth6, K. Fessele7,

S. Sheehan1, M. Harkin8, L. Rogers2, 1DCU - Dublin City University, Dublin, IE,
2University College Dublin, Dublin, IE, 3Tallaght University Hospital, Dublin, IE, 4St.
Vincent's University Hospital, Dublin, IE, 5University Hospital Waterford, Waterford, IE,
6HSE - Health Service Executive, Dublin, IE, 7Memorial Sloan Kettering Cancer Center,
New York, US, 8Age and Opportunity, Dublin, IE
09:35 - 09:45 CN4 - Enabling Patient Empowerment Through Digital Symptom Monitoring
E. Haukland1, S.G. Aanes1, V. Kataja2, L. Lang2, 1Nordlandsykehuset HF, Bodoe, NO,

2Kaiku Health, Helsinki, FI

08:45 - 10:00 Type: Multidisciplinary session Málaga Auditorium -
Title: The positive sentinel lymph node: What does it Hall 10
mean for treatment?
Chair(s): Shani Paluch-Shimon, IL; Evandro de Azambuja, BE
08:45 - 08:50 Case presentation: 50-year-old woman HR+ HER2+ EBC with 1/2 positive
sentinel nodes
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL
08:50 - 09:10 A medical oncologist’s perspective

E. De Azambuja, Institute Jules Bordet, Brussels, BE
09:10 - 09:30 A surgeon’s perspective

P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk,
Antwerpen, BE
08:45 - 09:30 Type: Challenge your Expert Toledo Auditorium

Title: Antibody drug conjugates: Current data and future - Hall 3
role in drug development
Chair(s): Sarat Chandarlapaty, US

I. Braña, Vall d'Hebron University Hospital, Barcelona, ES

S. Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
08:45 - 09:30 Type: Challenge your Expert Oviedo Auditorium -

Title: Molecular evolution of brain metastases and Hall 7
therapeutic implications
Chair(s): Giuseppe Minniti, IT

S. Formenti, Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US

G. Minniti, Sapienza Università di Roma, Rome, IT

10:15 - 11:45 Type: Proffered Paper session Barcelona Auditorium - Hall
Title: Proffered Paper session 2 - NSCLC, 9
metastatic
Chair(s): Noemi Reguart Aransay, ES
10:15 - 10:25 One LBA TBC
10:25 - 10:35 One LBA TBC
10:35 - 10:45 One LBA TBC
10:45 - 10:55 Invited Discussant three LBAs TBC
10:55 - 11:05 Q&A
11:05 - 11:15 One LBA TBC
11:15 - 11:25 One LBA TBC
11:25 - 11:35 One LBA TBC
11:35 - 11:45 Invited Discussant three LBAs TBC

11:45 - 11:55 Q&A

10:15 - 11:45 Type: Special symposium Sevilla Auditorium -
Title: Novel targets, therapies and toxicities in Hall 9
genitourinary cancers
Chair(s): Yohann Loriot, FR; Debbie Robbrecht, NL

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL
10:20 - 10:35 Screening new agents in “window of opportunity” neoadjuvant trials
A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT
10:35 - 10:50 Antibody drug conjugates and FGFR-directed therapies: New toxicities
Y. Loriot, Institut Gustave Roussy, Villejuif, Cedex, FR
10:50 - 11:05 Prediction of toxicity in current systemic treatment of genitourinary cancers

S. Gusev, Dana Farber Cancer Institute, Boston, US
11:05 - 11:20 Advances in the molecular understanding of GU cancers: The next generation of
therapeutic targets
S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL

10:15 - 11:45 Type: Special symposium Granada
Title: Challenging the status quo of early phase clinical Auditorium - Hall 3
trial design: Project Optimus
Chair(s): Emiliano Calvo, ES; Mirat Shah, US

E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara
Campal, Madrid, ES
10:20 - 10:35 Project Optimus update

M. Ratain, University of Chicago Department of Medicine - Section of
10:35 - 10:50 Investigator perspective

E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara
Campal, Madrid, ES
10:50 - 11:00 Regulatory perspective: FDA
M. Shah, U.S. Food and Drug Administration, Silver Spring, US
11:00 - 11:10 Pharmaceutical industry perspective

S. Arora, AstraZeneca Pharmaceuticals LP, Gaithersburg, US
11:10 - 11:25 Patient advocacy perspective

J. Feldman, EGFR Resisters, Deerfield, US

M. Shah, U.S. Food and Drug Administration, Silver Spring, US
10:15 - 11:40 Type: Proffered Paper session Burgos Auditorium -

Title: Proffered Paper session - Investigational Hall 3
immunotherapy
Chair(s): Gary Middleton, GB; Alessandra Curioni-Fontecedro, CH
10:15 - 10:25 1016O - Autoimmunity against surfactant protein B drives immune checkpoint
inhibitor-related pneumonitis in patients with NSCLC
L. Flatz1, M. Frueh2, V. Walter3, A.-K. Jochum2, S. Diem4, E. Jaeger5, C. Antonio6, C.

Schürch3, C. Driessen4, M. Brutsche6, J. Walz7, H.-G. Rammensee3, B. Becher8, A.
Tufman9, N. Nunez10, M. Joerger4, L. Zender7, H. Läubli11, F. Berner4, N. Wyss2,
1Universitätsklinikum Tübingen, Tuebingen, DE, 2Cantonal Hospital, St. Gallen, CH,
3Universität Tübingen, Tübingen, DE, 4Kantonsspital St. Gallen, St. Gallen, CH, 5KHNW -
Krankenhaus Nordwest GmbH, Frankfurt am Main, DE, 6Cantonal Hospital, St.Gallen,

CH, 7University Clinic Tübingen, Tuebingen, DE, 8UZH - Universität Zürich, Zurich, CH,
9LMU Klinikum der Universität München, Munich, DE, 10Universidad Nacional de
Cordoba, Cordoba, AR, 11Universitatsspital Basel, Basel, CH

G. Middleton, Institute of Cancer and Genomic Sciences - University of Birmingham,
Birmingham, GB
10:35 - 10:45 Q&A
10:45 - 10:55 1017O - NTC-001: A phase I study to test safety and efficacy of BNT221, a non-
engineered neoantigen-specific T cell product, in patients with advanced or
metastatic melanoma
J. Borgers1, D. Lenkala2, B. Mccarthy2, V. Kohler2, S. Hymson2, K. Esaulova2, O. Finney2,

K. Balogh2, S. Klobuch1, C. Nijenhuis3, R. Gaynor2, M. Demario2, J. Haanen1, M. Van
Buuren2, 1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL, 2BioNTech US, Cambridge, US, 3Netherlands Cancer Institute,
Amsterdam, NL
10:55 - 11:05 1018O - Phase I Study of GCC CAR-T therapy IM96 in Patients With Advanced
Colorectal Cancer
C. Qi1, L. Chang1, J. Li1, J. Gong1, X. Wang1, Z. Wang1, X. Lu2, T. He2, Y. Ding2, F. Wu2, D.
Liu2, L. Shen1, 1Peking University Cancer Hospital and Institute, Beijing, CN, 2Beijing
Imunopharm Technology Co., Ltd., Beijing, CN
11:05 - 11:15 1019O - Clinical and translational data from the Phase 1 SURPASS trial of ADP-
A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab
in solid tumors
V. Moreno Garcia1, E. Calvo2, A. Asch3, M. Butler4, J. Zugazagoitia5, J. Charlson6, A.

Cervantes7, B. Van Tine8, D. Aggen9, J. Clarke10, M. Johnson11, M. Wileman12, A.
Liddle12, R. Naidoo12, F. Brophy13, M. Rosenberg13, D. Jolliffe14, D. Williams15, E.
Norry13, D. Hong16, 1START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES,
2Centro Integral Oncológico Clara Campal, Madrid, ES, 3Stephenson Cancer Center,
Oklahoma University Health Science Center, Oklahoma City, US, 4Department of

Immunology, University of Toronto, Toronto, CA, 5Hospital Universitario 12 de Octubre,
Madrid, ES, 6Medical College of Wisconsin, Milwaukee, US, 7University of Valencia,
Valencia, ES, 8Washington University School of Medicine, St. Louis, US, 9Memorial Sloan
Kettering Cancer Center, New York, US, 10Duke Cancer Center, Durham, US, 11Sarah
Cannon Research Institute, Nashville, US, 12Adaptimmune Ltd, Abingdon-on-Thames,
GB, 13Adaptimmune, Philadelphia, US, 14Adaptimmune, Abingdon, Oxfordshire, GB,
15Adaptimmune Therapeutics plc, Philadelphia, US, 16The University of Texas MD

Herlev, DK

11:30 - 11:40 Q&A
10:15 - 11:45 Type: Multidisciplinary session Salamanca

Title: What is the optimal therapeutic approach following Auditorium -
progression on front line PARP inhibitor maintenance therapy in Hall 3
ovarian cancer?
Chair(s): Antonio Gonzalez Martin, ES; Sven Mahner, DE

10:20 - 10:35 The role of surgery

S. Mahner, University Hospital, LMU Munich, München, DE
10:35 - 10:50 Systemic treatment options following progression on PARPi

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
10:50 - 11:05 Novel treatment options for PARPi resistant ovarian cancer
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB
11:05 - 11:20 Understanding and overcoming resistance to PARP inhibitors: What is the way
forward?
J. Jonkers, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL

10:15 - 11:45 Type: Special session León
Title: ESMO/ASCO Global Curriculum: Medical oncology Auditorium -
Training: Challenges and opportunities Hall 7
Chair(s): Tanja Cufer, SI; Kalijn Bol, NL

K. Bol, Radboud University Medical Center, Nijmegen, Nijmegen, NL
10:20 - 10:35 Development and update of the ESMO/ASCO Global Curriculum: Why and how
T. Cufer, University of Ljubljana - Faculty of Medicine, Ljubljana, SI
10:35 - 10:50 Using the ESMO/ASCO Global Curriculum and Log Book to improve educational
content: The perspective of the mentor
K. Bol, Radboud University Medical Center, Nijmegen, Nijmegen, NL
10:50 - 11:05 Optimizing learning in a fast-paced training environment: The perspective of the
trainee
M. Fontes E Sousa, Hospital CUF Tejo, Lisbon, PT
11:05 - 11:20 Integrating global standards in medical oncology training: The perspective of
the trainee
K. Sharma, AKUH - Aga Khan University Hospital - Nairobi, Nairobi, KE
11:20 - 11:35 The role of the Global Curriculum in the era of digital health and artificial
intelligence
R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR
11:35 - 11:45 Discussion and Q&A

10:15 - 11:45 Type: Special session Cádiz
Title: In collaboration with the IARC - Cancer prevention: What Auditorium -
every oncologist must know NCC
Chair(s): Jean-Yves Blay, FR; Elisabete Weiderpass, FR

J.-Y. Blay , Centre Léon Bérard, Lyon, FR
10:20 - 10:35 Presentation of the IARC-ESMO survey results on the educational needs of
medical oncologists on cancer
J.-Y. Blay , Centre Léon Bérard, Lyon, FR
10:35 - 10:50 The IARC World Cancer Report Updates Learning Platform – Supported by ESMO
E. Weiderpass, International Agency for Research on Cancer, Lyon, FR
10:50 - 11:05 The present and future of lung cancer screening: What does the scientific
evidence show?
J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL
11:05 - 11:20 IARC’s European Code Against Cancer: The EONS-ESMO campaign
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE
11:20 - 11:35 WHO’s cancer prevention policy resolutions, best buys, and framework
convention on tobacco control
A. Ilbawi, WHO - World Health Organization, Geneva, CH

10:15 - 11:45 Type: EONS session Alicante Auditorium -
Title: EONS16: Professional and educational issues in Hall 10
cancer nursing
Chair(s): Julio de la Torre-Montero, ES
10:15 - 10:30 Moral dilemmas of (cancer) nurses

W. Oldenmenger, Erasmus MC Cancer Institute, Rotterdam, NL
10:30 - 10:45 Evaluation of the ABC4Nurses education programme

A. Drury, DCU - Dublin City University, Dublin, IE
10:45 - 11:00 European College of Cancer Nursing: An evaluation of learning

W. Mcinally, Open University, Edinburgh, GB
11:00 - 11:15 Developing cancer nursing services in low- and middle-income countries
M. Fowler, Heartlands Hospital - University Hospitals Birmingham NHS Foundation
Trust, Birmingham, GB
11:15 - 11:25 CN5 - Shared decision making in rectal cancer surgery: the way to go?
E. Pape1, J. Dobbelaer1, D. Van De Putte2, K. Geboes3, A. Van Hecke4, I. Vlerick4, G. Van

Ramshorst1, Y. Van Nieuwenhove1, 1UZ Gent - University Hospital Ghent, Gent, BE, 2UZ
Gent - University Hospital Ghent, Ghent, BE, 3UZ Gent - Universitair Ziekenhuis Gent,
Gent, BE, 4Ghent University - University Centre for Nursing and Midwifery, Ghent, BE
11:25 - 11:35 CN77 - EONS Advocacy Toolkit: How to let your voice be heard as a cancer nurse
D. Protogiros1, M. Van Klinken2, G. Suchodolska3, T. Theologia4, G. Catania5, G.

Knötgen6, 1Ministry of Health, Athens, GR, 2Netherlands Cancer Institute/Antoni van
Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, 3Medical University of Gdańsk,
Gdansk, PL, 4Cyprus University of Technology - Nursing Science, Limassol, CY,
5University of Genova, Genova, IT, 6German Cancer Nursing Society, Munich, DE

10:30 - 11:15 Type: Challenge your Expert Valencia
Title: When and from where is tumour DNA sequencing needed Auditorium -
for patients with metastatic breast cancer (mBC)? Hall 10
Chair(s): Karen Gelmon, CA

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

K. Gelmon, BC Cancer Agency - Vancouver, Vancouver, CA
10:30 - 11:15 Type: Challenge your Expert Málaga Auditorium -

Title: Looking ahead in SCLC: From biology to clinical Hall 10
practice
Chair(s): Maurice Pérol, FR

T. Owonikoko, University of Pittsburgh, Pittsburgh, US

M. Pérol, Centre Léon Bérard, Lyon, FR

10:30 - 11:45 Type: Multidisciplinary session Santander Auditorium - Hall 9
Title: Rectal cancer with oligometastatic disease
Chair(s): Thomas Gruenberger, AT; Claudia Cardone, IT
10:30 - 10:35 Case/condition presentation

C. Cardone, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT
10:35 - 10:50 How to perform an accurate staging?

R. Beets-Tan, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL),
Amsterdam, NL
10:50 - 11:05 Options for the choice of the systemic therapy

G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE
11:05 - 11:20 Radiotherapy and timing

K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg,
Leuven, BE
11:20 - 11:35 Timing and modality of surgical intervention

T. Gruenberger, Wiener Gesundheitsverbund - Klinik Favoriten, Vienna, AT
10:30 - 11:15 Type: Challenge your Expert Toledo Auditorium - Hall 3

Title: Adrenocortical carcinoma
Chair(s): Cristina Ronchi, GB

A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

C. Ronchi, The University of Birmingham - Medical School, Birmingham, GB

10:30 - 11:15 Type: Challenge your Expert Oviedo
Title: When to stop systemic anticancer treatment in patients Auditorium - Hall
with advanced malignancy? 7
Chair(s): Gudrun Kreye, AT

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT
11:00 - 11:45 Type: Young Oncologists session Ávila Auditorium

Title: YO Brunch 3: Establishing successful global research - NCC
collaborations and network
Chair(s): Kevin Punie, BE
11:00 - 11:15 Establishing successful global research collaborations and networks

A. Awada, Institute Jules Bordet, Brussels, BE

K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
12:00 - 12:30 Type: Keynote lecture Barcelona

Title: Elucidating cancer biology, and transforming cancer Auditorium - Hall
care, through academic drug development 9
Chair(s): Lillian Siu, CA

L. Siu, Princess Margaret Cancer Centre, Toronto, CA
12:05 - 12:30 Elucidating cancer biology, and transforming cancer care, through academic
drug development
J. De Bono, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

Title: MSD - Treatment and management of IO +/- TKi in Auditorium - Hall
advanced and recurrent endometrial cancer 10
Chair(s): Silvia Mazzanti, IT
12:00 - 12:05 Introductions and Objectives

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT
12:05 - 12:25 Current landscape in the treatment and management of endometrial cancer
patients
V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US
12:25 - 12:50 Understanding the AE management of patients receiving the IO +/- TKI
treatments
12:50 - 13:15 Challenges in endometrial cancer patient education and preparation prior to
treatment
J. Serra López, Hospital de la Santa Creu i Sant Pau, Barcelona, ES
13:15 - 13:25 Q&A
S. Mazzanti1, V. Makker2, J. Serra López3, 1IEO - Istituto Europeo di Oncologia IRCCS,

Milan, IT, 2Memorial Sloan-Kettering Cancer Center, New York City, US, 3Hospital de la
Santa Creu i Sant Pau, Barcelona, ES


Title: Exact Sciences - Shifting the Paradigm in Cancer Auditorium -
Screening: Multi-cancer Early Detection (MCED) Testing Hall 3
Chair(s): Elizabeth O'Donnell, US; Tomasz Beer, US

E. O'Donnell, Dana Farber Cancer Institute, Boston, US
13:05 - 13:15 Meeting the Unmet Needs in Cancer Screening

C. Marinac, Dana Farber Cancer Institute, Boston, US
13:15 - 13:30 Advancements in Tumor Biology and Circulating Biomarkers: Application in

Early Cancer Detection
N. Papadopoulos, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer
Center, Baltimore, US
13:30 - 13:45 A Multi-Biomarker Approach to MCED Test Design: Optimizing Performance to

Help Enhance Future Clinical Impact
F. Diehl, Exact Sciences Corporation, Madison, US
13:45 - 14:00 Demonstrating the Potential Clinical Value of MCED Testing

T. Beer, Exact Sciences Corporation, Madison, US
14:00 - 14:10 The Future Paradigm of Cancer Screening

E. O'Donnell, Dana Farber Cancer Institute, Boston, US
14:10 - 14:30 Summary and Q&A

C. Marinac, Dana Farber Cancer Institute, Boston, US

Title: Mirati Therapeutics, Inc. - New horizons in the Auditorium - Hall
treatment of KRAS-driven NSCLC and GI cancers 10
Chair(s): Luis Paz-Ares, ES
13:00 - 13:05 Welcome & Introduction

13:05 - 13:30 Recent advances in targeting KRASG12C-mutated NSCLC

13:30 - 13:55 Targeting KRAS in GI cancers: where are we now?

A. Parikh, MGH - Massachusetts General Hospital, Boston, US
13:55 - 14:15 The key role of biomarker testing in precision medicine

K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB
14:15 - 14:30 Q&A
L. Paz-Ares1, A. Parikh2, K. Kerr3, 1Hospital Universitario 12 de Octubre, Madrid, ES,

2MGH - Massachusetts General Hospital, Boston, US, 3Aberdeen Royal Infirmary - NHS
Grampian, Aberdeen, GB

Title: Sanofi Regeneron - Considerations for Frontline Auditorium - Hall
Immunotherapy in NSCLC: A Case-Based Discussion 3
Chair(s): Martin Reck, DE

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE
13:05 - 13:30 Mono vs combination therapy: identifying if less is more in complex patient
cases
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE
13:30 - 13:55 Tailoring the approach: selecting the optimal immunotherapy combination
regimen
13:55 - 14:20 Navigating difficult-to-treat populations: additional considerations for using

immunotherapy
14:20 - 14:30 Group Discussion
M. Reck1, L. Hendriks2, D. Rodriguez Abreu3, 1Krankenhaus Grosshansdorf,

Grosshansdorf, DE, 2Maastricht University Medical Center (MUMC), Maastricht, NL,
3Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular,
Las Palmas de Gran Canaria, ES

Title: Bristol Myers Squibb - The Changing Paradigm of Auditorium -
Melanoma Treatment: A Clinical Update for 2023 Hall 10
Chair(s): Eva Muñoz Couselo, ES

E. Muñoz Couselo, Vall d'Hebron University Hospital, Barcelona, ES
13:05 - 13:25 Navigating the Adjuvant Setting: Who, When, and What?
13:25 - 13:45 Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma
S. Patel, MD Anderson Cancer Center, Houston, US
13:45 - 14:05 Panel Discussion: Factors Impacting Treatment Selection for Resectable
Melanoma
E. Muñoz Couselo1, S. Patel2, D. Schadendorf3, 1Vall d'Hebron University Hospital,

Barcelona, ES, 2MD Anderson Cancer Center, Houston, US, 3WTZ - Westdeutsches
Tumorzentrum Essen, Essen, DE
14:05 - 14:25 Evidence-Based Considerations for the First-Line Treatment of Metastatic

Melanoma


Title: Seagen - Case by Case: Strategic Sequencing Auditorium -
Considerations in 3L HER2+ Metastatic Breast Cancer (MBC) Hall 9
Chair(s): Cristina Saura Manich, ES

13:05 - 13:20 Embracing Change: Uncovering Challenges and Opportunities in the Changing
Treatment Landscape of HER2+ MBC
13:20 - 13:40 Decision-making in 3L Following T-DXd Progression (Case-based discussion)

J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US
13:40 - 14:00 Decision-making in 3L Progression With CNS Involvement (Case-based

discussion)
M. De Laurentiis, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT
14:00 - 14:15 Charting the Course: Navigating the Landscape From Real-world Evidence to
Future Studies
J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital
Tenon, Paris, FR
14:15 - 14:25 Q&A
C. Saura Manich1, J. O'Shaughnessy2, M. De Laurentiis3, J. Gligorov4, 1Vall d'Hebron

University Hospital, Barcelona, ES, 2Texas Oncology - Baylor Sammons Cancer Center,
Dallas, US, 3Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT,
4Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris,
FR


Title: Myriad Genetics - Accessing cutting-edge precision Auditorium - Hall
oncology through local testing 3
Chair(s): Carsten Denkert, DE; Pascal Pujol, FR
13:00 - 13:05 HRD round table

P. Pujol, Hopital Arnaud de Villeneuve, Montpellier, FR
13:05 - 13:25 Optimal HRD ovarian cancer treatment - Are genomic tests interchangeable?
C. Denkert1, B. You2, F. Marmé3, 1UKGM - Uniklinikum Giessen und Marburg - Standort

Marburg, Marburg, DE, 2Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, 3UMM -
Universitaetsklinikum Mannheim - Medizinische Fakultaet, Mannheim, DE
13:25 - 13:40 How to implement local LoE1A HRD testing: experience of a center of excellence
C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE
13:40 - 13:50 Live Q&A
P. Pujol1, C. Denkert2, B. You3, F. Marmé4, 1Hopital Arnaud de Villeneuve, Montpellier,

FR, 2UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE,
3Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, 4UMM - Universitaetsklinikum
Mannheim - Medizinische Fakultaet, Mannheim, DE
13:50 - 14:10 Real world prospective data support prognostic and predictive second-
generation breast cancer signature performance
M. Kiechle, E. Klein, Klinikum Rechts der Isar - Technische Universitaet Muenchen,
Munich, DE
14:10 - 14:20 Live Q&A
C. Denkert1, M. Kiechle2, E. Klein2, 1UKGM - Uniklinikum Giessen und Marburg -

Standort Marburg, Marburg, DE, 2Klinikum Rechts der Isar - Technische Universitaet
Muenchen, Munich, DE


Title: Novocure GmbH - The evolving role of TTFields Hall 7
therapy in solid tumors
Chair(s): Jalid Sehouli, DE; Joachim Aerts, NL
13:00 - 13:05 Welcome
J. Sehouli1, J. Aerts2, 1Charité - Universitaetsmedizin Berlin, Berlin, DE, 2Erasmus MC -

University Medical Center, Rotterdam, NL
13:05 - 13:20 Practice changing experience of TTFields therapy in Glioblastoma

S. Rieken, Universitätsmedizin Göttingen, Goettingen, DE
13:20 - 13:35 Evolving role of TTFields therapy in NSCLC

J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL
13:35 - 13:50 Bringing change with TTFields therapy in ovarian cancer

J. Sehouli, Charité - Universitaetsmedizin Berlin, Berlin, DE
13:50 - 14:30 Fireside chat
B. Monk1, J. Aerts2, J. Sehouli3, S. Rieken4, T. Macarulla5, 1The University of Arizona,

Tucson, US, 2Erasmus MC - University Medical Center, Rotterdam, NL, 3Charité -
Universitaetsmedizin Berlin, Berlin, DE, 4Universitätsmedizin Göttingen, Goettingen, DE,
5Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

13:00 - 14:30 Type: Industry Satellite Symposium León Auditorium
Title: Novartis - Navigating the evolving mCRPC landscape: - Hall 7
Your questions, their answers
Chair(s): Alicia Morgans, US
13:00 - 13:10 Welcome, introduction and educational objectives: Treatment landscape

evolution in mCRPC
13:10 - 13:29 Treatment of advanced prostate cancer: Frequently asked questions - How do I
choose the right treatment for my patient with mCRPC?
A. Morgans1, E. Castro2, B. Hadaschik3, I. Burger4, 1Dana Farber Cancer Institute,

Boston, US, 2Hospital Universitario 12 de Octubre, Madrid, ES, 3WTZ - Westdeutsches
Tumorzentrum Essen, Essen, DE, 4KSB - Kantonsspital Baden, Baden, CH
13:29 - 13:47 Is there a right sequence in advanced prostate cancer?

13:47 - 14:05 What is the right approach to interdisciplinary/MDT collaborations?

14:05 - 14:25 Patient case discussion



13:00 - 14:30 Type: Patient Advocacy session Cádiz Auditorium - NCC
Title: People at the centre of cancer care
Chair(s): Stefan Gijssels, BE
13:00 - 13:15 People at the centre

S. Gijssels, Patient Expert Center, Brussels, BE
13:15 - 13:30 Patient satisfaction during treatment and after care

J. Geissler, Leukemia Patient Advocates Foundation - LeukaNET e.V., Riemerling
(Hohenbrunn), DE
13:30 - 13:45 Personalised treatment: Reflections on CAR-T therapy
J. Clark, Lymphoma Coalition, Motovun, HR
13:45 - 14:00 A journalist's approach to advocacy for improved access to diagnosis and
treatment
I. Mantiñan Búa, ASARGA - La Asociación Sarcomas de Galicia, Carballo, ES
14:00 - 14:15 Advocating for cancer care in Armenia

H. Martirosyan, "HENARAN" charitable foundation, Yerevan, AM

Title: EONS16: EONS-EBMT collaborative session
Chair(s): Johan De Munter, BE
13:45 - 14:00 Developing a CAR-T service

A. Tooley, Southampton General Hospital, Southampton, GB
14:00 - 14:15 CAR-T therapy and impact to patient outcomes and experience of treatment
M. Hellberg-Naegele, Kantonsspital St. Gallen, St. Gallen, CH
14:15 - 14:25 CN7 - The Effect of Using Mobile Application on Supportive Care Needs, Distress
and Quality of Life in Hematopoietic Stem Cell Transplant Patients: Randomized
Controlled Study
D. Başcı1, S. Kav2, 1University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara

Oncology Training and Research Hospital, Ankara, TR, 2Baskent University Faculty of
Health Sciences, Ankara, TR
14:25 - 14:35 CN78 - Chimeric Antigen Receptor T cell (CAR T) Nursing Educational Pathway –
Reporting on Participant Feedback
A. O'Halloran1, S. Impey2, D. Byrne1, M. Gillespie1, K. Mc Tague2, 1St. James's Hospital,

Dublin, IE, 2Trinity College Dublin, Dublin, IE

14:45 - 16:15 Type: Special symposium Barcelona Auditorium -
Title: Controversies in early stage triple negative Hall 9
breast cancer
Chair(s): Valentina Guarneri, IT; Rebecca Dent, SG

V. Guarneri, University of Padua, Padova, IT
14:50 - 15:05 Optimal neo-adjuvant therapy in TNBC: Does one size fit all?
15:05 - 15:20 Individualisation of adjuvant therapy in TNBC: Who gets what?

15:20 - 15:35 What to do with stage 1 TNBC: Can we deescalate systemic therapy?
15:35 - 15:50 Role of biomarkers / ctDNA monitoring in therapy decisions

A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:45 - 15:55 Type: Mini Oral session Sevilla Auditorium

Title: Mini oral session 2 - Non-metastatic NSCLC and other - Hall 9
thoracic malignancies
Chair(s): Matthias Guckenberger, CH
14:45 - 14:50 LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3
CheckMate 816 study: 3-y results by tumor PD-L1 expression
M. Provencio Pulla1, P. Forde2, J. Spicer3, C. Wang4, S. Lu5, T. Mitsudomi6, M. Awad7, E.

Felip8, S. Broderick2, S.J. Swanson7, J. Brahmer2, K. Kerr9, G. Saylors10, F. Tanaka11, K.-
N. Chen12, M. Tran13, J.L. Cai13, J. Mahmood13, S. Meadows-Shropshire13, N. Girard14,
1Hospital Universitario Puerta de Hierro, Madrid, ES, 2The Bloomberg–Kimmel Institute
for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive
Cancer Center, Baltimore, US, 3McGill University Health Centre, Montreal, CA, 4Tianjin
Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN,
5Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University,
Shanghai, CN, 6Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP,

7Dana-Farber Cancer Institute, Boston, US, 8Vall d’Hebron University Hospital, Vall
d’Hebron Institute of Oncology, Barcelona, ES, 9Aberdeen Royal Infirmary, Aberdeen, GB,
10Charleston Oncology, Charleston, US, 11University of Occupational and Environmental

Health, Kitakyushu, JP, 12Peking University School of Oncology, Beijing Cancer Hospital,
Beijing, CN, 13Bristol Myers Squibb, Princeton, US, 14Institut Curie, Paris, FR
14:50 - 14:55 1264MO - IMpower010: exploratory analysis of disease-free survival (DFS) by

TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients
(pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive
care (BSC)
N. Altorki1, M. Reck2, H. Wakelee3, E. Felip4, E. Vallieres5, R. Liersch6, S. Oizumi7, H.

Tanaka8, S. Novello9, S. Mccune10, H. Li11, L. Molinero12, S. Müller12, E. Bennett12, B.
Gitlitz12, V. Mcnally13, M. Ballinger12, B. Nabet12, M. Srivastava12, C. Zhou14, 1NewYork-
Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, 2Lung Clinic
Grosshansdorf, Airway Research Center North, German Center of Lung Research,
Grosshansdorf, DE, 3Stanford University School of Medicine, Stanford Cancer Institute,
Stanford, US, 4Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology
(VHIO), Barcelona, ES, 5Swedish Cancer Institute, Seattle, US, 6Clemenshospital
Muenster, Muenster, DE, 7National Hospital Organization Hokkaido Cancer Center,
Hokkaido University Hospital, Sapporo, JP, 8Niigata Cancer Center Hospital, Niigata, JP,
9University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, IT, 10Northwest Georgia
Oncology Centers, Marietta, US, 11Hoffmann-La Roche Limited, Mississauga, CA,

12Genentech, Inc., South San Francisco, US, 13Roche Products Ltd, Welwyn Garden City,
GB, 14Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, CN
14:55 - 15:00 LBA58 - Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus

Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC
Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial
D. Yue1, W. Wang2, H. Liu3, Q. Chen4, C. Chen5, J. Zhang6, F. Bai7, C. Wang1, 1Tianjin

Medical University Cancer Institute and Hospital, Tianjin, CN, 2Hunan Cancer Hospital,
Hunan, CN, 3Liaoning Cancer Hospital and Institute, Shenyang, CN, 4Zhejiang Cancer
Hospital, Hangzhou, CN, 5Fujian Medical University Union Hospital, Fuzhou, CN,
6BeiGene USA, Inc., San Mateo, US, 7BeiGene (Shanghai) Co., Ltd., Shanghai, CN
15:00 - 15:05 LBA59 - Associations of ctDNA clearance and pathological response with
neoadjuvant treatment in patients with resectable NSCLC from the phase 3
AEGEAN trial
M. Reck1, D. Gale2, D. Harpole3, J. Taube4, T. Mitsudomi5, M. Hochmair6, T. Winder7, Z.

Zhu8, Z. Lai9, R. Stewart2, D. Hodgson2, G. Doherty2, J. Heymach10, 1Airway Research
Center North, German Center for Lung Research, Grosshansdorf, DE, 2AstraZeneca,
Cambridge, GB, 3Duke University Medical Center, Durham, US, 4Bloomberg–Kimmel
Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore,
US, 5Kindai University Faculty of Medicine, Osaka-Sayama, JP, 6 Karl Landsteiner
Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT,
7Landeskrankenhaus Feldkirch, Feldkirch, AT, 8AstraZeneca, Gaithersburg, US,
9AstraZeneca, Waltham, US, 10The University of Texas, M.D. Anderson Cancer Center,
Houston, US
15:05 - 15:20 Invited Discussant LBA57, 1264MO, LBA58 and LBA59
15:20 - 15:25 LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in

patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6
M. Garassino1, J. Mazieres2, M. Reck3, C. Chouaid4, H. Bischoff5, N. Reinmuth6, L. Cove-

Smith7, T. Mansy8, D. Cortinovis9, M.R. Migliorino10, A. Delmonte11, J. García Sanchez12,
L.E. Chara Velarde13, R. Bernabe Caro14, L. Paz-Ares15, P. Chander16, I. Diaz Perez16, K.
Foroutanpour16, C. Faivre-Finn17, 1University of Chicago, Chicago, US, 2Institut
Universitaire du Cancer de Toulouse, Toulouse, FR, 3Lung Clinic Grosshansdorf, Airway
Research Center North, German Center for Lung Research, Grosshansdorf, DE, 4Centre
Hospitalier Intercommunal de Créteil, Créteil, FR, 5Universitätsklinikum Heidelberg,
Heidelberg, DE, 6Asklepios Fachkliniken München-Gauting, and German Center for Lung
Research (DZL), Gauting, DE, 7The Christie NHS Foundation Trust and Manchester
University Hospitals Foundation Trust, Manchester, GB, 8James Cook University
Hospital, Middlesbrough, GB, 9Fondazione IRCCS San Gerardo dei Tintori, Monza, IT,
10San Camillo-Forlanini Hospital, Rome, IT, 11IRCCS Istituto Romagnolo per lo Studio dei
Tumori "Dino Amadori" (IRST), Meldola, IT, 12Hospital Arnau de Vilanova, Fundación
para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana
(FISABIO), Valencia, ES, 13Hospital Universitario de Guadalajara, Guadalajara, ES,
14Hospital Universitario Virgen del Rocio, Seville, ES, 15Universidad Complutense,
CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, ES, 16AstraZeneca,

Gaithersburg, US, 17The University of Manchester and The Christie NHS Foundation
Trust, Manchester, GB
15:25 - 15:30 1292MO - A phase II study of daily carboplatin plus irradiation followed by
durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or
elderly (≧75 years): NEJ039A
R. Ko1, A. Mouri2, A. Kisohara3, R. Morita4, T. Nakagawa5, T. Makiguchi6, K. Isobe7, N.

Ishikawa8, T. Kondo9, M. Akiyama10, A. Bessho11, R. Honda12, K. Yoshimura13, H.
Kagamu2, S. Kato14, K. Kobayashi2, K. Kaira2, 1Shizuoka Cancer Center, Shizuoka, JP,
2Saitama Medical University International Medical Center, Hidaka, JP, 3Kasukabe
medical center, Kasukabe,Saitama Prefecture, JP, 4Akita Kousei Medical Center, Akita, JP,
5Omagari Kosei Medical Center, Daisen, JP, 6Hirosaki University Graduate School of
Medicine, Hirosaki, JP, 7Toho university Medical Center Oomori Hospital, Tokyo, JP,
8Hiroshima Prefectural Hospital, Hiroshima, JP, 9Kanagawa Cancer Center, Yokohama, JP,
10Iwate Medical University, Shiwa-gun, JP, 11Japanese Red Cross Okayama Hospital,
Okayama, JP, 12Asahi Gereral Hospital, Asahi, JP, 13Hiroshima University Hospital,
Hiroshima, JP, 14International Medical Center, Saitama Medical University, Hidaka, JP
15:30 - 15:35 LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable Stage
III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART
study
A.R. Filippi1, M.R. García-Campelo2, J.-B. Paoli3, D. Kowalski4, C. Bennati5, P. Borghetti6,

D. Cortinovis7, A. Delmonte8, C. Genova9, S. Van Hulst10, R. Mroz11, S. Nawrocki12, I.
Toledano13, G. Tonini14, I. Diaz Perez15, N. Georgoulia15, K. Foroutanpour15, R.
Dziadziuszko16, 1Fondazione IRCCS Policlinico San Matteo and University of Pavia,
Pavia, IT, 2University Hospital A Coruña, A Coruña, ES, 3Hôpital Privé Clairval, Marseille,
FR, 4Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, 5S
Maria delle Croci Hospital, AUSL della Romagna, Ravenna, IT, 6ASST Spedali Civili and
University of Brescia, Brescia, IT, 7Fondazione IRCCS San Gerardo dei Tintori Monza,
Monza, IT, 8IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST),
Meldola, IT, 9IRCCS Ospedale Policlinico San Martino/University of Genoa, Genova, IT,

10University Hospital of Nîmes, Nîmes, FR, 11Medical University of Bialystok, Bialystok,
PL, 12University of Warmia and Mazury in Olsztyn, Olsztyn, PL, 13CCGM, Clinique
Clémentville, Montpellier, FR, 14Fondazione Policlinico Universitario Campus Bio-
Medico/Università Campus Bio-Medico di Roma, Rome, IT, 15AstraZeneca, Gaithersburg,
US, 16Medical University of Gdansk, Gdansk, PL
15:35 - 15:40 1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic
radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit
for chemotherapy – interim results from the TRADE-hypo trial
F. Bozorgmehr1, E. Buchmeier2, M. Hammer-Hellmig2, U. Nestle3, C. Meyer Zum

Bueschenfelde4, F. Weykamp5, J. Claßen6, P. Schuett7, T. Riedel8, T. Wehler9, S. Hey-
Koch9, T. Overbeck10, J. Alt11, H. Schmidberger12, R. Behnisch13, I. Chung1, M. Thomas1,
S. Rieken14, 1Heidelberg, Germany; Translational Lung Research Center Heidelberg
(TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE,
2Klinikum Köln-Merheim, Köln, DE, 3Kliniken Maria Hilf, Mönchengladbach, DE, 4St.
Vincentius Hospital Medizinische Klinik II, Karlsruhe, DE, 5University Hospital

Heidelberg, Heidelberg University, Heidelberg, DE, 6ViDia Karlsruhe
Diakonissenkrankenhaus, Karlsruhe, DE, 7Onkologische Schwerpunktpraxis, Gütersloh,
DE, 8Radioonkologische Praxis, Gütersloh, DE, 9Sana Klinikum Offenbach GmbH,
Offenbach am Main, DE, 10University Medical Center Göttingen, Göttingen University,
Goettingen, DE, 11University Medical Center of the Johannes Gutenberg-University
Mainz, Mainz, DE, 12Universitätsmedizin der Johannes Gutenberg-Universität Mainz,
Mainz, DE, 13Heidelberg University Hospital, Heidelberg, DE, 14Universitätsmedizin
Göttingen, Goettingen, DE
15:40 - 15:55 Invited Discussant LBA61, 1292MO, LBA62 and 1293MO

M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH

14:45 - 16:15 Type: Special symposium Bilbao Auditorium -
Title: Long term survivors in the era of immunotherapy of NCC
cancer
Chair(s): Teresa Amaral, DE; Michiel van der Heijden, NL
14:45 - 15:05 Long-term toxicity of immunotherapeutics

D. Mcdermott, Beth Israel Deaconess Medical Center, Boston, US
15:05 - 15:25 Quality of life in IO-treated long-term survivors

L. Van De Poll-Franse, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
15:25 - 15:45 Cognitive defects in long term IO

A. Rogiers, CHU Brugmann UVB, Brussels, BE
15:45 - 16:05 Ideal duration of IT: How to define it and what are the implications
14:45 - 16:15 Type: Special session Granada Auditorium - Hall 3

Title: Artificial Intelligence in prognostication
Chair(s): Sanjay Aneja, US; Anne Vincent-Salomon, FR
14:45 - 15:10 AI for breast cancer prognostication

A. Vincent-Salomon, Institut Curie, Paris, FR
15:10 - 15:35 Biomarkers of response to drugs and radiotherapy

B. Haibe-Kains, UHN - University Health Network - Princess Margaret Cancer Center,
Toronto, CA
15:35 - 16:00 Digital pathology for immuno-oncology

M. Salto-Tellez, Patrick G Johnston Centre for Cancer Research, Queen's University
Belfast, Belfast, GB

14:45 - 16:15 Type: Special session Valencia Auditorium - Hall
Title: How do we best monitor patients during 10
follow-up?
Chair(s): Marina Garassino, US; Paolo Bossi, IT

M. Garassino, University of Chicago Department of Medicine - Section of
14:50 - 15:05 Minimalist or maximalist? From literature to real-world data

P. Zola, Università di Torino, Torino, IT
15:05 - 15:20 Radiological imaging vs clinical examination: When less is more

R. Maroldi, Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT
15:20 - 15:35 Liquid biopsy may improve a tailored follow up

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US
15:35 - 15:50 The patient's perspective and expectations

A. Cardone, Cancer Patients Europe, Brussels, BE
15:50 - 16:05 It is not just survival: Rehabilitation, quality of life and late toxicities
F. Jansen, Amsterdam University Medical Centers UMC, Amsterdam, NL

14:45 - 16:15 Type: Educational session Salamanca Auditorium -
Title: Bringing together thyroid cancer and Hall 3
neuroendocrine tumours
Chair(s): Eric Baudin, FR; Emily Bergsland, US
14:45 - 15:05 State-of-the-art in the treatment of advanced neuroendocrine tumours

E. Bergsland, UCSF - University of California San Francisco - Parnassus Campus, San
Francisco, US
15:05 - 15:25 State-of-the-art in the treatment of advanced thyroid cancer

C. Spitzweg, LMU Klinikum der Universität München, Munich, DE
15:25 - 15:45 What we could learn from each tumour type to improve the management of both
E. Baudin, Gustave Roussy - Cancer Campus, Villejuif, FR
15:45 - 16:05 Future directions on targeted agents and beyond in thyroid and neuroendocrine
tumours

14:45 - 16:15 Type: Educational session Málaga Auditorium - Hall
Title: Genetic predisposition in patients with 10
sarcoma
Chair(s): Nadia Hindi, ES; Tom Wei-Wu Chen, TW
14:45 - 15:05 When and why to test a patient with sarcoma for hereditary predisposition
D. Thomas, Garvan Institute of Medical Research, Darlinghurst, AU
15:05 - 15:20 How to use radiology in patients with hereditary syndromes

C. Messiou, The Royal Marsden Hospital - Chelsea, London, GB
15:20 - 15:35 How to treat bone, soft tissue and GIST patients with a hereditary
predisposition: A surgeon’s perspective
S. Bonvalot, Institut Curie, Paris, FR
15:35 - 15:50 How to treat bone, soft tissue and GIST patients with a hereditary
predisposition: A medical oncologist’s perspective
W. Van Der Graaf, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
15:50 - 16:05 How to treat sarcoma patients with a hereditary predisposition: A radiation
oncologist’s perspective
B. Timmermann, University Hospital Essen - Westdeutsches Protonentherapiezentrum,
Essen, DE

15:00 - 16:00 Type: Controversy session Burgos
Title: Can we avoid preoperative (chemo)radio-therapy in Auditorium -
locally advanced rectal cancer patients? Hall 3
Chair(s): Andres Cervantes, ES

15:05 - 15:20 Yes

S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
15:20 - 15:35 No
D. Sebag-Montefiore, St. James's University Hospital - Leeds Teaching Hospitals NHS
Trust, Leeds, GB


15:00 - 16:15 Type: Multidisciplinary session Santander
Title: Management of (very) high-risk localised PCA: How hard Auditorium -
should you look and how long should we treat? Hall 9
Chair(s): Gwenaëlle Gravis, FR; Boris Hadaschik, DE

B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
15:05 - 15:15 Usefulness and limitations of PSMA imaging/PET in high-risk localised disease
K. Goffin, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
15:15 - 15:30 Dose intensification and field expansion of EBRT

A. Bossi, Gustave Roussy - Cancer Campus, Villejuif, FR
15:30 - 15:45 Delineating staging pelvic LND before RT and positioning primary prostatectomy
D. Tilki, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
15:45 - 16:00 How much systemic treatment is needed and how long?
G. Gravis, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

Title: Checkpoint inhibition and beyond: New approaches in Auditorium -
advanced gastric oesophageal cancer Hall 3
Chair(s): Tania Fleitas, ES

S.-E. Al-Batran, Nordwest-Krankenhaus, Frankfurt am Main, DE


15:00 - 15:45 Type: Challenge your Expert Oviedo Auditorium -
Title: Challenges in the management of Waldenström's Hall 7
macroglobulinemia
Chair(s): Meletios Dimopoulos, GR

A. Tedeschi, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT

M. Dimopoulos, Alexandra Hospital, Athens, GR
15:00 - 16:15 Type: Multidisciplinary session León Auditorium - Hall 7

Title: Challenging common problems in neuro-
oncology
Chair(s): Enrico Franceschi, IT; Emma van Kessel, NL
15:00 - 15:15 Presentation of case: Low-grade glioma

E. Van Kessel, UMC - University Medical Center Utrecht, Utrecht, NL
15:15 - 15:30 Upfront and salvage surgery for low grade gliomas: Do tumour mutations need
different strategies?
A. Jakola, University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE
15:30 - 15:45 Radiotherapy for low grade gliomas with and without mutations: Wait or treat?
H. Shih, MGH - Massachusetts General Hospital, Boston, US
15:45 - 16:00 The optimal radiochemotherapeutic combination for low grade gliomas: Lessons
from trials
E. Franceschi, Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT
15:00 - 15:45 Type: Challenge your Expert Cádiz

Title: Alcohol consumption and cancer risk: The sobering facts Auditorium -
about alcohol and cancer NCC
Chair(s): Gilberto Morgan, SE

I. Soerjomataram, IARC - International Agency for Research on Cancer, Lyon, FR

G. Morgan, Skane University Hospital, Lund, SE

Title: EONS16: YCN/YO collaborative session
Chair(s): Nikolina Dodlek, HR
15:00 - 15:15 Personalised cancer care: The physician's perspective

P. Aftimos, Institute Jules Bordet, Anderlecht, BE
15:15 - 15:30 Nursing in clinical trials

H. Mccallig, University Hospital Limerick, Limerick, IE
15:30 - 15:40 CN60 - Dynamics and processes in the perception of colorectal cancer patients
facing skin toxicity due to an EGFR-inhibitor
M. De Kegel1, K. Geboes2, S. De Meyer2, P. Vandecandelaere3, E. Pape4, 1Ghent

University - Campus Ufo, Gent, BE, 2UZ Gent - University Hospital Ghent, Gent, BE, 3AZ
Delta Campus Rumbeke, Roeselare, BE, 4UZ Gent - Universitair Ziekenhuis Gent, Gent,
BE
15:40 - 15:50 CN61 - Recognizing and managing immune checkpoint – related symptoms with
expert advice from dedicated oncology nurse
A. Muratovic, S. Sopaj, U. Janzic, University Clinic of Respiratory and Allergic Diseases
Golnik, Golnik, SI

16:00 - 17:00 Type: Young Oncologists session Pamplona Auditorium - Hall 9
Title: YO Clinical Case Discussion sessions
16:00 - 16:00 Table 1: Immunotherapy in patients with autoimmune disease
C. Robert1, A. Tecic Vuger2, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2University
Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR
16:00 - 16:00 Table 2: Integration of liquid biopsy in decision making in the management of
patients with colon cancer
A. De Stefano1, E. Mariamidze2, 1Istituto Nazionale Tumori IRCCS - Fondazione G.

Pascale, Napoli, IT, 2Todua Clinic, Tbilisi, GE
16:00 - 16:00 Table 3: HER2+ breast cancer with brain metastases
E. De Azambuja1, P. Mando2, 1Institute Jules Bordet, Brussels, BE, 2CEMIC - Centro de

Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR
16:00 - 16:00 Table 4: Molecular profiling for cancer of unknown primary
N. Cook1, K. Punie2, 1The Christie NHS Foundation Trust, Manchester, GB, 2UZ Leuven -
University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
16:00 - 16:00 Table 5: Rare sarcomas and the importance of centralised and multidisciplinary
care
K. Kozak1, P. Sobczuk2, 1Maria Sklodowska-Curie National Research Institute of

Oncology, Warsaw, PL, 2Maria Skłodowska-Curie National Research Institute of Oncology,
Warsaw, PL

Title: EONS16: EONS closing session
16:15 - 16:20 EONS Poster Awards
16:20 - 16:25 ECND 2023 winners
16:25 - 16:30 Closing remarks and Farewell
16:30 - 18:00 Type: Mini Oral session Bilbao Auditorium - NCC

Title: Mini oral session - Breast cancer, early stage
Chair(s): Ines Vaz Luis, FR; Carsten Denkert, DE; Ava Kwong, HK
16:30 - 16:35 238MO - Longterm residential and workplace exposure to air pollution and
breast cancer risk: a case-control study nested in the French E3N cohort from
1990 to 2011

B. Fervers1, M. Duboeuf1, A. Amadou1, T. Coudon1, L. Grassot1, E. Faure2, G. Severi2, F.
Mancini2, P. Salizzoni3, J. Gulliver4, D. Praud1, 1Centre Léon Bérard, Lyon, FR, 2Gustave
Roussy, Villejuif, FR, 3Ecole Centrale, Ecully, FR, 4University of Leicester, Leicester, GB
16:35 - 16:40 LBA22 - Connected device and therapeutic patient education to promote physical
activity among in women with localized breast cancer: results from the DISCO
randomized trial
B. Fervers1, B. Fournier1, T. Durand1, D. Perol1, C. Schiffler1, A. Maire1, L. Perrier1, M.

Préau2, T. Bachelot1, P.-E. Heudel1, C. Faure1, M. Heinemann1, S. Kingler1, D. Mouttet1,
L. Rossi1, P. Toussaint1, J. Grenier3, O. Tredan1, J.-Y. Blay 1, O. Pérol1, 1Centre Léon
Bérard, Lyon, FR, 2Université Lyon 2, Lyon, FR, 3Institut Ste Catherine, Avignon, FR
16:40 - 16:45 239MO - Impact of body mass index and its change on survival outcomes in
patients with early breast cancer: a pooled analysis of individual-level data from
BCIRG-001 and BCIRG-005 trials
H. Chen1, X. Qian2, Y. Tao3, D. Wang4, Y. Wang1, Y. Yu1, H. Yao1, 1Guangdong Provincial

Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen
Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, 2Henan Provincial People’s
Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan
University, Zhengzhou, CN, 3The Affiliated Hospital of Xuzhou Medical University,
Xuzhou, CN, 4State Key Laboratory of Oncology in South China, Collaborative Innovation
Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN
16:45 - 17:00 Invited Discussant 238MO, LBA22 and 239MO

I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR
17:00 - 17:05 240MO - Prognostic and predictive impact of estrogen/progesterone receptor

(ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial
in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
M. Goetz1, N. Turner2, H. Sasano3, C. Arteaga4, S. Chandarlapaty5, S. Loi6, J. Reis-Filho5,

H. Kreipe7, N. Harbeck8, P. Fasching9, C. Rubenstein10, S. Wijayawardana10, M.
Muñoz10, L. Litchfield10, S. Johnston2, 1Mayo Clinic, Rochester, US, 2Royal Marsden
NHS Foundation Trust & Institute of Cancer Research, London, GB, 3Tohoku University
Hospital, Sendai, JP, 4University of Texas Southwestern Medical Center, Dallas, US,
5Memorial Sloan Kettering Cancer Center, New York, US, 6Peter MacCallum Cancer
Centre, Melbourne, AU, 7Hannover Medical School, Hannover, DE, 8Ludwig Maximilians
University Hospital, Munich, DE, 9Universitätsklinikum Erlangen, Erlangen, DE, 10Eli
Lilly and Company, Indianapolis, US
17:05 - 17:10 LBA23 - Invasive disease–free survival (iDFS) across key subgroups from the
Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase
inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
A. Bardia1, G. Hortobagyi2, O. Lipatov3, N. Mcandrew4, A. Lacko5, J. Sohn6, L. Hart7, J.

Crown8, S.-A. Im9, N. Harbeck10, J. O'Shaughnessy11, B. Xu12, C. Barrios13, R.
Moroose14, V. Gonzalez15, R. Fresco16, F. Ghaznawi17, S. Waters18, A. Chakravartty19, D.
Slamon20, 1Massachusetts General Hospital Cancer Center, Harvard Medical School,
Boston, US, 2The University of Texas M. D. Anderson Cancer Center, Houston, US,
3Bashkirian Republican Oncology Center, Bashkortostan, RU, 4UCLA Santa Monica
Hematology / Oncology Regulatory-2, Santa Monica, US, 5Dolnoslaskie Centrum

Onkologii, Wrocław, PL, 6Yonsei Cancer Center, Seoul, KR, 7Florida Cancer Specialists,
Fort Myers, US, 8St Vincent's University Hospital, Dublin, IE, 9SNUH - Seoul National
University Hospital, Seoul, KR, 10LMU University Hospital, Munich, DE, 11Texas
Oncology-Baylor University Medical Center and The US Oncology Research Network,
Dallas, US, 12Chinese Academy of Medical Sciences and Peking Union Medical College -
National Cancer Center, Cancer Hospital, Beijing, CN, 13Latin American Cooperative
Oncology Group (LACOG), Porto Alegre, BR, 14Orlando Health Cancer Institute, Orlando,
US, 15TRIO - Translational Research in Oncology, Montevideo, UY, 16TRIO-Translational
Research in Oncology, Montevideo, UY, 17Novartis Pharmaceuticals Corporation, East
Hanover, US, 18Novartis Ireland Limited, Dublin, IE, 19Novartis Pharmaceuticals Corp.,
East Hanover, US, 20UCLA - David Geffen School of Medicine, Los Angeles, US
17:10 - 17:15 241MO - Patient characteristics and real-world outcomes in HER2 negative/ ER
zero and ER low patients treated as triple-negative breast cancer in Sweden
2008-2020
I. Fredriksson1, B. Acs1, J. Hartman1, D. Sönmez2, H. Lindman3, 1Karolinska Institutet &

Karolinska University Hospital, Comprehensive Cancer Center, Stockholm, SE, 2MSD -
Merck Sharp & Dohme (Sweden) AB, Stockholm, SE, 3University Hospital
Uppsala/Akademiska Sjukhuset, Uppsala, SE
17:15 - 17:20 242MO - Association of tumor-infiltrating lymphocytes (TILs) with Recurrence

Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative
(HER2-) early breast cancer (BC) - a translational analysis of four prospective
multicentric studies.
F. Miglietta1, M.V. Dieci2, T. Giarratano3, V. Torri4, M. Giuliano5, F. Zustovich6, M. Mion7,

C. Tondini8, E. Bria9, M. Franchi10, L. Merlini11, R. Giannatiempo12, D. Russo13, V.
Fotia8, P. Poletti8, E. Rota Caremoli8, G. Arpino14, G. De Salvo3, A. Zambelli15, V.
Guarneri2, 1IOV - Istituto Oncologico Veneto IRCCS; Unipd, Padova, IT, 2University of
Padua, Padova, IT, 3IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, 4Istituto Di
Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT, 5AOU "Federico II", Napoli, IT,
6Ospedale di Belluno, Belluno, IT, 7Camposampiero-Cittadella, AULSS6,,
Camposampiero, IT, 8ASST Papa Giovanni XXIII, Bergamo, IT, 9Medical Oncology,
Università Cattolica del Sacro Cuore, Rome, Italy, Rome, IT, 10FROM Fondazione per la
Ricerca Ospedale Maggiore, Bergamo, IT, 11UOSD Montecchio Maggiore, Vicenza, IT,
12Ospedale Evangelico Betania, Napoli, IT, 13University of Naples Federico II, Napoli, IT,
14Università degli Studi di Napoli Federico II - Dipartimento di Farmacia, Napoli, IT,
15Humanitas University, Milan, IT
17:20 - 17:25 LBA24 - Multiparametric prognostic score in early HR+/HER2- breast cancer:
impact of Recurrence Score, clinical-pathological factors, gene mutations and
histology
O. Gluz1, M. Christgen2, C. Zu Eulenburg3, U. Nitz3, S. Kummel4, M. Braun5, B. Aktas6,

K. Luedtke-Heckenkamp7, H. Forstbauer8, E.-M. Grischke9, C. Schumacher10, R.
Baehner11, R. Kates3, M. Graeser12, R. Würstlein13, H. Kreipe14, N. Harbeck15, 1Evang.
Krankenhaus "Bethesda" Klinik, Mönchengladbach, DE, 2MHH - Medizinische
Hochschule Hannover, Hannover, DE, 3Westdeutsche Studiengruppe GmbH,
Mönchengladbach, DE, 4Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE,
5Rotkreuzklinikum München - Frauenklinik, Munich, DE, 6Universitätsklinikum Leipzig -
Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, 7Franziskus-Hospital Harderberg

- Niels-Stensen-KlinikenGmbH, Georgsmarienhütte, DE, 8Praxisnetzwerk Onkologie,
Troisdorf, DE, 9Universitätsklinikum Tübingen, Tuebingen, DE, 10St. Elisabeth
Krankenhaus Köln-Hohenlind, Köln, DE, 11Exact Sciences Corporation, Redwood City,
US, 12Evang. Krankenhaus Johanniter Bethesda, Mönchengladbach, DE, 13LMU Klinikum
der Universität München, Munich, DE, 14Hannover Medical School, Hannover, DE,
15Ludwig Maximilians University - Grosshadern, Munich, DE
17:25 - 17:40 Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24
17:40 - 17:45 243MO - Omission of breast surgery after neoadjuvant systemic therapy for
invasive cancer: three-year preplanned primary-endpoint on a phase 2
multicentre prospective trial
H.M. Kuerer1, G. Rauch2, S. Krishnamurthy1, E. Diego3, W. Yang1, Y. Shen2, H. Lin4, A.

Lucci4, T. Moseley2, D. Ramirez5, J. Mouabbi2, J. Boughey6, S. Shaitelman1, R. White7, K.
Hunt2, M. Mitchell1, M. Teshome1, H. Johnson1, B. Smith1, V. Valero8, 1The University of
Texas MD Anderson Cancer Center, Houston, US, 2MD Anderson Cancer Center,
Houston, US, 3University of Pittsburgh Medical Center Hillman Cancer Cente,
Pittsburgh, US, 4The University of Texas M. D. Anderson Cancer Center, Houston, US,
5The University of Texas MD Anderson Cancer Center - Breast Medical Oncology,
Houston, US, 6Mayo Clinic, Rochester, US, 7Levine Cancer Institute-Concord - Carolinas
HealthCare System, Concord, US, 8The M.D. Anderson Cancer Center, Houston, US
17:45 - 17:50 244MO - A Phase II Trial Targeting Disseminated Dormant Tumor Cells with
Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent
Breast Cancer (“CLEVER”)
A. Demichele1, A. Clark1, L. Bayne1, K. Rohn1, I. Nivar1, P. Wileyto2, L. Berry3, S.

Deluca1, J. Savage1, I. Makhlin1, T.C. Pan2, J. Graves2, G. Belka2, J. Wang2, N. Shih1, D.
Berry3, A. Nayak1, M. Feldman4, L. Chodosh2, 1University of Pennsylvania, Philadelphia,
US, 2University Of Pennsylvania, Philadelphia, US, 3Berry Consultants, Austin, US,
4Indiana University, Indianapolis, US

A. Kwong, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong,
HK

Title: Adjuvant / neoadjuvant therapy of operable Hall 3
NSCLC in 2023
Chair(s): Heather Wakelee, US; Jarushka Naidoo, IE
16:30 - 16:55 Current standard of care in adjuvant / neoadjuvant therapy of operable NSCLC
H. Wakelee, Standford University, Stanford, US
16:55 - 17:20 Predictive biomarkers for adjuvant / neoadjuvant IO

N. Girard, Institut Curie, Paris, FR
17:20 - 17:45 Management of relapse on/after perioperative IO
M. Frueh, Kantonsspital St. Gallen, St. Gallen, CH
16:30 - 18:05 Type: Mini Oral session Cádiz Auditorium - NCC

Title: Mini oral session - Policy and preventive
strategies
Chair(s): James McKay, FR; Tit Albreht, SI; Wendy Tse Yared, BE
16:30 - 16:35 1692MO - Is Project Orbis successful? - The Swiss perspective

M. Pavic, Q. Li, E. Atiek, A. Wolfer, U.-P. Rohr, Swissmedic Swiss Agency for Therapeutic
Products, Bern, CH
16:35 - 16:40 1693MO - The high burden of long-term and late health-related problems among
adolescent and young adult cancer survivors: results of the SURVAYA study
S. Janssen1, C. Vlooswijk2, R. Van Leeuwen3, S. Kaal4, J. Kerst1, J. Tromp5, M. Bos6, T.

Van Der Hulle7, R.I. Lalisang8, J. Nuver9, M. Kouwenhoven5, W. Van Der Graaf1, O.
Husson1, 1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, NL, 2IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL,
3UMC - University Medical Center Utrecht, Utrecht, NL, 4Radboud University Medical
Center, Nijmegen, Nijmegen, NL, 5Amsterdam UMC - Vrije University Medical Centre
(VUmc), Amsterdam, NL, 6Erasmus MC - University Medical Center, Rotterdam, NL,
7LUMC - Universitair Medisch Centrum, Leiden, NL, 8Maastricht University Medical
Center (MUMC), Maastricht, NL, 9University Medical Center Groningen - umcg,

Groningen, NL
16:40 - 16:45 1694MO - Socio-economic consequences among adolescent and young adult
cancer patients: a European perspective
S. Janssen1, J. Vancoppenolle1, N. Franzen1, W. Van Der Graaf1, O. Husson1, V. Retel1, W.

Van Harten2, 1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Amsterdam, NL, 2University of Twente, Enschede, NL
16:45 - 16:50 1695MO - Cancer care during armed conflict: factors associated with adult

patient transfer for treatment abroad during the war in Ukraine
I. Huivaniuk1, D. Kizub2, V. Kopetskyi1, A. Dzhemiliev3, A. Kacharian1, V. Strilka1, A.

Beznosenko1, N. Melnitchouk4, 1National Cancer Institute of the Ministry of Health of
Ukraine, Kiev, UA, 2MD Anderson Cancer Center, Houston, US, 3Brigham and Women's
Hospital, Boston, US, 4Harvard Medical School, Boston, US
16:50 - 17:05 Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO

J. Mckay, IARC - International Agency for Research on Cancer, Lyon, FR
17:05 - 17:10 1759MO - Clinical breast examination for early diagnosis of breast cancer: An
Egyptian nationwide study
H. Azim1, L. Kassem1, K. Shohdy1, Y. Safwat1, E. Khallaf1, S. Naguib1, M. Hegazy2, A.

Selim1, N. Hussein3, A. Abdelaziz4, H. El Ghazaly4, M. Hassany3, A. Abdelaziz1, A.
Kandil5, B.A. El Sayed3, T. Hashem6, S. Eid7, A. Morsy3, K. Abdelghaffar3, H. Zaid3,
1Cairo University, Giza, EG, 2Mansoura University, Mansoura, EG, 3Ministry of Health
and Population, Cairo, EG, 4Ain Shams University, Cairo, EG, 5Alexandria University,
Alexandria, EG, 6Menoufia University, Shebeen El-Kom, EG, 7Assiut University, Assiut,
EG
17:10 - 17:15 1696MO - Partial orphan cancer drugs: FDA approval, clinical benefit, trials,
epidemiology, price, beneficiaries, and spending
D. Michaeli1, C. Michaeli2, 1Medizinische Fakultät Mannheim der Universität Heidelberg,

Mannheim, DE, 2UMM - Universitaetsklinikum Mannheim, Mannheim, DE
17:15 - 17:20 1697MO - Spending on and beneficiaries of orphan cancer drugs for ultra-rare,
rare, and common diseases
J.C. Michaeli1, C. Michaeli2, D. Michaeli3, 1LMU University Hospital, LMU Munich,

Munich, DE, 2UMM - Universitaetsklinikum Mannheim, Mannheim, DE, 3Medizinische
Fakultät Mannheim der Universität Heidelberg, Mannheim, DE

17:35 - 17:40 1698MO - Prevalence of E-Cigarette Use among US Ever-Smoking Cancer

Survivors and its Implications on Lung Cancer Screening
Q. Wang1, M. Hsu1, C. Wen2, A. Dowlati1, Y. Zhang3, C. Jiang4, D. Bruno1, Y. Li5, L.

Deng4, L. Chiec1, G. Dutcher1, C.Y. Kong2, 1University Hospitals Seidman Cancer Center
and Case Western Reserve University, Cleveland, US, 2Icahn School of Medicine at
Mount Sinai, New York, US, 3Ascension Providence Hospital, Southfield, US, 4Roswell
Park Comprehensive Cancer Center, Buffalo, US, 5UBC - The University of British
Columbia, Vancouver, CA
17:40 - 17:45 1699MO - Intervening Factors for Participation and Non-participation in

colorectal cancer screening in Spain
M.L. Amador1, D. De Haro2, B. Fernández Sánchez1, M. Lopez3, M. Blanco Álvarez1, A.

Fernández Marcos1, 1Headquarters Spanish Association Against Cancer (AECC), Madrid,
ES, 2AECC - Asociación Española Contra El Cáncer, MADRID, ES, 3Asociación Española
Contra el Cáncer, MADRID, ES
17:45 - 17:50 1700MO - Knowledge of Cancer Risk Factors and Risk-reduction in 20 High- and
Middle-income Countries
P. Carrera, S. Calderazzo, DKFZ - German Cancer Research Center, Heidelberg, DE

W. Tse Yared, Association of European Cancer Leagues, Brussels, BE

Chair(s): Fabrice André, FR; Karin Jordan, DE
16:30 - 16:42 One LBA TBC
16:42 - 16:54 LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated

advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of
the randomized phase 3 study TROPION-Lung01
M.-J. Ahn1, A. Lisberg2, L. Paz-Ares3, R. Cornelissen4, N. Girard5, E. Pons-Tostivint 6, D.

Vicente Baz7, S. Sugawara8, M. Cobo Dols9, M. Pérol10, C. Mascaux11, E. Poddubskaya12,
S. Kitazono13, H. Hayashi14, J. Sands15, R. Hall16, Y. Zhang17, H. Zebger-Gong18, D.
Uema17, I. Okamoto19, 1Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, KR, 2Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US,
3Hospital Universitario 12 de Octubre, Madrid, ES, 4Erasmus MC Cancer Institute,
Rotterdam, NL, 5Institut Curie, Paris, FR, 6University Hospital Nantes, Nantes, FR,
7Hospital Universitario Virgen Macarena, Seville, ES, 8Sendai Kousei Hospital, Sendai,
JP, 9Regional and Virgen de la Victoria University Hospitals, Malaga, ES, 10Léon Bérard
Cancer Centre, Lyon, FR, 11Hôpitaux Universitaires de Strasbourg (CHRU), Strasbourg,
FR, 12Vitamed LLC, Moscow, RU, 13The Cancer Institute Hospital of JFCR, Tokyo, JP,
14Kindai University, Osaka, JP, 15Dana-Farber Cancer Institute, Boston, US, 16University
of Virginia Health System, Charlottesville, US, 17Daiichi Sankyo, Inc, Basking Ridge, US,
18Daiichi Sankyo Europe GmbH, Munich, DE, 19Kyushu University, Fukuoka, JP
16:54 - 17:04 Invited Discussant one LBA TBC and LBA12

S. Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
17:04 - 17:10 Q&A
17:10 - 17:22 LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with

metastatic castration-resistant prostate cancer (PSMAfore)
O. Sartor1, D. Castellano Gauna2, K. Herrmann3, J. De Bono4, N. Shore5, K.N. Chi6, M.

Crosby7, J.M. Piulats Rodriguez8, A. Flechon9, X. Wei10, H. Mahammedi11, G. Roubaud12,
H. Studentova13, S. Ghebremariam14, E. Kpamegan14, T. Kreisl14, N. Delgoshaie15, K.
Lehnhoff15, M. Morris16, K. Fizazi17, 1Mayo Clinic - Rochester, Rochester, US, 2Hospital
Universitario 12 de Octubre, Madrid, ES, 3University of Duisburg-Essen and German
cancer consortium (DKTK), partner site University Hospital Essen, Essen, DE, 4The
Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, 5Carolina Urologic
Research Center/GenesisCare US, Myrtle Beach, US, 6BC Cancer and Vancouver Prostate
Centre, Vancouver, CA, 7Veterens Prostate Cancer Awareness Inc, Washington DC, US,
8ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de
Llobregat, ES, 9Centre Leon Berard, Lyon, FR, 10Dana Farber Cancer Institute, Boston,
US, 11Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, 12Institute Bergonié,
Bordeaux, FR, 13FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, 14Novartis
Pharmaceuticals Corporation, East Hanover, US, 15Novartis International AG - Basel,
Basel, CH, 16MSKCC - Memorial Sloan Kettering Cancer Center, New York, US,
17Gustave Roussy, University Paris Saclay, Villejuif, FR
17:30 - 17:35 Q&A
17:35 - 17:47 LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in

Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC):
Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled
Trial
B.C. Cho1, E. Felip2, A. Spira3, N. Girard4, J.-S. Lee5, S.-H. Lee6, Y. Ostapenko7, P.
Danchaivijitr8, B. Liu9, A. Alip10, E. Korbenfeld11, J. Dias12, T. Sun13, M. Martinez13, J.
Bauml14, M. Shreeve15, S. Sethi14, R. Knoblauch14, H. Hayashi16, S. Lu17, 1Division of
Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,
KR, 2Vall d'Hebron University Hospital and Vall d’Hebron Institute of Oncology,
Barcelona, ES, 3Virginia Cancer Specialists, Fairfax, US, 4Institut du Thorax Curie-
Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, 5Seoul National
University Bundang Hospital, Seongnam, KR, 6Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, KR, 7National Cancer Institute, Kyiv, UA, 8Siriraj
Hospital, Mahidol University, Bangkok, TH, 9Harbin Medical University Cancer Hospital,
Harbin, CN, 10University Malaya Medical Centre, Kuala Lumpur, MY, 11Hospital
Britanico de Buenos Aires, Buenos Aires, AR, 12Barretos Cancer Hospital, Barretos, BR,
13Janssen R&D, Raritan, US, 14Janssen R&D, Spring House, US, 15Janssen R&D, San
Diego, US, 16Kindai University Faculty of Medicine, Osaka, JP, 17Shanghai Lung Cancer
Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN
17:47 - 17:59 LBA15 - Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs

Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on
Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial
A. Passaro1, B.C. Cho2, Y. Wang3, B. Melosky4, R. Califano5, S.-H. Lee6, N. Girard7, K.

Reckamp8, T. Takahashi9, E. Felip10, R.D. Gentzler11, S. Popat12, W. Nassib William
Junior13, T. Sun14, S. Shah15, B. Diorio16, R. Knoblauch15, J. Bauml15, M.R. García-
Campelo17, J. Wang18, 1European Institute of Oncology, IRCCS, Milan, IT, 2Yonsei Cancer

Center, Yonsei University College of Medicine, Seoul, KR, 3West China Hospital, Sichuan
University, Chengdu, CN, 4British Columbia Cancer Agency, Vancouver, CA, 5Christie
NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester,
Manchester, GB, 6Sungkyunkwan University School of Medicine, Seoul, KR, 7Institut du
Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR,
8Cedars-Sinai Medical Center, Los Angeles, US, 9Shizuoka Cancer Center, Nagaizumi, JP,
10Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona,
ES, 11University of Virginia Cancer Center, Charlottesville, US, 12Royal Marsden Hospital
NHS Foundation Trust and The Institute of Cancer Research, London, GB, 13Beneficência
Portuguesa de São Paulo and Grupo Oncoclínicas, São Paulo, BR, 14Janssen R&D,
Raritan, US, 15Janssen R&D, Spring House, US, 16Janssen R&D, Titusville, US,
17University Hospital A Coruña, A Coruña, ES, 18Chinese Academy of Medical Sciences
& Peking Union Medical College, Beijing, CN

18:09 - 18:15 Q&A
16:30 - 18:00 Type: Mini Oral session Valencia Auditorium - Hall

Title: Mini oral session - Developmental 10
therapeutics
Chair(s): Funda Meric-Bernstam, US; Ulrik Lassen, DK
16:30 - 16:35 656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated

advanced non-breast solid tumors (STs): results from the global phase 1 study
H. Yao1, M.H. Ryu2, J. Park3, M. Voskoboynik4, J.H. Kim5, K. Liu6, M. Barve7, A. Acuna-
Villaorduna8, S.-A. Im9, A.C. Roy10, L.-Y. Bai 11, C.-J. Yen12, J. Zhang13, V. Ganju14, L.
Wu15, M. Yan16, L. Bao17, Y. Zhao1, S. Rong18, E. Song1, 1Sun Yat-sen Memorial Hospital,
Sun Yat-sen University, Guangzhou, CN, 2Asan Medical Center, Seoul, KR, 3Macquarie
University, Sydney, AU, 4Alfred Health, Melbourne, AU, 5Seoul National University
Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR,
6Hunan Cancer Hospital, Changsha, CN, 7Mary Crowley Cancer Research, Dallas, US,
8Montefiore-Einstein Center for Cancer Care, Bronx, US, 9Seoul National University,
Seoul, KR, 10Southern Oncology Clinical Research Unit, Adelaide, AU, 11China Medical
University Hospital, Taichung, TW, 12National Cheng Kung University Hospital, Tainan,
TW, 13Fudan University Shanghai Cancer Center, Shanghai, CN, 14PASO Medical,
Melbourne, AU, 15Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN,
16Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University &
Henan Cancer Hospital, Zhengzhou, CN, 17HuBei Cancer Hospital, Wuhan, CN, 18Jiangsu
Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN
16:35 - 16:40 657MO - Recommended phase 2 dose (RP2D) selection and pharmacodynamic
(PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC)
BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
B. Li1, K.-W. Lee 2, M. Pegram3, M. Sharma4, J. Lee5, A. Spira6, Y.-K. Kang7, K. Moore8, D.
Rasco9, G. Hanna10, B. Weinberg11, T. Yu12, M. Alonso12, J. Ptacek12, M. Yin12, C.
Tapia12, L. Xu12, E. Perez12, E. Dumbrava13, 1Memorial Sloan Kettering Cancer Center,

New York, US, 2Seoul National University College of Medicine, Seoul National University
Bundang Hospital, Seongnam-si, KR, 3Stanford Comprehensive Cancer Institute,
Stanford, US, 4START Midwest, Grand Rapids, US, 5Samsung Medical Center (SMC) -
Sungkyunkwan University School of Medicine, Seoul, KR, 6Virginia Cancer Specialist,
Fairfax, US, 7Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR,
8Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, 9South Texas
Accelerated Research Therapeutics (START), San Antonio, US, 10Dana Farber Cancer
Institute, Boston, US, 11Lombardi Cancer Center Georgetown University, Washington,
US, 12Bolt Biotherapeutics, Inc., Redwood City, US, 13The University of Texas M. D.
16:40 - 16:45 LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with
HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02
(DP-02) study
F. Meric-Bernstam1, V. Makker2, A. Oaknin3, D.-Y. Oh 4, S. Banerjee5, A. Gonzalez

Martin6, K. Jung7, I. Lugowska8, L. Manso Sanchez9, A. Manzano Fernández10, B.
Melichar11, S. Siena12, D. Stroyakovskiy13, A. Fielding14, Y. Ma15, S. Puvvada14, J.-Y.
Lee16, 1MD Anderson Cancer Center, University of Texas, Houston, US, 2Memorial Sloan-
Kettering Cancer Center, New York City, US, 3Vall d'Hebron University Hospital, Vall
d'Hebron Institute of Oncology (VHIO), Barcelona, ES, 4Seoul National University
Hospital, Seoul, KR, 5The Royal Marsden NHS Foundation Trust, London, GB, 6Clinica
Universidad de Navarra, Madrid, ES, 7Asan Medical Center, University of Ulsan, College
of Medicine, Seoul, KR, 8Maria Sklodowska-Curie National Research Institute of
Oncology, Warsaw, PL, 9Hospital Universitario 12 de Octubre, Madrid, ES, 10Hospital
Clinico San Carlos, School of Medicine, Universidad Complutense de Madrid, Madrid,
Spain, Madrid, ES, 11University Hospital, Palacký University Medical School, Olomouc,
Czech Republic, Prague, CZ, 12Niguarda Cancer Center, Grande Ospedale Metropolitano
Niguarda, Università degli Studi di Milano, Milan, Italy, Milan, IT, 13Moscow Municipal
Oncology Hospital No. 62, Istra, RU, 14AstraZeneca, South San Francisco, US,
15AstraZeneca, Northolt, GB, 16Yonsei University College of Medicine, Seoul, Republic of
Korea, Seoul, KR
16:45 - 16:50 658MO - Phase 1 study of SHR-A2009, a HER3-targeted ADC, in advanced solid
tumors
Q. Zhou1, Y.-L. Wu1, J. Li2, A. Liu2, J. Cui3, Y. Kuboki4, N. Yamamoto5, S.-W. Han 6, G. Lin7,
J.-M. Sun8, L. Wu9, Z. Zhu10, J. Shuang10, F. Qiu10, W. Shi10, 1Guangdong Provincial
People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical
University, Guangzhou, CN, 2The Second Affiliated Hospital of Nanchang University,
Nanchang, CN, 3The First Hospital of Jilin University, Changchun, CN, 4National Cancer
Center Hospital East, Kashiwa, JP, 5National Cancer Center Hospital-Tsukiji Campus,
Chuo-ku, JP, 6Seoul National University Hospital, Seoul, KR, 7Fujian Cancer Hospital and
Fujian Medical University Cancer Hospital, Fuzhou, CN, 8Samsung Medical Center
(SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, 9Hunan Cancer
Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South
University, Changsha, CN, 10Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, CN
16:50 - 17:05 Invited Discussant 656MO, 657MO, LBA34 and 658MO

P. Munster, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

17:05 - 17:10 659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-
drug conjugate targeting Nectin-4, in patients with advanced solid tumors
J. Zhang1, R. Liu1, S. Gao1, X. Li2, J. Chen3, X. Yao4, Y. Fang5, R. Li6, M. Zhang7, F. Qiu8,
Y. Li9, T. Liu10, H. Huang11, X. Zhang12, H. Guo13, B. Hu14, J.-Y. Liu 15, Q. Yang16, P.
Zhao17, P. Wang18, 1Fudan University Shanghai Cancer Center, Shanghai, CN, 2The First
Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, 3Yantai Yuhunagding
Hospital, Yantai, CN, 4Tianjin Cancer Hospital, Tianjin, CN, 5Affiliated Cancer Hospital of
Chongqing University, Chongqing, CN, 6Chongqing University Cancer Hospital,
Chongqing, CN, 7The Second Hospital of Anhui Medical University, Hefei, CN, 8The
Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1,
Hangzhou, CN, 9Shenyang Tenth People's Hospital, Shenyang, CN, 10Zhongshan Hospital
Affiliated to Fudan University, Shanghai, CN, 11The First Affiliated Hospital of Wenzhou
Medical University - Nanbaixiang Site, Wenzhou, CN, 12Wuhan Union Hospital, Wuhan,
CN, 13The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing,
CN, 14Liaoning Cancer Hospital and Institute, Shenyang, CN, 15West China School of
Medicine/West China Hospital of Sichuan University, Chengdu, CN, 16The Second
Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, 17The First Affiliated
Hospital of Medical School of Zhejiang University, Hangzhou, CN, 18Mabwell (Shanghai)
Bioscience Co., Ltd., Shanghai, CN
17:10 - 17:15 660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in

patients with advanced solid tumors: Preliminary results of a phase 1 study
(SGNB7H4V-001)
C. Perez1, J. Henry2, N. Lakhani3, J. Call4, E. Hamilton5, G. Colon-Otero6, J. Diamond7, B.

O’Neil8, A. Kalyan9, G. Sonpavde10, I. Moreno11, A. Awan12, E. Fontana13, P. Xu14, F.
Zhang14, N. Nazarenko14, A. Patnaik15, 1University of Central Florida Lake Nona Cancer
Center, Orlando, US, 2Sarah Cannon Research Institute at HealthONE, Denver, US,
3START Midwest, Grand Rapids, US, 4START Mountain Region, West Valley City, US,
5Tennessee Oncology, Nashville, US, 6Mayo Clinic, Jacksonville, US, 7University of
Colorado, Aurora, US, 8Community Health Network, Indianapolis, US, 9Northwestern

University, Chicago, US, 10AdventHealth Cancer Institute, Celebration, US, 11Centro
Integral Oncológico Clara Campal, Madrid, ES, 12Ottawa Hospital Research Institute,
Ottawa, CA, 13Sarah Cannon Research Institute SCRI UK, London, GB, 14Seagen Inc.,
Bothell, US, 15START San Antonio, San Antonio, US

U. Lassen, Rigshospitalet, Copenhagen, DK
17:30 - 17:35 LBA35 - BNT211-01: Interim results from a repeat dose escalation study of
CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-
encoding CAR-T cell-Amplifying RNA Vaccine (CARVac)
J. Haanen1, W. Alsdorf2, C. Koenecke3, E. Wagner-Drouet4, P. Borchmann5, D.

Heudobler6, A. Busse7, S. Klobuch1, N. Kutsch8, F. Müller9, C. Bokemeyer10, A. Desuki11,
F. Lueke6, T. Ho12, K. Vemuri12, L. Preussner13, B. Rengstl13, Ö. Türeci13, U. Sahin13,
1NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam,
NL, 2University Medical Center Hamburg-Eppendorf, Hamburg, DE, 3MHH -

Medizinische Hochschule Hannover, Hannover, DE, 4University Medical Center Mainz,
Mainz, DE, 5University Hospital Cologne, Köln, DE, 6UKR - University Hospital

Regensburg, Regensburg, DE, 7Charite, Campus Benjamin Franklin Medizinische Klinik
III, Berlin, DE, 8University Hospital of Cologne, Cologne, DE, 9Universitätsklinikums
Erlangen, Erlangen, DE, 10UKE Universitätsklinikum Hamburg-Eppendorf KMTZ,
Hamburg, DE, 11Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz,
DE, 12BioNTech US, Cambridge, US, 13BioNTech SE, Mainz, DE
17:35 - 17:40 661MO - Anti-Tumor Activity of Belvarafenib in combination with Cobimetinib in

patients with metastatic solid tumors harboring BRAF fusions or BRAF class
II/III mutation
T.W. Kim1, J. Lee2, S.J. Shin3, S.-W. Han 4, Y.J. Kim5, J.-S. Kim6, S.Y. Oh7, D.H. Lee1, M.H.
Kim3, S. Kim2, Y. Hong8, S. Kim8, T. Kim8, B. Lee8, J. Eng-Wong 9, Y. Yan9, C. Chou9, Y.S.
Noh8, 1Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR,
2Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR,
3Yonsei University College of Medicine, Seoul, KR, 4Seoul National University Hospital,
Seoul, KR, 5Seoul National University Bundang Hospital, Seoul National University
College of Medicine, Seongnam, KR, 6Boramae Medical Center, Seoul, KR, 7Dong-A
University College of Medicine, Busan, KR, 8Hanmi Pharmaceutical Co., Ltd, Seoul, KR,
9Genentech, Inc., South San Francisco, US
17:40 - 17:45 662MO - Phase 1, Multi-Center, Dose-escalation and Dose-expansion Study of

IMP7068, a WEE1 Inhibitor, in Patients with Advanced Solid Tumors
C.-C. Lin1, J. Grewal2, J. Baranda3, R. Schneider4, J. Zhang5, L.-Y. Bai 6, Y.-M. Yeh7, D.
Sommerhalder8, G. Li9, L. Shen10, H.-C. Hsu11, O. Alese12, R. Yin13, C.-Y. Hsieh 14, S.X.
Cai14, Y.E. Tian14, H. Xia15, B. Li14, M. Zhang14, C. Zhang14, 1NTUH - National Taiwan
University Hospital, Taipei City, TW, 2Norton Cancer Institute, Louisville, US, 3University
of Kansas Clinical Research Center, Kansas City, US, 4Mary Crowley Cancer Research
Center, Dallas, US, 5Fudan University Shanghai Cancer Center, Shanghai, CN, 6China
Medical University Hospital , New Taipei City, TW, 7NCKUH - National Cheng Kung
University Hospital, Tainan City, TW, 8NEXT Oncology, San Antonio, US, 9Union Hospital,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN,
10Beijing Cancer Hospital, Beijing, CN, 11Chang Gung Medical Foundation - Linkou
Chang Gung Memorial Hospital, Taoyuan City, TW, 12Emory University Hospital, Atlanta,
US, 13West China Second University Hospital, Sichuan University/ West China Women's
and Children's Hospital, Chengdu, CN, 14IMPACT Therapeutics, Inc. (Shanghai),
Shanghai, CN, 15Impact Therapeutics, Shanghai, CN
17:45 - 18:00 Invited Discussant LBA35, 661MO and 662MO

P. Cassier, Centre Léon Bérard, Lyon, FR

16:30 - 18:00 Type: Educational session Málaga Auditorium - Hall
Title: Advances in the management of locally 10
advanced NPC
Chair(s): Brigette Ma, HK; Lisa Licitra, IT
16:30 - 16:50 Recent advances in the clinical application of plasma EBV DNA in individualizing
treatment of LA-NPC
M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG
16:50 - 17:10 Navigating the undulating landscape of radiotherapy escalation/ de-escalation in

the treatment of LA-NPC
Q.-T. Le, Stanford University, Stanford, US
17:10 - 17:30 Induction versus adjuvant chemotherapy in LA-NPC: Deciphering the latest
evidence for the practicing oncologist
P. Blanchard, Institut Gustave Roussy, Villejuif, Cedex, FR
17:30 - 17:50 How to transfer results from endemic to non-endemic settings

L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

Title: GSK - The Need for Better Patient Outcomes: Latest Auditorium -
Investigational Approaches for dMMR/MSI-H CRC Hall 3
Chair(s): Jenny Seligmann, GB
18:30 - 18:45 The Need for New Approaches in Locally Advanced dMMR/MSI-H CRC
18:45 - 19:05 Locally Advanced dMMR/MSI-H Rectal Cancer: New Approaches Under
Investigation
A. Parikh, MGH - Massachusetts General Hospital, Boston, US
19:05 - 19:25 Locally Advanced dMMR/MSI-H Colon Cancer: New Approaches Under
Investigation
V. Heinemann, LMU Klinikum der Universität München, Munich, DE
19:25 - 19:45 The Multidisciplinary Approach to Locally Advanced dMMR/MSI-H CRC:

Reducing the Patient Burden
19:45 - 20:00 Q&A | Panel Discussion
J. Seligmann1, V. Heinemann2, A. Parikh3, 1The University of Leeds, Leeds, GB, 2LMU

Klinikum der Universität München, Munich, DE, 3MGH - Massachusetts General
Hospital, Boston, US

Title: Stemline. A Menarini Group Company - Current and upcoming Auditorium
treatment strategies after CDK4/6 inhibitors for patients with - Hall 10
ER+/HER2- advanced breast cancer
Chair(s): Antonio Llombart Cussac, ES

A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES
18:40 - 19:10 The current and future treatment landscape for ER+/HER2- metastatic breast
cancer
V. Kaklamani, Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center,
San Antonio, US
19:10 - 19:30 Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1
mutation testing
V. Mueller, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
19:30 - 19:40 Key takeaways

A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES
19:40 - 20:00 Q&A
A. Llombart Cussac1, V. Kaklamani2, V. Mueller3, 1Hospital Arnau de Vilanova, Valencia,

ES, 2Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San
Antonio, US, 3UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

Title: F. Hoffmann-La Roche LTD - Shaping the future of Auditorium - Hall
personalised healthcare for cancer patients 3
Chair(s): Vivek Subbiah, US
18:30 - 18:35 Understanding the patient's perspective

T. Knott, Sarah Jennifer Knott Foundation, DUBLIN, IE
18:35 - 18:45 CUPISCO as an innovative example in precision oncology

L. Mileshkin, Peter MacCallum Cancer Center, Melbourne, AU
18:45 - 18:55 Changing the trajectory for cancer patients with liquid biopsy
C.B. Westphalen, LMU Klinikum der Universität München, Munich, DE
18:55 - 19:10 Panel discussion: including Q&A: Considerations for future clinical decision
making
T. Knott1, V. Subbiah2, C.B. Westphalen3, A. Krämer4, 1Sarah Jennifer Knott Foundation,

DUBLIN, IE, 2The University of Texas M. D. Anderson Cancer Center, Houston, US, 3LMU
Klinikum der Universität München, Munich, DE, 4German Cancer Research Center
(DKFZ) and University of Heidelberg, Heidelberg, DE
19:10 - 19:20 Translating scientific evidence into drug approvals

19:20 - 19:30 Shaping public healthcare systems to accelerate treatment access

D. Thomas, Garvan Institute of Medical Research, Darlinghurst, AU
19:30 - 19:55 Panel discussion including Q&A: Considerations for our future healthcare
systems
V. Subbiah1, D. Thomas2, 1The University of Texas M. D. Anderson Cancer Center,

Houston, US, 2Garvan Institute of Medical Research, Darlinghurst, AU
19:55 - 20:00 Call to action


18:30 - 20:00 Type: Industry Satellite Symposium Málaga Auditorium - Hall 10
Title: AbbVie Inc. - The Future of ADCs in NSCLC
Chair(s): Federico Cappuzzo, IT

F. Cappuzzo, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT
18:35 - 19:00 An introduction to ADCs in the treatment of NSCLC

19:00 - 19:25 The emerging role for ADCs in the NSCLC treatment landscape
F. Cappuzzo1, B. Besse2, E. Felip3, 1IRCCS Istiuto Nazionale Tumori Regina Elena (IRE),
Rome, IT, 2Institut Gustave Roussy, Villejuif, FR, 3Vall d'Hebron University Hospital,
Barcelona, ES
19:55 - 20:00 Closing


Title: F. Hoffmann-La Roche LTD - HER future: Pathways to Auditorium -
better care for women with HER2+ breast cancer Hall 9
Chair(s): Matteo Lambertini, IT

Cancro, Genova, IT
18:33 - 18:53 Delivering women-centric cancer care for optimal outcomes

Cancro, Genova, IT
18:53 - 19:13 Changing the SCript: Rewriting the patient experience with subcutaneous
formulations of HER2-targeted antibodies
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US
19:13 - 19:33 Decentralised cancer care: Providing healthcare closer to home

S.C. Lee, Cancer Science Institute (CSI) - National University of Singapore (NUS),
Singapore, SG
19:33 - 20:00 Live Q&A, discussion and closing remarks

Cancro, Genova, IT

Title: Pfizer Oncology - ALK+ NSCLC: Maximising the potential Auditorium -
for patients throughout their treatment journey Hall 3
Chair(s): Geoffrey Liu, CA

G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
18:35 - 19:55 Follow a fictional patient on their ALK+ NSCLC treatment journey: Diagnosis,
Treatment selection, 1L treatment, Experiencing adverse events, Beyond
progression
G. Liu1, M.R. García-Campelo2, M. Dietrich3, 1UHN - University Health Network -

Princess Margaret Cancer Center, Toronto, CA, 2CHUAC - Complexo Hospitalario
Universitario A Coruña, A Coruña, ES, 3Florida Cancer Specialists & Research Institute -
Lake Mary Cancer Center, Lake Mary, US
19:55 - 20:00 Meeting close

G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

Title: MSD - Immune Checkpoint Inhibitors & beyond: Evolving Auditorium -
treatment landscape of Kidney Cancer Hall 7
Chair(s): Toni Choueiri, US
18:30 - 18:35 Welcome

18:35 - 18:55 Management of post-nephrectomy RCC patients: Adjuvant treatment options and
Patient case discussion
J. Bedke1, T. Choueiri2, 1Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE,

2Dana Farber Cancer Institute, Boston, US
18:55 - 19:00 Q&A
J. Bedke1, T. Choueiri2, 1Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE,

19:00 - 19:20 First line advanced RCC treatment landscape: current standard of care,
treatment decision making for both clear-cell and non-clear cell RCC treatment
options and Patient Case discussion
L. Albiges1, T. Choueiri2, 1Institut Gustave Roussy, Villejuif, Cedex, FR, 2Dana Farber
Cancer Institute, Boston, US
19:20 - 19:35 2L+ treatment options for advanced RCC patients post IO and/or TKI: Current
treatment options & Patient case discussion
C. Suarez Rodriguez1, T. Choueiri2, 1Vall d'Hebron University Hospital, Barcelona, ES,

19:35 - 20:00 Expert Panel & Q&A
T. Choueiri1, J. Bedke2, L. Albiges3, C. Suarez Rodriguez4, 1Dana Farber Cancer Institute,

Boston, US, 2Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, 3Institut
Gustave Roussy, Villejuif, Cedex, FR, 4Vall d'Hebron University Hospital, Barcelona, ES

Title: Daiichi Sankyo AstraZeneca - From Bench to Bedside: Auditorium
Interdisciplinary Management of HER2-Low Breast Cancer in the - Hall 7
Clinic
Chair(s): Eva Ciruelos, ES
18:30 - 18:35 Welcome & Introduction

18:35 - 18:55 Inside the HER2 Expression Spectrum

P. Sinn, University Hospital Heidelberg, Heidelberg, DE
18:55 - 19:15 Treatment of HR+ Metastatic Breast Cancer: Considerations
19:15 - 19:35 Optimising Patient Management in the Real-World

19:35 - 19:55 Panel Discussion and Q&A
E. Ciruelos1, V. Guarneri2, P. Sinn3, 1Hospital Universitario 12 de Octubre, Madrid, ES,

2University of Padua, Padova, IT, 3University Hospital Heidelberg, Heidelberg, DE
19:55 - 20:00 Wrap-up and Meeting Close


24.10.2023
09:00 - 12:40 Type: Scientific Congress highlights Barcelona Auditorium - Hall 9
Title: Scientific Congress Highlights 1
Chair(s): Fabrice André, FR; Silke Gillessen, CH
09:00 - 09:20 Breast cancer, early stage

09:20 - 09:40 Breast cancer, metastatic

G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT
09:40 - 10:00 Gynaecological cancers

10:00 - 10:20 CNS tumours

10:20 - 10:40 Policy and preventive strategies

10:40 - 11:00 Break
11:00 - 11:20 Basic science & translational research

K. Rouschop, Maastricht University, Maastricht, NL
11:20 - 11:40 Developmental therapeutics

L. Siu, Princess Margaret Cancer Centre, Toronto, CA
11:40 - 12:00 GU prostate

M. Gizzi, GHdC - Grand Hopital de Charleroi - Site Notre Dame, Charleroi, BE
12:00 - 12:20 GU non-prostate

12:20 - 12:40 Investigational immunotherapy

J. Hassel, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

09:00 - 12:40 Type: Scientific Congress highlights Sevilla Auditorium - Hall 9
Title: Scientific Congress Highlights 2
Chair(s): Andres Cervantes, ES; Solange Peters, CH
09:00 - 09:20 Melanoma and other skin tumours

I. Marquez-Rodas, Hospital General Universitario Gregorio Marañon - Fundación
Investigación Biomedica, Madrid, ES
09:20 - 09:40 Sarcoma

C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES
09:40 - 10:00 Head and neck cancer

P. Bossi, IRCCS Humanitas Research Hospital, Rozzano, IT
10:00 - 10:20 Supportive and palliative care

10:20 - 10:40 Haematological malignancies

D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH
10:40 - 11:00 Break
11:00 - 11:20 GI, lower digestive

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG
11:20 - 11:40 GI, upper digestive: HPB and Gastroesophageal
A. Ko1, S. Lorenzen2, 1UCSF - University of California San Francisco - Parnassus

Campus, San Francisco, US, 2Klinikum Rechts der Isar - Technische Universitaet
Muenchen, Munich, DE
11:40 - 12:00 NETs and endocrine tumours

C. De La Fouchardiere, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR
12:00 - 12:20 Non-metastatic NSCLC and other thoracic malignancies

12:20 - 12:40 NSCLC, metastatic

G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

Final Programme Esmo2023

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Final Programme Esmo2023

Uploaded by

Copyright:

Available Formats

-

Chair(s): Kosei Hasegawa, JP; Mansoor Raza Mirza, DK

07:08 - 07:13 One LBA TBC

07:28 - 07:33 One LBA TBC

07:33 - 07:48 Invited Discussant one LBA TBC and 747MO

10:15 - 10:20 Welcome and Introduction

10:45 - 11:10 Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion

11:10 - 11:30 New Antibody-Drug Conjugates on the Horizon

11:30 - 11:40 Audience Q&A

J. Cortés1, P. Fasching2, S. Hurvitz3, P. Schmid4, 1Hospital Ruber Internacional, Madrid,

11:40 - 11:45 Concluding Remarks

Last update: 28-09-2023 07:08:08am Programme

Chair(s): Salvatore Siena, IT

10:15 - 10:20 Welcome and Introduction

10:20 - 10:35 HER2 as an Actionable Target in HER2+ mCRC

10:35 - 10:55 The Role of HER2 Testing in mCRC

11:15 - 11:40 Panel Discussion and Interactive Q&A

11:40 - 11:45 Closing Remarks

Last update: 28-09-2023 07:08:08am Programme

10:15 - 10:20 Welcome and introduction

11:20 - 11:40 Discussion and conclusions

Last update: 28-09-2023 07:08:08am Programme

10:15 - 10:20 Housekeeping and introductions

10:30 - 10:50 Overview of current trials investigating first-line treatment of LA/mUC

10:50 - 11:30 Clinical experiences with first-line treatment of LA/mUC

F. Schlürmann1, T. Friedlander2, 1CHRU Brest - Hopital Augustin Morvan, Brest, FR,

11:30 - 11:40 Panel discussion

I. Duran Martinez1, F. Schlürmann2, T. Friedlander3, 1HUMV - Hospital Universitario

11:40 - 11:45 Summary and close

Last update: 28-09-2023 07:08:08am Programme

10:15 - 10:20 Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices

10:20 - 10:40 Immunotherapeutic Advances in the Treatment of Esophageal Cancer

10:40 - 11:00 Update on Immuno-Oncology for the Treatment of Gastric Cancer

11:00 - 11:20 Advances in Immuno-Oncology for the Treatment of Colorectal Cancer

11:20 - 11:40 Roundtable Case Discussion, Q&A

J. Bridgewater1, M.E. Elez Fernandez2, P. Thuss-Patience3, T. Fleitas4, 1UCL Cancer

11:40 - 11:45 Summary and Close

Last update: 28-09-2023 07:08:08am Programme

11:00 - 11:15 The evolving paradigm for clinical management of glioma

11:30 - 11:45 Q&A Session

C. Balana1, G. Tabatabai2, T. Cloughesy3, M. Van Den Bent4, S. Erridge5, 1ICO - Institut

Last update: 28-09-2023 07:08:08am Programme

12:00 - 12:17 Welcome and Presidential address

12:17 - 12:22 Scientific Chair address

12:22 - 12:27 Presentation of the ESMO awards 2023

12:27 - 12:46 ESMO Award 2023

12:46 - 13:05 ESMO Award for Translational Research 2023

13:05 - 13:24 ESMO Women for Oncology Award 2023

13:24 - 13:43 ESMO Lifetime Achievement Award 2023

13:43 - 13:45 Closure of the Opening Ceremony

14:00 - 15:40 Type: Proffered Paper session Barcelona Auditorium

14:00 - 14:10 LBA74 - Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and

K. Shitara1, S.Y. Rha2, L. Wyrwicz3, T. Oshima4, N. Karaseva5, M. Osipov6, H. Yasui7, H.

Last update: 28-09-2023 07:08:08am Programme

14:10 - 14:20 LBA73 - Pathological complete response (pCR) to durvalumab plus 5-

Y. Janjigian1, S.-E. Al-Batran2, Z. Wainberg3, E. Van Cutsem4, D. Molena1, K. Muro5, W.J.

14:20 - 14:30 Invited Discussant LBA74 and LBA73

14:30 - 14:40 Q&A

14:40 - 14:50 LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active

Center, Leiden, NL, 9ETZ - Elisabeth-TweeSteden Hospital, Tilburg, NL,

Last update: 28-09-2023 07:08:08am Programme

14:50 - 15:00 Invited Discussant LBA75

15:00 - 15:10 Q&A